{"PMC7457622": [["INTRODUCTIONOver the past 18 years, spillover events have introduced the highly transmissible beta-coronavirus strains SARS CoV, MERS CoV, SARS CoV-2 into the human population.[1\u20133] Although case fatality ratios have varied, each has demonstrated the ability to induce substantial morbidity and mortality \u2013 especially among those over 55 and/or those with underlying co-morbid medical conditions.[4,5] Although SARS CoV and MERS CoV were largely contained by epidemiological interventions, the current outbreak has evolved into a global pandemic responsible for over 23 million infections and over 800,000 deaths.[6] With over 5.5 million cases and over 175,000 deaths at this writing, the US is now the center of the epidemic.", [["SARS", "DISEASE", 119, 123], ["infections", "DISEASE", 578, 588], ["deaths", "DISEASE", 606, 612], ["deaths", "DISEASE", 662, 668], ["beta-coronavirus strains", "ORGANISM", 94, 118], ["SARS CoV", "ORGANISM", 119, 127], ["MERS CoV", "ORGANISM", 129, 137], ["SARS CoV-2", "ORGANISM", 139, 149], ["human", "ORGANISM", 159, 164], ["SARS CoV", "ORGANISM", 411, 419], ["MERS CoV", "ORGANISM", 424, 432], ["human", "SPECIES", 159, 164], ["SARS CoV", "SPECIES", 119, 127], ["MERS CoV", "SPECIES", 129, 137], ["SARS CoV", "SPECIES", 139, 147], ["human", "SPECIES", 159, 164], ["SARS CoV", "SPECIES", 411, 419], ["MERS CoV", "SPECIES", 424, 432], ["spillover events", "PROBLEM", 36, 52], ["SARS CoV", "TEST", 139, 147], ["substantial morbidity", "PROBLEM", 269, 290], ["underlying co-morbid medical conditions", "PROBLEM", 356, 395], ["SARS CoV", "PROBLEM", 411, 419], ["MERS CoV", "PROBLEM", 424, 432], ["the US", "TEST", 686, 692], ["substantial", "OBSERVATION_MODIFIER", 269, 280], ["morbidity", "OBSERVATION", 281, 290], ["epidemic", "OBSERVATION", 718, 726]]], ["Intensive economically disruptive social distancing measures are blunting the epidemic but they are not sustainable and experience elsewhere demonstrates viral resurgence when they are prematurely eased.", [["blunting the epidemic", "PROBLEM", 65, 86], ["blunting", "OBSERVATION_MODIFIER", 65, 73], ["viral", "OBSERVATION", 154, 159]]], ["[7] Although intensive efforts to develop safe and effective SARS CoV-2 vaccines have been launched using a slew of novel approaches, the effort is challenged by strain diversity, the possibility that vaccine-induced immunity will be short lived, potentially reduced immune recognition by individuals as young as 30 and the possibility that antibody dependent enhancement will be observed.[8,9] Indeed, a recently reported molecularly proven case of reinfection raises substantial new concerns about long-lasting immunity \u2013 even after recovery from natural infection.", [["infection", "DISEASE", 557, 566], ["CoV-2", "ORGANISM", 66, 71], ["SARS CoV", "SPECIES", 61, 69], ["effective SARS CoV-2 vaccines", "TREATMENT", 51, 80], ["novel approaches", "TREATMENT", 116, 132], ["vaccine", "TREATMENT", 201, 208], ["antibody dependent enhancement", "PROBLEM", 341, 371], ["reinfection", "PROBLEM", 450, 461], ["natural infection", "PROBLEM", 549, 566], ["reinfection", "OBSERVATION", 450, 461], ["substantial", "OBSERVATION_MODIFIER", 469, 480], ["new", "OBSERVATION_MODIFIER", 481, 484], ["natural", "OBSERVATION_MODIFIER", 549, 556], ["infection", "OBSERVATION", 557, 566]]], ["[10] While there is hope that the SARS CoV-2 vaccine effort will succeed, after a third of a century the AIDS vaccine is, alas, still around the corner.", [["AIDS", "DISEASE", 105, 109], ["CoV-2", "ORGANISM", 39, 44], ["the SARS CoV-2 vaccine effort", "TREATMENT", 30, 59], ["a century the AIDS vaccine", "TREATMENT", 91, 117]]], ["Despite admonitions that we \u201ccould not treat our way out of the epidemic\u201d, a highly successful drug development effort changed the face of HIV by providing extremely effective, affordable and scalable prevention and treatment tools.", [["HIV", "ORGANISM", 139, 142], ["HIV", "SPECIES", 139, 142], ["HIV", "PROBLEM", 139, 142], ["scalable prevention", "TREATMENT", 192, 211], ["treatment tools", "TREATMENT", 216, 231]]], ["As the coronavirus vaccine effort ramps up, it is essential that we also mount an equally intense therapeutics effort.", [["coronavirus", "ORGANISM", 7, 18], ["coronavirus", "SPECIES", 7, 18], ["the coronavirus vaccine effort ramps", "TREATMENT", 3, 39], ["intense", "OBSERVATION_MODIFIER", 90, 97]]], ["Remdesivir nucleoside triphosphate (RVn triphosphate) potently inhibits enzymatic activity of the polymerase of every coronavirus tested thus far, including SARS CoV-2.", [["Remdesivir", "CHEMICAL", 0, 10], ["nucleoside triphosphate", "CHEMICAL", 11, 34], ["RVn triphosphate", "CHEMICAL", 36, 52], ["Remdesivir nucleoside triphosphate", "CHEMICAL", 0, 34], ["RVn triphosphate", "CHEMICAL", 36, 52], ["Remdesivir nucleoside triphosphate", "SIMPLE_CHEMICAL", 0, 34], ["RVn triphosphate", "SIMPLE_CHEMICAL", 36, 52], ["coronavirus", "ORGANISM", 118, 129], ["CoV-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["SARS CoV", "SPECIES", 157, 165], ["Remdesivir nucleoside triphosphate (RVn triphosphate)", "TREATMENT", 0, 53], ["the polymerase", "TEST", 94, 108], ["every coronavirus", "PROBLEM", 112, 129], ["SARS CoV", "TEST", 157, 165]]], ["[11\u201314] This broad activity reflects the relative molecular conservation of the coronavirus RNA dependent RNA polymerase (RdRp).", [["coronavirus", "ORGANISM", 80, 91], ["coronavirus RNA dependent RNA polymerase", "PROTEIN", 80, 120], ["RdRp", "PROTEIN", 122, 126], ["This broad activity", "PROBLEM", 8, 27], ["the coronavirus RNA dependent RNA polymerase", "PROBLEM", 76, 120], ["molecular conservation", "OBSERVATION", 50, 72], ["coronavirus RNA", "OBSERVATION", 80, 95]]], ["Remdesivir (RDV) is an aryloxy phosphoramidate triester prodrug that must be converted by a series of reactions to RVn triphosphate, the active antiviral metabolite.", [["Remdesivir", "CHEMICAL", 0, 10], ["RDV", "CHEMICAL", 12, 15], ["RVn triphosphate", "CHEMICAL", 115, 131], ["Remdesivir", "CHEMICAL", 0, 10], ["aryloxy phosphoramidate", "CHEMICAL", 23, 46], ["RVn triphosphate", "CHEMICAL", 115, 131], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["RDV", "SIMPLE_CHEMICAL", 12, 15], ["aryloxy phosphoramidate triester prodrug", "SIMPLE_CHEMICAL", 23, 63], ["RVn triphosphate", "SIMPLE_CHEMICAL", 115, 131], ["Remdesivir (RDV)", "TREATMENT", 0, 16], ["an aryloxy phosphoramidate triester prodrug", "TREATMENT", 20, 63], ["RVn triphosphate", "TREATMENT", 115, 131], ["the active antiviral metabolite", "TREATMENT", 133, 164], ["active", "OBSERVATION_MODIFIER", 137, 143], ["antiviral metabolite", "OBSERVATION", 144, 164]]], ["(Fig 1) Although RVn-triphosphate is an excellent inhibitor of the viral RdRp [15], RDV\u2019s antiviral activity is highly variable in different cell types which may be due to variable expression of the four enzymes required for conversion to RVn-P [14].", [["cell", "ANATOMY", 141, 145], ["RVn-triphosphate", "CHEMICAL", 17, 33], ["RVn-triphosphate", "CHEMICAL", 17, 33], ["RVn-P", "CHEMICAL", 239, 244], ["RVn-triphosphate", "SIMPLE_CHEMICAL", 17, 33], ["RDV", "GENE_OR_GENE_PRODUCT", 84, 87], ["cell", "CELL", 141, 145], ["RDV", "PROTEIN", 84, 87], ["enzymes", "PROTEIN", 204, 211], ["RVn", "TEST", 17, 20], ["triphosphate", "TREATMENT", 21, 33], ["the viral RdRp", "PROBLEM", 63, 77], ["RDV", "TREATMENT", 84, 87], ["antiviral activity", "PROBLEM", 90, 108], ["the four enzymes", "TEST", 195, 211], ["viral RdRp", "OBSERVATION", 67, 77], ["antiviral activity", "OBSERVATION", 90, 108], ["different cell types", "OBSERVATION", 131, 151]]], ["RDV\u2019s base is a 1\u2019-cyano-substituted adenine C nucleoside (GS-441524, RVn) that is thought to be poorly phosphorylated.", [["RDV", "CHEMICAL", 0, 3], ["1\u2019-cyano", "CHEMICAL", 16, 24], ["adenine", "CHEMICAL", 37, 44], ["nucleoside", "CHEMICAL", 47, 57], ["GS-441524", "CHEMICAL", 59, 68], ["RDV", "CHEMICAL", 0, 3], ["1\u2019-cyano-substituted adenine C nucleoside", "CHEMICAL", 16, 57], ["GS-441524", "CHEMICAL", 59, 68], ["RVn", "CHEMICAL", 70, 73], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["1\u2019-cyano-substituted adenine C nucleoside", "SIMPLE_CHEMICAL", 16, 57], ["GS-441524", "SIMPLE_CHEMICAL", 59, 68], ["RVn", "SIMPLE_CHEMICAL", 70, 73], ["RDV", "SPECIES", 0, 3], ["cyano", "TEST", 19, 24], ["adenine C nucleoside (GS", "TEST", 37, 61], ["poorly phosphorylated", "PROBLEM", 97, 118], ["base", "ANATOMY_MODIFIER", 6, 10], ["thought to be", "UNCERTAINTY", 83, 96]]], ["To bypass the perceived slow first phosphorylation the developers relied on an aryloxy phosphoramidate triester prodrug that is converted by a complex series of four reactions to remdesivir nucleoside monophosphate (RVn-P) that is then efficiently converted to RVn triphosphate, the active metabolite.", [["remdesivir nucleoside monophosphate", "CHEMICAL", 179, 214], ["RVn-P", "CHEMICAL", 216, 221], ["RVn triphosphate", "CHEMICAL", 261, 277], ["aryloxy phosphoramidate", "CHEMICAL", 79, 102], ["remdesivir nucleoside monophosphate", "CHEMICAL", 179, 214], ["RVn-P", "CHEMICAL", 216, 221], ["RVn triphosphate", "CHEMICAL", 261, 277], ["aryloxy phosphoramidate triester prodrug", "SIMPLE_CHEMICAL", 79, 119], ["remdesivir nucleoside monophosphate", "SIMPLE_CHEMICAL", 179, 214], ["RVn-P", "SIMPLE_CHEMICAL", 216, 221], ["RVn triphosphate", "SIMPLE_CHEMICAL", 261, 277], ["bypass", "TREATMENT", 3, 9], ["an aryloxy phosphoramidate triester prodrug", "TREATMENT", 76, 119], ["remdesivir nucleoside monophosphate", "TREATMENT", 179, 214], ["RVn triphosphate", "TREATMENT", 261, 277], ["bypass", "OBSERVATION", 3, 9], ["active metabolite", "OBSERVATION", 283, 300]]], ["RDV may be more active in some SARS-CoV-2 infected tissues than in others, a possible reason for its incomplete clinical impact on SARS-CoV-2.", [["tissues", "ANATOMY", 51, 58], ["RDV", "CHEMICAL", 0, 3], ["SARS-CoV-2 infected", "DISEASE", 31, 50], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["SARS-CoV-2", "ORGANISM", 31, 41], ["tissues", "TISSUE", 51, 58], ["SARS-CoV-2", "ORGANISM", 131, 141], ["RDV", "SPECIES", 0, 3], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 131, 139], ["some SARS", "PROBLEM", 26, 35], ["CoV-2 infected tissues", "PROBLEM", 36, 58], ["CoV", "TEST", 136, 139], ["may be", "UNCERTAINTY", 4, 10], ["more", "OBSERVATION_MODIFIER", 11, 15], ["active", "OBSERVATION_MODIFIER", 16, 22], ["infected tissues", "OBSERVATION_MODIFIER", 42, 58]]], ["A recent report suggests that low levels of the four enzymes which activate RDV in some tissues may be responsible.", [["tissues", "ANATOMY", 88, 95], ["RDV", "GENE_OR_GENE_PRODUCT", 76, 79], ["tissues", "TISSUE", 88, 95], ["enzymes", "PROTEIN", 53, 60], ["RDV", "PROTEIN", 76, 79], ["low levels", "PROBLEM", 30, 40], ["the four enzymes", "TEST", 44, 60], ["low levels", "OBSERVATION_MODIFIER", 30, 40]]], ["[14] Yan and Muller have recently published a detailed analysis of the potential weaknesses of Remdesivir and suggested that RVn (GS-441524) might be a preferable therapy [16].", [["Remdesivir", "CHEMICAL", 95, 105], ["RVn", "CHEMICAL", 125, 128], ["GS-441524", "CHEMICAL", 130, 139], ["Remdesivir", "CHEMICAL", 95, 105], ["RVn", "CHEMICAL", 125, 128], ["GS-441524", "CHEMICAL", 130, 139], ["Remdesivir", "SIMPLE_CHEMICAL", 95, 105], ["RVn", "SIMPLE_CHEMICAL", 125, 128], ["GS-441524", "SIMPLE_CHEMICAL", 130, 139], ["GS", "TEST", 130, 132]]], ["Remdesivir has beneficial antiviral and clinical effects in animal models of coronavirus infection.", [["Remdesivir", "CHEMICAL", 0, 10], ["coronavirus infection", "DISEASE", 77, 98], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["coronavirus", "ORGANISM", 77, 88], ["Remdesivir", "TREATMENT", 0, 10], ["beneficial antiviral", "TREATMENT", 15, 35], ["coronavirus infection", "PROBLEM", 77, 98], ["coronavirus", "OBSERVATION_MODIFIER", 77, 88], ["infection", "OBSERVATION", 89, 98]]], ["[17,18] These effects are primarily demonstrable when administered before or very soon after viral challenge.", [["viral challenge", "TREATMENT", 93, 108]]], ["RDV is not highly bioavailable following oral administration and must be administered intravenously, functionally limiting its clinical application to hospitalized patients with relatively advanced disease.", [["oral", "ANATOMY", 41, 45], ["intravenously", "ANATOMY", 86, 99], ["RDV", "CHEMICAL", 0, 3], ["RDV", "CHEMICAL", 0, 3], ["RDV", "SIMPLE_CHEMICAL", 0, 3], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["RDV", "SPECIES", 0, 3], ["oral administration", "TREATMENT", 41, 60], ["relatively advanced disease", "PROBLEM", 178, 205], ["not", "UNCERTAINTY", 7, 10], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["bioavailable", "OBSERVATION_MODIFIER", 18, 30], ["advanced", "OBSERVATION_MODIFIER", 189, 197], ["disease", "OBSERVATION", 198, 205]]], ["It would be useful to have a highly active, orally bioavailable analog of RVn which provides sustained levels of intact antiviral drug in plasma since RDV persistence in plasma is known to be very short, 20 to 30 minutes.", [["orally", "ANATOMY", 44, 50], ["plasma", "ANATOMY", 138, 144], ["plasma", "ANATOMY", 170, 176], ["RVn", "CHEMICAL", 74, 77], ["RDV", "CHEMICAL", 151, 154], ["RVn", "SIMPLE_CHEMICAL", 74, 77], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["RDV", "SIMPLE_CHEMICAL", 151, 154], ["plasma", "ORGANISM_SUBSTANCE", 170, 176], ["RDV", "SPECIES", 151, 154], ["a highly active, orally bioavailable analog of RVn", "PROBLEM", 27, 77], ["intact antiviral drug", "TREATMENT", 113, 134], ["antiviral drug", "OBSERVATION", 120, 134]]], ["[16]INTRODUCTIONHere we report the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in Vero E6 cells infected with SARS-CoV-2.", [["Vero E6 cells", "ANATOMY", 180, 193], ["RVn-monophosphate", "CHEMICAL", 108, 125], ["Remdesivir", "CHEMICAL", 166, 176], ["RVn-monophosphate", "CHEMICAL", 108, 125], ["Remdesivir", "CHEMICAL", 166, 176], ["RVn-monophosphate", "SIMPLE_CHEMICAL", 108, 125], ["Remdesivir", "SIMPLE_CHEMICAL", 166, 176], ["Vero E6 cells", "CELL", 180, 193], ["SARS-CoV-2", "ORGANISM", 208, 218], ["Vero E6 cells", "CELL_LINE", 180, 193], ["Vero E6", "SPECIES", 180, 187], ["SARS-CoV", "SPECIES", 208, 216], ["the synthesis", "TREATMENT", 31, 44], ["antiviral evaluation", "TEST", 49, 69], ["three novel lipophilic prodrugs of RVn", "TREATMENT", 73, 111], ["monophosphate", "TREATMENT", 112, 125], ["Remdesivir", "TREATMENT", 166, 176], ["Vero E6 cells", "TREATMENT", 180, 193], ["CoV", "TEST", 213, 216]]], ["These compounds are expected to be orally bioavailable based on our prior work with antivirals of this general design.", [["antivirals", "TREATMENT", 84, 94]]], ["[19, 20] If further developed, this type of prodrug could allow earlier and more effective treatment at the time of diagnosis of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 129, 149], ["SARS-CoV-2", "ORGANISM", 129, 139], ["SARS-CoV-2", "SPECIES", 129, 139], ["prodrug", "TREATMENT", 44, 51], ["SARS", "PROBLEM", 129, 133], ["CoV", "PROBLEM", 134, 137], ["2 infection", "PROBLEM", 138, 149], ["SARS", "OBSERVATION", 129, 133], ["infection", "OBSERVATION", 140, 149]]], ["In addition, one of these prodrugs represents an approach that may be able to target the antiviral to the lung and away from the liver, the site of Remdesivir\u2019s dose-limiting toxicity.", [["lung", "ANATOMY", 106, 110], ["liver", "ANATOMY", 129, 134], ["Remdesivir", "CHEMICAL", 148, 158], ["toxicity", "DISEASE", 175, 183], ["Remdesivir", "CHEMICAL", 148, 158], ["lung", "ORGAN", 106, 110], ["liver", "ORGAN", 129, 134], ["Remdesivir", "SIMPLE_CHEMICAL", 148, 158], ["these prodrugs", "TREATMENT", 20, 34], ["an approach", "TREATMENT", 46, 57], ["Remdesivir", "TREATMENT", 148, 158], ["limiting toxicity", "PROBLEM", 166, 183], ["antiviral", "OBSERVATION", 89, 98], ["lung", "ANATOMY", 106, 110], ["liver", "ANATOMY", 129, 134]]], ["[21,22]Synthesis of RVn monophosphate prodrugs: ::: RESULTSWe synthesized the hexadecyloxypropyl-, octadecyloxyethyl- and 1-O-octadecyl-2-O-benzyl-sn-glycerylesters of RVn monophosphate.", [["RVn monophosphate", "CHEMICAL", 20, 37], ["hexadecyloxypropyl-", "CHEMICAL", 78, 97], ["octadecyloxyethyl- and 1-O-octadecyl-2-O-benzyl-sn-glycerylesters", "CHEMICAL", 99, 164], ["RVn monophosphate", "CHEMICAL", 168, 185], ["RVn monophosphate", "CHEMICAL", 20, 37], ["hexadecyloxypropyl-", "CHEMICAL", 78, 97], ["octadecyloxyethyl- and 1-O-octadecyl-2-O-benzyl-sn-glycerylesters", "CHEMICAL", 99, 164], ["RVn monophosphate", "CHEMICAL", 168, 185], ["RVn monophosphate prodrugs", "SIMPLE_CHEMICAL", 20, 46], ["hexadecyloxypropyl-", "SIMPLE_CHEMICAL", 78, 97], ["octadecyloxyethyl- and 1-O-octadecyl-2-O-benzyl-sn-glycerylesters", "SIMPLE_CHEMICAL", 99, 164], ["RVn monophosphate", "SIMPLE_CHEMICAL", 168, 185], ["the hexadecyloxypropyl-", "TREATMENT", 74, 97], ["octadecyloxyethyl", "TEST", 99, 116], ["O-octadecyl", "TREATMENT", 124, 135], ["benzyl", "TREATMENT", 140, 146], ["RVn monophosphate", "TREATMENT", 168, 185]]], ["Analyses by NMR, ESI mass spec and HPLC were consistent with each structure and demonstrated purities of > 95%.Antiviral Activity: ::: RESULTSWe generated concentration-response curves for ODBG-P-RVn, ODE-P-RVn, and HDP-P-RVn, Remdesivir (RDV) and Remdesivir nucleoside (RVn) for SARS-CoV-2 infection in Vero E6 cells in two separate experiments performed in duplicate (Figure 3).Antiviral Activity: ::: RESULTSTable 1 shows the effective concentrations (EC50, EC90), 50% cytotoxic concentration (CC50), and selectivity index of the compounds, mean \u00b1 SD.", [["Vero E6 cells", "ANATOMY", 304, 317], ["ODE-P-RVn", "CHEMICAL", 201, 210], ["HDP-P-RVn", "CHEMICAL", 216, 225], ["Remdesivir", "CHEMICAL", 227, 237], ["RDV", "CHEMICAL", 239, 242], ["Remdesivir nucleoside", "CHEMICAL", 248, 269], ["RVn", "CHEMICAL", 271, 274], ["infection", "DISEASE", 291, 300], ["ODBG-P-RVn", "CHEMICAL", 189, 199], ["ODE-P-RVn", "CHEMICAL", 201, 210], ["Remdesivir", "CHEMICAL", 227, 237], ["RDV", "CHEMICAL", 239, 242], ["Remdesivir nucleoside", "CHEMICAL", 248, 269], ["RVn", "CHEMICAL", 271, 274], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 189, 199], ["ODE-P-RVn", "SIMPLE_CHEMICAL", 201, 210], ["HDP-P-RVn", "SIMPLE_CHEMICAL", 216, 225], ["Remdesivir", "SIMPLE_CHEMICAL", 227, 237], ["RDV", "SIMPLE_CHEMICAL", 239, 242], ["Remdesivir nucleoside", "SIMPLE_CHEMICAL", 248, 269], ["RVn", "SIMPLE_CHEMICAL", 271, 274], ["CoV-2", "ORGANISM", 285, 290], ["Vero E6 cells", "CELL", 304, 317], ["Vero E6 cells", "CELL_LINE", 304, 317], ["RDV", "SPECIES", 239, 242], ["SARS-CoV-2", "SPECIES", 280, 290], ["Vero E6", "SPECIES", 304, 311], ["NMR", "TEST", 12, 15], ["ESI mass spec", "TEST", 17, 30], ["HPLC", "TEST", 35, 39], ["purities", "TEST", 93, 101], ["response curves", "TEST", 169, 184], ["ODBG", "TEST", 189, 193], ["P", "TEST", 194, 195], ["RVn", "TEST", 196, 199], ["ODE", "TEST", 201, 204], ["RVn", "TEST", 207, 210], ["HDP", "TEST", 216, 219], ["RVn", "TREATMENT", 222, 225], ["Remdesivir (RDV)", "TREATMENT", 227, 243], ["Remdesivir nucleoside (RVn", "TREATMENT", 248, 274], ["SARS", "PROBLEM", 280, 284], ["CoV", "PROBLEM", 285, 288], ["2 infection", "PROBLEM", 289, 300], ["Vero E6 cells", "TREATMENT", 304, 317], ["EC50", "TEST", 455, 459], ["EC90", "TEST", 461, 465], ["cytotoxic concentration", "TEST", 472, 495], ["consistent with", "UNCERTAINTY", 45, 60], ["purities", "OBSERVATION_MODIFIER", 93, 101], ["selectivity index", "OBSERVATION", 508, 525], ["compounds", "OBSERVATION_MODIFIER", 533, 542]]], ["Cytotoxicity (CC50) was assessed using Cell Titer Glo (Supplementary Materials, Figure S1).", [["Cell", "ANATOMY", 39, 43], ["Cytotoxicity", "TEST", 0, 12], ["Cell Titer Glo (Supplementary Materials", "TREATMENT", 39, 78]]], ["The EC50 values of RDV and RVn were 4.6 and 1.7 \u03bcM, respectively.", [["RDV", "CHEMICAL", 19, 22], ["RVn", "CHEMICAL", 27, 30], ["RVn", "SIMPLE_CHEMICAL", 27, 30], ["The EC50 values", "TEST", 0, 15], ["RDV", "TEST", 19, 22], ["RVn", "TEST", 27, 30], ["EC50", "OBSERVATION_MODIFIER", 4, 8]]], ["The lipid prodrugs were more active with EC50s ranging from 0.19 \u00b1 0.023 to 0.96 \u00b1 0.17.", [["lipid prodrugs", "SIMPLE_CHEMICAL", 4, 18], ["The lipid prodrugs", "TREATMENT", 0, 18], ["EC50s", "TEST", 41, 46], ["lipid prodrugs", "OBSERVATION", 4, 18]]], ["ODBG-P-RVn and ODE-P-RVn were the most active and selective compounds.", [["ODBG-P-RVn", "CHEMICAL", 0, 10], ["ODE-P-RVn", "CHEMICAL", 15, 24], ["ODBG-P-RVn", "CHEMICAL", 0, 10], ["ODE-P-RVn", "CHEMICAL", 15, 24], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 0, 10], ["ODE-P-RVn", "SIMPLE_CHEMICAL", 15, 24], ["P", "DNA", 5, 6], ["P", "DNA", 19, 20], ["RVn", "DNA", 21, 24], ["ODBG", "TEST", 0, 4], ["RVn", "TEST", 7, 10], ["ODE", "TEST", 15, 18], ["RVn", "PROBLEM", 21, 24], ["selective", "OBSERVATION_MODIFIER", 50, 59], ["compounds", "OBSERVATION", 60, 69]]], ["Based on the EC50 values the most active compound, ODBG-P-RVn, was 24 times more active than RDV and 8.9 times more active than RVn (p <0.001 and 0.005) with a selectivity index of 240.DISCUSSIONRDV is a prodrug designed to bypass the first phosphorylation of the Remdesivir nucleoside (RVn) which may be rate limiting in the synthesis of RVn-triphosphate, the active metabolite.", [["ODBG-P-RVn", "CHEMICAL", 51, 61], ["Remdesivir nucleoside", "CHEMICAL", 264, 285], ["RVn", "CHEMICAL", 287, 290], ["RVn-triphosphate", "CHEMICAL", 339, 355], ["ODBG-P-RVn", "CHEMICAL", 51, 61], ["RDV", "CHEMICAL", 93, 96], ["Remdesivir nucleoside", "CHEMICAL", 264, 285], ["RVn", "CHEMICAL", 287, 290], ["RVn-triphosphate", "CHEMICAL", 339, 355], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 51, 61], ["RVn", "SIMPLE_CHEMICAL", 128, 131], ["Remdesivir nucleoside", "SIMPLE_CHEMICAL", 264, 285], ["RVn", "SIMPLE_CHEMICAL", 287, 290], ["RVn-triphosphate", "SIMPLE_CHEMICAL", 339, 355], ["the EC50 values", "TEST", 9, 24], ["ODBG", "TEST", 51, 55], ["P-RVn", "TEST", 56, 61], ["RDV", "TEST", 93, 96], ["a selectivity index", "TEST", 158, 177], ["bypass", "TREATMENT", 224, 230], ["the Remdesivir nucleoside", "TREATMENT", 260, 285], ["triphosphate", "TREATMENT", 343, 355], ["active", "OBSERVATION_MODIFIER", 34, 40], ["compound", "OBSERVATION_MODIFIER", 41, 49], ["active metabolite", "OBSERVATION", 361, 378]]], ["This occurs by the successive action of carboxyesterases, cathepsin A and phosphoramidases [16,23].", [["carboxyesterases", "GENE_OR_GENE_PRODUCT", 40, 56], ["cathepsin A", "GENE_OR_GENE_PRODUCT", 58, 69], ["phosphoramidases", "SIMPLE_CHEMICAL", 74, 90], ["carboxyesterases", "PROTEIN", 40, 56], ["cathepsin A", "PROTEIN", 58, 69], ["carboxyesterases", "TREATMENT", 40, 56], ["cathepsin A and phosphoramidases", "TREATMENT", 58, 90]]], ["However, this approach does not appear to provide any benefit in Vero E6 cells, a monkey kidney cell line, as shown by Pruijssers et al [24] and by our results showing the antiviral activity of RVn is greater than that of RDV.", [["Vero E6 cells", "ANATOMY", 65, 78], ["kidney cell line", "ANATOMY", 89, 105], ["RVn", "CHEMICAL", 194, 197], ["RDV", "CHEMICAL", 222, 225], ["Vero E6 cells", "CELL", 65, 78], ["monkey", "ORGANISM", 82, 88], ["kidney cell line", "CELL", 89, 105], ["RVn", "SIMPLE_CHEMICAL", 194, 197], ["RDV", "SIMPLE_CHEMICAL", 222, 225], ["Vero E6 cells", "CELL_LINE", 65, 78], ["monkey kidney cell line", "CELL_LINE", 82, 105], ["Vero E6", "SPECIES", 65, 72], ["RDV", "SPECIES", 222, 225], ["Vero E6 cells", "TREATMENT", 65, 78], ["a monkey kidney cell line", "TREATMENT", 80, 105], ["the antiviral activity of RVn", "PROBLEM", 168, 197], ["kidney", "ANATOMY", 89, 95], ["cell line", "OBSERVATION", 96, 105], ["antiviral activity", "OBSERVATION", 172, 190], ["greater", "OBSERVATION_MODIFIER", 201, 208]]], ["Other perceived disadvantages of RDV include a lack of oral bioavailability, a difficult synthesis, instability in plasma, inadequate delivery to lung and hepatotoxicity.", [["oral", "ANATOMY", 55, 59], ["plasma", "ANATOMY", 115, 121], ["lung", "ANATOMY", 146, 150], ["RDV", "CHEMICAL", 33, 36], ["hepatotoxicity", "DISEASE", 155, 169], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["lung", "ORGAN", 146, 150], ["RDV", "TREATMENT", 33, 36], ["oral bioavailability", "TREATMENT", 55, 75], ["a difficult synthesis", "PROBLEM", 77, 98], ["instability in plasma", "PROBLEM", 100, 121], ["hepatotoxicity", "PROBLEM", 155, 169], ["lung", "ANATOMY", 146, 150], ["hepatotoxicity", "OBSERVATION", 155, 169]]], ["[14,16] In patients with Covid-19 and in the Syrian hamster model of SARS-CoV-2 disease, in addition to high viral loads in nasal turbinate, trachea and lung, many other tissues are infected with SARS-CoV-2 as the infection proceeds including intestine, heart, liver, spleen, kidney, brain, lymph nodes and vascular endothelium.", [["nasal turbinate", "ANATOMY", 124, 139], ["trachea", "ANATOMY", 141, 148], ["lung", "ANATOMY", 153, 157], ["tissues", "ANATOMY", 170, 177], ["intestine", "ANATOMY", 243, 252], ["heart", "ANATOMY", 254, 259], ["liver", "ANATOMY", 261, 266], ["spleen", "ANATOMY", 268, 274], ["kidney", "ANATOMY", 276, 282], ["brain", "ANATOMY", 284, 289], ["lymph nodes", "ANATOMY", 291, 302], ["vascular endothelium", "ANATOMY", 307, 327], ["SARS-CoV-2 disease", "DISEASE", 69, 87], ["SARS", "DISEASE", 196, 200], ["infection", "DISEASE", 214, 223], ["patients", "ORGANISM", 11, 19], ["Syrian hamster", "ORGANISM", 45, 59], ["SARS-CoV-2", "ORGANISM", 69, 79], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 124, 139], ["trachea", "MULTI-TISSUE_STRUCTURE", 141, 148], ["lung", "ORGAN", 153, 157], ["tissues", "TISSUE", 170, 177], ["SARS-CoV-2", "ORGANISM", 196, 206], ["intestine", "ORGAN", 243, 252], ["heart", "ORGAN", 254, 259], ["liver", "ORGAN", 261, 266], ["spleen", "ORGAN", 268, 274], ["kidney", "ORGAN", 276, 282], ["brain", "ORGAN", 284, 289], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 291, 302], ["vascular endothelium", "TISSUE", 307, 327], ["patients", "SPECIES", 11, 19], ["hamster", "SPECIES", 52, 59], ["Syrian hamster", "SPECIES", 45, 59], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 196, 204], ["Covid", "TEST", 25, 30], ["SARS", "PROBLEM", 69, 73], ["CoV-2 disease", "PROBLEM", 74, 87], ["high viral loads in nasal turbinate, trachea and lung", "PROBLEM", 104, 157], ["many other tissues", "PROBLEM", 159, 177], ["SARS", "PROBLEM", 196, 200], ["CoV", "TEST", 201, 204], ["the infection proceeds including intestine, heart, liver, spleen, kidney, brain, lymph nodes", "PROBLEM", 210, 302], ["SARS", "OBSERVATION", 69, 73], ["high", "OBSERVATION_MODIFIER", 104, 108], ["viral loads", "OBSERVATION", 109, 120], ["nasal turbinate", "ANATOMY", 124, 139], ["trachea", "ANATOMY", 141, 148], ["lung", "ANATOMY", 153, 157], ["infected", "OBSERVATION", 182, 190], ["infection", "OBSERVATION", 214, 223], ["intestine", "ANATOMY", 243, 252], ["heart", "ANATOMY", 254, 259], ["liver", "ANATOMY", 261, 266], ["spleen", "ANATOMY", 268, 274], ["kidney", "ANATOMY", 276, 282], ["brain", "ANATOMY", 284, 289], ["lymph nodes", "OBSERVATION", 291, 302], ["vascular endothelium", "ANATOMY", 307, 327]]], ["[25\u201329] However, RDV antiviral activity appears to vary widely in lung and kidney cell lines with EC50 values of 1.65 \u03bcM in Vero E6 cells, 0.28 \u03bcM in Calu3 2B4, 0.010 \u03bcM in human alveolar epithelial cells (HAE), a 165-fold difference.", [["lung", "ANATOMY", 66, 70], ["kidney cell lines", "ANATOMY", 75, 92], ["Vero E6 cells", "ANATOMY", 124, 137], ["alveolar epithelial cells", "ANATOMY", 179, 204], ["HAE", "ANATOMY", 206, 209], ["HAE", "DISEASE", 206, 209], ["RDV", "SIMPLE_CHEMICAL", 17, 20], ["lung", "CELL", 66, 70], ["kidney cell lines", "CELL", 75, 92], ["Vero E6 cells", "CELL", 124, 137], ["Calu3 2B4", "GENE_OR_GENE_PRODUCT", 150, 159], ["human", "ORGANISM", 173, 178], ["alveolar epithelial cells", "CELL", 179, 204], ["HAE", "CELL", 206, 209], ["lung and kidney cell lines", "CELL_LINE", 66, 92], ["Vero E6 cells", "CELL_LINE", 124, 137], ["Calu3 2B4", "PROTEIN", 150, 159], ["human alveolar epithelial cells", "CELL_TYPE", 173, 204], ["human", "SPECIES", 173, 178], ["Vero E6", "SPECIES", 124, 131], ["human", "SPECIES", 173, 178], ["RDV antiviral activity", "PROBLEM", 17, 39], ["EC50 values", "TEST", 98, 109], ["Vero E6 cells", "TEST", 124, 137], ["M", "TEST", 145, 146], ["Calu3", "TEST", 150, 155], ["2B4", "TEST", 156, 159], ["human alveolar epithelial cells", "TEST", 173, 204], ["HAE", "TEST", 206, 209], ["a 165-fold difference", "PROBLEM", 212, 233], ["antiviral activity", "OBSERVATION", 21, 39], ["lung", "ANATOMY", 66, 70], ["kidney", "ANATOMY", 75, 81], ["cell lines", "OBSERVATION", 82, 92], ["alveolar", "ANATOMY_MODIFIER", 179, 187], ["epithelial cells", "ANATOMY", 188, 204]]], ["[24] It has been suggested that this may be due to variable amounts of the enzymes which convert RDV to RVn.", [["RDV", "CHEMICAL", 97, 100], ["RVn", "CHEMICAL", 104, 107], ["RDV", "SIMPLE_CHEMICAL", 97, 100], ["RVn", "GENE_OR_GENE_PRODUCT", 104, 107], ["enzymes", "PROTEIN", 75, 82], ["RDV", "PROTEIN", 97, 100], ["RVn", "PROTEIN", 104, 107], ["the enzymes", "TEST", 71, 82], ["RVn", "TREATMENT", 104, 107]]], ["[14,16] It will be important to evaluate the antiviral activity of RDV, RVn and these 3 novel lipid prodrugs of RVn in cells representing various tissues which are infected by SARS-CoV-2 and must be treated successfully if the infection is to be cleared.DISCUSSIONOf all the perceived disadvantages of RDV, we chose to design prodrugs of RVn which could provide oral bioavailability because an effective oral drug would allow for much earlier treatment of persons diagnosed with SARS-CoV-2 infection.", [["cells", "ANATOMY", 119, 124], ["tissues", "ANATOMY", 146, 153], ["oral", "ANATOMY", 362, 366], ["oral", "ANATOMY", 404, 408], ["RDV", "CHEMICAL", 67, 70], ["RVn", "CHEMICAL", 72, 75], ["RVn", "CHEMICAL", 112, 115], ["infection", "DISEASE", 227, 236], ["RDV", "CHEMICAL", 302, 305], ["RVn", "CHEMICAL", 338, 341], ["SARS-CoV-2 infection", "DISEASE", 479, 499], ["RDV", "CHEMICAL", 67, 70], ["RVn", "CHEMICAL", 72, 75], ["RDV", "CHEMICAL", 302, 305], ["RVn", "CHEMICAL", 338, 341], ["RDV", "SIMPLE_CHEMICAL", 67, 70], ["RVn", "SIMPLE_CHEMICAL", 72, 75], ["lipid prodrugs", "SIMPLE_CHEMICAL", 94, 108], ["RVn", "SIMPLE_CHEMICAL", 112, 115], ["cells", "CELL", 119, 124], ["tissues", "TISSUE", 146, 153], ["SARS-CoV-2", "ORGANISM", 176, 186], ["RDV", "SIMPLE_CHEMICAL", 302, 305], ["RVn", "SIMPLE_CHEMICAL", 338, 341], ["oral", "ORGANISM_SUBDIVISION", 362, 366], ["oral", "ORGANISM_SUBDIVISION", 404, 408], ["persons", "ORGANISM", 456, 463], ["SARS-CoV-2", "ORGANISM", 479, 489], ["persons", "SPECIES", 456, 463], ["RDV", "SPECIES", 67, 70], ["SARS-CoV", "SPECIES", 176, 184], ["RDV", "PROBLEM", 67, 70], ["RVn", "TREATMENT", 72, 75], ["these 3 novel lipid prodrugs", "TREATMENT", 80, 108], ["RVn in cells", "PROBLEM", 112, 124], ["various tissues", "PROBLEM", 138, 153], ["the infection", "PROBLEM", 223, 236], ["RDV", "TREATMENT", 302, 305], ["prodrugs of RVn", "TREATMENT", 326, 341], ["oral bioavailability", "TREATMENT", 362, 382], ["an effective oral drug", "TREATMENT", 391, 413], ["SARS", "PROBLEM", 479, 483], ["CoV-2 infection", "PROBLEM", 484, 499], ["various tissues", "OBSERVATION", 138, 153], ["infection", "OBSERVATION", 227, 236], ["infection", "OBSERVATION", 490, 499]]], ["As shown in this report, we accomplished this by constructing liponucleotides of RVn resembling lysophospholipids that are normally absorbed in the GI tract.", [["GI tract", "ANATOMY", 148, 156], ["lysophospholipids", "CHEMICAL", 96, 113], ["RVn", "SIMPLE_CHEMICAL", 81, 84], ["lysophospholipids", "SIMPLE_CHEMICAL", 96, 113], ["GI tract", "ORGANISM_SUBDIVISION", 148, 156], ["RVn", "TREATMENT", 81, 84], ["lysophospholipids", "TREATMENT", 96, 113], ["absorbed", "OBSERVATION_MODIFIER", 132, 140], ["GI tract", "ANATOMY", 148, 156]]], ["The RVn liponucleotides are not metabolized rapidly in plasma and gain rapid entry to the cell often exhibiting greatly increased antiviral activity.", [["plasma", "ANATOMY", 55, 61], ["cell", "ANATOMY", 90, 94], ["RVn", "CHEMICAL", 4, 7], ["RVn liponucleotides", "SIMPLE_CHEMICAL", 4, 23], ["plasma", "ORGANISM_SUBSTANCE", 55, 61], ["cell", "CELL", 90, 94], ["The RVn liponucleotides", "PROBLEM", 0, 23], ["greatly increased antiviral activity", "PROBLEM", 112, 148], ["not", "UNCERTAINTY", 28, 31], ["metabolized", "OBSERVATION_MODIFIER", 32, 43], ["rapidly", "OBSERVATION_MODIFIER", 44, 51], ["greatly", "OBSERVATION_MODIFIER", 112, 119], ["increased", "OBSERVATION_MODIFIER", 120, 129], ["antiviral activity", "OBSERVATION", 130, 148]]], ["In contrast to the activation of RDV which requires four transformations, intracellular kinase bypass with this kind of compound generates the nucleoside monophosphate when the lipid ester moiety is cleaved in a single reaction catalyzed by acid phospholipase C [32, 33] or acid sphingomyelinase (sphingomyelin phosphodiesterase I) (K. Sandhoff and K. Hostetler, unpublished, 2013).", [["intracellular", "ANATOMY", 74, 87], ["nucleoside monophosphate", "CHEMICAL", 143, 167], ["lipid ester", "CHEMICAL", 177, 188], ["acid phospholipase C [32, 33]", "CHEMICAL", 241, 270], ["sphingomyelin phosphodiesterase", "CHEMICAL", 297, 328], ["nucleoside monophosphate", "CHEMICAL", 143, 167], ["ester", "CHEMICAL", 183, 188], ["sphingomyelin", "CHEMICAL", 297, 310], ["RDV", "GENE_OR_GENE_PRODUCT", 33, 36], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 87], ["nucleoside monophosphate", "SIMPLE_CHEMICAL", 143, 167], ["lipid ester", "SIMPLE_CHEMICAL", 177, 188], ["acid phospholipase C [32, 33]", "SIMPLE_CHEMICAL", 241, 270], ["acid sphingomyelinase", "SIMPLE_CHEMICAL", 274, 295], ["sphingomyelin phosphodiesterase I", "GENE_OR_GENE_PRODUCT", 297, 330], ["RDV", "PROTEIN", 33, 36], ["intracellular kinase", "PROTEIN", 74, 94], ["acid sphingomyelinase", "PROTEIN", 274, 295], ["sphingomyelin phosphodiesterase I", "PROTEIN", 297, 330], ["four transformations", "TREATMENT", 52, 72], ["intracellular kinase bypass", "TREATMENT", 74, 101], ["the nucleoside monophosphate", "TREATMENT", 139, 167], ["the lipid ester moiety", "TREATMENT", 173, 195], ["a single reaction catalyzed", "TREATMENT", 210, 237], ["acid phospholipase C", "TEST", 241, 261], ["acid sphingomyelinase (sphingomyelin phosphodiesterase I", "TREATMENT", 274, 330]]], ["One of the compounds, ODBG-P-RVn, is likely to deliver relatively more drug to lung and less to liver as shown previously in lethal mousepox infection.", [["lung", "ANATOMY", 79, 83], ["liver", "ANATOMY", 96, 101], ["ODBG-P-RVn", "CHEMICAL", 22, 32], ["mousepox infection", "DISEASE", 132, 150], ["ODBG-P-RVn", "CHEMICAL", 22, 32], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 22, 32], ["lung", "ORGAN", 79, 83], ["liver", "ORGAN", 96, 101], ["the compounds", "TEST", 7, 20], ["ODBG", "TEST", 22, 26], ["lethal mousepox infection", "PROBLEM", 125, 150], ["compounds", "OBSERVATION_MODIFIER", 11, 20], ["lung", "ANATOMY", 79, 83], ["liver", "ANATOMY", 96, 101], ["lethal mousepox", "OBSERVATION_MODIFIER", 125, 140], ["infection", "OBSERVATION", 141, 150]]], ["[34,35] Finally, the synthesis of these lipid prodrugs is much simpler than RDV and is readily scalable.DISCUSSIONIn conclusion, we synthesized three lipid prodrugs of RVn that are substantially more active than RDV or RVn in Vero E6 cells.", [["Vero E6 cells", "ANATOMY", 226, 239], ["RVn", "CHEMICAL", 168, 171], ["RVn", "CHEMICAL", 168, 171], ["RDV", "CHEMICAL", 212, 215], ["lipid prodrugs", "SIMPLE_CHEMICAL", 40, 54], ["RVn", "SIMPLE_CHEMICAL", 168, 171], ["RDV", "SIMPLE_CHEMICAL", 212, 215], ["RVn", "SIMPLE_CHEMICAL", 219, 222], ["Vero E6 cells", "CELL", 226, 239], ["Vero E6 cells", "CELL_LINE", 226, 239], ["RDV", "SPECIES", 212, 215], ["Vero E6", "SPECIES", 226, 233], ["these lipid prodrugs", "TREATMENT", 34, 54], ["three lipid prodrugs of RVn", "TREATMENT", 144, 171], ["RDV", "PROBLEM", 212, 215], ["RVn in Vero E6 cells", "PROBLEM", 219, 239], ["Vero E6 cells", "OBSERVATION", 226, 239]]], ["The two most active compounds ODBG-P-RVn and ODE-P-RVn were 24 and 9.8 times more active than RDV.", [["ODBG-P-RVn", "CHEMICAL", 30, 40], ["ODE-P-RVn", "CHEMICAL", 45, 54], ["ODBG-P-RVn", "CHEMICAL", 30, 40], ["ODE-P-RVn", "CHEMICAL", 45, 54], ["RDV", "CHEMICAL", 94, 97], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 30, 40], ["ODE-P-RVn", "SIMPLE_CHEMICAL", 45, 54], ["RDV", "SIMPLE_CHEMICAL", 94, 97], ["RDV", "SPECIES", 94, 97], ["ODBG", "TEST", 30, 34], ["ODE", "TEST", 45, 48], ["two", "OBSERVATION_MODIFIER", 4, 7], ["most", "OBSERVATION_MODIFIER", 8, 12], ["active", "OBSERVATION_MODIFIER", 13, 19], ["compounds ODBG", "OBSERVATION", 20, 34]]], ["These compounds are expected to be orally bioavailable, stable in plasma and provide significant exposure and antiviral activity to all tissues infected with SARS-CoV-2.Chemistry: ::: MATERIALS AND METHODSAll reagents were of commercial quality and used without further purification unless indicated otherwise.", [["plasma", "ANATOMY", 66, 72], ["tissues", "ANATOMY", 136, 143], ["SARS", "DISEASE", 158, 162], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["tissues", "TISSUE", 136, 143], ["SARS-CoV-2", "ORGANISM", 158, 168], ["SARS-CoV", "SPECIES", 158, 166], ["significant exposure", "PROBLEM", 85, 105], ["antiviral activity", "TREATMENT", 110, 128], ["METHODSAll reagents", "TREATMENT", 198, 217], ["further purification", "TREATMENT", 262, 282], ["stable", "OBSERVATION_MODIFIER", 56, 62], ["antiviral activity", "OBSERVATION", 110, 128]]], ["Chromatographic purification was done using the flash method with silica gel 60 (EMD Chemicals, Inc., 230\u2013400 mesh).", [["silica gel", "CHEMICAL", 66, 76], ["silica gel", "CHEMICAL", 66, 76], ["Chromatographic purification", "TEST", 0, 28], ["the flash method with silica gel", "TREATMENT", 44, 76]]], ["1H, 13C and 31P nuclear magnetic resonance (NMR) spectra were recorded on either a Varian VX-500 or a Varian HG-400 spectrometer and are reported in units of ppm relative to internal tetramethylsilane at 0.00 ppm.", [["VX", "CHEMICAL", 90, 92], ["tetramethylsilane", "CHEMICAL", 183, 200], ["1H", "CHEMICAL", 0, 2], ["13C", "CHEMICAL", 4, 7], ["31P", "CHEMICAL", 12, 15], ["tetramethylsilane", "CHEMICAL", 183, 200], ["1H", "SIMPLE_CHEMICAL", 0, 2], ["13C", "SIMPLE_CHEMICAL", 4, 7], ["31P", "SIMPLE_CHEMICAL", 12, 15], ["tetramethylsilane", "SIMPLE_CHEMICAL", 183, 200], ["31P nuclear magnetic resonance", "TEST", 12, 42], ["a Varian VX", "TEST", 81, 92], ["a Varian HG", "TEST", 100, 111], ["ppm", "TREATMENT", 158, 161], ["internal tetramethylsilane", "TREATMENT", 174, 200]]], ["Electrospray ionization mass spectra (ESI-MS) were recorded on a Finnigan LCQDECA mass spectrometer at the small molecule facility in the Department of Chemistry at University of California, San Diego.", [["Electrospray ionization mass spectra", "PROBLEM", 0, 36], ["a Finnigan LCQDECA mass spectrometer", "TREATMENT", 63, 99], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["Purity of the target compounds was characterized by high performance liquid chromatography (HPLC) using a Beckman Coulter System Gold chromatography system.", [["a Beckman Coulter System", "TREATMENT", 104, 128]]], ["The analytical column was Phenomenex Synergi\u2122 Polar-RP (4.6 \u00d7 150 mm) equipped with a SecurityGuard\u2122 protection column.", [["The analytical column", "TEST", 0, 21], ["a SecurityGuard\u2122 protection column", "TREATMENT", 84, 118], ["column", "OBSERVATION_MODIFIER", 15, 21], ["RP", "OBSERVATION_MODIFIER", 52, 54]]], ["Mobile phase A was 95% water/5% methanol and mobile phase B was 95% methanol/5% water.", [["methanol", "CHEMICAL", 32, 40], ["methanol", "CHEMICAL", 32, 40], ["methanol", "CHEMICAL", 68, 76], ["methanol", "SIMPLE_CHEMICAL", 32, 40], ["methanol", "SIMPLE_CHEMICAL", 68, 76], ["water", "SIMPLE_CHEMICAL", 80, 85], ["mobile phase B", "TREATMENT", 45, 59], ["methanol", "TREATMENT", 68, 76]]], ["At a flow rate of 0.8 mL/min, gradient elution was as follows: 10% B (0\u20133 min.); 10\u201395% B (3\u201320 min.); 95% B (20\u201325 min.); 95% to 10% B (25\u201334 min.).", [["a flow rate", "TEST", 3, 14], ["gradient elution", "TEST", 30, 46]]], ["Purity of compounds was also assessed by thin layer chromatography (TLC) using Analtech silica gel-GF (250 \u03bcm) plates and the solvent system: CHCl3/MeOH/conc NH4OH/H2O (70:30:3:3 v/v).", [["Analtech silica", "CHEMICAL", 79, 94], ["CHCl3", "CHEMICAL", 142, 147], ["conc NH4OH", "CHEMICAL", 153, 163], ["H2O", "CHEMICAL", 164, 167], ["silica", "CHEMICAL", 88, 94], ["CHCl3", "CHEMICAL", 142, 147], ["MeOH", "CHEMICAL", 148, 152], ["NH4OH", "CHEMICAL", 158, 163], ["H2O", "CHEMICAL", 164, 167], ["CHCl3", "SIMPLE_CHEMICAL", 142, 147], ["MeOH", "SIMPLE_CHEMICAL", 148, 152], ["conc NH4OH/H2O", "SIMPLE_CHEMICAL", 153, 167], ["thin layer chromatography", "TEST", 41, 66], ["Analtech silica gel", "TREATMENT", 79, 98]]], ["TLC results were visualized with UV light, phospray (Supelco, Bellefonte, PA, USA) and charring at 400 \u00b0C.Synthesis of HDP-P-RVn: 5a.", [["HDP-P-RVn", "CHEMICAL", 119, 128], ["HDP-P-RVn", "CHEMICAL", 119, 128], ["HDP-P-RVn", "SIMPLE_CHEMICAL", 119, 128], ["P", "DNA", 123, 124], ["TLC results", "TEST", 0, 11], ["UV light", "TREATMENT", 33, 41], ["phospray", "TREATMENT", 43, 51], ["HDP", "TEST", 119, 122]]], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate. ::: Compounds: ::: MATERIALS AND METHODSN,N-Dicyclohexylcarbodiimide (DCC, 619 mg, 3 mmol) was added to a mixture of 2a (300 mg, 0.91 mmol, prepared as in Warren et al [36], HDP-phosphate (4a, 414 mg, 1.10 mmol, prepared as in Kim et al [37], and 4-dimethylaminopyridine (DMAP, 122 mg, 1.0 mmol) in 25 mL of dry pyridine, and then the mixture was heated to 90 \u00b0C and stirred for 24h.", [["2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 2, 108], ["3-(hexadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 110, 152], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 196, 222], ["DCC", "CHEMICAL", 224, 227], ["HDP-phosphate", "CHEMICAL", 328, 341], ["4-dimethylaminopyridine", "CHEMICAL", 401, 424], ["DMAP", "CHEMICAL", 426, 430], ["pyridine", "CHEMICAL", 466, 474], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 0, 152], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 196, 222], ["DCC", "CHEMICAL", 224, 227], ["HDP-phosphate", "CHEMICAL", 328, 341], ["4-dimethylaminopyridine", "CHEMICAL", 401, 424], ["DMAP", "CHEMICAL", 426, 430], ["pyridine", "CHEMICAL", 466, 474], ["(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "SIMPLE_CHEMICAL", 1, 152], ["N-Dicyclohexylcarbodiimide", "SIMPLE_CHEMICAL", 196, 222], ["DCC", "SIMPLE_CHEMICAL", 224, 227], ["HDP-phosphate", "SIMPLE_CHEMICAL", 328, 341], ["4-dimethylaminopyridine", "SIMPLE_CHEMICAL", 401, 424], ["DMAP", "SIMPLE_CHEMICAL", 426, 430], ["pyridine", "SIMPLE_CHEMICAL", 466, 474], ["aminopyrrolo", "TEST", 20, 32], ["triazin", "TEST", 46, 53], ["cyano", "TEST", 62, 67], ["dihydroxytetrahydrofuran-2", "TREATMENT", 72, 98], ["methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "TREATMENT", 102, 152], ["Dicyclohexylcarbodiimide (DCC", "TREATMENT", 198, 227], ["HDP-phosphate (4a", "TREATMENT", 328, 345], ["dimethylaminopyridine", "TREATMENT", 403, 424], ["DMAP", "TREATMENT", 426, 430], ["dry pyridine", "TREATMENT", 462, 474]]], ["Pyridine was then evaporated and the residue was purified by flash column chromatography on silica gel 60.", [["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "SIMPLE_CHEMICAL", 0, 8], ["Pyridine", "TREATMENT", 0, 8], ["the residue", "PROBLEM", 33, 44], ["flash column chromatography", "TEST", 61, 88], ["silica gel", "TREATMENT", 92, 102]]], ["Gradient elution (CH2Cl2/methanol 10\u201320%) afforded 423 mg (67% yield) of 2\u2019,3\u2019-isopropylidene derivative of 5a.", [["CH2Cl2/methanol 10\u2013", "CHEMICAL", 18, 37], ["2\u2019,3\u2019-isopropylidene", "CHEMICAL", 73, 93], ["CH2Cl2", "CHEMICAL", 18, 24], ["methanol", "CHEMICAL", 25, 33], ["2\u2019,3\u2019-isopropylidene", "CHEMICAL", 73, 93], ["2\u2019,3\u2019-isopropylidene derivative", "SIMPLE_CHEMICAL", 73, 104], ["Gradient elution (CH2Cl2/methanol", "TREATMENT", 0, 33]]], ["1H NMR (500 MHz, chloroform-d) \u03b4 8.42 (s, 1H), 7.98 (s, 1H), 7.70 (s, 2H), 6.22 (d, J = 6.0 Hz, 1H), 5.68 (d, J = 6.2 Hz, 1H), 5.15 (d, J = 1.0 Hz, 1H), 4.70 (dd, J = 3.8, 0.9 Hz, 1H), 4.48 \u2013 4.42 (m, 1H), 4.26 (ddd, J = 11.2, 8.5, 2.6 Hz, 1H), 4.15 (ddd, J = 11.1, 8.5, 2.6 Hz, 1H), 4.02 (dt, J = 8.5, 6.3 Hz, 2H), 3.49 (t, J = 6.1 Hz, 2H), 3.40 (t, J = 6.1 Hz, 2H), 1.95 (p, J = 6.2 Hz, 2H), 1.54 (tt, J = 7.4, 6.1 Hz, 2H), 1.31 (s, 3H), 1.32 \u2013 1.24 (m, 26H), 0.94 \u2013 0.85 (m, 3H).", [["1H", "CHEMICAL", 0, 2], ["chloroform", "CHEMICAL", 17, 27], ["1H", "CHEMICAL", 42, 44], ["1H", "CHEMICAL", 56, 58], ["2H", "CHEMICAL", 70, 72], ["1H", "CHEMICAL", 96, 98], ["1H", "CHEMICAL", 122, 124], ["1H", "CHEMICAL", 148, 150], ["1H", "CHEMICAL", 180, 182], ["1H", "CHEMICAL", 201, 203], ["1H", "CHEMICAL", 240, 242], ["1H", "CHEMICAL", 279, 281], ["1H", "SIMPLE_CHEMICAL", 0, 2], ["NMR", "TEST", 3, 6], ["chloroform", "TEST", 17, 27], ["d", "TEST", 81, 82], ["J", "TEST", 84, 85], ["Hz", "TEST", 92, 94], ["1H", "TEST", 96, 98], ["d", "TEST", 107, 108], ["J", "TEST", 110, 111], ["Hz", "TEST", 118, 120], ["1H", "TEST", 122, 124], ["d", "TEST", 133, 134], ["J", "TEST", 136, 137], ["Hz", "TEST", 144, 146], ["1H", "TEST", 148, 150], ["dd", "TEST", 159, 161], ["J", "TEST", 163, 164], ["Hz", "TEST", 176, 178], ["1H", "TEST", 180, 182], ["m", "TEST", 198, 199], ["1H", "TEST", 201, 203], ["ddd", "TEST", 212, 215], ["J", "TEST", 217, 218], ["Hz", "TEST", 236, 238], ["1H", "TEST", 240, 242], ["ddd", "TEST", 251, 254], ["J", "TEST", 256, 257], ["Hz", "TEST", 275, 277], ["1H", "TEST", 279, 281], ["dt", "TEST", 290, 292], ["J", "TEST", 294, 295], ["Hz", "TEST", 307, 309], ["2H", "TEST", 311, 313], ["t", "TEST", 322, 323], ["J", "TEST", 325, 326], ["Hz", "TEST", 333, 335], ["2H", "TEST", 337, 339], ["t", "TEST", 348, 349], ["J", "TEST", 351, 352], ["Hz", "TEST", 359, 361], ["2H", "TEST", 363, 365], ["J", "TEST", 377, 378], ["Hz", "TEST", 385, 387], ["2H", "TEST", 389, 391], ["tt", "TEST", 400, 402], ["J", "TEST", 404, 405], ["Hz", "TEST", 417, 419], ["2H", "TEST", 421, 423], ["s", "TEST", 432, 433], ["3H", "TEST", 435, 437], ["\u2013", "TEST", 445, 446]]], ["ESI MS 691.6 [M-H]\u2212.Synthesis of HDP-P-RVn: 5a.", [["HDP-P-RVn", "CHEMICAL", 33, 42], ["HDP-P-RVn", "CHEMICAL", 33, 42], ["HDP-P-RVn", "SIMPLE_CHEMICAL", 33, 42], ["P", "DNA", 37, 38], ["ESI MS", "TEST", 0, 6], ["HDP", "TEST", 33, 36]]], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate. ::: Compounds: ::: MATERIALS AND METHODSConcentrated HCl (0.1 mL) in tetrahydrofuran (THF) was added to a stirred solution of 2\u2019,3\u2019-isopropylidene-5a (100 mg, 0.14 mmol) in THF (10 mL) at room temperature.", [["2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 2, 108], ["3-(hexadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 110, 152], ["HCl", "CHEMICAL", 207, 210], ["tetrahydrofuran", "CHEMICAL", 223, 238], ["THF", "CHEMICAL", 240, 243], ["2\u2019,3\u2019-isopropylidene-5a", "CHEMICAL", 280, 303], ["THF", "CHEMICAL", 327, 330], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 0, 152], ["HCl", "CHEMICAL", 207, 210], ["tetrahydrofuran", "CHEMICAL", 223, 238], ["THF", "CHEMICAL", 240, 243], ["2\u2019,3\u2019-isopropylidene-5a", "CHEMICAL", 280, 303], ["THF", "CHEMICAL", 327, 330], ["(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "SIMPLE_CHEMICAL", 1, 152], ["HCl", "SIMPLE_CHEMICAL", 207, 210], ["tetrahydrofuran", "SIMPLE_CHEMICAL", 223, 238], ["THF", "SIMPLE_CHEMICAL", 240, 243], ["2\u2019,3\u2019-isopropylidene-5a", "SIMPLE_CHEMICAL", 280, 303], ["THF", "SIMPLE_CHEMICAL", 327, 330], ["aminopyrrolo", "TEST", 20, 32], ["triazin", "TEST", 46, 53], ["cyano", "TEST", 62, 67], ["dihydroxytetrahydrofuran-2", "TREATMENT", 72, 98], ["methyl (3-(hexadecyloxy)propyl) hydrogen phosphate", "TREATMENT", 102, 152], ["METHODSConcentrated HCl (0.1 mL) in tetrahydrofuran (THF)", "TREATMENT", 187, 244], ["a stirred solution", "TREATMENT", 258, 276], ["isopropylidene", "TREATMENT", 286, 300]]], ["The mixture was stirred for 3h and then sodium bicarbonate (50 mg) and water (2 mL) were added.", [["sodium bicarbonate", "CHEMICAL", 40, 58], ["sodium bicarbonate", "CHEMICAL", 40, 58], ["sodium", "SIMPLE_CHEMICAL", 40, 46], ["bicarbonate", "SIMPLE_CHEMICAL", 47, 58], ["water", "SIMPLE_CHEMICAL", 71, 76], ["The mixture", "TREATMENT", 0, 11], ["sodium bicarbonate", "TREATMENT", 40, 58]]], ["After stirring an additional 15 min. the solvents were evaporated and cold water (10 mL) was added to the residue.", [["the solvents", "TREATMENT", 37, 49], ["cold water", "TREATMENT", 70, 80]]], ["The solid product was collected by vacuum filtration and dried under vacuum to yield compound 5a (79 mg, 87% yield) as an off-white solid.", [["compound 5a", "CHEMICAL", 85, 96], ["vacuum filtration", "TREATMENT", 35, 52], ["solid", "OBSERVATION_MODIFIER", 4, 9], ["vacuum filtration", "OBSERVATION", 35, 52]]], ["1H NMR (500 MHz, CDCl3-methanol-d4) \u03b4 ppm 1H NMR (500 MHz, Chloroform-d) \u03b4 8.42 (s, 1H), 7.98 (s, 1H), 7.70 (s, 1H), 6.22 (d, J = 6.0 Hz, 1H), 5.70 (d, J = 6.0 Hz, 1H), 5.12 (d, J = 4.2 Hz, 1H), 4.55 (ddd, J = 5.5, 2.7, 0.9 Hz, 1H), 4.40 (dtd, J = 6.8, 2.6, 0.8 Hz, 1H), 4.33 \u2013 4.27 (m, 2H), 4.25 (ddd, J = 11.1, 8.4, 2.6 Hz, 1H), 4.16 (ddd, J = 11.3, 8.5, 2.6 Hz, 1H), 4.02 (dt, J = 8.5, 6.3 Hz, 2H), 3.49 (t, J = 6.1 Hz, 2H), 3.40 (t, J = 6.1 Hz, 2H), 1.95 (p, J = 6.2 Hz, 2H), 1.59 \u2013 1.50 (m, 1H), 1.34 \u2013 1.24 (m, 23H), 0.94 \u2013 0.85 (m, 3H).", [["1H", "CHEMICAL", 0, 2], ["CDCl3", "CHEMICAL", 17, 22], ["methanol", "CHEMICAL", 23, 31], ["1H", "CHEMICAL", 42, 44], ["Chloroform", "CHEMICAL", 59, 69], ["1H", "CHEMICAL", 84, 86], ["1H", "CHEMICAL", 98, 100], ["1H", "CHEMICAL", 112, 114], ["1H", "CHEMICAL", 138, 140], ["1H", "CHEMICAL", 164, 166], ["1H", "CHEMICAL", 190, 192], ["1H", "CHEMICAL", 228, 230], ["1H", "CHEMICAL", 266, 268], ["1H", "CHEMICAL", 326, 328], ["1H", "CHEMICAL", 365, 367], ["1H", "CHEMICAL", 496, 498], ["1H", "SIMPLE_CHEMICAL", 0, 2], ["NMR", "TEST", 3, 6], ["MHz", "TEST", 12, 15], ["CDCl3", "TEST", 17, 22], ["J", "TEST", 126, 127], ["Hz", "TEST", 134, 136], ["1H", "TEST", 138, 140], ["d", "TEST", 149, 150], ["J", "TEST", 152, 153], ["Hz", "TEST", 160, 162], ["1H", "TEST", 164, 166], ["d", "TEST", 175, 176], ["J", "TEST", 178, 179], ["Hz", "TEST", 186, 188], ["1H", "TEST", 190, 192], ["ddd", "TEST", 201, 204], ["J", "TEST", 206, 207], ["Hz", "TEST", 224, 226], ["1H", "TEST", 228, 230], ["dtd", "TEST", 239, 242], ["J", "TEST", 244, 245], ["Hz", "TEST", 262, 264], ["1H", "TEST", 266, 268], ["\u2013", "TEST", 276, 277], ["m", "TEST", 284, 285], ["2H", "TEST", 287, 289], ["ddd", "TEST", 298, 301], ["J", "TEST", 303, 304], ["Hz", "TEST", 322, 324], ["1H", "TEST", 326, 328], ["ddd", "TEST", 337, 340], ["J", "TEST", 342, 343], ["Hz", "TEST", 361, 363], ["1H", "TEST", 365, 367], ["dt", "TEST", 376, 378], ["J", "TEST", 380, 381], ["Hz", "TEST", 393, 395], ["2H", "TEST", 397, 399], ["t", "TEST", 408, 409], ["J", "TEST", 411, 412], ["Hz", "TEST", 419, 421], ["2H", "TEST", 423, 425], ["t", "TEST", 434, 435], ["J", "TEST", 437, 438], ["Hz", "TEST", 445, 447], ["2H", "TEST", 449, 451], ["J", "TEST", 463, 464], ["Hz", "TEST", 471, 473], ["2H", "TEST", 475, 477], ["\u2013", "TEST", 485, 486], ["1H", "TEST", 496, 498], ["\u2013", "TEST", 506, 507]]], ["Purity by HPLC: 99.7%Synthesis of ODE-P-RVn, 5b.", [["ODE-P-RVn", "CHEMICAL", 34, 43], ["ODE-P-RVn", "SIMPLE_CHEMICAL", 34, 43], ["Purity", "TEST", 0, 6], ["HPLC", "TEST", 10, 14], ["Synthesis", "TEST", 21, 30], ["ODE", "TEST", 34, 37]]], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (2-(octadecyloxy)ethyl) hydrogen phosphate ::: Compounds: ::: MATERIALS AND METHODSN,N-Dicyclohexylcarbodiimide (DCC, 0.3 g, 1.4 mmol) was added to a mixture of 2a (0.23 g, 0.7 mmol), ODE-phosphate (4b, 0.27 g, 0.68 mmol), and 4-dimethylaminopyridine (DMAP, 0.07 g, 0.6 mmol) in 10 mL of dry pyridine, and then the mixture was heated to 90 \u00b0C and stirred for 3 days.", [["2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 2, 108], ["2-(octadecyloxy)ethyl) hydrogen phosphate", "CHEMICAL", 110, 151], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 194, 220], ["DCC", "CHEMICAL", 222, 225], ["ODE-phosphate", "CHEMICAL", 293, 306], ["4-dimethylaminopyridine", "CHEMICAL", 336, 359], ["DMAP", "CHEMICAL", 361, 365], ["pyridine", "CHEMICAL", 401, 409], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 0, 108], ["2-(octadecyloxy)ethyl) hydrogen phosphate", "CHEMICAL", 110, 151], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 194, 220], ["DCC", "CHEMICAL", 222, 225], ["ODE-phosphate", "CHEMICAL", 293, 306], ["4-dimethylaminopyridine", "CHEMICAL", 336, 359], ["DMAP", "CHEMICAL", 361, 365], ["pyridine", "CHEMICAL", 401, 409], ["(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl (2-(octadecyloxy)ethyl) hydrogen phosphate ::", "SIMPLE_CHEMICAL", 1, 154], ["N-Dicyclohexylcarbodiimide", "SIMPLE_CHEMICAL", 194, 220], ["DCC", "SIMPLE_CHEMICAL", 222, 225], ["ODE-phosphate", "SIMPLE_CHEMICAL", 293, 306], ["4-dimethylaminopyridine", "SIMPLE_CHEMICAL", 336, 359], ["DMAP", "SIMPLE_CHEMICAL", 361, 365], ["pyridine", "SIMPLE_CHEMICAL", 401, 409], ["aminopyrrolo", "TEST", 20, 32], ["triazin", "TEST", 46, 53], ["cyano", "TEST", 62, 67], ["dihydroxytetrahydrofuran-2", "TREATMENT", 72, 98], ["methyl (2-(octadecyloxy)ethyl) hydrogen phosphate", "TREATMENT", 102, 151], ["Dicyclohexylcarbodiimide (DCC", "TREATMENT", 196, 225], ["ODE-phosphate", "TREATMENT", 293, 306], ["dimethylaminopyridine (DMAP", "TREATMENT", 338, 365], ["dry pyridine", "TREATMENT", 397, 409]]], ["Pyridine was then evaporated and the residue was purified by flash column chromatography on silica gel 60.", [["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "SIMPLE_CHEMICAL", 0, 8], ["Pyridine", "TREATMENT", 0, 8], ["the residue", "PROBLEM", 33, 44], ["flash column chromatography", "TEST", 61, 88], ["silica gel", "TREATMENT", 92, 102]]], ["Gradient elution (CH2Cl2/methanol 10\u201320%) afforded 0.22 g (45% yield) of 2\u2019,3\u2019-isopropylidene-5b.", [["CH2Cl2/methanol 10\u2013", "CHEMICAL", 18, 37], ["2\u2019,3\u2019-isopropylidene-5b", "CHEMICAL", 73, 96], ["CH2Cl2", "CHEMICAL", 18, 24], ["methanol", "CHEMICAL", 25, 33], ["2\u2019,3\u2019-isopropylidene-5b", "CHEMICAL", 73, 96], ["2\u2019,3\u2019-isopropylidene-5b", "SIMPLE_CHEMICAL", 73, 96], ["Gradient elution (CH2Cl2/methanol", "TREATMENT", 0, 33], ["isopropylidene", "TREATMENT", 79, 93]]], ["Concentrated HCl (0.3 mL) was added slowly to a stirred solution of 2\u2019,3\u2019-isopropylidene-5b (0.2 g, 0.28 mmol) in tetrahydrofuran (2 mL) at 0 \u00b0C. The mixture was allowed to warm to room temperature overnight and then was diluted with water (2 mL) and adjusted to pH = 8 by adding saturated sodium bicarbonate.", [["HCl", "CHEMICAL", 13, 16], ["2\u2019,3\u2019-isopropylidene-5b", "CHEMICAL", 68, 91], ["tetrahydrofuran", "CHEMICAL", 114, 129], ["sodium bicarbonate", "CHEMICAL", 290, 308], ["HCl", "CHEMICAL", 13, 16], ["2\u2019,3\u2019-isopropylidene-5b", "CHEMICAL", 68, 91], ["tetrahydrofuran", "CHEMICAL", 114, 129], ["sodium bicarbonate", "CHEMICAL", 290, 308], ["HCl", "SIMPLE_CHEMICAL", 13, 16], ["2\u2019,3\u2019-isopropylidene-5b", "SIMPLE_CHEMICAL", 68, 91], ["tetrahydrofuran", "SIMPLE_CHEMICAL", 114, 129], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 290, 308], ["Concentrated HCl", "TREATMENT", 0, 16], ["a stirred solution", "TREATMENT", 46, 64], ["isopropylidene", "TREATMENT", 74, 88], ["tetrahydrofuran", "TREATMENT", 114, 129], ["pH", "TEST", 263, 265], ["saturated sodium bicarbonate", "TREATMENT", 280, 308]]], ["The product was extracted with chloroform (3 \u00d7 30 mL) and the organic layer was concentrated under reduced pressure.", [["chloroform", "CHEMICAL", 31, 41], ["chloroform", "CHEMICAL", 31, 41], ["chloroform", "SIMPLE_CHEMICAL", 31, 41], ["chloroform", "TREATMENT", 31, 41], ["the organic layer", "TREATMENT", 58, 75], ["reduced pressure", "OBSERVATION", 99, 115]]], ["The residue was purified by flash chromatography on silica gel.", [["silica gel", "CHEMICAL", 52, 62], ["silica gel", "CHEMICAL", 52, 62], ["silica", "SIMPLE_CHEMICAL", 52, 58], ["The residue", "PROBLEM", 0, 11], ["flash chromatography", "PROBLEM", 28, 48], ["silica gel", "TREATMENT", 52, 62]]], ["Elution with 20% MeOH/CH2Cl2 gave 0.10 g (55% yield) of compound 5b.", [["MeOH", "CHEMICAL", 17, 21], ["CH2Cl2", "CHEMICAL", 22, 28], ["MeOH", "CHEMICAL", 17, 21], ["CH2Cl2", "CHEMICAL", 22, 28], ["CH2Cl2", "SIMPLE_CHEMICAL", 22, 28], ["20% MeOH/CH2Cl2", "TREATMENT", 13, 28], ["compound 5b", "PROBLEM", 56, 67]]], ["1H NMR (400 MHz, CDCl3-methanol-d4) \u03b4 ppm 7.89 (s, 1 H), 6.94 (d, J=4.65 Hz, 1H), 6.89 (d, J=4.65 Hz, 1H), 4.40 (d, J=4.65 Hz, 2H), 4.21 \u2013 4.28 (m, 1H), 4.12 \u2013 4.20 (m, 1H), 4.04 \u2013 4.12 (m, 1H), 3.91 (d, J=4.89 Hz, 2H), 3.46 \u2013 3.57 (m, 2H), 3.42 (td, J=6.85, 1.96 Hz, 2H), 3.34 (dt, J=3.18, 1.59 Hz, 2H), 1.53 (d, J=6.85 Hz, 2H), 1.20 \u2013 1.37 (m, 30H), 0.89 (t, J=6.97 Hz, 3H).", [["1H", "CHEMICAL", 0, 2], ["CDCl3", "CHEMICAL", 17, 22], ["methanol", "CHEMICAL", 23, 31], ["1H", "CHEMICAL", 77, 79], ["1H", "CHEMICAL", 102, 104], ["2H", "CHEMICAL", 127, 129], ["1H", "CHEMICAL", 148, 150], ["1H", "CHEMICAL", 169, 171], ["1H", "CHEMICAL", 190, 192], ["2H", "CHEMICAL", 215, 217], ["1H", "SIMPLE_CHEMICAL", 0, 2], ["NMR", "TEST", 3, 6], ["MHz", "TEST", 12, 15], ["CDCl3", "TEST", 17, 22], ["ppm", "TEST", 38, 41], ["J", "TEST", 66, 67], ["Hz", "TEST", 73, 75], ["1H", "TEST", 77, 79], ["J", "TEST", 91, 92], ["Hz", "TEST", 98, 100], ["1H", "TEST", 102, 104], ["d", "TEST", 113, 114], ["J", "TEST", 116, 117], ["Hz", "TEST", 123, 125], ["2H", "TEST", 127, 129], ["\u2013", "TEST", 137, 138], ["m", "TEST", 145, 146], ["1H", "TEST", 148, 150], ["\u2013", "TEST", 158, 159], ["m", "TEST", 166, 167], ["1H", "TEST", 169, 171], ["m", "TEST", 187, 188], ["1H", "TEST", 190, 192], ["d", "TEST", 201, 202], ["J", "TEST", 204, 205], ["Hz", "TEST", 211, 213], ["2H", "TEST", 215, 217], ["\u2013", "TEST", 225, 226], ["m", "TEST", 233, 234], ["2H", "TEST", 236, 238], ["td", "TEST", 247, 249], ["J", "TEST", 251, 252], ["Hz", "TEST", 264, 266], ["2H", "TEST", 268, 270], ["dt", "TEST", 279, 281], ["J", "TEST", 283, 284], ["Hz", "TEST", 296, 298], ["2H", "TEST", 300, 302], ["d", "TEST", 311, 312], ["J", "TEST", 314, 315], ["Hz", "TEST", 321, 323], ["2H", "TEST", 325, 327], ["\u2013", "TEST", 335, 336], ["m", "TEST", 343, 344], ["30H", "TEST", 346, 349], ["t", "TEST", 358, 359], ["J", "TEST", 361, 362], ["Hz", "TEST", 368, 370], ["3H", "TEST", 372, 374]]], ["Purity by HPLC 98.4%.Synthesis of ODBG-P-RVn, 5c.", [["ODBG-P-RVn", "CHEMICAL", 34, 44], ["ODBG-P-RVn", "CHEMICAL", 34, 44], ["ODBG-P-RVn", "SIMPLE_CHEMICAL", 34, 44], ["P", "DNA", 39, 40], ["Purity", "TEST", 0, 6], ["HPLC", "TEST", 10, 14], ["ODBG", "TEST", 34, 38]]], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ((R)-2-(benzyloxy)-3-(octadecyloxy)propyl) hydrogen phosphate. ::: Compounds: ::: MATERIALS AND METHODSN,N-Dicyclohexylcarbodiimide (DCC, 310 mg, 1.5 mmol) was added to a mixture of 2a (300 mg, 0.91 mmol), ODBG-phosphate (4c, 515 mg, 1.0 mmol), and 4-dimethylaminopyridine (DMAP, 122 mg, 1.0 mmol) in 25 mL of dry pyridine, and then the mixture was heated to 90 \u00b0C and stirred for 24h.", [["2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 2, 108], ["(R)-2-(benzyloxy)-3-(octadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 110, 170], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 214, 240], ["DCC", "CHEMICAL", 242, 245], ["ODBG-phosphate", "CHEMICAL", 315, 329], ["4-dimethylaminopyridine", "CHEMICAL", 358, 381], ["DMAP", "CHEMICAL", 383, 387], ["pyridine", "CHEMICAL", 423, 431], ["((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl", "CHEMICAL", 0, 108], ["(R)-2-(benzyloxy)-3-(octadecyloxy)propyl) hydrogen phosphate", "CHEMICAL", 110, 170], ["N-Dicyclohexylcarbodiimide", "CHEMICAL", 214, 240], ["DCC", "CHEMICAL", 242, 245], ["ODBG-phosphate", "CHEMICAL", 315, 329], ["4-dimethylaminopyridine", "CHEMICAL", 358, 381], ["DMAP", "CHEMICAL", 383, 387], ["pyridine", "CHEMICAL", 423, 431], ["(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl ((R)-2-(benzyloxy)-3-(octadecyloxy)propyl) hydrogen phosphate", "SIMPLE_CHEMICAL", 1, 170], ["N-Dicyclohexylcarbodiimide", "SIMPLE_CHEMICAL", 214, 240], ["DCC", "SIMPLE_CHEMICAL", 242, 245], ["ODBG-phosphate", "SIMPLE_CHEMICAL", 315, 329], ["4-dimethylaminopyridine", "SIMPLE_CHEMICAL", 358, 381], ["DMAP", "SIMPLE_CHEMICAL", 383, 387], ["pyridine", "SIMPLE_CHEMICAL", 423, 431], ["aminopyrrolo", "TEST", 20, 32], ["triazin", "TEST", 46, 53], ["cyano", "TEST", 62, 67], ["dihydroxytetrahydrofuran-2", "TREATMENT", 72, 98], ["methyl", "TEST", 102, 108], ["benzyloxy", "TREATMENT", 117, 126], ["octadecyloxy)propyl) hydrogen phosphate", "TREATMENT", 131, 170], ["Dicyclohexylcarbodiimide (DCC", "TREATMENT", 216, 245], ["ODBG-phosphate", "TREATMENT", 315, 329], ["dimethylaminopyridine", "TREATMENT", 360, 381], ["DMAP", "TREATMENT", 383, 387], ["dry pyridine", "TREATMENT", 419, 431]]], ["Pyridine was then evaporated and the residue was purified by flash column chromatography on silica gel 60.", [["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "CHEMICAL", 0, 8], ["silica gel", "CHEMICAL", 92, 102], ["Pyridine", "SIMPLE_CHEMICAL", 0, 8], ["Pyridine", "TREATMENT", 0, 8], ["the residue", "PROBLEM", 33, 44], ["flash column chromatography", "TEST", 61, 88], ["silica gel", "TREATMENT", 92, 102]]], ["Gradient elution (CH2Cl2/methanol 10\u201320%) afforded 210 mg (28% yield) of compound 2\u2019,3\u2019-isopropylidene-5c.", [["CH2Cl2/methanol 10\u2013", "CHEMICAL", 18, 37], ["compound 2\u2019,3\u2019-isopropylidene-5c", "CHEMICAL", 73, 105], ["CH2Cl2", "CHEMICAL", 18, 24], ["methanol", "CHEMICAL", 25, 33], ["2\u2019,3\u2019-isopropylidene-5c", "CHEMICAL", 82, 105], ["compound 2\u2019,3\u2019-isopropylidene-5c", "SIMPLE_CHEMICAL", 73, 105], ["Gradient elution (CH2Cl2/methanol", "TREATMENT", 0, 33], ["isopropylidene", "TREATMENT", 88, 102]]], ["ESI MS 826.58 [M-H]\u2212.", [["ESI MS", "TEST", 0, 6]]], ["Concentrated HCl (0.1 mL) in tetrahydrofuran (THF) was added to a stirred solution of 2\u2019,3\u2019-isopropylidene-5c (210 mg, 0.25 mmol) in THF(10 mL) at room temperature.", [["HCl", "CHEMICAL", 13, 16], ["tetrahydrofuran", "CHEMICAL", 29, 44], ["THF", "CHEMICAL", 46, 49], ["2\u2019,3\u2019-isopropylidene-5c", "CHEMICAL", 86, 109], ["THF", "CHEMICAL", 133, 136], ["HCl", "CHEMICAL", 13, 16], ["tetrahydrofuran", "CHEMICAL", 29, 44], ["THF", "CHEMICAL", 46, 49], ["2\u2019,3\u2019-isopropylidene-5c", "CHEMICAL", 86, 109], ["THF", "CHEMICAL", 133, 136], ["HCl", "SIMPLE_CHEMICAL", 13, 16], ["tetrahydrofuran", "SIMPLE_CHEMICAL", 29, 44], ["THF", "SIMPLE_CHEMICAL", 46, 49], ["2\u2019,3\u2019-isopropylidene-5c", "SIMPLE_CHEMICAL", 86, 109], ["THF", "SIMPLE_CHEMICAL", 133, 136], ["Concentrated HCl", "TREATMENT", 0, 16], ["tetrahydrofuran (THF)", "TREATMENT", 29, 50], ["a stirred solution", "TREATMENT", 64, 82], ["isopropylidene", "TREATMENT", 92, 106]]], ["The mixture was stirred for 3h and then sodium bicarbonate (50 mg) and water (2 mL) were added.", [["sodium bicarbonate", "CHEMICAL", 40, 58], ["sodium bicarbonate", "CHEMICAL", 40, 58], ["sodium", "SIMPLE_CHEMICAL", 40, 46], ["bicarbonate", "SIMPLE_CHEMICAL", 47, 58], ["water", "SIMPLE_CHEMICAL", 71, 76], ["The mixture", "TREATMENT", 0, 11], ["sodium bicarbonate", "TREATMENT", 40, 58]]], ["After stirring an additional 15 min. the solvents were evaporated and cold water (10 mL) was added to the residue.", [["the solvents", "TREATMENT", 37, 49], ["cold water", "TREATMENT", 70, 80]]], ["The solid product was collected by vacuum filtration and dried under vacuum to yield compound 5c (71 mg, 36% yield) as an off-white solid.", [["compound 5c", "CHEMICAL", 85, 96], ["vacuum filtration", "TREATMENT", 35, 52], ["solid", "OBSERVATION_MODIFIER", 4, 9], ["vacuum filtration", "OBSERVATION", 35, 52]]], ["1H NMR (400 MHz, CDCl3-methanol-d4) \u03b4 ppm 7.70 (s, 1H), 7.36 \u2013 7.32 (m, 1H), 7.36 \u2013 7.26 (m, 1H), 6.22 (d, J = 6.0 Hz, 1H), 5.70 (d, J = 6.0 Hz, 1H), 5.12 (d, J = 4.2 Hz, 1H), 4.60 \u2013 4.51 (m, 2H), 4.40 (dtd, J = 6.8, 2.6, 0.8 Hz, 1H), 4.33 \u2013 4.27 (m, 1H), 4.25 (ddd, J = 11.0, 8.4, 2.6 Hz, 1H), 4.20 \u2013 4.02 (m, 2H), 3.94 (p, J = 4.5 Hz, 1H), 3.59 (d, J = 4.4 Hz, 1H), 3.46 (t, J = 6.4 Hz, 1H), 1.59 \u2013 1.50 (m, 1H), 1.34 \u2013 1.24 (m, 18H), 0.94 \u2013 0.85 (m, 2H).", [["1H", "CHEMICAL", 0, 2], ["CDCl3", "CHEMICAL", 17, 22], ["methanol", "CHEMICAL", 23, 31], ["1H", "CHEMICAL", 51, 53], ["1H", "CHEMICAL", 72, 74], ["1H", "CHEMICAL", 93, 95], ["1H", "CHEMICAL", 119, 121], ["1H", "CHEMICAL", 145, 147], ["1H", "CHEMICAL", 171, 173], ["1H", "CHEMICAL", 230, 232], ["1H", "CHEMICAL", 251, 253], ["1H", "CHEMICAL", 290, 292], ["1H", "CHEMICAL", 337, 339], ["1H", "CHEMICAL", 363, 365], ["1H", "CHEMICAL", 389, 391], ["1H", "CHEMICAL", 410, 412], ["1H", "SIMPLE_CHEMICAL", 0, 2], ["NMR", "TEST", 3, 6], ["MHz", "TEST", 12, 15], ["CDCl3", "TEST", 17, 22], ["J", "TEST", 107, 108], ["Hz", "TEST", 115, 117], ["1H", "TEST", 119, 121], ["d", "TEST", 130, 131], ["J", "TEST", 133, 134], ["Hz", "TEST", 141, 143], ["1H", "TEST", 145, 147], ["d", "TEST", 156, 157], ["J", "TEST", 159, 160], ["Hz", "TEST", 167, 169], ["1H", "TEST", 171, 173], ["\u2013", "TEST", 181, 182], ["m", "TEST", 189, 190], ["2H", "TEST", 192, 194], ["dtd", "TEST", 203, 206], ["J", "TEST", 208, 209], ["Hz", "TEST", 226, 228], ["1H", "TEST", 230, 232], ["\u2013", "TEST", 240, 241], ["m", "TEST", 248, 249], ["1H", "TEST", 251, 253], ["ddd", "TEST", 262, 265], ["J", "TEST", 267, 268], ["Hz", "TEST", 286, 288], ["1H", "TEST", 290, 292], ["\u2013", "TEST", 300, 301], ["m", "TEST", 308, 309], ["2H", "TEST", 311, 313], ["J", "TEST", 325, 326], ["Hz", "TEST", 333, 335], ["1H", "TEST", 337, 339], ["d", "TEST", 348, 349], ["J", "TEST", 351, 352], ["Hz", "TEST", 359, 361], ["1H", "TEST", 363, 365], ["t", "TEST", 374, 375], ["J", "TEST", 377, 378], ["Hz", "TEST", 385, 387], ["1H", "TEST", 389, 391], ["\u2013", "TEST", 399, 400], ["1H", "TEST", 410, 412], ["\u2013", "TEST", 420, 421]]], ["ESI MS: 786.48 [M-H]\u2212.", [["H", "CHEMICAL", 18, 19]]], ["Purity by HPLC: 97.6%.Cells: ::: MATERIALS AND METHODSVero E6 were obtained from ATCC and grown in DMEM (Corning) with 10% FBS and Penicillin-Streptomycin (Gibco).SARS-CoV-2 infection: ::: MATERIALS AND METHODSSARS-CoV-2 isolate USA-WA1/2020 (BEI Resources) was propagated and infectious units quantified by plaque assay using Vero E6 (ATCC) cells.", [["Cells", "ANATOMY", 22, 27], ["ATCC", "ANATOMY", 81, 85], ["plaque", "ANATOMY", 308, 314], ["Vero E6 (ATCC) cells", "ANATOMY", 327, 347], ["FBS", "CHEMICAL", 123, 126], ["Penicillin", "CHEMICAL", 131, 141], ["Streptomycin", "CHEMICAL", 142, 154], ["SARS-CoV-2 infection", "DISEASE", 163, 183], ["Penicillin", "CHEMICAL", 131, 141], ["Streptomycin", "CHEMICAL", 142, 154], ["Cells", "CELL", 22, 27], ["E6", "ORGANISM", 59, 61], ["ATCC", "CELL", 81, 85], ["FBS", "ORGANISM_SUBSTANCE", 123, 126], ["Penicillin-Streptomycin", "SIMPLE_CHEMICAL", 131, 154], ["Gibco", "ORGANISM_SUBSTANCE", 156, 161], ["SARS-CoV-2", "ORGANISM", 163, 173], ["METHODSSARS-CoV-2", "ORGANISM", 203, 220], ["USA", "ORGANISM", 229, 232], ["Vero E6 (ATCC) cells", "CELL", 327, 347], ["Vero E6 (ATCC) cells", "CELL_LINE", 327, 347], ["ATCC", "SPECIES", 81, 85], ["Vero E6", "SPECIES", 327, 334], ["Purity", "TEST", 0, 6], ["HPLC", "TEST", 10, 14], ["METHODSVero E6", "TEST", 47, 61], ["ATCC", "TEST", 81, 85], ["10% FBS", "TREATMENT", 119, 126], ["Penicillin", "TREATMENT", 131, 141], ["Streptomycin", "TREATMENT", 142, 154], ["SARS", "PROBLEM", 163, 167], ["METHODSSARS", "TEST", 203, 214], ["CoV", "TEST", 215, 218], ["plaque assay", "TEST", 308, 320], ["Vero E6 (ATCC) cells", "TREATMENT", 327, 347], ["infection", "OBSERVATION", 174, 183]]], ["Approximately 104 Vero E6 cells per well were seeded in a 96 well plate and incubated overnight.", [["cells", "ANATOMY", 26, 31], ["E6 cells", "CELL", 23, 31], ["Vero E6 cells", "CELL_LINE", 18, 31], ["Vero E6 cells", "TREATMENT", 18, 31]]], ["Compounds or controls were added at the indicated concentrations 30 minutes prior to infection followed by the addition of SARS-CoV-2 at a multiplicity of infection equal to 0.01.", [["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 155, 164], ["SARS-CoV", "SPECIES", 123, 131], ["infection", "PROBLEM", 85, 94], ["SARS", "PROBLEM", 123, 127], ["CoV", "TEST", 128, 131], ["infection", "PROBLEM", 155, 164], ["infection", "OBSERVATION", 85, 94], ["infection", "OBSERVATION", 155, 164]]], ["After incubation for 48 hours at 37\u00b0C and 5% CO2, cells were washed twice with PBS and lysed in 200ul TRIzol (ThermoFisher).RNA extraction, cDNA synthesis and qPCR: ::: MATERIALS AND METHODSRNA was purified from TRIzol lysates using Direct-zol RNA Microprep kits (Zymo Research) according to manufacturer recommendations that included DNase treatment.", [["cells", "ANATOMY", 50, 55], ["lysates", "ANATOMY", 219, 226], ["CO2", "CHEMICAL", 45, 48], ["CO2", "CHEMICAL", 45, 48], ["CO2", "SIMPLE_CHEMICAL", 45, 48], ["cells", "CELL", 50, 55], ["TRIzol", "ORGANISM", 212, 218], ["lysates", "ORGANISM_SUBSTANCE", 219, 226], ["Zymo", "ORGANISM", 264, 268], ["DNase", "GENE_OR_GENE_PRODUCT", 335, 340], ["DNase", "PROTEIN", 335, 340], ["PBS", "TREATMENT", 79, 82], ["RNA extraction", "TEST", 124, 138], ["cDNA synthesis", "TEST", 140, 154], ["METHODSRNA", "TREATMENT", 183, 193], ["TRIzol lysates", "TREATMENT", 212, 226], ["Direct-zol RNA Microprep kits", "TREATMENT", 233, 262], ["DNase treatment", "TREATMENT", 335, 350]]], ["RNA was converted to cDNA using the iScript cDNA synthesis kit (BioRad) and qPCR was performed using iTaq universal SYBR green supermix (BioRad) and an ABI 7300 real-time pcr system. cDNA was amplified using the following primers RPLP0 F \u2013 GTGTTCGACAATGGCAGCAT; RPLP0 R \u2013 GACACCCTCCAGGAAGCGA; SARS-CoV-2 Spike F \u2013 CCTACTAAATTAAATGATCTCTGCTTTACT; SARS-CoV-2 Spike R \u2013 CAAGCTATAACGCAGCCTGTA.", [["RNA", "RNA", 0, 3], ["cDNA", "DNA", 21, 25], ["iScript cDNA", "DNA", 36, 48], ["cDNA", "DNA", 183, 187], ["RPLP0 R", "DNA", 262, 269], ["CoV", "DNA", 298, 301], ["SARS-CoV-2 Spike R", "DNA", 346, 364], ["cDNA", "TREATMENT", 21, 25], ["the iScript cDNA synthesis kit", "TREATMENT", 32, 62], ["qPCR", "TEST", 76, 80], ["an ABI", "TEST", 149, 155], ["GTGTTCGACAATGGCAGCAT", "TEST", 240, 260], ["SARS", "TEST", 293, 297], ["CoV", "TEST", 298, 301], ["CCTACTAAATTAAATGATCTCTGCTTTACT", "TEST", 314, 344], ["CoV", "TEST", 351, 354]]], ["Relative expression of SARS-CoV-2 Spike RNA was calculated by delta-delta-Ct by first normalizing to the housekeeping gene RPLP0 and then comparing to SARS-CoV-2 infected Vero E6 cells that were untreated (reference control).", [["cells", "ANATOMY", 179, 184], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["delta-delta-Ct", "GENE_OR_GENE_PRODUCT", 62, 76], ["RPLP0", "GENE_OR_GENE_PRODUCT", 123, 128], ["SARS-CoV-2", "ORGANISM", 151, 161], ["Vero E6 cells", "CELL", 171, 184], ["SARS-CoV-2 Spike RNA", "RNA", 23, 43], ["delta-delta", "PROTEIN", 62, 73], ["housekeeping gene RPLP0", "DNA", 105, 128], ["Vero E6 cells", "CELL_LINE", 171, 184], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV", "SPECIES", 151, 159], ["Vero E6", "SPECIES", 171, 178], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["Spike RNA", "PROBLEM", 34, 43], ["Ct", "TEST", 74, 76], ["SARS", "TEST", 151, 155], ["CoV", "TEST", 156, 159], ["2 infected Vero E6 cells", "PROBLEM", 160, 184], ["SARS", "OBSERVATION", 23, 27], ["E6 cells", "OBSERVATION", 176, 184]]], ["Curves were fit and 50 and 90% effective concentrations EC50 and EC90 values calculated using Prism 8.CellTiter-glo luminescent cell viability assay: ::: MATERIALS AND METHODSApproximately 104 Vero E6 cells per well were seeded in opaque walled 96 well cell culture plates and incubated overnight.", [["cell", "ANATOMY", 128, 132], ["cells", "ANATOMY", 201, 206], ["CellTiter-glo", "CHEMICAL", 102, 115], ["cell", "CELL", 128, 132], ["E6 cells", "CELL", 198, 206], ["cell", "CELL", 253, 257], ["Vero E6 cells", "CELL_LINE", 193, 206], ["Curves", "TEST", 0, 6], ["EC50", "TEST", 56, 60], ["EC90 values", "TEST", 65, 76], ["Prism", "TEST", 94, 99], ["CellTiter", "TEST", 102, 111], ["glo luminescent cell viability assay", "TEST", 112, 148], ["METHODSApproximately", "TREATMENT", 168, 188], ["Vero E6 cells", "TREATMENT", 193, 206], ["cell culture plates", "TEST", 253, 272], ["cell viability", "OBSERVATION", 128, 142]]], ["After incubation for 48.5 hours at 37\u00b0C and 5% CO2, an equal volume of CellTiter-Glo reagent (Cat. # G7570, Promega, Madison, WI) was added, mixed and luminescence recorded on an EnSpire Multimode Plate Reader (PerkinElmer) according to manufacturer recommendations.", [["CO2", "CHEMICAL", 47, 50], ["CellTiter-Glo", "CHEMICAL", 71, 84], ["CO2", "CHEMICAL", 47, 50], ["Glo", "CHEMICAL", 81, 84], ["CO2", "SIMPLE_CHEMICAL", 47, 50], ["CellTiter-Glo reagent", "SIMPLE_CHEMICAL", 71, 92], ["CellTiter", "TEST", 71, 80], ["Glo reagent", "TREATMENT", 81, 92], ["an EnSpire Multimode Plate Reader (PerkinElmer)", "TREATMENT", 176, 223]]], ["Viability was calculated compared to untreated controls and CC50 values were calculated using Prism 8 (Supplemental Materials, Table S1).", [["Viability", "TEST", 0, 9], ["CC50 values", "TEST", 60, 71], ["Prism 8 (Supplemental Materials", "TREATMENT", 94, 125]]]], "d8265364e5ed0c62b7a2b72c565a8560a5f3c08a": [["Abstract Asians are disproportionately affected by chronic hepatitis B (HBV) infection and its fatal consequences.", [["chronic hepatitis B (HBV) infection", "DISEASE", 51, 86], ["chronic hepatitis B", "ORGANISM", 51, 70], ["HBV", "ORGANISM", 72, 75], ["HBV", "SPECIES", 72, 75], ["chronic hepatitis B (HBV) infection", "PROBLEM", 51, 86], ["its fatal consequences", "PROBLEM", 91, 113], ["chronic", "OBSERVATION_MODIFIER", 51, 58], ["hepatitis", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 77, 86]]], ["The Hep B Free campaign was launched to eliminate HBV in San Francisco by increasing awareness, testing, vaccination and linkage to care.", [["Hep B", "CHEMICAL", 4, 9], ["Hep B", "CELL", 4, 9], ["HBV", "ORGANISM", 50, 53], ["HBV", "SPECIES", 50, 53], ["The Hep B Free campaign", "TREATMENT", 0, 23], ["HBV", "PROBLEM", 50, 53], ["testing", "TEST", 96, 103], ["vaccination", "TREATMENT", 105, 116]]], ["The campaign conducted 306 street intercept and telephone interviews of San Francisco Asians to assess current levels of HBV knowledge, testing behaviors and effectiveness of existing campaign media materials.", [["HBV", "ORGANISM", 121, 124], ["HBV", "SPECIES", 121, 124], ["existing campaign media materials", "TREATMENT", 175, 208]]], ["One-third of respondents ranked HBV as a key health issue in the Asian community, second to diabetes.", [["diabetes", "DISEASE", 92, 100], ["respondents", "ORGANISM", 13, 24], ["HBV", "ORGANISM", 32, 35], ["HBV", "SPECIES", 32, 35], ["diabetes", "PROBLEM", 92, 100], ["diabetes", "OBSERVATION", 92, 100]]], ["General HBV awareness is high (85%); however, a majority could not name an effective prevention method.", [["HBV", "SPECIES", 8, 11], ["General HBV awareness", "PROBLEM", 0, 21], ["HBV", "OBSERVATION", 8, 11], ["high", "OBSERVATION_MODIFIER", 25, 29]]], ["Sixty percent reported having been tested for HBV; provider recommendation was the most often cited reason for testing.", [["HBV", "ORGANISM", 46, 49], ["HBV", "SPECIES", 46, 49], ["HBV", "PROBLEM", 46, 49], ["testing", "TEST", 111, 118]]], ["Respondents reported a high level of trust in their providers to correctly assess which health issues they may be at risk for developing and test accordingly, confirming that efforts to increase HBV testing among Asians must simultaneously mobilize the public to request testing and compel providers to test high-risk patients.", [["HBV", "ORGANISM", 195, 198], ["patients", "ORGANISM", 318, 326], ["patients", "SPECIES", 318, 326], ["HBV", "SPECIES", 195, 198], ["HBV testing", "TEST", 195, 206]]], ["Regarding community awareness, more than half reported hearing more about HBV recently; younger respondents were more likely to have encountered campaign materials and recall correct HBV facts.", [["HBV", "ORGANISM", 74, 77], ["HBV", "SPECIES", 74, 77], ["HBV", "SPECIES", 183, 186], ["HBV", "PROBLEM", 74, 77]]], ["Assessment of specific campaign materials found that while upbeat images and taglines captured attention and destigmatized HBV, messages that emphasize the pervasiveness and deadly consequence of infection were more likely to drive respondents to seek education and testing.", [["infection", "DISEASE", 196, 205], ["HBV", "SPECIES", 123, 126], ["upbeat images", "TEST", 59, 72], ["infection", "PROBLEM", 196, 205], ["testing", "TEST", 266, 273], ["infection", "OBSERVATION", 196, 205]]]], "PMC7121852": [["Microbes Were First: Bacteria Have Existed from Very Early in the History of Life on EarthWith billions of years of evolution before the appearance of animals, prokaryotes shaped and continue to shape both the Earth\u2019s biogeochemical landscape and the setting for animal existence (Fig. 2.1) (Knoll 2003).", [["Bacteria", "PROBLEM", 21, 29], ["Bacteria", "OBSERVATION", 21, 29]]]], "2f1fd09967a2bb1a9b3a1aa62683d14998c347a0": [], "PMC7137144": [["IntroductionHajj is the pilgrimage to Mecca and related holy sites.", [["Mecca and related holy sites", "DNA", 38, 66], ["the pilgrimage to Mecca", "TREATMENT", 20, 43], ["holy sites", "OBSERVATION", 56, 66]]], ["The pilgrim makes overnight stops in Mina en route to Arafat, and in Muzdaliffah on return (figure 1).", [["The pilgrim", "TREATMENT", 0, 11]]], ["On returning to Mina, the pilgrim stops at Jamarat to stone the pillars that are effigies of Satan.", [["the pilgrim", "TREATMENT", 22, 33], ["stone the pillars", "TREATMENT", 54, 71], ["stone", "OBSERVATION", 54, 59], ["pillars", "OBSERVATION", 64, 71]]], ["The new Hajjee (a pilgrim who has completed the Hajj) then makes an animal sacrifice (usually by proxy) as thanks for an accepted Hajj.", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["After a farewell Tawaf, the pilgrim leaves Mecca.IntroductionMecca is also the setting for a smaller ritual called Umrah, performed year-round.", [["the pilgrim leaves Mecca", "TREATMENT", 24, 48]]], ["Improved international travel renders Umrah also very congested, especially in the three months preceding the Hajj (figure 2).", [["very congested", "PROBLEM", 49, 63], ["very", "OBSERVATION_MODIFIER", 49, 53], ["congested", "OBSERVATION", 54, 63]]], ["Many pilgrims also travel to Medina, north of Mecca, where the Prophet Mohammed is buried.", [["pilgrims", "OBSERVATION", 5, 13]]], ["Although the Medina visit is a non-essential part of the Hajj, millions complete this ritual.IntroductionThis mass migration (figure 3) entails some of the world's most important public-health and infection-control problems.1 Although distances are small, the congestion of the Hajj (figure 4) poses high physical, environmental, and health-care demands.", [["infection", "DISEASE", 197, 206], ["This mass migration", "PROBLEM", 105, 124], ["infection", "PROBLEM", 197, 206], ["the congestion of the Hajj", "PROBLEM", 256, 282], ["mass", "OBSERVATION", 110, 114], ["infection", "OBSERVATION", 197, 206], ["small", "OBSERVATION_MODIFIER", 249, 254], ["congestion", "OBSERVATION", 260, 270]]], ["Not only that, the Hajj is marked on a lunar calendar, which is 10 days shorter than the Gregorian one.", [["marked", "OBSERVATION_MODIFIER", 27, 33]]], ["This continuous seasonal movement has implications for the spread of disease and other health risks, challenging public-health policy planners further.", [["disease", "PROBLEM", 69, 76]]], ["The severe congestion of people means that emerging infectious diseases have the potential to quickly turn into epidemics.", [["infectious diseases", "DISEASE", 52, 71], ["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["The severe congestion of people means", "PROBLEM", 0, 37], ["emerging infectious diseases", "PROBLEM", 43, 71], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["congestion", "OBSERVATION", 11, 21]]], ["With each Hajj, authorities refine the management of Hajj health procedures.2, 3, 4, 5, 6", [["Hajj health procedures", "TREATMENT", 53, 75]]]], "32b6ecf50c62b0c312394d6082c1824391f9d994": [["IntroductionHuman rhinoviruses (HRVs) belong to Picornaviridae family, genus Enterovirus, and are divided in three species (HRV-A, HRV-B, and HRV-C) with about 100 serotypes within these species.", [["Enterovirus", "DISEASE", 77, 88], ["IntroductionHuman rhinoviruses", "ORGANISM", 0, 30], ["HRVs", "CANCER", 32, 36], ["Picornaviridae", "GENE_OR_GENE_PRODUCT", 48, 62], ["genus Enterovirus", "ORGANISM", 71, 88], ["HRV-A", "ORGANISM", 124, 129], ["HRV-B", "CELL", 131, 136], ["HRV-C", "ORGANISM", 142, 147], ["IntroductionHuman rhinoviruses", "PROBLEM", 0, 30], ["genus Enterovirus", "PROBLEM", 71, 88], ["HRV", "TEST", 124, 127], ["HRV", "TEST", 131, 134], ["HRV", "TEST", 142, 145]]], ["1, 2 The development of highly-sensitive molecular techniques for characterization of the HRV genome has recently allowed recognition of the HRV-C species.", [["HRV genome", "DNA", 90, 100], ["the HRV genome", "PROBLEM", 86, 100], ["the HRV", "TEST", 137, 144], ["C species", "PROBLEM", 145, 154]]], ["3 There is already evidence that this new species may be more virulent and more strongly associated with lower respiratory tract infections than HRV-A and HRV-B.", [["lower respiratory tract", "ANATOMY", 105, 128], ["respiratory tract infections", "DISEASE", 111, 139], ["respiratory tract", "ORGANISM_SUBDIVISION", 111, 128], ["HRV-B.", "ORGANISM", 155, 161], ["HRV-A", "SPECIES", 145, 150], ["HRV-B.", "SPECIES", 155, 161], ["this new species", "PROBLEM", 33, 49], ["virulent", "PROBLEM", 62, 70], ["lower respiratory tract infections", "PROBLEM", 105, 139], ["lower", "ANATOMY_MODIFIER", 105, 110], ["respiratory tract", "ANATOMY", 111, 128], ["infections", "OBSERVATION", 129, 139]]], ["4 HRV is the most common cause of upper respiratory tract infections, being responsible for at least 50% of cases of the common cold.", [["upper respiratory tract", "ANATOMY", 34, 57], ["respiratory tract infections", "DISEASE", 40, 68], ["upper", "ORGANISM_SUBDIVISION", 34, 39], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["upper respiratory tract infections", "PROBLEM", 34, 68], ["the common cold", "PROBLEM", 117, 132], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57], ["infections", "OBSERVATION", 58, 68], ["common cold", "ANATOMY", 121, 132]]], ["This leads to considerable economic burden in terms of medical visits and both school and work absenteeism.", [["considerable", "OBSERVATION_MODIFIER", 14, 26], ["economic", "OBSERVATION_MODIFIER", 27, 35], ["burden", "OBSERVATION", 36, 42]]], ["2, 4 HRVs have also been linked to lower airway effects that result in significant morbidity and mortality, 1 such as exacerbations of chronic pulmonary disease, severe bronchiolitis in infants and children, as well as fatal pneumonia in elderly and immunocompromised adults.", [["airway", "ANATOMY", 41, 47], ["pulmonary", "ANATOMY", 143, 152], ["chronic pulmonary disease", "DISEASE", 135, 160], ["bronchiolitis", "DISEASE", 169, 182], ["pneumonia", "DISEASE", 225, 234], ["HRVs", "GENE_OR_GENE_PRODUCT", 5, 9], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["pulmonary", "ORGAN", 143, 152], ["infants", "ORGANISM", 186, 193], ["children", "ORGANISM", 198, 206], ["infants", "SPECIES", 186, 193], ["children", "SPECIES", 198, 206], ["lower airway effects", "PROBLEM", 35, 55], ["significant morbidity", "PROBLEM", 71, 92], ["chronic pulmonary disease", "PROBLEM", 135, 160], ["severe bronchiolitis in infants and children", "PROBLEM", 162, 206], ["fatal pneumonia", "PROBLEM", 219, 234], ["immunocompromised adults", "PROBLEM", 250, 274], ["lower", "ANATOMY_MODIFIER", 35, 40], ["airway", "ANATOMY", 41, 47], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["morbidity", "OBSERVATION", 83, 92], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["pulmonary", "ANATOMY", 143, 152], ["disease", "OBSERVATION", 153, 160], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["bronchiolitis", "OBSERVATION", 169, 182], ["fatal", "OBSERVATION_MODIFIER", 219, 224], ["pneumonia", "OBSERVATION", 225, 234]]], ["4, 5 In general, HRV infections occur during spring and autumn, 6 and manifest differently depending on whether the lower or upper respiratory tract is infected.", [["upper respiratory tract", "ANATOMY", 125, 148], ["HRV infections", "DISEASE", 17, 31], ["upper respiratory", "ORGANISM_SUBDIVISION", 125, 142], ["tract", "ORGANISM_SUBDIVISION", 143, 148], ["HRV infections", "PROBLEM", 17, 31], ["the lower or upper respiratory tract", "PROBLEM", 112, 148], ["infections", "OBSERVATION", 21, 31], ["lower", "ANATOMY_MODIFIER", 116, 121], ["upper", "ANATOMY_MODIFIER", 125, 130], ["respiratory tract", "ANATOMY", 131, 148], ["infected", "OBSERVATION", 152, 160]]], ["Infections of the upper respiratory tract ordinarily include symptoms of the common cold, but can present as acute otitis media or rhinosinusitis.", [["upper respiratory tract", "ANATOMY", 18, 41], ["Infections of the upper respiratory tract", "DISEASE", 0, 41], ["acute otitis media", "DISEASE", 109, 127], ["rhinosinusitis", "DISEASE", 131, 145], ["upper", "ORGANISM_SUBDIVISION", 18, 23], ["respiratory tract", "ORGANISM_SUBDIVISION", 24, 41], ["Infections of the upper respiratory tract", "PROBLEM", 0, 41], ["symptoms", "PROBLEM", 61, 69], ["the common cold", "PROBLEM", 73, 88], ["acute otitis media", "PROBLEM", 109, 127], ["rhinosinusitis", "PROBLEM", 131, 145], ["upper", "ANATOMY_MODIFIER", 18, 23], ["respiratory tract", "ANATOMY", 24, 41], ["common cold", "ANATOMY", 77, 88], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["otitis", "OBSERVATION", 115, 121], ["rhinosinusitis", "OBSERVATION", 131, 145]]], ["On the other hand, infections of the lower respiratory tract can cause severe symptoms and result in bronchiolitis and pneumonia.", [["lower respiratory tract", "ANATOMY", 37, 60], ["infections of the lower respiratory tract", "DISEASE", 19, 60], ["bronchiolitis", "DISEASE", 101, 114], ["pneumonia", "DISEASE", 119, 128], ["lower", "ORGANISM_SUBDIVISION", 37, 42], ["respiratory tract", "ORGANISM_SUBDIVISION", 43, 60], ["infections of the lower respiratory tract", "PROBLEM", 19, 60], ["severe symptoms", "PROBLEM", 71, 86], ["bronchiolitis", "PROBLEM", 101, 114], ["pneumonia", "PROBLEM", 119, 128], ["infections", "OBSERVATION", 19, 29], ["lower", "ANATOMY_MODIFIER", 37, 42], ["respiratory tract", "ANATOMY", 43, 60], ["bronchiolitis", "OBSERVATION", 101, 114], ["pneumonia", "OBSERVATION", 119, 128]]], ["4 In Brazil, since the influenza A pandemic of 2009, referral hospitals have been conducting active surveillance to detect respiratory viruses.", [["respiratory viruses", "DISEASE", 123, 142], ["respiratory viruses", "PROBLEM", 123, 142], ["respiratory viruses", "OBSERVATION", 123, 142]]], ["Such surveillance includes notification and laboratory investigation of cases meeting the diagnostic criteria of severe acute respiratory infection (SARI).", [["respiratory", "ANATOMY", 126, 137], ["acute respiratory infection", "DISEASE", 120, 147], ["SARI", "DISEASE", 149, 153], ["laboratory investigation", "TEST", 44, 68], ["severe acute respiratory infection", "PROBLEM", 113, 147], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory", "ANATOMY", 126, 137], ["infection", "OBSERVATION", 138, 147]]], ["This viral respiratory infection monitoring has resulted in important information about the circulation of other community-acquired respiratory viruses (CRV).", [["respiratory", "ANATOMY", 11, 22], ["respiratory infection", "DISEASE", 11, 32], ["respiratory viruses", "DISEASE", 132, 151], ["CRV", "SPECIES", 153, 156], ["This viral respiratory infection monitoring", "PROBLEM", 0, 43], ["respiratory", "ANATOMY", 11, 22], ["infection", "OBSERVATION", 23, 32], ["respiratory viruses", "OBSERVATION", 132, 151]]], ["The present study reports the epidemiological features, clinical characteristics, and outcomes of HRV infections in comparison with other CRV infections in patients hospitalized in a referral hospital in Southern Brazil, for two consecutive years.Patient selection and data acquisitionPatients hospitalized at an academic tertiary care center in Southern Brazil from whom respiratory samples were collected and sent for investigation, or who were diagnosed with SARI in 2012 or 2013, were included in the study.", [["respiratory samples", "ANATOMY", 372, 391], ["HRV infections", "DISEASE", 98, 112], ["CRV infections", "DISEASE", 138, 152], ["SARI", "DISEASE", 462, 466], ["patients", "ORGANISM", 156, 164], ["Patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 156, 164], ["Patient", "SPECIES", 247, 254], ["Patients", "SPECIES", 285, 293], ["HRV", "SPECIES", 98, 101], ["CRV", "SPECIES", 138, 141], ["The present study", "TEST", 0, 17], ["HRV infections", "PROBLEM", 98, 112], ["data acquisition", "TEST", 269, 285], ["respiratory samples", "TEST", 372, 391], ["investigation", "TEST", 420, 433], ["SARI", "PROBLEM", 462, 466], ["the study", "TEST", 501, 510], ["infections", "OBSERVATION", 102, 112], ["infections", "OBSERVATION", 142, 152]]], ["Respiratory samples (nasal swab or nasopharyngeal aspirate, or bronchoalveolar lavage) were collected in different periods of hospitalization according to medical recommendation.", [["Respiratory samples", "ANATOMY", 0, 19], ["nasal swab", "ANATOMY", 21, 31], ["nasopharyngeal aspirate", "ANATOMY", 35, 58], ["bronchoalveolar lavage", "ANATOMY", 63, 85], ["Respiratory samples", "CANCER", 0, 19], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 21, 31], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 35, 58], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 63, 85], ["Respiratory samples", "TEST", 0, 19], ["nasal swab", "TEST", 21, 31], ["nasopharyngeal aspirate", "TEST", 35, 58], ["bronchoalveolar lavage", "TEST", 63, 85], ["nasal", "ANATOMY", 21, 26], ["nasopharyngeal", "ANATOMY", 35, 49]]], ["Individuals with more than one sample collected during the same symptomatic period were considered as a single case and only the first result was evaluated, so that the number of respiratory viral detections was not overestimated.", [["respiratory viral detections", "TEST", 179, 207], ["respiratory viral", "OBSERVATION", 179, 196]]], ["The medical records and influenza notification forms of patients with detectable respiratory virus were reviewed, focusing on epidemiology, clinical manifestation, outcome, laboratory findings, and diagnosis of SARI.", [["SARI", "DISEASE", 211, 215], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["detectable respiratory virus", "PROBLEM", 70, 98], ["laboratory findings", "TEST", 173, 192], ["SARI", "PROBLEM", 211, 215], ["respiratory virus", "OBSERVATION", 81, 98]]], ["SARI was defined as a flu-like syndrome with signs of severity (dyspnea or oxygen saturation below 95%).Patient selection and data acquisitionDuring the study, a total of 1002 cases were identified in both databases.", [["SARI", "DISEASE", 0, 4], ["flu-like syndrome", "DISEASE", 22, 39], ["dyspnea", "DISEASE", 64, 71], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["Patient", "SPECIES", 104, 111], ["SARI", "PROBLEM", 0, 4], ["a flu-like syndrome", "PROBLEM", 20, 39], ["severity", "PROBLEM", 54, 62], ["dyspnea", "PROBLEM", 64, 71], ["oxygen saturation", "TEST", 75, 92], ["the study", "TEST", 149, 158]]], ["Of these, five cases were excluded because the researchers could not access the medical records and a further 242 were excluded as no samples had been sent for virus detection.", [["samples", "ANATOMY", 134, 141], ["samples", "CANCER", 134, 141], ["samples", "TEST", 134, 141], ["virus detection", "TEST", 160, 175]]], ["Thus, 755 patients with respiratory samples investigated for respiratory virus detection were included.", [["respiratory samples", "ANATOMY", 24, 43], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["respiratory samples", "TEST", 24, 43], ["respiratory virus detection", "TEST", 61, 88]]], ["The Institutional Ethics Review Board approved the study (No. #18714013.4.0000.0096).Respiratory virus (RV) detectionRVs were detected using a multiplex reverse transcription polymerase chain reaction (RT-PCR) technique.", [["Respiratory virus", "ORGANISM", 85, 102], ["Respiratory virus", "SPECIES", 85, 102], ["RV", "SPECIES", 104, 106], ["the study", "TEST", 47, 56], ["Respiratory virus (RV) detectionRVs", "PROBLEM", 85, 120], ["a multiplex reverse transcription polymerase chain reaction", "TREATMENT", 141, 200], ["virus", "OBSERVATION", 97, 102]]], ["The viral genome was extracted using a High Pure Viral RNA Kit (Roche Inc., Mannheim, Germany) in accordance with the manufacturer's instructions.", [["viral genome", "DNA", 4, 16], ["The viral genome", "PROBLEM", 0, 16], ["viral genome", "OBSERVATION", 4, 16]]], ["First strand cDNA synthesis was achieved using random primers and an ImProm-II reverse transcription system (Promega Inc., WI, USA).", [["First strand cDNA synthesis", "TREATMENT", 0, 27], ["random primers", "TREATMENT", 47, 61]]], ["The resulting cDNA was then subject to PCR by using a Seeplex \u00ae RV15 ACE Detection Kit (Seegene Inc., Korea), in accordance with the manufacturer's protocol.", [["cDNA", "DNA", 14, 18], ["The resulting cDNA", "PROBLEM", 0, 18], ["PCR", "TEST", 39, 42], ["a Seeplex \u00ae", "TREATMENT", 52, 63], ["the manufacturer's protocol", "TREATMENT", 129, 156]]], ["This multiplex PCR technology enables a simultaneous detection of 15 respiratory viruses: human adenovirus (AdV), human metapneumovirus (MPV), parainfluenza virus type 1, 2, 3, and 4 (PIV-1, PIV-2, PIV-3, and PIV-4), influenza A (FLUA), influenza B (FLUB), respiratory syncytial virus type A and B (RSV-A, RSV-B), human rhinovirus types A/B/C (HRV), human enterovirus (EV), human bocavirus (BoV), and human coronavirus (CoV) types 229E/NL63 (alpha coronaviruses) and OC43/HKU1 (beta coronaviruses).Statistical analysisData were compiled using JMP version 5.2.1 (SAS Institute Inc., Cary, NC, USA) and analyzed using GraphPad Prism version 5.03 (GraphPad Software Inc., CA, USA).", [["respiratory viruses", "DISEASE", 69, 88], ["influenza A", "DISEASE", 217, 228], ["influenza B", "DISEASE", 237, 248], ["respiratory syncytial virus", "DISEASE", 257, 284], ["human enterovirus (EV), human bocavirus", "DISEASE", 350, 389], ["human adenovirus", "ORGANISM", 90, 106], ["AdV", "ORGANISM", 108, 111], ["human metapneumovirus", "ORGANISM", 114, 135], ["MPV", "GENE_OR_GENE_PRODUCT", 137, 140], ["parainfluenza virus type 1", "ORGANISM", 143, 169], ["2", "GENE_OR_GENE_PRODUCT", 171, 172], ["3", "GENE_OR_GENE_PRODUCT", 174, 175], ["4", "GENE_OR_GENE_PRODUCT", 181, 182], ["PIV-1", "ORGANISM", 184, 189], ["PIV-2", "ORGANISM", 191, 196], ["PIV-3", "ORGANISM", 198, 203], ["PIV-4", "ORGANISM", 209, 214], ["influenza A (FLUA),", "ORGANISM", 217, 236], ["influenza B (FLUB),", "ORGANISM", 237, 256], ["respiratory syncytial virus type A", "ORGANISM", 257, 291], ["B (", "ORGANISM", 296, 299], ["RSV-A,", "ORGANISM", 299, 305], ["RSV-B", "ORGANISM", 306, 311], ["human rhinovirus types A/B/C (HRV", "ORGANISM", 314, 347], ["human enterovirus (EV)", "ORGANISM", 350, 372], ["human", "ORGANISM", 374, 379], ["bocavirus", "ORGANISM", 380, 389], ["BoV", "CANCER", 391, 394], ["human coronavirus", "ORGANISM", 401, 418], ["CoV", "ORGANISM", 420, 423], ["NL63", "GENE_OR_GENE_PRODUCT", 436, 440], ["alpha coronaviruses", "ORGANISM", 442, 461], ["OC43", "GENE_OR_GENE_PRODUCT", 467, 471], ["HKU1", "GENE_OR_GENE_PRODUCT", 472, 476], ["beta coronaviruses", "ORGANISM", 478, 496], ["OC43", "PROTEIN", 467, 471], ["HKU1", "PROTEIN", 472, 476], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 114, 119], ["metapneumovirus", "SPECIES", 120, 135], ["parainfluenza virus type 1", "SPECIES", 143, 169], ["respiratory syncytial virus", "SPECIES", 257, 284], ["human", "SPECIES", 314, 319], ["rhinovirus", "SPECIES", 320, 330], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 374, 379], ["human", "SPECIES", 401, 406], ["coronavirus", "SPECIES", 407, 418], ["human adenovirus", "SPECIES", 90, 106], ["AdV", "SPECIES", 108, 111], ["human metapneumovirus", "SPECIES", 114, 135], ["MPV", "SPECIES", 137, 140], ["parainfluenza virus type 1", "SPECIES", 143, 169], ["PIV-1", "SPECIES", 184, 189], ["respiratory syncytial virus type A", "SPECIES", 257, 291], ["RSV-A", "SPECIES", 299, 304], ["RSV", "SPECIES", 306, 309], ["human rhinovirus types A/B/C", "SPECIES", 314, 342], ["HRV", "SPECIES", 344, 347], ["human", "SPECIES", 350, 355], ["EV", "SPECIES", 369, 371], ["human", "SPECIES", 374, 379], ["BoV", "SPECIES", 391, 394], ["human coronavirus", "SPECIES", 401, 418], ["CoV", "SPECIES", 420, 423], ["This multiplex PCR technology", "TEST", 0, 29], ["a simultaneous detection", "TEST", 38, 62], ["15 respiratory viruses", "PROBLEM", 66, 88], ["human adenovirus", "TEST", 90, 106], ["human metapneumovirus (MPV", "TEST", 114, 140], ["parainfluenza virus type", "TEST", 143, 167], ["PIV", "TEST", 184, 187], ["PIV", "TEST", 191, 194], ["PIV", "TEST", 198, 201], ["PIV", "TEST", 209, 212], ["influenza", "PROBLEM", 217, 226], ["FLUA", "TEST", 230, 234], ["influenza B (FLUB)", "TEST", 237, 255], ["respiratory syncytial virus type A", "PROBLEM", 257, 291], ["RSV", "TEST", 299, 302], ["RSV", "TEST", 306, 309], ["human rhinovirus types A/B/C", "PROBLEM", 314, 342], ["human enterovirus", "PROBLEM", 350, 367], ["human bocavirus (BoV)", "TEST", 374, 395], ["human coronavirus (CoV) types", "TEST", 401, 430], ["alpha coronaviruses", "TEST", 442, 461], ["OC43", "TEST", 467, 471], ["HKU1", "TEST", 472, 476], ["Statistical analysisData", "TEST", 498, 522], ["JMP version", "TEST", 543, 554], ["GraphPad Prism version", "TEST", 616, 638], ["respiratory viruses", "OBSERVATION", 69, 88], ["respiratory syncytial", "ANATOMY", 257, 278], ["human coronavirus", "ANATOMY", 401, 418]]], ["Parametric and non-parametric tests were used as appropriate.", [["Parametric and non-parametric tests", "TEST", 0, 35]]], ["The nonparametric Spearman correlation coefficient was used to analyze meteorological data.", [["meteorological data", "TEST", 71, 90]]], ["Variables with an associated pvalue < 0.05 in the univariate analysis and those considered as confounding factors (age and length of hospitalization) were subjected to multivariate logistic regression to identify independent predictors for severe disease.", [["an associated pvalue", "PROBLEM", 15, 35], ["the univariate analysis", "TEST", 46, 69], ["severe disease", "PROBLEM", 240, 254], ["severe", "OBSERVATION_MODIFIER", 240, 246], ["disease", "OBSERVATION", 247, 254]]], ["All p-values were two-tailed and a value of <0.05 was considered significant.Meteorological dataCuritiba is located in Southern Brazil and has a temperate climate.", [["All p-values", "TEST", 0, 12], ["a value", "TEST", 33, 40]]], ["Data on monthly measures of temperature and rainfall were supplied by the Meteorological System of Paran\u00e1 (Sistema Meteorol\u00f3gico do Paran\u00e1 [SIMEPAR]). were compared with those with other CRV infections, groups 1 and 2, respectively) ( Table 1) .", [["infections", "DISEASE", 191, 201], ["other CRV infections", "PROBLEM", 181, 201], ["infections", "OBSERVATION", 191, 201]]], ["For this analysis, only cases with single infections were included, excluding nosocomial infections, since given that patients with nosocomial infections were already in the hospital, it would be expected that they would have some underlying illness, which could overestimate the severity of infections.", [["infections", "DISEASE", 42, 52], ["nosocomial infections", "DISEASE", 78, 99], ["nosocomial infections", "DISEASE", 132, 153], ["infections", "DISEASE", 292, 302], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["this analysis", "TEST", 4, 17], ["single infections", "PROBLEM", 35, 52], ["nosocomial infections", "PROBLEM", 78, 99], ["nosocomial infections", "PROBLEM", 132, 153], ["some underlying illness", "PROBLEM", 226, 249], ["infections", "PROBLEM", 292, 302], ["illness", "OBSERVATION", 242, 249], ["infections", "OBSERVATION", 292, 302]]], ["Most HRV infected patients were younger than 2 years (57%), 53% were younger than 1 year, and 37% were younger than 6 months of age.", [["HRV infected", "DISEASE", 5, 17], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["infected", "OBSERVATION", 9, 17]]], ["The groups showed no statistically significant difference in median age.", [["no", "UNCERTAINTY", 18, 20], ["statistically", "OBSERVATION_MODIFIER", 21, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["difference", "OBSERVATION_MODIFIER", 47, 57]]], ["Gender was unequally distributed between the groups.ResultsThe main clinical manifestations observed in both groups included fever, cough, and dyspnea.", [["fever", "DISEASE", 125, 130], ["cough", "DISEASE", 132, 137], ["dyspnea", "DISEASE", 143, 150], ["fever", "PROBLEM", 125, 130], ["cough", "PROBLEM", 132, 137], ["dyspnea", "PROBLEM", 143, 150], ["unequally", "OBSERVATION_MODIFIER", 11, 20], ["distributed", "OBSERVATION_MODIFIER", 21, 32], ["main", "OBSERVATION_MODIFIER", 63, 67], ["cough", "OBSERVATION", 132, 137]]], ["However, the HRV positive group had a significantly lower proportion of cases with fever (62%, p = 0.001), and more comorbidities than the other group (40% vs. 27%, p = 0.043).", [["fever", "DISEASE", 83, 88], ["fever", "PROBLEM", 83, 88], ["p", "TEST", 95, 96], ["p", "TEST", 165, 166]]], ["Although immunosuppression, chronic lung disease, and heart disease were the major medical conditions present in both groups, chronic lung disease was more frequent in the HRV group (17%), but without significant difference.", [["lung", "ANATOMY", 36, 40], ["heart", "ANATOMY", 54, 59], ["lung", "ANATOMY", 134, 138], ["chronic lung disease", "DISEASE", 28, 48], ["heart disease", "DISEASE", 54, 67], ["chronic lung disease", "DISEASE", 126, 146], ["lung", "ORGAN", 36, 40], ["heart", "ORGAN", 54, 59], ["lung", "ORGAN", 134, 138], ["immunosuppression", "TREATMENT", 9, 26], ["chronic lung disease", "PROBLEM", 28, 48], ["heart disease", "PROBLEM", 54, 67], ["chronic lung disease", "PROBLEM", 126, 146], ["significant difference", "PROBLEM", 201, 223], ["immunosuppression", "OBSERVATION", 9, 26], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["lung", "ANATOMY", 36, 40], ["disease", "OBSERVATION", 41, 48], ["heart", "ANATOMY", 54, 59], ["disease", "OBSERVATION", 60, 67], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["lung", "ANATOMY", 134, 138], ["disease", "OBSERVATION", 139, 146], ["without", "UNCERTAINTY", 193, 200], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["difference", "OBSERVATION", 213, 223]]], ["Concerning the diagnosis of SARI, there were fewer patients diagnosed with this syndrome in the HRV group (60%, p = 0.006) than in the other CRV group.", [["SARI", "DISEASE", 28, 32], ["SARI", "CANCER", 28, 32], ["patients", "ORGANISM", 51, 59], ["CRV", "CANCER", 141, 144], ["patients", "SPECIES", 51, 59], ["SARI", "PROBLEM", 28, 32], ["this syndrome", "PROBLEM", 75, 88], ["SARI", "OBSERVATION", 28, 32]]], ["In the multivariate analysis of the relationship between clinical characteristics significantly different between the HRV-and other CRV-groups, only the higher prevalence of previous comorbidities in the HRV group was significant.", [["the HRV", "TEST", 114, 121], ["previous comorbidities", "PROBLEM", 174, 196], ["comorbidities", "OBSERVATION", 183, 196], ["significant", "OBSERVATION_MODIFIER", 218, 229]]], ["Patients with no comorbidities were 1.6 (95% CI: 1.04---2.34) times more likely to be infected CRVs other than HRV, in comparison to patients with comorbidities.ResultsDespite the fact that most of chest X-rays of HRV infected cases were missed (53%), radiologic alterations were described in 83% of the performed exams.", [["HRV infected", "DISEASE", 214, 226], ["Patients", "ORGANISM", 0, 8], ["CRVs", "CANCER", 95, 99], ["patients", "ORGANISM", 133, 141], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 133, 141], ["comorbidities", "PROBLEM", 17, 30], ["CI", "TEST", 45, 47], ["infected CRVs", "PROBLEM", 86, 99], ["HRV", "PROBLEM", 111, 114], ["comorbidities", "PROBLEM", 147, 160], ["chest X-rays", "TEST", 198, 210], ["HRV infected cases", "PROBLEM", 214, 232], ["radiologic alterations", "TEST", 252, 274], ["the performed exams", "TEST", 300, 319], ["no", "UNCERTAINTY", 14, 16], ["infected", "OBSERVATION", 86, 94], ["chest", "ANATOMY", 198, 203]]], ["Most of the findings observed were interstitial infiltrate (33%) and pulmonary consolidation (28%), with no significant difference between both groups.ResultsSevere disease was defined as that requiring mechanical ventilatory support, or intensive care unit (ICU) admission, or death during hospitalization; no significant difference was found between the groups.", [["interstitial infiltrate", "ANATOMY", 35, 58], ["pulmonary", "ANATOMY", 69, 78], ["pulmonary consolidation", "DISEASE", 69, 92], ["death", "DISEASE", 278, 283], ["pulmonary", "ORGAN", 69, 78], ["interstitial infiltrate", "PROBLEM", 35, 58], ["pulmonary consolidation", "PROBLEM", 69, 92], ["Severe disease", "PROBLEM", 158, 172], ["mechanical ventilatory support", "TREATMENT", 203, 233], ["death", "PROBLEM", 278, 283], ["interstitial", "OBSERVATION_MODIFIER", 35, 47], ["infiltrate", "OBSERVATION", 48, 58], ["pulmonary", "ANATOMY", 69, 78], ["consolidation", "OBSERVATION", 79, 92], ["no", "UNCERTAINTY", 105, 107], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["difference", "OBSERVATION_MODIFIER", 120, 130], ["Severe", "OBSERVATION_MODIFIER", 158, 164], ["disease", "OBSERVATION", 165, 172]]], ["Two HRV infected patients died during hospitalization, both from respiratory infection complications.ResultsHRV had the highest rates of coinfection (69%) of the 128 samples with more than one CRV detected.", [["respiratory", "ANATOMY", 65, 76], ["samples", "ANATOMY", 166, 173], ["HRV infected", "DISEASE", 4, 16], ["respiratory infection", "DISEASE", 65, 86], ["coinfection", "DISEASE", 137, 148], ["patients", "ORGANISM", 17, 25], ["samples", "CANCER", 166, 173], ["CRV", "CANCER", 193, 196], ["patients", "SPECIES", 17, 25], ["respiratory infection complications", "PROBLEM", 65, 100], ["ResultsHRV", "TEST", 101, 111], ["coinfection", "PROBLEM", 137, 148], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["respiratory", "ANATOMY", 65, 76], ["infection", "OBSERVATION", 77, 86], ["highest", "OBSERVATION_MODIFIER", 120, 127], ["coinfection", "OBSERVATION", 137, 148]]], ["The viruses most co-detected with HRV were EV (40/88; 45%) and RSV (29/88; 33%), as shown in Fig. 1 .", [["RSV", "ORGANISM", 63, 66], ["RSV", "SPECIES", 63, 66], ["The viruses", "PROBLEM", 0, 11], ["HRV", "TEST", 34, 37], ["EV", "TEST", 43, 45], ["RSV", "TEST", 63, 66], ["viruses", "OBSERVATION", 4, 11]]], ["In 52% of cases, the co-detection involved HRV plus another virus, and in 16% of cases, HRV was associated with two or more viruses.", [["HRV", "SPECIES", 88, 91], ["HRV", "PROBLEM", 43, 46], ["another virus", "PROBLEM", 52, 65], ["HRV", "PROBLEM", 88, 91], ["viruses", "OBSERVATION", 124, 131]]], ["In 65 cases, HRV was the only virus detected.ResultsA comparison of the clinical characteristics of monoinfected HRV patients with co-infected HRV patients was performed, and no relation between viral co-detection and disease severity (p = 0.717) was found.", [["HRV", "ORGANISM", 113, 116], ["patients", "ORGANISM", 117, 125], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 117, 125], ["patients", "SPECIES", 147, 155], ["HRV", "SPECIES", 13, 16], ["HRV", "PROBLEM", 13, 16], ["virus", "PROBLEM", 30, 35], ["monoinfected HRV", "PROBLEM", 100, 116], ["co-infected HRV patients", "PROBLEM", 131, 155], ["viral co-detection", "PROBLEM", 195, 213], ["disease severity", "PROBLEM", 218, 234], ["virus", "OBSERVATION", 30, 35], ["viral co-detection", "OBSERVATION", 195, 213]]], ["The clinical features significantly associated with HRV co-detection were as follows: age 6---48 months (OR = 3.2; 95% CI: 1.3---8.1), length of hospitalization more than 30 days (OR = 9.7; 95% CI: 2.5---36.8), and no SARI diagnosis (OR = 4.0; 95% CI: 1.7---9.3).", [["HRV co-detection", "TEST", 52, 68], ["CI", "TEST", 119, 121], ["CI", "TEST", 194, 196], ["SARI diagnosis", "TEST", 218, 232], ["CI", "TEST", 248, 250], ["no", "UNCERTAINTY", 215, 217]]], ["As co-infection with HRV alone was not related with severe disease, a second analysis was performed comparing disease severity between HRV co-infected patients and patients infected with other CRVs.", [["co-infection", "DISEASE", 3, 15], ["HRV co-infected", "DISEASE", 135, 150], ["patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 164, 172], ["co-infection", "PROBLEM", 3, 15], ["severe disease", "PROBLEM", 52, 66], ["a second analysis", "TEST", 68, 85], ["disease severity", "PROBLEM", 110, 126], ["other CRVs", "TREATMENT", 187, 197], ["not related with", "UNCERTAINTY", 35, 51], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["disease", "OBSERVATION", 59, 66], ["infected", "OBSERVATION", 142, 150], ["infected", "OBSERVATION", 173, 181]]], ["Neither the presence nor absence of HRV co-detection was associated with disease severity (p = 0.196).ResultsCases of HRV infection occurred throughout the study period (Fig. 2) .", [["HRV infection", "DISEASE", 118, 131], ["HRV co-detection", "PROBLEM", 36, 52], ["disease severity", "PROBLEM", 73, 89], ["HRV infection", "PROBLEM", 118, 131], ["HRV", "OBSERVATION_MODIFIER", 118, 121], ["infection", "OBSERVATION", 122, 131]]], ["The months of May to August demonstrated the highest number of HRV infections during 2012, peaking in August (17 cases; 10%).", [["HRV infections", "DISEASE", 63, 77], ["HRV infections", "PROBLEM", 63, 77], ["infections", "OBSERVATION", 67, 77]]], ["In 2013, the seasonality of HRV infection was from March to May, peaking in May (19 cases; 12%).", [["HRV infection", "DISEASE", 28, 41], ["HRV infection", "PROBLEM", 28, 41], ["infection", "OBSERVATION", 32, 41]]], ["Comparing the monthly distribution of HRV cases with average temperature ( \u2022 C) and rainfall (mm), a negative correlation between the number of HRV cases and the average temperature (rs = \u22120.636, p < 0.001) was demonstrated, but there was no significant correlation with rainfall (rs = \u22120.036, p = 0.866).DiscussionSince the implementation of systematic investigation into respiratory viruses in hospitalized patients with SARI, HRV has been found with high frequency, either alone or codetected with other respiratory viruses.", [["respiratory viruses", "DISEASE", 373, 392], ["SARI", "DISEASE", 423, 427], ["patients", "ORGANISM", 409, 417], ["patients", "SPECIES", 409, 417], ["HRV cases", "TEST", 38, 47], ["average temperature", "TEST", 53, 72], ["the average temperature", "TEST", 158, 181], ["rs", "TEST", 183, 185], ["rs", "TEST", 281, 283], ["p", "TEST", 294, 295], ["systematic investigation", "TEST", 343, 367], ["respiratory viruses", "PROBLEM", 373, 392], ["SARI", "PROBLEM", 423, 427], ["HRV", "PROBLEM", 429, 432], ["high frequency", "PROBLEM", 453, 467], ["other respiratory viruses", "PROBLEM", 501, 526], ["respiratory viruses", "OBSERVATION", 373, 392], ["respiratory", "ANATOMY", 507, 518], ["viruses", "OBSERVATION", 519, 526]]], ["Since some of these infections may have a poor prognosis, including death, it is critical to know and better characterize this infection to be prepared for its early diagnosis, appropriate clinical management, and prevention of nosocomial spread.DiscussionThe high frequency of HRV found in clinical samples from patients with SARI was similar to that reported by Kim et al. 7 in a tertiary hospital in Korea.", [["samples", "ANATOMY", 300, 307], ["infections", "DISEASE", 20, 30], ["death", "DISEASE", 68, 73], ["infection", "DISEASE", 127, 136], ["SARI", "DISEASE", 327, 331], ["samples", "CANCER", 300, 307], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["these infections", "PROBLEM", 14, 30], ["death", "PROBLEM", 68, 73], ["this infection", "PROBLEM", 122, 136], ["appropriate clinical management", "TREATMENT", 177, 208], ["nosocomial spread", "PROBLEM", 228, 245], ["HRV", "PROBLEM", 278, 281], ["SARI", "PROBLEM", 327, 331], ["infections", "OBSERVATION", 20, 30], ["infection", "OBSERVATION", 127, 136], ["nosocomial spread", "OBSERVATION", 228, 245]]], ["This difference between age groups was observed in this study, emphasizing the greater vulnerability of children to this infection, probably as consequence of a more intense inflammatory process triggered by primary infection or by favorable anatomical conditions of the respiratory tract in younger children.DiscussionRSV was the first pathogen identified to be associated with the severe respiratory disease in children.", [["respiratory tract", "ANATOMY", 271, 288], ["respiratory", "ANATOMY", 390, 401], ["infection", "DISEASE", 121, 130], ["primary infection", "DISEASE", 208, 225], ["respiratory disease", "DISEASE", 390, 409], ["children", "ORGANISM", 104, 112], ["respiratory tract", "ORGANISM_SUBDIVISION", 271, 288], ["children", "ORGANISM", 300, 308], ["children", "ORGANISM", 413, 421], ["children", "SPECIES", 104, 112], ["children", "SPECIES", 300, 308], ["children", "SPECIES", 413, 421], ["this study", "TEST", 51, 61], ["this infection", "PROBLEM", 116, 130], ["a more intense inflammatory process", "PROBLEM", 159, 194], ["primary infection", "PROBLEM", 208, 225], ["the first pathogen", "PROBLEM", 327, 345], ["the severe respiratory disease in children", "PROBLEM", 379, 421], ["infection", "OBSERVATION", 121, 130], ["more intense", "OBSERVATION_MODIFIER", 161, 173], ["inflammatory", "OBSERVATION", 174, 186], ["primary", "OBSERVATION_MODIFIER", 208, 215], ["infection", "OBSERVATION", 216, 225], ["favorable", "OBSERVATION_MODIFIER", 232, 241], ["anatomical conditions", "OBSERVATION", 242, 263], ["respiratory tract", "ANATOMY", 271, 288], ["severe", "OBSERVATION_MODIFIER", 383, 389], ["respiratory disease", "OBSERVATION", 390, 409]]], ["However, since the development of molecular techniques to detect HRV, this virus has been the focus of the most recent studies in this field.", [["HRV", "PROBLEM", 65, 68], ["this virus", "PROBLEM", 70, 80]]], ["Nowadays, HRV infections have been linked with exacerbations of chronic lung diseases and fatal pneumonia in patients at the extremes of age or with pre-existing comorbidities.", [["lung", "ANATOMY", 72, 76], ["HRV infections", "DISEASE", 10, 24], ["chronic lung diseases", "DISEASE", 64, 85], ["pneumonia", "DISEASE", 96, 105], ["lung", "ORGAN", 72, 76], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["HRV infections", "PROBLEM", 10, 24], ["chronic lung diseases", "PROBLEM", 64, 85], ["fatal pneumonia", "PROBLEM", 90, 105], ["pre-existing comorbidities", "PROBLEM", 149, 175], ["infections", "OBSERVATION", 14, 24], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["lung", "ANATOMY", 72, 76], ["diseases", "OBSERVATION", 77, 85], ["fatal", "OBSERVATION_MODIFIER", 90, 95], ["pneumonia", "OBSERVATION", 96, 105], ["comorbidities", "OBSERVATION", 162, 175]]], ["4, 5 The importance of one study that evaluated the characteristics of HRV infections in a tertiary hospital is based on these new concerns.", [["HRV infections", "DISEASE", 71, 85], ["one study", "TEST", 23, 32], ["HRV infections", "PROBLEM", 71, 85], ["infections", "OBSERVATION", 75, 85]]], ["Marcone et al. 10 reported a higher number of HRV infections in hospitalized children in Argentina when compared with pediatric outpatients with acute respiratory infection, demonstrating a scenario that contributed to the increased concern about HRV infection in the hospital setting.DiscussionPrevious studies have reported that the HRV infection rate in hospitals varies from 21% to 41%.", [["respiratory", "ANATOMY", 151, 162], ["HRV infections", "DISEASE", 46, 60], ["acute respiratory infection", "DISEASE", 145, 172], ["HRV infection", "DISEASE", 247, 260], ["HRV infection", "DISEASE", 335, 348], ["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["outpatients", "SPECIES", 128, 139], ["acute respiratory infection", "PROBLEM", 145, 172], ["HRV infection", "PROBLEM", 247, 260], ["DiscussionPrevious studies", "TEST", 285, 311], ["the HRV infection rate", "TEST", 331, 353], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory", "ANATOMY", 151, 162], ["infection", "OBSERVATION", 163, 172], ["infection", "OBSERVATION", 251, 260], ["infection", "OBSERVATION", 339, 348]]], ["8, 11, 12 However, this variation is probably accounted for by the differences in age and clinical characteristics of patients analyzed in each study.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["each study", "TEST", 139, 149], ["probably accounted for", "UNCERTAINTY", 37, 59]]], ["Although this study included all age groups, a predominance of pediatric patients infected with HRV was observed, mostly younger than 1 year old.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["this study", "TEST", 9, 19], ["HRV", "PROBLEM", 96, 99], ["infected", "OBSERVATION", 82, 90]]], ["In addition, the HRV-positive group had a greater proportion of patients with pre-existing comorbidities than the group with other identified CRVs.", [["CRVs", "DISEASE", 142, 146], ["patients", "ORGANISM", 64, 72], ["CRVs", "PATHOLOGICAL_FORMATION", 142, 146], ["patients", "SPECIES", 64, 72], ["the HRV", "TEST", 13, 20], ["pre-existing comorbidities", "PROBLEM", 78, 104]]], ["6,7,11---14 Among the comorbidities observed in this study, chronic lung diseases were frequent in the HRV group, a correlation that has already been demonstrated in another similar study, 14 which corroborates the close association of HRV infection and exacerbations of chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.", [["lung", "ANATOMY", 68, 72], ["lung", "ANATOMY", 279, 283], ["pulmonary", "ANATOMY", 322, 331], ["cystic", "ANATOMY", 360, 366], ["6,7,11---14", "CHEMICAL", 0, 11], ["chronic lung diseases", "DISEASE", 60, 81], ["HRV infection", "DISEASE", 236, 249], ["chronic lung diseases", "DISEASE", 271, 292], ["chronic obstructive pulmonary disease", "DISEASE", 302, 339], ["COPD", "DISEASE", 341, 345], ["asthma", "DISEASE", 348, 354], ["cystic fibrosis", "DISEASE", 360, 375], ["lung", "ORGAN", 68, 72], ["lung", "ORGAN", 279, 283], ["pulmonary", "ORGAN", 322, 331], ["the comorbidities", "PROBLEM", 18, 35], ["this study", "TEST", 48, 58], ["chronic lung diseases", "PROBLEM", 60, 81], ["another similar study", "TEST", 166, 187], ["HRV infection", "PROBLEM", 236, 249], ["chronic lung diseases", "PROBLEM", 271, 292], ["chronic obstructive pulmonary disease", "PROBLEM", 302, 339], ["COPD)", "PROBLEM", 341, 346], ["asthma", "PROBLEM", 348, 354], ["cystic fibrosis", "PROBLEM", 360, 375], ["comorbidities", "OBSERVATION", 22, 35], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["lung", "ANATOMY", 68, 72], ["diseases", "OBSERVATION", 73, 81], ["infection", "OBSERVATION", 240, 249], ["chronic", "OBSERVATION_MODIFIER", 271, 278], ["lung", "ANATOMY", 279, 283], ["diseases", "OBSERVATION", 284, 292], ["chronic", "OBSERVATION_MODIFIER", 302, 309], ["obstructive", "OBSERVATION_MODIFIER", 310, 321], ["pulmonary", "ANATOMY", 322, 331], ["disease", "OBSERVATION", 332, 339], ["COPD", "OBSERVATION", 341, 345], ["asthma", "OBSERVATION", 348, 354], ["cystic", "OBSERVATION_MODIFIER", 360, 366], ["fibrosis", "OBSERVATION", 367, 375]]], ["4 Of 444 samples positive for CRVs, 128 samples (29%) had at least two co-detected viruses, in keeping with the expected 10---31% encountered in hospitalized individuals.", [["samples", "ANATOMY", 9, 16], ["samples", "ANATOMY", 40, 47], ["samples", "CANCER", 9, 16], ["CRVs", "CANCER", 30, 34], ["samples", "CANCER", 40, 47], ["444 samples", "TEST", 5, 16], ["CRVs", "TEST", 30, 34], ["samples", "TEST", 40, 47], ["two co-detected viruses", "PROBLEM", 67, 90], ["co-detected viruses", "OBSERVATION", 71, 90]]], ["7, 8, 15 The viruses most frequently co-detected with HRV were EV (45%), RSV (33%), and AdV (18%); consistent with previously reported patterns.", [["RSV", "ORGANISM", 73, 76], ["AdV", "ORGANISM", 88, 91], ["RSV", "SPECIES", 73, 76], ["AdV", "SPECIES", 88, 91], ["HRV", "TEST", 54, 57], ["EV", "TEST", 63, 65], ["RSV", "TEST", 73, 76], ["AdV", "TEST", 88, 91], ["consistent with", "UNCERTAINTY", 99, 114]]], ["14, 15 However, the high frequency of EV and HRV co-detection may be as a result of using the 5 NRT region of the viral genome to identify both pathogens, which may have lowered the specificity of the RT-PCR test.", [["5 NRT region", "DNA", 94, 106], ["viral genome", "DNA", 114, 126], ["HRV co-detection", "TEST", 45, 61], ["the viral genome", "PROBLEM", 110, 126], ["both pathogens", "PROBLEM", 139, 153], ["the RT-PCR test", "TEST", 197, 212], ["viral genome", "OBSERVATION", 114, 126], ["pathogens", "OBSERVATION", 144, 153]]], ["16 A more appropriate means to discern between these species would be to carry out the RT-PCR followed by nucleotide sequencing of amplicons.", [["nucleotide", "CHEMICAL", 106, 116], ["nucleotide", "CHEMICAL", 106, 116], ["these species", "PROBLEM", 47, 60], ["the RT-PCR", "TREATMENT", 83, 93], ["nucleotide sequencing of amplicons", "TREATMENT", 106, 140]]], ["17 The high level of dual infection involving HRV and RSV is often explained both by the coexistence of these viruses throughout the year and their similar seasonal variation, 15 but this hypothesis is not unanimous.", [["infection", "DISEASE", 26, 35], ["RSV", "DISEASE", 54, 57], ["RSV", "ORGANISM", 54, 57], ["HRV", "SPECIES", 46, 49], ["RSV", "SPECIES", 54, 57], ["dual infection", "PROBLEM", 21, 35], ["RSV", "PROBLEM", 54, 57], ["these viruses", "PROBLEM", 104, 117], ["high", "OBSERVATION_MODIFIER", 7, 11], ["dual", "OBSERVATION_MODIFIER", 21, 25], ["infection", "OBSERVATION", 26, 35], ["RSV", "OBSERVATION", 54, 57], ["viruses", "OBSERVATION", 110, 117], ["seasonal variation", "OBSERVATION", 156, 174], ["not", "UNCERTAINTY", 202, 205], ["unanimous", "OBSERVATION", 206, 215]]], ["12 In contrast to findings reported by Goka et al., 15 this study did not show an association between disease severity and viral co-detections.", [["this study", "TEST", 55, 65], ["an association between disease severity", "PROBLEM", 79, 118], ["viral co-detections", "PROBLEM", 123, 142], ["viral co-detections", "OBSERVATION", 123, 142]]], ["Furthermore, HRV was not found to have a protective influence in cases where it was involved in codetection, as there was no significant difference in disease severity when comparing the groups with or without HRV co-detection.", [["significant difference in disease severity", "PROBLEM", 125, 167], ["HRV co-detection", "TEST", 210, 226], ["no", "UNCERTAINTY", 122, 124], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["difference", "OBSERVATION_MODIFIER", 137, 147], ["disease", "OBSERVATION", 151, 158]]], ["Likewise, in contradiction to the present findings, Asner et al. 18 observed an increased disease severity in children infected with HRV alone.", [["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["an increased disease severity", "PROBLEM", 77, 106], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["disease", "OBSERVATION", 90, 97]]], ["Among the probable factors associated with these contrasting findings, the following may be cited: (i) analysis in different groups of patients (outpatient and hospitalized), (ii) assessing a small number of patients, and (iii) adoption of different severity criteria.DiscussionFever was less frequent in patients infected with HRV compared to other CRVs.", [["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 208, 216], ["patients", "ORGANISM", 305, 313], ["CRVs", "CANCER", 350, 354], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 305, 313], ["HRV", "PROBLEM", 328, 331], ["small", "OBSERVATION_MODIFIER", 192, 197]]], ["19, 20 Chest X-ray findings were normal in 17%, showed interstitial infiltrate in 33%, and demonstrated pulmonary consolidation in 28% of cases, with no significant difference between the HRV and other CRV groups.", [["interstitial infiltrate", "ANATOMY", 55, 78], ["pulmonary", "ANATOMY", 104, 113], ["pulmonary consolidation", "DISEASE", 104, 127], ["pulmonary", "ORGAN", 104, 113], ["Chest X-ray findings", "TEST", 7, 27], ["interstitial infiltrate", "PROBLEM", 55, 78], ["pulmonary consolidation", "PROBLEM", 104, 127], ["the HRV", "TEST", 184, 191], ["Chest", "ANATOMY", 7, 12], ["normal", "OBSERVATION", 33, 39], ["interstitial", "ANATOMY_MODIFIER", 55, 67], ["infiltrate", "OBSERVATION", 68, 78], ["33%", "OBSERVATION_MODIFIER", 82, 85], ["pulmonary", "ANATOMY", 104, 113], ["consolidation", "OBSERVATION", 114, 127], ["no", "UNCERTAINTY", 150, 152], ["significant", "OBSERVATION_MODIFIER", 153, 164], ["difference", "OBSERVATION", 165, 175]]], ["There were significantly fewer cases of SARI diagnosed in the patients infected with HRV than other CRVs.", [["SARI", "DISEASE", 40, 44], ["SARI", "CANCER", 40, 44], ["patients", "ORGANISM", 62, 70], ["CRVs", "CANCER", 100, 104], ["patients", "SPECIES", 62, 70], ["SARI", "PROBLEM", 40, 44], ["significantly", "OBSERVATION_MODIFIER", 11, 24], ["fewer", "OBSERVATION_MODIFIER", 25, 30], ["infected", "OBSERVATION", 71, 79]]], ["Overall, 14% (110/770) of patients with SARI were infected with HRV.", [["SARI", "DISEASE", 40, 44], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["Overall", "TEST", 0, 7], ["SARI", "PROBLEM", 40, 44], ["HRV", "PROBLEM", 64, 67], ["infected", "OBSERVATION", 50, 58]]], ["This concurs with a previous study.", [["a previous study", "TEST", 18, 34]]], ["20 Reports about the seasonality of HRV infection, including a study from Argentina, 10 which is in close geographical proximity of Southern Brazil, show that it circulates mainly in autumn and spring.", [["HRV infection", "DISEASE", 36, 49], ["HRV infection", "PROBLEM", 36, 49], ["a study", "TEST", 61, 68], ["infection", "OBSERVATION", 40, 49], ["autumn", "OBSERVATION", 183, 189]]], ["7, 8, 19 Although HRV occurred in almost all months of the study period, different peaks were observed in 2012 and 2013, and neither peak included spring.", [["HRV", "PROBLEM", 18, 21], ["the study", "TEST", 55, 64]]], ["In 2013, the highest prevalence of HRV infection was in autumn, followed by winter, and vice versa in 2012.", [["HRV infection", "DISEASE", 35, 48], ["HRV infection", "PROBLEM", 35, 48], ["infection", "OBSERVATION", 39, 48]]], ["The analysis of meteorological data found a negative correlation between the number of HRV cases and the average temperature, but no significant correlation with rainfall.", [["The analysis", "TEST", 0, 12], ["meteorological data", "TEST", 16, 35], ["the average temperature", "TEST", 101, 124]]], ["However, in order to more accurately establish the seasonality of HRV infections, the analysis should include additional years.DiscussionThis research had some limitations: (i) it was a retrospective study and some medical records were incomplete; (ii) HRV species were not identified, which would have yielded important data since the genotypes reportedly have different virulence; (iii) this analysis was carried out only with hospitalized patients, which may have overestimated the impact of HRV infection; and (iv) it was not possible to evaluate the frequency of nosocomial HRV infection, data critical to guide preventive measures in the most affected settings.", [["HRV infections", "DISEASE", 66, 80], ["HRV infection", "DISEASE", 495, 508], ["HRV infection", "DISEASE", 579, 592], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 442, 450], ["HRV", "SPECIES", 66, 69], ["HRV", "SPECIES", 579, 582], ["HRV infections", "PROBLEM", 66, 80], ["the analysis", "TEST", 82, 94], ["a retrospective study", "TEST", 184, 205], ["HRV species", "PROBLEM", 253, 264], ["the genotypes", "PROBLEM", 332, 345], ["different virulence", "PROBLEM", 362, 381], ["this analysis", "TEST", 389, 402], ["HRV infection", "PROBLEM", 495, 508], ["nosocomial HRV infection", "PROBLEM", 568, 592], ["preventive measures", "TREATMENT", 617, 636], ["infections", "OBSERVATION", 70, 80], ["infection", "OBSERVATION", 499, 508], ["infection", "OBSERVATION", 583, 592]]], ["However, this is the first report about HRV infections in the region and a critical analysis of the data is important to obtain greater awareness of the dynamics of dispersion and impact of these respiratory viruses in the community.DiscussionIn conclusion, HRV has a high prevalence in the hospitalized children and was present in cases of severe disease, including death.", [["HRV infections", "DISEASE", 40, 54], ["respiratory viruses", "DISEASE", 196, 215], ["death", "DISEASE", 367, 372], ["children", "ORGANISM", 304, 312], ["children", "SPECIES", 304, 312], ["HRV infections in the region", "PROBLEM", 40, 68], ["these respiratory viruses", "PROBLEM", 190, 215], ["severe disease", "PROBLEM", 341, 355], ["death", "PROBLEM", 367, 372], ["infections", "OBSERVATION", 44, 54], ["respiratory viruses", "OBSERVATION", 196, 215], ["severe", "OBSERVATION_MODIFIER", 341, 347], ["disease", "OBSERVATION", 348, 355]]], ["However, a dependent relationship between the presence of HRV in viral co-detections and severity of disease was not observed in this study.", [["HRV in viral co-detections", "PROBLEM", 58, 84], ["disease", "PROBLEM", 101, 108], ["this study", "TEST", 129, 139], ["dependent", "OBSERVATION_MODIFIER", 11, 20], ["viral co-detections", "OBSERVATION", 65, 84], ["severity", "OBSERVATION_MODIFIER", 89, 97], ["disease", "OBSERVATION", 101, 108]]], ["Conflicts in the literature demand a closer analysis of cases of co-detection involving HRV with review of the data to determine the impact of this, since the lack of standardization between studies probably contributes to the divergent data.", [["the data", "TEST", 107, 115], ["studies", "TEST", 191, 198], ["the divergent data", "TEST", 223, 241]]], ["HRV infection is closely associated with comorbidities, mainly chronic lung diseases, and is an important factor in exacerbations of these underlying lung diseases.", [["lung", "ANATOMY", 71, 75], ["lung", "ANATOMY", 150, 154], ["HRV infection", "DISEASE", 0, 13], ["chronic lung diseases", "DISEASE", 63, 84], ["lung diseases", "DISEASE", 150, 163], ["lung", "ORGAN", 71, 75], ["lung", "ORGAN", 150, 154], ["HRV infection", "PROBLEM", 0, 13], ["comorbidities", "PROBLEM", 41, 54], ["mainly chronic lung diseases", "PROBLEM", 56, 84], ["these underlying lung diseases", "PROBLEM", 133, 163], ["infection", "OBSERVATION", 4, 13], ["closely associated with", "UNCERTAINTY", 17, 40], ["mainly", "OBSERVATION_MODIFIER", 56, 62], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["lung", "ANATOMY", 71, 75], ["diseases", "OBSERVATION", 76, 84], ["lung", "ANATOMY", 150, 154], ["diseases", "OBSERVATION", 155, 163]]], ["The colder seasons were the period with higher frequency of HRV infections in Southern Brazil, and therefore must be a period to warn clinicians about young age children affected by respiratory infections, especially those with comorbidities such as chronic lung disease.", [["respiratory", "ANATOMY", 182, 193], ["lung", "ANATOMY", 258, 262], ["HRV infections", "DISEASE", 60, 74], ["respiratory infections", "DISEASE", 182, 204], ["chronic lung disease", "DISEASE", 250, 270], ["children", "ORGANISM", 161, 169], ["lung", "ORGAN", 258, 262], ["children", "SPECIES", 161, 169], ["HRV infections", "PROBLEM", 60, 74], ["respiratory infections", "PROBLEM", 182, 204], ["comorbidities", "PROBLEM", 228, 241], ["chronic lung disease", "PROBLEM", 250, 270], ["infections", "OBSERVATION", 64, 74], ["respiratory", "ANATOMY", 182, 193], ["infections", "OBSERVATION", 194, 204], ["chronic", "OBSERVATION_MODIFIER", 250, 257], ["lung", "ANATOMY", 258, 262], ["disease", "OBSERVATION", 263, 270]]], ["Patients with this profile should have respiratory samples collected to identify possible viral infection, and if HRV is detected, the medical staff should be ready for adequate management, taking into consideration the possible poor outcomes.FundingSMR is sponsored by a CNPq fellowship.Conflicts of interestThe authors declare no conflicts of interest.", [["respiratory samples", "ANATOMY", 39, 58], ["viral infection", "DISEASE", 90, 105], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["respiratory samples", "TEST", 39, 58], ["viral infection", "PROBLEM", 90, 105], ["HRV", "PROBLEM", 114, 117], ["adequate management", "TREATMENT", 169, 188], ["possible", "UNCERTAINTY", 81, 89], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105]]]], "2a6b8fd9ae38d9c204f43f32d8b5ab824cf721a4": [["To the Editor-The lack of resources for and limitations placed upon testing for the 2019 novel coronavirus disease (COVID-19) have been well documented.", [["coronavirus disease", "DISEASE", 95, 114], ["coronavirus", "ORGANISM", 95, 106], ["testing", "TEST", 68, 75], ["novel coronavirus disease", "PROBLEM", 89, 114], ["COVID", "TEST", 116, 121]]], ["[1] [2] [3] On March 12, 2020, the governor of Delaware declared a state of emergency with identification of the first local cases of COVID-19, which led to an increase in testing interest among the public.", [["COVID", "TEST", 134, 139], ["increase", "OBSERVATION_MODIFIER", 160, 168]]]], "78e6b7c152de9d4a93ec7be318b196d5f993a35f": [["IntroductionRabies is a dreadful disease caused by a virus belonging to genus Lyssavirus of family Rhabdoviridae.", [["IntroductionRabies", "DISEASE", 0, 18], ["a dreadful disease", "PROBLEM", 22, 40], ["Rhabdoviridae", "TREATMENT", 99, 112]]], ["Rabies virus (RABV) infection is considered to be one of the oldest and most fatal neurological diseases known to mankind.", [["neurological", "ANATOMY", 83, 95], ["Rabies virus (RABV) infection", "DISEASE", 0, 29], ["neurological diseases", "DISEASE", 83, 104], ["Rabies virus", "ORGANISM", 0, 12], ["RABV", "ORGANISM", 14, 18], ["Rabies virus", "SPECIES", 0, 12], ["Rabies virus", "SPECIES", 0, 12], ["RABV", "SPECIES", 14, 18], ["Rabies virus (RABV) infection", "PROBLEM", 0, 29], ["most fatal neurological diseases", "PROBLEM", 72, 104], ["fatal", "OBSERVATION_MODIFIER", 77, 82], ["neurological diseases", "OBSERVATION", 83, 104]]], ["Present practice of rabies control in animals and humans is to take prophylactic pre-exposure vaccination.", [["rabies", "ORGANISM", 20, 26], ["humans", "ORGANISM", 50, 56], ["humans", "SPECIES", 50, 56], ["rabies", "SPECIES", 20, 26], ["humans", "SPECIES", 50, 56], ["rabies control", "TREATMENT", 20, 34], ["prophylactic pre-exposure vaccination", "TREATMENT", 68, 105]]], ["Post-exposure vaccination is obligatory in all cases as treatment after human exposure to infected animal bites (Wiktor Abbreviations: Ad, adenovirus; BHK-21, baby hamster kidney-21; CNS, central nervous system; CVS-11, challenge virus standard-11; EGFP, enhanced green fluorescent protein; ffu, fluorescent foci unit; HEK-293, human embryonic kidney-293; L, large polymerase; LD50, lethal dose 50%; MOI, multiplicity of infection; N, nucleoprotein; PV-11, Pasteur virus-11; RFP, red fluorescent protein; RNAi, RNA interference; RABV, rabies virus; shRNA, small hairpin RNA; siRNA, small interfering RNA.Introduction* Corresponding author.", [["kidney-21", "ANATOMY", 172, 181], ["CNS", "ANATOMY", 183, 186], ["central nervous system", "ANATOMY", 188, 210], ["HEK-293", "ANATOMY", 319, 326], ["embryonic kidney-293", "ANATOMY", 334, 354], ["infected animal bites", "DISEASE", 90, 111], ["HEK-293", "CHEMICAL", 319, 326], ["infection", "DISEASE", 421, 430], ["human", "ORGANISM", 72, 77], ["Ad", "ORGANISM", 135, 137], ["adenovirus", "ORGANISM", 139, 149], ["BHK-21", "ORGANISM", 151, 157], ["baby hamster kidney-21", "ORGANISM", 159, 181], ["CNS", "ANATOMICAL_SYSTEM", 183, 186], ["central nervous system", "ANATOMICAL_SYSTEM", 188, 210], ["EGFP", "GENE_OR_GENE_PRODUCT", 249, 253], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 264, 289], ["ffu", "GENE_OR_GENE_PRODUCT", 291, 294], ["HEK-293", "CELL", 319, 326], ["human", "ORGANISM", 328, 333], ["embryonic kidney-293; L", "CELL", 334, 357], ["Pasteur virus-11", "ORGANISM", 457, 473], ["RFP", "GENE_OR_GENE_PRODUCT", 475, 478], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 480, 503], ["RABV", "ORGANISM", 529, 533], ["rabies virus", "ORGANISM", 535, 547], ["EGFP", "PROTEIN", 249, 253], ["green fluorescent protein", "PROTEIN", 264, 289], ["ffu", "PROTEIN", 291, 294], ["HEK-293", "CELL_LINE", 319, 326], ["RFP", "PROTEIN", 475, 478], ["red fluorescent protein", "PROTEIN", 480, 503], ["RNAi, RNA interference", "RNA", 505, 527], ["RABV, rabies virus; shRNA, small hairpin RNA", "RNA", 529, 573], ["siRNA, small interfering RNA", "RNA", 575, 603], ["human", "SPECIES", 72, 77], ["hamster", "SPECIES", 164, 171], ["human", "SPECIES", 328, 333], ["Pasteur virus", "SPECIES", 457, 470], ["rabies virus", "SPECIES", 535, 547], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 328, 333], ["Pasteur virus-11", "SPECIES", 457, 473], ["RABV", "SPECIES", 529, 533], ["rabies virus", "SPECIES", 535, 547], ["Post-exposure vaccination", "TREATMENT", 0, 25], ["treatment", "TREATMENT", 56, 65], ["infected animal bites", "PROBLEM", 90, 111], ["BHK", "TEST", 151, 154], ["baby hamster kidney", "TEST", 159, 178], ["CVS", "TEST", 212, 215], ["challenge virus standard", "TEST", 220, 244], ["EGFP", "TEST", 249, 253], ["green fluorescent protein", "TEST", 264, 289], ["ffu", "TEST", 291, 294], ["HEK", "TEST", 319, 322], ["human embryonic kidney", "TEST", 328, 350], ["large polymerase", "PROBLEM", 359, 375], ["LD50", "TEST", 377, 381], ["lethal dose", "TEST", 383, 394], ["MOI", "PROBLEM", 400, 403], ["infection", "PROBLEM", 421, 430], ["nucleoprotein", "TEST", 435, 448], ["PV", "TEST", 450, 452], ["Pasteur virus", "TEST", 457, 470], ["RFP", "TEST", 475, 478], ["red fluorescent protein", "TEST", 480, 503], ["RNAi", "TEST", 505, 509], ["RNA interference", "PROBLEM", 511, 527], ["RABV", "PROBLEM", 529, 533], ["rabies virus", "PROBLEM", 535, 547], ["shRNA", "PROBLEM", 549, 554], ["small hairpin RNA", "PROBLEM", 556, 573], ["siRNA", "PROBLEM", 575, 580], ["small interfering RNA", "PROBLEM", 582, 603], ["kidney", "ANATOMY", 172, 178], ["central nervous", "ANATOMY", 188, 203], ["kidney", "ANATOMY", 344, 350], ["infection", "OBSERVATION", 421, 430], ["small", "OBSERVATION_MODIFIER", 556, 561], ["hairpin RNA", "OBSERVATION", 562, 573], ["siRNA", "ANATOMY", 575, 580], ["small", "OBSERVATION_MODIFIER", 582, 587], ["interfering RNA", "OBSERVATION", 588, 603]]], ["Tel.: +91 581 2301584; fax: +91 581 2301940.IntroductionE-mail address: praveen.indian@gmail.com (P.K. Gupta). et al., 1984) .", [["+91 581 2301584", "CHEMICAL", 6, 21], ["+91 581 2301584", "CHEMICAL", 6, 21]]], ["Sometimes, due to unnoticed exposure or vaccination failure, the disease is diagnosed after the onset of clinical symptoms and death becomes unavoidable due to unavailability of any effective line of treatment for clinical cases of rabies.", [["death", "DISEASE", 127, 132], ["rabies", "DISEASE", 232, 238], ["rabies", "ORGANISM", 232, 238], ["rabies", "SPECIES", 232, 238], ["unnoticed exposure", "PROBLEM", 18, 36], ["vaccination failure", "PROBLEM", 40, 59], ["the disease", "PROBLEM", 61, 72], ["clinical symptoms", "PROBLEM", 105, 122], ["death", "PROBLEM", 127, 132], ["treatment", "TREATMENT", 200, 209], ["rabies", "PROBLEM", 232, 238], ["disease", "OBSERVATION", 65, 72]]], ["Therefore, efforts are being made to develop an effective antiviral strategy against rabies with the potential to suppress virus infection in cells and clear the infection without damaging the cell.", [["cells", "ANATOMY", 142, 147], ["cell", "ANATOMY", 193, 197], ["rabies", "DISEASE", 85, 91], ["infection", "DISEASE", 129, 138], ["infection", "DISEASE", 162, 171], ["rabies", "ORGANISM", 85, 91], ["cells", "CELL", 142, 147], ["cell", "CELL", 193, 197], ["rabies", "SPECIES", 85, 91], ["an effective antiviral strategy", "TREATMENT", 45, 76], ["rabies", "PROBLEM", 85, 91], ["virus infection in cells", "PROBLEM", 123, 147], ["the infection", "PROBLEM", 158, 171], ["damaging the cell", "PROBLEM", 180, 197], ["infection", "OBSERVATION", 162, 171]]], ["The various approaches include strategy based on RNA interference (RNAi).IntroductionConsidering the potential of RNAi as antiviral agent, few groups have evaluated RNAi based antiviral agents against rabies (Brandao et al., 2007; Israsena et al., 2009) .IntroductionRNAi mediated by small interfering RNAs (siRNAs) is a powerful technology allowing the silencing of genes with great specificity and potency.", [["rabies", "DISEASE", 201, 207], ["rabies", "ORGANISM", 201, 207], ["small interfering RNAs", "GENE_OR_GENE_PRODUCT", 284, 306], ["small interfering RNAs", "RNA", 284, 306], ["siRNAs", "DNA", 308, 314], ["rabies", "SPECIES", 201, 207], ["RNAi", "TREATMENT", 114, 118], ["antiviral agent", "TREATMENT", 122, 137], ["RNAi based antiviral agents", "TREATMENT", 165, 192], ["small interfering RNAs (siRNAs)", "PROBLEM", 284, 315], ["small", "OBSERVATION_MODIFIER", 284, 289], ["interfering RNAs", "OBSERVATION", 290, 306]]], ["It is a highly conserved natural mechanism described for plants, fungi, worms, insects, and mammals (Ma et al., 2007, for review) .", [["worms", "ANATOMY", 72, 77], ["worms", "SPECIES", 72, 77], ["fungi", "PROBLEM", 65, 70]]], ["The gene silencing mechanism is mediated by short RNA, named siRNAs, whereby an RNA-induced silencing complex forms an activated complex that target mRNA with sequence complementary to the siRNAs.", [["short RNA", "RNA", 44, 53], ["RNA-induced silencing complex", "PROTEIN", 80, 109], ["mRNA", "RNA", 149, 153], ["siRNAs", "DNA", 189, 195], ["The gene silencing mechanism", "PROBLEM", 0, 28], ["short RNA, named siRNAs", "PROBLEM", 44, 67], ["an RNA-induced silencing complex", "PROBLEM", 77, 109], ["silencing mechanism", "OBSERVATION", 9, 28], ["siRNAs", "ANATOMY", 189, 195]]], ["This renders the mRNA transcripts inert and degradable resulting in a specific knockdown of the targeted gene expression.", [["mRNA transcripts", "RNA", 17, 33], ["gene expression", "OBSERVATION", 105, 120]]], ["The sequence-specific knockdown of viral genes in infected cells generated great interest in development of siRNAsbased antiviral agents. siRNA-based antiviral activity has been reported for many RNA and DNA viruses in vitro and in vivo, including, human immunodeficiency virus, poliovirus, hepatitis B virus, hepatitis C virus, human papilloma virus, dengue virus, hepatitis delta virus, murine gamma herpesviruses, severe acute coronavirus and respiratory syncytial virus infections (Sliva and Schnierle, 2010, for review) .IntroductionIn the present study, we report siRNA-based RNAi to inhibit RABV multiplication.", [["cells", "ANATOMY", 59, 64], ["human immunodeficiency virus", "DISEASE", 249, 277], ["hepatitis B", "DISEASE", 291, 302], ["hepatitis C", "DISEASE", 310, 321], ["human papilloma virus", "DISEASE", 329, 350], ["dengue virus", "DISEASE", 352, 364], ["hepatitis delta virus", "DISEASE", 366, 387], ["gamma herpesviruses", "DISEASE", 396, 415], ["acute coronavirus", "DISEASE", 424, 441], ["respiratory syncytial virus infections", "DISEASE", 446, 484], ["cells", "CELL", 59, 64], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["human immunodeficiency virus", "ORGANISM", 249, 277], ["poliovirus,", "ORGANISM", 279, 290], ["hepatitis B virus", "ORGANISM", 291, 308], ["hepatitis C virus", "ORGANISM", 310, 327], ["human papilloma virus", "ORGANISM", 329, 350], ["dengue virus", "ORGANISM", 352, 364], ["hepatitis delta virus", "ORGANISM", 366, 387], ["murine gamma herpesviruses", "ORGANISM", 389, 415], ["acute coronavirus", "ORGANISM", 424, 441], ["respiratory syncytial virus", "ORGANISM", 446, 473], ["RABV", "ORGANISM", 598, 602], ["viral genes", "DNA", 35, 46], ["infected cells", "CELL_TYPE", 50, 64], ["human immunodeficiency virus", "SPECIES", 249, 277], ["hepatitis B virus", "SPECIES", 291, 308], ["hepatitis C virus", "SPECIES", 310, 327], ["human papilloma virus", "SPECIES", 329, 350], ["dengue virus", "SPECIES", 352, 364], ["hepatitis delta virus", "SPECIES", 366, 387], ["murine", "SPECIES", 389, 395], ["coronavirus", "SPECIES", 430, 441], ["respiratory syncytial virus", "SPECIES", 446, 473], ["human immunodeficiency virus", "SPECIES", 249, 277], ["hepatitis B virus", "SPECIES", 291, 308], ["hepatitis C virus", "SPECIES", 310, 327], ["human papilloma virus", "SPECIES", 329, 350], ["dengue virus", "SPECIES", 352, 364], ["hepatitis delta virus", "SPECIES", 366, 387], ["respiratory syncytial virus", "SPECIES", 446, 473], ["RABV", "SPECIES", 598, 602], ["The sequence", "TEST", 0, 12], ["viral genes in infected cells", "PROBLEM", 35, 64], ["siRNAsbased antiviral agents", "TREATMENT", 108, 136], ["siRNA", "TREATMENT", 138, 143], ["many RNA", "PROBLEM", 191, 199], ["DNA viruses", "PROBLEM", 204, 215], ["human immunodeficiency virus", "PROBLEM", 249, 277], ["poliovirus", "PROBLEM", 279, 289], ["hepatitis B virus", "PROBLEM", 291, 308], ["hepatitis C virus", "PROBLEM", 310, 327], ["human papilloma virus", "PROBLEM", 329, 350], ["dengue virus", "PROBLEM", 352, 364], ["hepatitis delta virus", "PROBLEM", 366, 387], ["murine gamma herpesviruses", "PROBLEM", 389, 415], ["severe acute coronavirus", "PROBLEM", 417, 441], ["respiratory syncytial virus infections", "PROBLEM", 446, 484], ["the present study", "TEST", 541, 558], ["viral genes", "OBSERVATION", 35, 46], ["infected cells", "OBSERVATION", 50, 64], ["siRNAsbased antiviral agents", "OBSERVATION", 108, 136], ["antiviral activity", "OBSERVATION", 150, 168], ["papilloma virus", "OBSERVATION", 335, 350], ["gamma herpesviruses", "OBSERVATION", 396, 415], ["severe", "OBSERVATION_MODIFIER", 417, 423], ["acute", "OBSERVATION_MODIFIER", 424, 429], ["coronavirus", "OBSERVATION", 430, 441], ["respiratory", "ANATOMY", 446, 457], ["syncytial virus", "OBSERVATION", 458, 473], ["RABV multiplication", "OBSERVATION", 598, 617]]], ["The siRNAs targeting RABV-N and L genes were designed and delivered using an adenoviral vector and inhibition of RABV multiplication was evaluated in vitro in BHK-21 cells.", [["BHK-21 cells", "ANATOMY", 159, 171], ["RABV-N", "GENE_OR_GENE_PRODUCT", 21, 27], ["adenoviral", "ORGANISM", 77, 87], ["RABV", "ORGANISM", 113, 117], ["BHK-21 cells", "CELL", 159, 171], ["RABV-N and L genes", "DNA", 21, 39], ["BHK-21 cells", "CELL_LINE", 159, 171], ["RABV", "SPECIES", 21, 25], ["RABV", "SPECIES", 113, 117], ["BHK-21", "SPECIES", 159, 165], ["The siRNAs targeting RABV", "TEST", 0, 25], ["an adenoviral vector", "TREATMENT", 74, 94], ["inhibition of RABV multiplication", "TREATMENT", 99, 132]]], ["The protection against lethal RABV challenge was evaluated in vivo in mice after intracerebral treatment with adenoviruses expressing siRNAs targeting RABV genes.Cells and virusBaby hamster kidney-21 (BHK-21) and human embryonic kidney-293 (HEK-293) cells, used in this study, were procured from National Centre for Cell Science (NCCS), Pune, India and grown at 37 \u2022 C under 5% CO 2 in Dulbecco's modified minimum essential medium (DMEM, Hyclone), supplemented with 10% fetal bovine serum (FBS, Hyclone) and 50 g/ml gentamicin.Cells and virusThe mouse brain-adapted RABV challenge virus standard-11 (CVS-11) strain was used to amplify RABV genes in RT-PCR and for in vivo challenge in mice.", [["intracerebral", "ANATOMY", 81, 94], ["Cells", "ANATOMY", 162, 167], ["kidney-21", "ANATOMY", 190, 199], ["BHK-21", "ANATOMY", 201, 207], ["embryonic kidney-293 (HEK-293) cells", "ANATOMY", 219, 255], ["Cell", "ANATOMY", 316, 320], ["fetal bovine serum", "ANATOMY", 470, 488], ["FBS", "ANATOMY", 490, 493], ["Cells", "ANATOMY", 527, 532], ["brain", "ANATOMY", 552, 557], ["gentamicin", "CHEMICAL", 516, 526], ["CO 2", "CHEMICAL", 378, 382], ["gentamicin", "CHEMICAL", 516, 526], ["RABV", "ORGANISM", 30, 34], ["mice", "ORGANISM", 70, 74], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["adenoviruses", "ORGANISM", 110, 122], ["RABV", "ORGANISM", 151, 155], ["Cells", "CELL", 162, 167], ["virusBaby hamster kidney-21", "CELL", 172, 199], ["BHK-21", "CELL", 201, 207], ["human", "ORGANISM", 213, 218], ["embryonic kidney-293 (HEK-293) cells", "CELL", 219, 255], ["bovine", "ORGANISM", 476, 482], ["serum", "ORGANISM_SUBSTANCE", 483, 488], ["FBS", "ORGANISM_SUBSTANCE", 490, 493], ["Hyclone", "ORGANISM_SUBSTANCE", 495, 502], ["gentamicin", "SIMPLE_CHEMICAL", 516, 526], ["Cells", "CELL", 527, 532], ["mouse", "ORGANISM", 546, 551], ["brain", "ORGAN", 552, 557], ["RABV challenge virus", "ORGANISM", 566, 586], ["RABV", "ORGANISM", 635, 639], ["mice", "ORGANISM", 685, 689], ["RABV genes", "DNA", 151, 161], ["virusBaby hamster kidney-21 (BHK-21", "CELL_LINE", 172, 207], ["human embryonic kidney-293 (HEK-293) cells", "CELL_LINE", 213, 255], ["RABV genes", "DNA", 635, 645], ["mice", "SPECIES", 70, 74], ["hamster", "SPECIES", 182, 189], ["human", "SPECIES", 213, 218], ["bovine", "SPECIES", 476, 482], ["mouse", "SPECIES", 546, 551], ["RABV challenge virus", "SPECIES", 566, 586], ["mice", "SPECIES", 685, 689], ["RABV", "SPECIES", 30, 34], ["mice", "SPECIES", 70, 74], ["RABV", "SPECIES", 151, 155], ["human", "SPECIES", 213, 218], ["bovine", "SPECIES", 476, 482], ["mouse", "SPECIES", 546, 551], ["RABV challenge virus", "SPECIES", 566, 586], ["RABV", "SPECIES", 635, 639], ["mice", "SPECIES", 685, 689], ["The protection", "TREATMENT", 0, 14], ["lethal RABV challenge", "TREATMENT", 23, 44], ["intracerebral treatment", "TREATMENT", 81, 104], ["adenoviruses", "TREATMENT", 110, 122], ["Cells", "TEST", 162, 167], ["virusBaby hamster kidney", "TEST", 172, 196], ["BHK", "TEST", 201, 204], ["human embryonic kidney", "TEST", 213, 235], ["HEK", "TEST", 241, 244], ["cells", "TEST", 250, 255], ["this study", "TEST", 265, 275], ["10% fetal bovine serum (FBS, Hyclone)", "TREATMENT", 466, 503], ["gentamicin", "TREATMENT", 516, 526], ["virus", "PROBLEM", 537, 542], ["The mouse brain", "PROBLEM", 542, 557], ["CVS", "TEST", 600, 603], ["strain", "PROBLEM", 608, 614], ["PCR", "TEST", 652, 655], ["RABV genes", "OBSERVATION", 151, 161], ["kidney", "ANATOMY", 190, 196], ["kidney", "ANATOMY", 229, 235], ["virus", "OBSERVATION", 537, 542], ["brain", "ANATOMY", 552, 557]]], ["The RABV Pasteur virus-11 (PV-11) strain adapted to BHK-21 was used for in vitro challenge studies in BHK-21 cells.Construction of RABV target gene reporter plasmidsThe target gene reporter plasmids, pDsRed-N and pDsRed-L, were constructed for expressing RABV-N and L protein, respectively, with C-terminal fusion with red fluorescent protein (RFP).", [["BHK-21", "ANATOMY", 52, 58], ["BHK-21 cells", "ANATOMY", 102, 114], ["plasmids", "ANATOMY", 190, 198], ["BHK-21", "CHEMICAL", 52, 58], ["C", "CHEMICAL", 296, 297], ["RABV Pasteur virus-11", "ORGANISM", 4, 25], ["PV-11", "ORGANISM", 27, 32], ["BHK-21", "CELL", 52, 58], ["BHK-21 cells", "CELL", 102, 114], ["RABV", "ORGANISM", 131, 135], ["pDsRed-N", "GENE_OR_GENE_PRODUCT", 200, 208], ["pDsRed-L", "GENE_OR_GENE_PRODUCT", 213, 221], ["RABV-N", "GENE_OR_GENE_PRODUCT", 255, 261], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 319, 342], ["RFP", "GENE_OR_GENE_PRODUCT", 344, 347], ["BHK-21 cells", "CELL_LINE", 102, 114], ["RABV target gene reporter plasmids", "DNA", 131, 165], ["target gene reporter plasmids", "DNA", 169, 198], ["pDsRed", "DNA", 200, 206], ["N", "DNA", 207, 208], ["pDsRed", "DNA", 213, 219], ["L", "DNA", 220, 221], ["RABV-N and L protein", "PROTEIN", 255, 275], ["C-terminal fusion", "PROTEIN", 296, 313], ["red fluorescent protein", "PROTEIN", 319, 342], ["RFP", "PROTEIN", 344, 347], ["RABV Pasteur virus", "SPECIES", 4, 22], ["RABV Pasteur virus-11 (PV-11", "SPECIES", 4, 32], ["BHK-21", "SPECIES", 52, 58], ["BHK-21", "SPECIES", 102, 108], ["RABV", "SPECIES", 131, 135], ["RABV", "SPECIES", 255, 259], ["The RABV Pasteur virus", "TEST", 0, 22], ["PV", "TEST", 27, 29], ["strain", "PROBLEM", 34, 40], ["BHK", "TEST", 52, 55], ["vitro challenge studies", "TEST", 75, 98], ["BHK", "TEST", 102, 105], ["RABV target gene reporter plasmids", "TREATMENT", 131, 165], ["The target gene reporter plasmids", "TEST", 165, 198], ["pDsRed", "TEST", 200, 206], ["RABV", "TEST", 255, 259], ["C-terminal fusion", "PROBLEM", 296, 313], ["red fluorescent protein", "TEST", 319, 342], ["terminal", "ANATOMY_MODIFIER", 298, 306], ["fusion", "OBSERVATION", 307, 313]]], ["For construction of pDsRed-N, the full-length (1380 bp) RABV-N gene was amplified by RT-PCR with primers (Supplementary Table 1 ) using cDNA prepared from total RNA isolated from RABV-CVS-11-infected mouse brain and inserted into HindIII and BamHI sites in pDSRed-N1 vector (Clontech).", [["brain", "ANATOMY", 206, 211], ["pDsRed-N", "GENE_OR_GENE_PRODUCT", 20, 28], ["RABV-N", "GENE_OR_GENE_PRODUCT", 56, 62], ["RABV-CVS-11", "ORGANISM", 179, 190], ["mouse", "ORGANISM", 200, 205], ["brain", "ORGAN", 206, 211], ["HindIII", "GENE_OR_GENE_PRODUCT", 230, 237], ["BamHI", "GENE_OR_GENE_PRODUCT", 242, 247], ["Clontech", "GENE_OR_GENE_PRODUCT", 275, 283], ["pDsRed", "DNA", 20, 26], ["N", "DNA", 27, 28], ["RABV-N gene", "DNA", 56, 67], ["cDNA", "DNA", 136, 140], ["HindIII and BamHI sites", "DNA", 230, 253], ["pDSRed-N1 vector", "DNA", 257, 273], ["mouse", "SPECIES", 200, 205], ["RABV-CVS-11", "SPECIES", 179, 190], ["mouse", "SPECIES", 200, 205], ["bp", "TEST", 52, 54], ["RABV", "TEST", 56, 60], ["primers (Supplementary Table", "TREATMENT", 97, 125], ["total RNA", "TEST", 155, 164], ["RABV", "TEST", 179, 183], ["CVS", "TEST", 184, 187], ["infected mouse brain", "PROBLEM", 191, 211], ["BamHI sites", "TREATMENT", 242, 253], ["brain", "ANATOMY", 206, 211], ["HindIII", "ANATOMY", 230, 237], ["N1 vector", "OBSERVATION", 264, 273]]], ["Similarly, pDsRed-L was constructed by amplifying 636 bp partial RABV-L polymerase gene fragment containing siRNA target site by RT-PCR using primers (Supplementary Table 1 ) and cloned into XhoI and BamHI sites in pDSRed-N1 vector.", [["pDsRed-L", "GENE_OR_GENE_PRODUCT", 11, 19], ["RABV-L polymerase", "GENE_OR_GENE_PRODUCT", 65, 82], ["XhoI", "GENE_OR_GENE_PRODUCT", 191, 195], ["BamHI", "GENE_OR_GENE_PRODUCT", 200, 205], ["pDSRed-N1", "GENE_OR_GENE_PRODUCT", 215, 224], ["pDsRed", "PROTEIN", 11, 17], ["L", "DNA", 18, 19], ["636 bp partial RABV-L polymerase gene fragment", "DNA", 50, 96], ["siRNA target site", "DNA", 108, 125], ["XhoI and BamHI sites", "DNA", 191, 211], ["pDSRed-N1 vector", "DNA", 215, 231], ["bp partial RABV-L polymerase gene fragment", "TREATMENT", 54, 96], ["siRNA target site", "TREATMENT", 108, 125], ["RT-PCR using primers (Supplementary Table", "TREATMENT", 129, 170], ["BamHI sites", "TREATMENT", 200, 211], ["partial", "OBSERVATION_MODIFIER", 57, 64], ["RABV", "OBSERVATION", 65, 69], ["fragment", "OBSERVATION_MODIFIER", 88, 96], ["siRNA target", "OBSERVATION", 108, 120], ["N1 vector", "OBSERVATION", 222, 231]]], ["The expression of red fluorescent protein (RFP) fusion proteins (N-RFP and L-RFP) was confirmed in transfected HEK-293 cells.Construction of silencing constructs encoding short hairpin RNAs (shRNAs)The siRNAs targeting RABV-N and L genes were designed using algorithm following sequence-motif and thermodynamics guidelines (Ui-Tei et al., 2008) .", [["HEK-293 cells", "ANATOMY", 111, 124], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 18, 41], ["RFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["N-RFP", "GENE_OR_GENE_PRODUCT", 65, 70], ["L-RFP", "GENE_OR_GENE_PRODUCT", 75, 80], ["HEK-293 cells", "CELL", 111, 124], ["short hairpin RNAs", "GENE_OR_GENE_PRODUCT", 171, 189], ["RABV-N", "GENE_OR_GENE_PRODUCT", 219, 225], ["red fluorescent protein (RFP) fusion proteins", "PROTEIN", 18, 63], ["N", "PROTEIN", 65, 66], ["RFP", "PROTEIN", 67, 70], ["L", "PROTEIN", 75, 76], ["RFP", "PROTEIN", 77, 80], ["transfected HEK-293 cells", "CELL_LINE", 99, 124], ["silencing constructs", "DNA", 141, 161], ["short hairpin RNAs", "RNA", 171, 189], ["shRNAs", "DNA", 191, 197], ["RABV-N and L genes", "DNA", 219, 237], ["HEK-293", "SPECIES", 111, 118], ["red fluorescent protein", "TEST", 18, 41], ["RFP) fusion proteins", "TEST", 43, 63], ["N", "TEST", 65, 66], ["RFP", "TEST", 67, 70], ["Construction of silencing constructs", "TREATMENT", 125, 161], ["short hairpin RNAs", "PROBLEM", 171, 189], ["The siRNAs", "TEST", 198, 208]]], ["Two siRNA sequences (si-N and si-L) along with antisense and loop sequences were synthesized as oligonucleotides (Supplementary Table 1 ), annealed and cloned into shRNA expressing plasmid pMCS-eGFP-containing enhanced green fluorescent protein (EGFP) as reporter gene.", [["plasmid", "ANATOMY", 181, 188], ["si-N", "GENE_OR_GENE_PRODUCT", 21, 25], ["si-L", "GENE_OR_GENE_PRODUCT", 30, 34], ["pMCS-eGFP-containing enhanced green fluorescent protein", "GENE_OR_GENE_PRODUCT", 189, 244], ["EGFP", "GENE_OR_GENE_PRODUCT", 246, 250], ["siRNA sequences", "DNA", 4, 19], ["si-N and si-L", "DNA", 21, 34], ["antisense and loop sequences", "DNA", 47, 75], ["shRNA expressing plasmid pMCS-eGFP-containing enhanced green fluorescent protein (EGFP) as reporter gene", "DNA", 164, 268], ["Two siRNA sequences", "TEST", 0, 19], ["si", "TEST", 21, 23], ["antisense and loop sequences", "TREATMENT", 47, 75], ["oligonucleotides (Supplementary Table", "TREATMENT", 96, 133]]], ["One scrambled siRNA (si-C) with no homology with the RABV genome was also cloned as shRNA for negative control siRNA (Supplementary Table 1 ).Co-transfection of RABV reporter target gene and shRNA expression plasmidsTo evaluate the efficiency of siRNAs silencing RABV genes, HEK-293 cells were transiently co-transfected with two plasmids: a reporter gene construct (encoding either RABV-N or L gene fused to RFP) and a silencing construct encoding a gene-specific siRNA (si-N or si-L) or negative control siRNA (si-C).", [["HEK-293 cells", "ANATOMY", 275, 288], ["plasmids", "ANATOMY", 330, 338], ["si-C", "GENE_OR_GENE_PRODUCT", 21, 25], ["RABV", "ORGANISM", 53, 57], ["RABV", "ORGANISM", 161, 165], ["RABV", "ORGANISM", 263, 267], ["HEK-293 cells", "CELL", 275, 288], ["RABV-N or L gene", "GENE_OR_GENE_PRODUCT", 383, 399], ["RFP", "GENE_OR_GENE_PRODUCT", 409, 412], ["si-N", "GENE_OR_GENE_PRODUCT", 472, 476], ["si-L", "GENE_OR_GENE_PRODUCT", 480, 484], ["si-C", "SIMPLE_CHEMICAL", 513, 517], ["RABV genome", "DNA", 53, 64], ["RABV reporter target gene", "DNA", 161, 186], ["shRNA expression plasmids", "DNA", 191, 216], ["RABV genes", "DNA", 263, 273], ["HEK-293 cells", "CELL_LINE", 275, 288], ["plasmids", "DNA", 330, 338], ["reporter gene construct", "DNA", 342, 365], ["RABV-N", "DNA", 383, 389], ["L gene", "DNA", 393, 399], ["RFP", "DNA", 409, 412], ["silencing construct", "DNA", 420, 439], ["si-L", "DNA", 480, 484], ["negative control siRNA", "DNA", 489, 511], ["si-C", "DNA", 513, 517], ["RABV", "SPECIES", 53, 57], ["RABV", "SPECIES", 161, 165], ["RABV", "SPECIES", 263, 267], ["HEK-293", "SPECIES", 275, 282], ["the RABV genome", "PROBLEM", 49, 64], ["RABV reporter target gene and shRNA expression plasmids", "TREATMENT", 161, 216], ["siRNAs silencing RABV genes", "PROBLEM", 246, 273], ["HEK", "TEST", 275, 278], ["a reporter gene construct", "TREATMENT", 340, 365], ["RABV", "TEST", 383, 387], ["RFP", "TEST", 409, 412], ["a silencing construct", "PROBLEM", 418, 439], ["siRNA", "OBSERVATION", 14, 19], ["RABV genome", "OBSERVATION", 53, 64], ["siRNAs silencing", "OBSERVATION", 246, 262]]], ["HEK-293 cells were co-transfected using Lipofectomine 2000 reagent (Invitrogen) in a 24-well plate and analyzed for RFP and EGFP expression 48 h posttransfection using Olympus IX51 fluorescent microscope.", [["HEK-293 cells", "ANATOMY", 0, 13], ["Lipofectomine 2000", "CHEMICAL", 40, 58], ["HEK-293 cells", "CELL", 0, 13], ["RFP", "GENE_OR_GENE_PRODUCT", 116, 119], ["EGFP", "GENE_OR_GENE_PRODUCT", 124, 128], ["HEK-293 cells", "CELL_LINE", 0, 13], ["RFP", "PROTEIN", 116, 119], ["EGFP", "PROTEIN", 124, 128], ["HEK", "TEST", 0, 3], ["cells", "TEST", 8, 13], ["Lipofectomine 2000 reagent", "TREATMENT", 40, 66], ["RFP", "TEST", 116, 119], ["Olympus", "TEST", 168, 175]]], ["Cells with EGFP expression indicated expression of shRNAs, while cells with RFP expression indicated RABV-N or L target reporter gene expression.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 65, 70], ["Cells", "CELL", 0, 5], ["EGFP", "GENE_OR_GENE_PRODUCT", 11, 15], ["shRNAs", "GENE_OR_GENE_PRODUCT", 51, 57], ["cells", "CELL", 65, 70], ["RFP", "GENE_OR_GENE_PRODUCT", 76, 79], ["RABV-N", "GENE_OR_GENE_PRODUCT", 101, 107], ["EGFP", "PROTEIN", 11, 15], ["shRNAs", "DNA", 51, 57], ["RFP", "PROTEIN", 76, 79], ["RABV", "SPECIES", 101, 105], ["EGFP expression", "TEST", 11, 26], ["expression of shRNAs", "PROBLEM", 37, 57], ["RFP expression", "TEST", 76, 90], ["RABV", "TEST", 101, 105]]], ["Cells with an apparent absence of red fluorescence indicated gene silencing.Construction of recombinant adenoviruses expressing shRNAsRecombinant adenoviruses expressing different siRNAs (si-N, si-L or si-C) were constructed using pSilencer adeno System (Ambion).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["adenoviruses", "ORGANISM", 104, 116], ["shRNAsRecombinant adenoviruses", "ORGANISM", 128, 158], ["si-N", "SIMPLE_CHEMICAL", 188, 192], ["si-C", "GENE_OR_GENE_PRODUCT", 202, 206], ["Ambion", "ORGANISM", 255, 261], ["si-L", "DNA", 194, 198], ["si-C", "DNA", 202, 206], ["red fluorescence", "PROBLEM", 34, 50], ["gene silencing", "PROBLEM", 61, 75], ["recombinant adenoviruses", "TREATMENT", 92, 116], ["pSilencer adeno System", "TREATMENT", 231, 253], ["red fluorescence", "OBSERVATION", 34, 50], ["gene silencing", "OBSERVATION", 61, 75]]], ["Briefly, sense and antisense oligonucleotides having cohesive restriction endonuclease site ends (Supplementary Table 1 ) were annealed and cloned into the Adeno shuttle vector.", [["cohesive restriction endonuclease site ends", "DNA", 53, 96], ["Supplementary Table 1", "DNA", 98, 119], ["Adeno shuttle vector", "DNA", 156, 176], ["antisense oligonucleotides", "TREATMENT", 19, 45], ["cohesive restriction endonuclease site", "TREATMENT", 53, 91]]], ["The recombinant Adeno shuttle vector was co-transfected with linear adenovirus LacZ backbone plasmid into HEK-293 cells and recombinant adenovirus was produced.", [["HEK-293 cells", "ANATOMY", 106, 119], ["Adeno", "GENE_OR_GENE_PRODUCT", 16, 21], ["adenovirus", "ORGANISM", 68, 78], ["LacZ", "GENE_OR_GENE_PRODUCT", 79, 83], ["HEK-293 cells", "CELL", 106, 119], ["adenovirus", "ORGANISM", 136, 146], ["recombinant Adeno shuttle vector", "DNA", 4, 36], ["linear adenovirus LacZ backbone plasmid", "DNA", 61, 100], ["HEK-293 cells", "CELL_LINE", 106, 119], ["HEK-293", "SPECIES", 106, 113], ["adenovirus", "SPECIES", 136, 146], ["The recombinant Adeno shuttle vector", "TREATMENT", 0, 36], ["linear adenovirus LacZ backbone plasmid", "TREATMENT", 61, 100], ["recombinant adenovirus", "PROBLEM", 124, 146]]], ["For in vitro and in vivo studies, different recombinant adenoviruses, namely, Ad-N, Ad-L and Ad-Neg were expanded in HEK-293 cells and purified using the AdEasy virus purification kit (Stratagene).", [["HEK-293 cells", "ANATOMY", 117, 130], ["adenoviruses", "ORGANISM", 56, 68], ["Ad-N", "ORGANISM", 78, 82], ["Ad-L", "ORGANISM", 84, 88], ["Ad", "ORGANISM", 93, 95], ["HEK-293 cells", "CELL", 117, 130], ["HEK-293 cells", "CELL_LINE", 117, 130], ["HEK-293", "SPECIES", 117, 124], ["AdEasy virus", "SPECIES", 154, 166], ["vivo studies", "TEST", 20, 32], ["different recombinant adenoviruses", "PROBLEM", 34, 68], ["Ad", "TEST", 78, 80], ["Ad", "TEST", 93, 95], ["the AdEasy virus purification", "TREATMENT", 150, 179]]], ["Purified adenovirus infectious unit titers were determined in HEK-293 cells by ten-fold limiting dilution and X-gal staining following the manufacturer's instructions (Ambion).", [["HEK-293 cells", "ANATOMY", 62, 75], ["adenovirus", "ORGANISM", 9, 19], ["HEK-293 cells", "CELL", 62, 75], ["X-gal", "GENE_OR_GENE_PRODUCT", 110, 115], ["HEK-293 cells", "CELL_LINE", 62, 75], ["HEK-293", "SPECIES", 62, 69], ["Purified adenovirus infectious unit titers", "PROBLEM", 0, 42], ["adenovirus", "OBSERVATION", 9, 19]]], ["To characterize recombinant adenoviruses, the viral genomic DNAs from Ad-N, Ad-L and Ad-Neg were isolated using the QIAamp DNA mini kit (Qiagen) and a 691 bp fragment containing the shRNA sequence was amplified by PCR using primers (pSiAdeno-F and R, Supplementary Table 1 ) and sequenced to verify the integrity of the siRNA.Transduction of BHK-21 cells with adenovirusTo analyze the anti-rabies effect of different siRNAs in vitro, the siRNAs were delivered into BHK-21 cells by treating with recombinant adenoviruses.", [["DNAs", "ANATOMY", 60, 64], ["BHK-21 cells", "ANATOMY", 342, 354], ["BHK-21 cells", "ANATOMY", 465, 477], ["adenoviruses", "ORGANISM", 28, 40], ["Ad-N", "ORGANISM", 70, 74], ["Ad-L", "ORGANISM", 76, 80], ["Ad", "ORGANISM", 85, 87], ["-Neg", "GENE_OR_GENE_PRODUCT", 87, 91], ["pSiAdeno-F", "GENE_OR_GENE_PRODUCT", 233, 243], ["BHK-21 cells", "CELL", 342, 354], ["adenovirus", "ORGANISM", 360, 370], ["BHK-21 cells", "CELL", 465, 477], ["adenoviruses", "ORGANISM", 507, 519], ["viral genomic DNAs", "DNA", 46, 64], ["QIAamp DNA mini kit", "DNA", 116, 135], ["691 bp fragment", "DNA", 151, 166], ["shRNA sequence", "DNA", 182, 196], ["pSiAdeno", "DNA", 233, 241], ["Supplementary Table 1", "DNA", 251, 272], ["BHK-21 cells", "CELL_LINE", 342, 354], ["BHK-21 cells", "CELL_LINE", 465, 477], ["BHK-21", "SPECIES", 465, 471], ["recombinant adenoviruses", "PROBLEM", 16, 40], ["the viral genomic DNAs", "TEST", 42, 64], ["Ad", "TEST", 70, 72], ["Ad", "TEST", 76, 78], ["Ad", "TEST", 85, 87], ["a 691 bp fragment", "TREATMENT", 149, 166], ["the shRNA sequence", "TREATMENT", 178, 196], ["primers", "TEST", 224, 231], ["BHK", "TEST", 342, 345], ["adenovirus", "PROBLEM", 360, 370], ["different siRNAs in vitro", "TREATMENT", 407, 432], ["the siRNAs", "TREATMENT", 434, 444], ["recombinant adenoviruses", "TREATMENT", 495, 519], ["recombinant", "OBSERVATION_MODIFIER", 16, 27], ["adenoviruses", "OBSERVATION", 28, 40], ["viral genomic DNAs", "OBSERVATION", 46, 64], ["siRNA", "ANATOMY", 320, 325], ["21 cells", "OBSERVATION_MODIFIER", 346, 354], ["siRNAs", "ANATOMY", 438, 444]]], ["Briefly, BHK-21 cells were infected with 100 multiplicity of infection (MOI) of different adenoviruses in presence of polybrene (6 g/ml) for 6 h.", [["BHK-21 cells", "ANATOMY", 9, 21], ["infection", "DISEASE", 61, 70], ["polybrene", "CHEMICAL", 118, 127], ["polybrene", "CHEMICAL", 118, 127], ["BHK-21 cells", "CELL", 9, 21], ["adenoviruses", "ORGANISM", 90, 102], ["polybrene", "SIMPLE_CHEMICAL", 118, 127], ["BHK-21 cells", "CELL_LINE", 9, 21], ["BHK", "TEST", 9, 12], ["infection", "PROBLEM", 61, 70], ["different adenoviruses", "TREATMENT", 80, 102], ["polybrene", "TREATMENT", 118, 127], ["21 cells", "OBSERVATION_MODIFIER", 13, 21], ["infection", "OBSERVATION", 61, 70]]], ["After 24 h treatment, transduction efficiency was analyzed by X-gal staining.RABV infection of BHK-21 cells and fluorescent antibody detectionThe efficiency of different siRNAs to inhibit RABV multiplication was evaluated in adenovirus-treated BHK-21 cells after in vitro challenge with RABV-PV-11.", [["BHK-21 cells", "ANATOMY", 95, 107], ["BHK-21 cells", "ANATOMY", 244, 256], ["infection", "DISEASE", 82, 91], ["X-gal", "GENE_OR_GENE_PRODUCT", 62, 67], ["RABV", "ORGANISM", 77, 81], ["BHK-21 cells", "CELL", 95, 107], ["RABV", "ORGANISM", 188, 192], ["adenovirus", "ORGANISM", 225, 235], ["BHK-21 cells", "CELL", 244, 256], ["RABV-PV-11", "ORGANISM", 287, 297], ["BHK-21 cells", "CELL_LINE", 95, 107], ["fluorescent antibody", "PROTEIN", 112, 132], ["adenovirus-treated BHK-21 cells", "CELL_LINE", 225, 256], ["RABV", "SPECIES", 77, 81], ["BHK-21", "SPECIES", 95, 101], ["RABV", "SPECIES", 188, 192], ["adenovirus", "SPECIES", 225, 235], ["BHK-21", "SPECIES", 244, 250], ["RABV-PV-11", "SPECIES", 287, 297], ["24 h treatment", "TREATMENT", 6, 20], ["transduction efficiency", "TREATMENT", 22, 45], ["RABV infection of BHK", "PROBLEM", 77, 98], ["fluorescent antibody detection", "TEST", 112, 142], ["different siRNAs", "PROBLEM", 160, 176], ["RABV multiplication", "TREATMENT", 188, 207], ["adenovirus", "PROBLEM", 225, 235], ["RABV", "TEST", 287, 291], ["PV", "TEST", 292, 294], ["infection", "OBSERVATION", 82, 91], ["21 cells", "OBSERVATION_MODIFIER", 99, 107], ["different siRNAs", "OBSERVATION", 160, 176]]], ["Briefly, 5 \u00d7 10 5 BHK-21 cells were infected with different adenoviruses in a 6-well plate for 24 h and then infected with 0.01 MOI of RABV-PV-11.", [["BHK-21 cells", "ANATOMY", 18, 30], ["BHK-21 cells", "CELL", 18, 30], ["adenoviruses", "ORGANISM", 60, 72], ["RABV", "ORGANISM", 135, 139], ["BHK-21 cells", "CELL_LINE", 18, 30], ["RABV-PV-11", "SPECIES", 135, 145], ["BHK", "TEST", 18, 21], ["different adenoviruses", "TREATMENT", 50, 72], ["RABV", "TEST", 135, 139], ["PV", "TEST", 140, 142]]], ["At 6 h postadsorption, the unadsorbed RABV in the inoculums was removed and infected cell monolayer was washed three times with PBS.", [["inoculums", "ANATOMY", 50, 59], ["cell monolayer", "ANATOMY", 85, 99], ["RABV", "ORGANISM", 38, 42], ["cell monolayer", "CELL", 85, 99], ["RABV", "SPECIES", 38, 42], ["the unadsorbed RABV", "TREATMENT", 23, 42], ["infected cell monolayer", "TREATMENT", 76, 99], ["PBS", "TREATMENT", 128, 131], ["infected cell monolayer", "OBSERVATION", 76, 99]]], ["At 48 h post-infection, the infected cell culture supernatant was harvested and stored at \u221280 \u2022 C for virus titer determination.", [["cell", "ANATOMY", 37, 41], ["supernatant", "ANATOMY", 50, 61], ["cell", "CELL", 37, 41], ["post-infection", "PROBLEM", 8, 22], ["the infected cell culture supernatant", "PROBLEM", 24, 61], ["virus titer determination", "TEST", 102, 127], ["infection", "OBSERVATION", 13, 22], ["infected cell", "OBSERVATION", 28, 41]]], ["The infected cell monolayer was fixed with 80% acetone and RABV in infected cells was detected by direct fluorescent antibody staining using rabies anti-nucleocapsid FITC-labeled antibody (BioRad) following the manufacturer's instructions.", [["cell monolayer", "ANATOMY", 13, 27], ["cells", "ANATOMY", 76, 81], ["acetone", "CHEMICAL", 47, 54], ["acetone", "CHEMICAL", 47, 54], ["FITC", "CHEMICAL", 166, 170], ["cell monolayer", "CELL", 13, 27], ["acetone", "SIMPLE_CHEMICAL", 47, 54], ["RABV", "ORGANISM", 59, 63], ["cells", "CELL", 76, 81], ["rabies", "ORGANISM", 141, 147], ["anti-nucleocapsid FITC", "SIMPLE_CHEMICAL", 148, 170], ["infected cells", "CELL_TYPE", 67, 81], ["rabies anti-nucleocapsid FITC-labeled antibody", "PROTEIN", 141, 187], ["RABV", "SPECIES", 59, 63], ["rabies", "SPECIES", 141, 147], ["The infected cell monolayer", "PROBLEM", 0, 27], ["80% acetone", "TREATMENT", 43, 54], ["RABV", "TREATMENT", 59, 63], ["infected cells", "PROBLEM", 67, 81], ["direct fluorescent antibody staining", "TEST", 98, 134], ["rabies anti-nucleocapsid FITC", "TEST", 141, 170], ["infected cell monolayer", "OBSERVATION", 4, 27], ["infected cells", "OBSERVATION", 67, 81]]], ["The cell monolayer was nuclear counterstained with Prolong gold antifade reagent with DAPI (Invitrogen).RABV infection of BHK-21 cells and fluorescent antibody detectionThe RABV titer in infected cell culture supernatant was determined by fluorescent foci unit (ffu) assay.", [["cell monolayer", "ANATOMY", 4, 18], ["nuclear", "ANATOMY", 23, 30], ["BHK-21 cells", "ANATOMY", 122, 134], ["cell culture supernatant", "ANATOMY", 196, 220], ["RABV infection", "DISEASE", 104, 118], ["DAPI", "CHEMICAL", 86, 90], ["cell monolayer", "CELL", 4, 18], ["nuclear", "CELLULAR_COMPONENT", 23, 30], ["DAPI", "SIMPLE_CHEMICAL", 86, 90], ["Invitrogen", "SIMPLE_CHEMICAL", 92, 102], ["RABV", "ORGANISM", 104, 108], ["BHK-21 cells", "CELL", 122, 134], ["RABV", "ORGANISM", 173, 177], ["cell", "CELL", 196, 200], ["BHK-21 cells", "CELL_LINE", 122, 134], ["fluorescent antibody", "PROTEIN", 139, 159], ["RABV", "SPECIES", 104, 108], ["BHK-21", "SPECIES", 122, 128], ["RABV", "SPECIES", 173, 177], ["Prolong gold antifade reagent", "TREATMENT", 51, 80], ["DAPI (Invitrogen)", "TREATMENT", 86, 103], ["RABV infection of BHK", "PROBLEM", 104, 125], ["fluorescent antibody detection", "TEST", 139, 169], ["The RABV titer", "TEST", 169, 183], ["infected cell culture supernatant", "TEST", 187, 220], ["cell monolayer", "OBSERVATION", 4, 18], ["infection", "OBSERVATION", 109, 118], ["21 cells", "OBSERVATION_MODIFIER", 126, 134], ["infected cell", "OBSERVATION", 187, 200]]], ["Briefly, serial 10-fold dilutions of virus supernatant, harvested at 48 h post-infection, was mixed with 1 \u00d7 10 4 BHK-21 cells in a flat-bottom 96-well plate in triplicate and incubated at 37 \u2022 C. Two days after infection, infected cells were fixed with 80% acetone and plaques were visualized by staining with rabies anti-nucleocapsid FITC-labeled antibody and ffu titer was determined.RNA isolation, cDNA synthesis and real-time PCRTo evaluate the efficiency of different siRNAs to silence expression of target RABV genes, a quantitative determination of RABV mRNAs was done using real-time PCR.", [["supernatant", "ANATOMY", 43, 54], ["BHK-21 cells", "ANATOMY", 114, 126], ["cells", "ANATOMY", 232, 237], ["plaques", "ANATOMY", 270, 277], ["infection", "DISEASE", 79, 88], ["infection", "DISEASE", 212, 221], ["acetone", "CHEMICAL", 258, 265], ["acetone", "CHEMICAL", 258, 265], ["FITC", "CHEMICAL", 336, 340], ["BHK-21 cells", "CELL", 114, 126], ["cells", "CELL", 232, 237], ["acetone", "SIMPLE_CHEMICAL", 258, 265], ["plaques", "ORGANISM_SUBSTANCE", 270, 277], ["rabies", "ORGANISM", 311, 317], ["anti-nucleocapsid FITC", "SIMPLE_CHEMICAL", 318, 340], ["ffu", "GENE_OR_GENE_PRODUCT", 362, 365], ["RABV", "ORGANISM", 513, 517], ["RABV", "ORGANISM", 557, 561], ["BHK-21 cells", "CELL_LINE", 114, 126], ["infected cells", "CELL_TYPE", 223, 237], ["rabies anti-nucleocapsid FITC-labeled antibody", "PROTEIN", 311, 357], ["RABV genes", "DNA", 513, 523], ["RABV mRNAs", "RNA", 557, 567], ["rabies", "SPECIES", 311, 317], ["RABV", "SPECIES", 513, 517], ["RABV", "SPECIES", 557, 561], ["serial 10-fold dilutions", "TREATMENT", 9, 33], ["virus supernatant", "PROBLEM", 37, 54], ["infection", "PROBLEM", 79, 88], ["BHK", "TEST", 114, 117], ["cells", "TEST", 121, 126], ["infection", "PROBLEM", 212, 221], ["infected cells", "PROBLEM", 223, 237], ["80% acetone", "TREATMENT", 254, 265], ["plaques", "PROBLEM", 270, 277], ["rabies anti-nucleocapsid FITC", "TEST", 311, 340], ["labeled antibody", "TEST", 341, 357], ["ffu titer", "TEST", 362, 371], ["RNA isolation", "TREATMENT", 387, 400], ["cDNA synthesis", "TEST", 402, 416], ["different siRNAs", "PROBLEM", 464, 480], ["RABV mRNAs", "TEST", 557, 567], ["infection", "OBSERVATION", 79, 88], ["infection", "OBSERVATION", 212, 221], ["infected cells", "OBSERVATION", 223, 237], ["plaques", "OBSERVATION", 270, 277], ["different siRNAs", "OBSERVATION", 464, 480], ["RABV genes", "OBSERVATION", 513, 523]]], ["Different adenovirustreated BHK-21 cells (5 \u00d7 10 5 ) in a 6-well plate were infected with RABV-PV-11 at 0.01 MOI.", [["BHK-21 cells", "ANATOMY", 28, 40], ["BHK-21 cells", "CELL", 28, 40], ["RABV", "ORGANISM", 90, 94], ["adenovirustreated BHK-21 cells", "CELL_LINE", 10, 40], ["RABV-PV-11", "SPECIES", 90, 100], ["Different adenovirustreated BHK", "TEST", 0, 31], ["cells", "TEST", 35, 40], ["RABV", "TEST", 90, 94], ["PV", "TEST", 95, 97], ["21 cells", "OBSERVATION_MODIFIER", 32, 40], ["infected", "OBSERVATION", 76, 84]]], ["At 24 h post-infection, total RNA was isolated using Trizol LS reagent (Invitrogen) and mRNA transcripts in total RNA were reverse transcribed into cDNAs using oligo dT primer and RevertAid M-MuLV reverse transcriptase (Fermentas) following the manufacturer's protocol.", [["Invitrogen", "GENE_OR_GENE_PRODUCT", 72, 82], ["total RNA", "RNA", 24, 33], ["mRNA transcripts", "RNA", 88, 104], ["cDNAs", "DNA", 148, 153], ["oligo dT primer", "DNA", 160, 175], ["MuLV reverse transcriptase", "PROTEIN", 192, 218], ["infection", "PROBLEM", 13, 22], ["total RNA", "TREATMENT", 24, 33], ["Trizol LS reagent", "TREATMENT", 53, 70], ["Invitrogen)", "TREATMENT", 72, 83], ["mRNA transcripts in total RNA", "TREATMENT", 88, 117], ["oligo dT primer", "TREATMENT", 160, 175], ["RevertAid M", "TREATMENT", 180, 191], ["the manufacturer's protocol", "TREATMENT", 241, 268], ["infection", "OBSERVATION", 13, 22]]], ["The RABV-N and L gene transcripts in 1:10 diluted cDNAs were quantified using gene specific real-time primers (Supplementary Table 1) using Kapa SYBR fast qPCR kit (Kapa Biosystems) following the manufacturer's instructions.", [["RABV-N", "GENE_OR_GENE_PRODUCT", 4, 10], ["RABV-N and L gene transcripts", "RNA", 4, 33], ["1:10 diluted cDNAs", "DNA", 37, 55], ["RABV", "SPECIES", 4, 8], ["The RABV", "TEST", 0, 8], ["L gene transcripts", "TREATMENT", 15, 33], ["gene specific real-time primers", "TREATMENT", 78, 109]]], ["For relative quantification, GAPDH gene transcripts were used as reference gene expression for normalization and n-fold changes in target mRNA transcript levels were determined by using the method described earlier (Pfaffl, 2001 ).Adenovirus inoculation of mice and lethal RABV challengeSwiss albino mice (3-4 weeks old) of either sex were grouped into four groups with twelve mice each.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 29, 34], ["Adenovirus", "ORGANISM", 231, 241], ["mice", "ORGANISM", 257, 261], ["RABV", "ORGANISM", 273, 277], ["Swiss albino mice", "ORGANISM", 287, 304], ["mice", "ORGANISM", 377, 381], ["GAPDH gene transcripts", "RNA", 29, 51], ["mice", "SPECIES", 257, 261], ["mice", "SPECIES", 300, 304], ["mice", "SPECIES", 377, 381], ["Adenovirus", "SPECIES", 231, 241], ["mice", "SPECIES", 257, 261], ["RABV", "SPECIES", 273, 277], ["Swiss albino", "SPECIES", 287, 299], ["mice", "SPECIES", 300, 304], ["mice", "SPECIES", 377, 381], ["GAPDH gene transcripts", "TREATMENT", 29, 51], ["normalization and n-fold changes", "PROBLEM", 95, 127], ["mRNA transcript levels", "TEST", 138, 160], ["Adenovirus inoculation of mice", "TREATMENT", 231, 261], ["lethal RABV challenge", "TREATMENT", 266, 287]]], ["Three groups of mice (n = 12, each) were injected intracerebrally with 1 \u00d7 10 9 infectious adenovirus particles of either Ad-N or Ad-L or Ad-Neg in 50 l volume.", [["intracerebrally", "ANATOMY", 50, 65], ["mice", "ORGANISM", 16, 20], ["adenovirus", "ORGANISM", 91, 101], ["Ad-N", "SIMPLE_CHEMICAL", 122, 126], ["Ad", "ORGANISM", 130, 132], ["-L", "GENE_OR_GENE_PRODUCT", 132, 134], ["Ad", "ORGANISM", 138, 140], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["mice (n = 12, each)", "TREATMENT", 16, 35], ["Ad", "TEST", 122, 124], ["Ad", "TEST", 138, 140]]], ["One group of mice (n = 12) was injected with saline and kept as negative control.", [["mice", "ORGANISM", 13, 17], ["saline", "SIMPLE_CHEMICAL", 45, 51], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["mice (n", "TREATMENT", 13, 20], ["saline", "TREATMENT", 45, 51]]], ["All groups of mice were challenged by intramuscular route in masseter muscle with 20 LD 50 of lethal RABV-CVS-11 in 50 l volume following the method of NIH test for potency (Wilbur and Aubert, 1996) .", [["intramuscular", "ANATOMY", 38, 51], ["masseter muscle", "ANATOMY", 61, 76], ["mice", "ORGANISM", 14, 18], ["masseter muscle", "TISSUE", 61, 76], ["RABV", "ORGANISM", 101, 105], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["RABV", "SPECIES", 101, 105], ["lethal RABV", "TEST", 94, 105], ["CVS", "TEST", 106, 109], ["NIH test", "TEST", 152, 160], ["masseter muscle", "ANATOMY", 61, 76]]], ["All the challenged mice were observed for 16 days for development of rabies-specific paralytic symptoms or death and percent survival was calculated.Statistical analysisThe RABV titer and gene transcripts were compared by statistical analysis using one-way ANOVA followed by Dunnett's test for treatment versus control.", [["rabies", "DISEASE", 69, 75], ["paralytic symptoms", "DISEASE", 85, 103], ["death", "DISEASE", 107, 112], ["mice", "ORGANISM", 19, 23], ["rabies", "ORGANISM", 69, 75], ["RABV", "ORGANISM", 173, 177], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["rabies", "SPECIES", 69, 75], ["RABV", "SPECIES", 173, 177], ["rabies", "PROBLEM", 69, 75], ["specific paralytic symptoms", "PROBLEM", 76, 103], ["death", "PROBLEM", 107, 112], ["percent survival", "TREATMENT", 117, 133], ["Statistical analysis", "TEST", 149, 169], ["The RABV titer", "TEST", 169, 183], ["statistical analysis", "TEST", 222, 242], ["Dunnett's test", "TEST", 275, 289], ["treatment versus control", "TREATMENT", 294, 318]]], ["Comparison of survival was done by Log-rank test following Mantel-Haenszel method using GraphPad Prism version 4.03 (GraphPad).", [["Mantel-Haenszel method", "TREATMENT", 59, 81]]], ["All data were presented as the mean \u00b1 SEM.", [["All data", "TEST", 0, 8]]], ["Differences between the groups with p \u2264 0.05 were considered statistically significant.Silencing effect of siRNAs targeting RABV-N and L genesTwo different siRNAs, targeting RABV-N mRNA nt 1120-1138 and L mRNA nt 1203-1221 were designed and sequences were cloned into shRNA expression plasmid pMCS-eGFP.", [["1203-1221", "CHEMICAL", 213, 222], ["RABV-N", "GENE_OR_GENE_PRODUCT", 124, 130], ["pMCS-eGFP", "GENE_OR_GENE_PRODUCT", 293, 302], ["RABV-N and L genes", "DNA", 124, 142], ["siRNAs", "DNA", 156, 162], ["shRNA expression plasmid", "DNA", 268, 292], ["pMCS", "DNA", 293, 297], ["eGFP", "DNA", 298, 302], ["Silencing effect", "PROBLEM", 87, 103], ["siRNAs", "TEST", 107, 113], ["RABV", "TEST", 124, 128], ["RABV", "TEST", 174, 178], ["mRNA nt", "TEST", 181, 188], ["L mRNA nt", "TEST", 203, 212], ["siRNAs", "OBSERVATION_MODIFIER", 107, 113]]], ["This generated silencing constructs expressing siRNA against RABV-N or L genes.", [["RABV-N or L", "GENE_OR_GENE_PRODUCT", 61, 72], ["silencing constructs", "DNA", 15, 35], ["RABV-N or L genes", "DNA", 61, 78], ["RABV", "SPECIES", 61, 65]]], ["Since pMCS-eGFP plasmid also included EGFP as reporter gene it was easy to identify cells with the shRNA expressing plasmid.", [["cells", "ANATOMY", 84, 89], ["plasmid", "ANATOMY", 116, 123], ["pMCS", "GENE_OR_GENE_PRODUCT", 6, 10], ["eGFP", "GENE_OR_GENE_PRODUCT", 11, 15], ["EGFP", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 84, 89], ["pMCS-eGFP plasmid", "DNA", 6, 23], ["EGFP", "DNA", 38, 42], ["reporter gene", "DNA", 46, 59], ["shRNA expressing plasmid", "DNA", 99, 123]]], ["We first examined whether these siRNAs could specifically knockdown or silence the expression of the corresponding RABV-N and L proteins.", [["RABV-N and L proteins", "GENE_OR_GENE_PRODUCT", 115, 136], ["RABV-N and L proteins", "PROTEIN", 115, 136], ["these siRNAs", "PROBLEM", 26, 38], ["the corresponding RABV", "TEST", 97, 119]]], ["The HEK-293 cells were transiently co-transfected with target reporter gene plasmids (pDsRed-N or pDsRed-L) and siRNAs expressing plasmids.", [["HEK-293 cells", "ANATOMY", 4, 17], ["plasmids", "ANATOMY", 76, 84], ["plasmids", "ANATOMY", 130, 138], ["HEK-293 cells", "CELL", 4, 17], ["pDsRed-N", "GENE_OR_GENE_PRODUCT", 86, 94], ["pDsRed-L", "GENE_OR_GENE_PRODUCT", 98, 106], ["HEK-293 cells", "CELL_LINE", 4, 17], ["target reporter gene plasmids", "DNA", 55, 84], ["pDsRed", "DNA", 86, 92], ["N", "DNA", 93, 94], ["pDsRed", "DNA", 98, 104], ["L", "DNA", 105, 106], ["siRNAs expressing plasmids", "DNA", 112, 138], ["HEK-293", "SPECIES", 4, 11], ["The HEK", "TEST", 0, 7], ["target reporter gene plasmids", "TEST", 55, 84], ["pDsRed", "TEST", 86, 92], ["pDsRed", "TEST", 98, 104], ["siRNAs expressing plasmids", "TREATMENT", 112, 138]]], ["The RFP-tagged version of RABV-N or L protein (N-RFP or L-RFP) was detected in all transfected cells.", [["cells", "ANATOMY", 95, 100], ["RFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["RABV-N or L protein", "GENE_OR_GENE_PRODUCT", 26, 45], ["N-RFP", "GENE_OR_GENE_PRODUCT", 47, 52], ["L-RFP", "GENE_OR_GENE_PRODUCT", 56, 61], ["cells", "CELL", 95, 100], ["RFP", "PROTEIN", 4, 7], ["RABV", "PROTEIN", 26, 30], ["N", "PROTEIN", 31, 32], ["L protein", "PROTEIN", 36, 45], ["N", "PROTEIN", 47, 48], ["RFP", "PROTEIN", 49, 52], ["L", "PROTEIN", 56, 57], ["RFP", "PROTEIN", 58, 61], ["transfected cells", "CELL_LINE", 83, 100], ["RABV", "SPECIES", 26, 30], ["The RFP", "TEST", 0, 7], ["RABV", "TEST", 26, 30], ["L protein", "TEST", 36, 45], ["RFP", "TEST", 49, 52], ["L-RFP", "TEST", 56, 61], ["transfected cells", "OBSERVATION", 83, 100]]], ["The cells containing the target reporter gene plasmid and specific siRNA silencing construct corroborated with the reduction in RFP expression (indicating reduction in target reporter gene expression) compared to controls (co-transfected with negative control siRNA expressing plasmid) (Fig. 1) .", [["cells", "ANATOMY", 4, 9], ["plasmid", "ANATOMY", 277, 284], ["cells", "CELL", 4, 9], ["RFP", "GENE_OR_GENE_PRODUCT", 128, 131], ["target reporter gene plasmid", "DNA", 25, 53], ["siRNA silencing construct", "DNA", 67, 92], ["RFP", "PROTEIN", 128, 131], ["target reporter gene", "DNA", 168, 188], ["siRNA expressing plasmid", "DNA", 260, 284], ["The cells", "TREATMENT", 0, 9], ["the target reporter gene plasmid", "TREATMENT", 21, 53], ["specific siRNA silencing construct", "TREATMENT", 58, 92], ["the reduction in RFP expression", "TREATMENT", 111, 142], ["target reporter gene expression", "TREATMENT", 168, 199], ["co", "TEST", 223, 225], ["siRNA silencing", "OBSERVATION", 67, 82], ["reduction", "OBSERVATION_MODIFIER", 115, 124], ["RFP expression", "OBSERVATION", 128, 142], ["reduction", "OBSERVATION_MODIFIER", 155, 164]]], ["This confirmed that there was expression of the siRNA which effectively silenced the target gene in a gene-specific manner.Production and characterization of recombinant adenoviruses expressing shRNAsIn order to develop an adenoviral siRNA delivery system, the siRNA sequences in shRNA form were cloned into the adeno shuttle vector and then inserted into the genome of adenovirus defective in the E1 early gene.", [["adenoviruses", "ORGANISM", 170, 182], ["shRNAsIn", "GENE_OR_GENE_PRODUCT", 194, 202], ["adenoviral", "ORGANISM", 223, 233], ["adenovirus", "ORGANISM", 370, 380], ["E1", "GENE_OR_GENE_PRODUCT", 398, 400], ["target gene", "DNA", 85, 96], ["shRNAsIn", "PROTEIN", 194, 202], ["siRNA sequences", "DNA", 261, 276], ["adeno shuttle vector", "DNA", 312, 332], ["E1 early gene", "DNA", 398, 411], ["the siRNA", "PROBLEM", 44, 53], ["recombinant adenoviruses", "TREATMENT", 158, 182], ["an adenoviral siRNA delivery system", "TREATMENT", 220, 255], ["the siRNA sequences in shRNA", "TREATMENT", 257, 285], ["the adeno shuttle vector", "TREATMENT", 308, 332], ["adenovirus defective", "PROBLEM", 370, 390], ["siRNA", "ANATOMY", 48, 53], ["adenoviral siRNA", "OBSERVATION", 223, 239], ["adenovirus defective", "OBSERVATION", 370, 390]]], ["The integrity of siRNA sequences in the recombinant adenoviruses (Ad-N or Ad-L or Ad-Neg) was confirmed by amplifying a 691 bp DNA fragment flanking the shRNA from the genomic DNA isolated from different recombinant adenoviruses and nucleotide sequences were determined ( Supplementary Fig. 1) .", [["nucleotide", "CHEMICAL", 233, 243], ["nucleotide", "CHEMICAL", 233, 243], ["adenoviruses", "ORGANISM", 52, 64], ["Ad-N", "ORGANISM", 66, 70], ["Ad-L", "GENE_OR_GENE_PRODUCT", 74, 78], ["Ad-Neg", "GENE_OR_GENE_PRODUCT", 82, 88], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["adenoviruses", "ORGANISM", 216, 228], ["siRNA sequences", "DNA", 17, 32], ["691 bp DNA fragment", "DNA", 120, 139], ["shRNA", "DNA", 153, 158], ["genomic DNA", "DNA", 168, 179], ["nucleotide sequences", "DNA", 233, 253], ["siRNA sequences", "TEST", 17, 32], ["the recombinant adenoviruses", "TEST", 36, 64], ["Ad", "TEST", 66, 68], ["a 691 bp DNA fragment flanking the shRNA", "TREATMENT", 118, 158], ["the genomic DNA", "PROBLEM", 164, 179], ["different recombinant adenoviruses", "TREATMENT", 194, 228], ["nucleotide sequences", "TEST", 233, 253], ["siRNA", "OBSERVATION", 17, 22], ["genomic DNA", "OBSERVATION", 168, 179]]], ["The infectivity titers of purified recombinant adenoviruses Ad-N, Ad-L and Ad-Neg were estimated in HEK-293 cells by X-gal staining and found to be 1.0 \u00d7 10 11 , 5.6 \u00d7 10 10 and 3.14 \u00d7 10 10 per ml, respectively.", [["HEK-293 cells", "ANATOMY", 100, 113], ["adenoviruses", "ORGANISM", 47, 59], ["Ad-N", "ORGANISM", 60, 64], ["Ad-L", "GENE_OR_GENE_PRODUCT", 66, 70], ["Ad-Neg", "GENE_OR_GENE_PRODUCT", 75, 81], ["HEK-293 cells", "CELL", 100, 113], ["X-gal", "GENE_OR_GENE_PRODUCT", 117, 122], ["HEK-293 cells", "CELL_LINE", 100, 113], ["HEK-293", "SPECIES", 100, 107], ["The infectivity titers", "TEST", 0, 22], ["purified recombinant adenoviruses", "TEST", 26, 59], ["Ad", "TEST", 66, 68], ["Ad", "TEST", 75, 77], ["HEK", "TEST", 100, 103], ["cells", "TEST", 108, 113], ["X-gal staining", "TEST", 117, 131]]], ["Since the adenovirus backbone contained LacZ gene, the infected HEK-293 cells had \u2424-galactocidase activity which gave blue plaques after X-gal staining ( Supplementary Fig. 2) .Production and characterization of recombinant adenoviruses expressing shRNAsBefore analyzing antiviral effect of the siRNAs in BHK-21 cells delivered by the adenoviral vector, it was necessary to determine the amount of recombinant adenovirus needed to yield the highest level of siRNA expression without cellular toxicity.", [["HEK-293 cells", "ANATOMY", 64, 77], ["BHK-21 cells", "ANATOMY", 305, 317], ["cellular", "ANATOMY", 483, 491], ["toxicity", "DISEASE", 492, 500], ["adenovirus", "ORGANISM", 10, 20], ["LacZ", "GENE_OR_GENE_PRODUCT", 40, 44], ["HEK-293 cells", "CELL", 64, 77], ["\u2424-galactocidase", "GENE_OR_GENE_PRODUCT", 82, 97], ["X-gal", "GENE_OR_GENE_PRODUCT", 137, 142], ["adenoviruses", "ORGANISM", 224, 236], ["BHK-21 cells", "CELL", 305, 317], ["adenoviral", "ORGANISM", 335, 345], ["adenovirus", "ORGANISM", 410, 420], ["cellular", "CELL", 483, 491], ["LacZ gene", "DNA", 40, 49], ["infected HEK-293 cells", "CELL_LINE", 55, 77], ["shRNAs", "DNA", 248, 254], ["BHK-21 cells", "CELL_LINE", 305, 317], ["HEK-293", "SPECIES", 64, 71], ["BHK-21", "SPECIES", 305, 311], ["the adenovirus backbone", "TREATMENT", 6, 29], ["LacZ gene", "TREATMENT", 40, 49], ["the infected HEK", "TEST", 51, 67], ["\u2424-galactocidase activity", "PROBLEM", 82, 106], ["blue plaques", "PROBLEM", 118, 130], ["Supplementary Fig", "TREATMENT", 154, 171], ["recombinant adenoviruses", "PROBLEM", 212, 236], ["the siRNAs in BHK", "TREATMENT", 291, 308], ["the adenoviral vector", "TREATMENT", 331, 352], ["recombinant adenovirus", "PROBLEM", 398, 420], ["siRNA expression", "PROBLEM", 458, 474], ["cellular toxicity", "PROBLEM", 483, 500], ["antiviral effect", "OBSERVATION", 271, 287], ["siRNA expression", "OBSERVATION", 458, 474], ["without", "UNCERTAINTY", 475, 482], ["cellular toxicity", "OBSERVATION", 483, 500]]], ["The BHK-21 cells were treated with different MOI of adenoviruses in presence and absence of polybrene (results not shown) and it was found that treatment of BHK-21 cells with 100 MOI of adenovirus in presence of polybrene (6 g/ml) was sufficient to transduce a high proportion of cells (>95%) without toxicity ( Supplementary Fig. 3 ).Effect of siRNAs delivered through adenoviral vector on RABV multiplication in vitroTo assess the effectiveness of siRNAs delivered by recombinant adenoviruses to inhibit RABV multiplication, adenovirus-treated BHK-21 cells were infected with RABV-PV-11.", [["BHK-21 cells", "ANATOMY", 4, 16], ["BHK-21 cells", "ANATOMY", 157, 169], ["cells", "ANATOMY", 280, 285], ["BHK-21 cells", "ANATOMY", 546, 558], ["polybrene", "CHEMICAL", 92, 101], ["polybrene", "CHEMICAL", 212, 221], ["toxicity", "DISEASE", 301, 309], ["polybrene", "CHEMICAL", 92, 101], ["polybrene", "CHEMICAL", 212, 221], ["BHK-21 cells", "CELL", 4, 16], ["adenoviruses", "ORGANISM", 52, 64], ["polybrene", "SIMPLE_CHEMICAL", 92, 101], ["BHK-21 cells", "CELL", 157, 169], ["adenovirus", "ORGANISM", 186, 196], ["polybrene", "SIMPLE_CHEMICAL", 212, 221], ["cells", "CELL", 280, 285], ["adenoviral", "ORGANISM", 370, 380], ["RABV", "ORGANISM", 391, 395], ["adenoviruses", "ORGANISM", 482, 494], ["RABV", "ORGANISM", 506, 510], ["adenovirus", "ORGANISM", 527, 537], ["BHK-21 cells", "CELL", 546, 558], ["RABV-PV-11", "ORGANISM", 578, 588], ["BHK-21 cells", "CELL_LINE", 4, 16], ["BHK-21 cells", "CELL_LINE", 157, 169], ["adenovirus-treated BHK-21 cells", "CELL_LINE", 527, 558], ["BHK-21", "SPECIES", 157, 163], ["RABV", "SPECIES", 391, 395], ["RABV", "SPECIES", 506, 510], ["RABV-PV-11", "SPECIES", 578, 588], ["The BHK", "TEST", 0, 7], ["adenoviruses", "TREATMENT", 52, 64], ["polybrene", "TREATMENT", 92, 101], ["BHK", "TEST", 157, 160], ["adenovirus", "TREATMENT", 186, 196], ["polybrene", "TREATMENT", 212, 221], ["toxicity", "PROBLEM", 301, 309], ["siRNAs", "TREATMENT", 345, 351], ["adenoviral vector", "TREATMENT", 370, 387], ["RABV multiplication", "TREATMENT", 391, 410], ["siRNAs", "TREATMENT", 450, 456], ["recombinant adenoviruses", "TREATMENT", 470, 494], ["RABV multiplication", "TREATMENT", 506, 525], ["adenovirus", "PROBLEM", 527, 537], ["BHK", "TEST", 546, 549], ["RABV", "TEST", 578, 582], ["PV", "TEST", 583, 585], ["21 cells", "OBSERVATION_MODIFIER", 8, 16], ["siRNAs", "OBSERVATION", 345, 351]]], ["At 48 h postinfection, the RABV multiplication was analyzed both in infected cell monolayer (for cell-associated virus) and in infected cell culture supernatant (cell-released virus).", [["cell monolayer", "ANATOMY", 77, 91], ["cell", "ANATOMY", 97, 101], ["cell culture supernatant", "ANATOMY", 136, 160], ["cell", "ANATOMY", 162, 166], ["RABV", "ORGANISM", 27, 31], ["cell monolayer", "CELL", 77, 91], ["cell", "CELL", 97, 101], ["cell", "CELL", 136, 140], ["cell", "CELL", 162, 166], ["RABV", "SPECIES", 27, 31], ["the RABV multiplication", "TREATMENT", 23, 46], ["infected cell monolayer", "TREATMENT", 68, 91], ["cell-associated virus", "PROBLEM", 97, 118], ["infected cell culture", "TEST", 127, 148], ["infected cell monolayer", "OBSERVATION", 68, 91], ["infected cell", "OBSERVATION", 127, 140]]], ["The presence of RABV, as evident after fluorescent foci staining, revealed reduction in RABV multiplication with both the siRNAs compared to control siRNA (Fig. 2) .", [["RABV", "ORGANISM", 16, 20], ["RABV", "ORGANISM", 88, 92], ["RABV", "SPECIES", 16, 20], ["RABV", "SPECIES", 88, 92], ["RABV", "PROBLEM", 16, 20], ["fluorescent foci staining", "PROBLEM", 39, 64], ["reduction in RABV multiplication", "PROBLEM", 75, 107], ["the siRNAs", "TREATMENT", 118, 128], ["RABV", "OBSERVATION", 16, 20], ["foci", "OBSERVATION", 51, 55], ["reduction", "OBSERVATION_MODIFIER", 75, 84], ["RABV multiplication", "OBSERVATION", 88, 107], ["siRNAs", "OBSERVATION", 122, 128]]], ["The reduction with Ad-N (adenovirus expressing siRNA against RABV-N) was more pronounced compared to Ad-L.Effect of siRNAs delivered through adenoviral vector on RABV multiplication in vitroTo estimate the inhibitory effect of siRNAs on RABV multiplication more precisely, their ability to limit infectious virus production was analyzed by RABV ffu count in infected cell culture supernatant.", [["cell culture supernatant", "ANATOMY", 367, 391], ["Ad-N", "CHEMICAL", 19, 23], ["Ad-L.", "CHEMICAL", 101, 106], ["Ad-N", "GENE_OR_GENE_PRODUCT", 19, 23], ["adenovirus", "ORGANISM", 25, 35], ["RABV", "ORGANISM", 61, 65], ["Ad-L.", "ORGANISM", 101, 106], ["adenoviral", "ORGANISM", 141, 151], ["RABV", "ORGANISM", 162, 166], ["vitroTo", "SIMPLE_CHEMICAL", 185, 192], ["RABV", "ORGANISM", 237, 241], ["RABV", "ORGANISM", 340, 344], ["cell", "CELL", 367, 371], ["L.", "SPECIES", 104, 106], ["RABV", "SPECIES", 61, 65], ["Ad-L.", "SPECIES", 101, 106], ["RABV", "SPECIES", 162, 166], ["RABV", "SPECIES", 237, 241], ["RABV", "SPECIES", 340, 344], ["The reduction", "TREATMENT", 0, 13], ["Ad-N (adenovirus expressing siRNA", "TREATMENT", 19, 52], ["siRNAs", "TREATMENT", 116, 122], ["adenoviral vector", "TREATMENT", 141, 158], ["RABV multiplication", "TREATMENT", 162, 181], ["siRNAs", "PROBLEM", 227, 233], ["RABV multiplication", "TREATMENT", 237, 256], ["infectious virus production", "PROBLEM", 296, 323], ["RABV ffu count", "TEST", 340, 354], ["infected cell culture", "TEST", 358, 379], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["more pronounced", "OBSERVATION_MODIFIER", 73, 88], ["siRNAs", "OBSERVATION", 116, 122], ["siRNAs", "OBSERVATION", 227, 233], ["infected cell culture supernatant", "OBSERVATION", 358, 391]]], ["The Ad-N-and Ad-L-treated BHK-21 cells showed 6 \u00b1 1.58 \u00d7 10 3 and 30 \u00b1 7.90 \u00d7 10 3 ffu/ml of RABV, respectively, while Ad-Negtreated BHK-21 cells showed 55 \u00b1 14.43 \u00d7 10 3 ffu/ml of RABV.", [["BHK-21 cells", "ANATOMY", 26, 38], ["BHK-21 cells", "ANATOMY", 133, 145], ["L-", "CHEMICAL", 16, 18], ["Ad-N", "SIMPLE_CHEMICAL", 4, 8], ["Ad-L-", "SIMPLE_CHEMICAL", 13, 18], ["BHK-21 cells", "CELL", 26, 38], ["RABV", "ORGANISM", 93, 97], ["Ad", "ORGANISM", 119, 121], ["BHK-21 cells", "CELL", 133, 145], ["RABV", "ORGANISM", 181, 185], ["Ad-N-and Ad-L-treated BHK-21 cells", "CELL_LINE", 4, 38], ["Negtreated BHK-21 cells", "CELL_LINE", 122, 145], ["RABV", "SPECIES", 93, 97], ["RABV", "SPECIES", 181, 185], ["The Ad", "TEST", 0, 6], ["BHK", "TEST", 26, 29], ["cells", "TEST", 33, 38], ["RABV", "TEST", 93, 97], ["BHK", "TEST", 133, 136], ["cells", "TEST", 140, 145], ["RABV", "TEST", 181, 185]]], ["Collectively, there was significant reduction (88.35 \u00b1 2.4%) in RABV ffu count with Ad-N expressing siRNA against RABV-N while reduction was 41.52 \u00b1 9.3%, however non-significant, with Ad-L expressing siRNA against RABV-L (Fig. 3) .", [["Ad-N", "CHEMICAL", 84, 88], ["RABV", "ORGANISM", 64, 68], ["Ad-N", "GENE_OR_GENE_PRODUCT", 84, 88], ["RABV-N", "ORGANISM", 114, 120], ["Ad-L", "GENE_OR_GENE_PRODUCT", 185, 189], ["RABV-L", "ORGANISM", 215, 221], ["RABV", "SPECIES", 64, 68], ["RABV", "SPECIES", 114, 118], ["RABV", "SPECIES", 215, 219], ["significant reduction", "PROBLEM", 24, 45], ["RABV ffu count", "TEST", 64, 78], ["Ad", "TEST", 84, 86], ["RABV", "TEST", 114, 118], ["reduction", "TEST", 127, 136], ["Ad", "TEST", 185, 187], ["RABV", "TEST", 215, 219], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["reduction", "OBSERVATION_MODIFIER", 36, 45]]], ["These results clearly indicated that At 48 h post-challenge, presence of RABV in infected cells was detected by staining with antirabies nucleocapsid FITC-labeled antibody and counterstained with DAPI.", [["cells", "ANATOMY", 90, 95], ["FITC", "CHEMICAL", 150, 154], ["DAPI", "CHEMICAL", 196, 200], ["RABV", "ORGANISM", 73, 77], ["cells", "CELL", 90, 95], ["FITC", "GENE_OR_GENE_PRODUCT", 150, 154], ["DAPI", "SIMPLE_CHEMICAL", 196, 200], ["infected cells", "CELL_TYPE", 81, 95], ["antirabies nucleocapsid FITC-labeled antibody", "PROTEIN", 126, 171], ["RABV", "SPECIES", 73, 77], ["RABV in infected cells", "PROBLEM", 73, 95], ["antirabies nucleocapsid FITC", "TEST", 126, 154], ["DAPI", "TEST", 196, 200], ["RABV", "OBSERVATION", 73, 77], ["infected cells", "OBSERVATION", 81, 95]]], ["The stained cells were observed with fluorescent microscope and representative fluorescent-field images (with FITC filter, left column) and relative nuclear stained-field images (with DAPI filter, right column) were recorded. both siRNAs, namely, si-N and si-L delivered using adenoviral vector could inhibit RABV multiplication in BHK-21 cells in which the inhibitory effect was more pronounced (>2-fold higher) with si-N compared to si-L.Effect of siRNAs delivered through adenoviral vector on RABV multiplication in vitroTo assess the ability of siRNAs to knockdown the expression of RABV genes, relative levels of RABV-N and L transcripts in different adenovirus-treated and RABV-infected BHK-21 cells were quantified by real-time PCR after normalization using GAPDH housekeeping gene and analyzed.", [["cells", "ANATOMY", 12, 17], ["nuclear", "ANATOMY", 149, 156], ["right column", "ANATOMY", 197, 209], ["BHK-21 cells", "ANATOMY", 332, 344], ["BHK-21 cells", "ANATOMY", 693, 705], ["FITC", "CHEMICAL", 110, 114], ["si-L", "CHEMICAL", 435, 439], ["cells", "CELL", 12, 17], ["si-N", "SIMPLE_CHEMICAL", 247, 251], ["si-L", "GENE_OR_GENE_PRODUCT", 256, 260], ["adenoviral", "ORGANISM", 277, 287], ["RABV", "ORGANISM", 309, 313], ["BHK-21 cells", "CELL", 332, 344], ["si-N", "SIMPLE_CHEMICAL", 418, 422], ["adenoviral", "ORGANISM", 475, 485], ["RABV", "ORGANISM", 496, 500], ["RABV", "ORGANISM", 587, 591], ["RABV-N", "GENE_OR_GENE_PRODUCT", 618, 624], ["L", "GENE_OR_GENE_PRODUCT", 629, 630], ["adenovirus", "ORGANISM", 656, 666], ["RABV", "ORGANISM", 679, 683], ["BHK-21 cells", "CELL", 693, 705], ["GAPDH", "GENE_OR_GENE_PRODUCT", 765, 770], ["stained cells", "CELL_TYPE", 4, 17], ["si-N", "DNA", 247, 251], ["si-L", "DNA", 256, 260], ["BHK-21 cells", "CELL_LINE", 332, 344], ["si-L", "PROTEIN", 435, 439], ["RABV genes", "DNA", 587, 597], ["RABV-N and L transcripts", "RNA", 618, 642], ["adenovirus-treated and RABV-infected BHK-21 cells", "CELL_LINE", 656, 705], ["GAPDH housekeeping gene", "DNA", 765, 788], ["RABV", "SPECIES", 309, 313], ["BHK-21", "SPECIES", 332, 338], ["RABV", "SPECIES", 496, 500], ["RABV", "SPECIES", 587, 591], ["RABV", "SPECIES", 618, 622], ["RABV", "SPECIES", 679, 683], ["BHK-21", "SPECIES", 693, 699], ["The stained cells", "TEST", 0, 17], ["fluorescent microscope", "TEST", 37, 59], ["representative fluorescent-field images", "TEST", 64, 103], ["FITC filter, left column", "TREATMENT", 110, 134], ["relative nuclear stained-field images", "TEST", 140, 177], ["DAPI filter, right column", "TREATMENT", 184, 209], ["si-N", "TREATMENT", 247, 251], ["adenoviral vector", "TREATMENT", 277, 294], ["RABV multiplication in BHK", "PROBLEM", 309, 335], ["siRNAs", "TREATMENT", 450, 456], ["adenoviral vector", "TREATMENT", 475, 492], ["RABV multiplication", "TREATMENT", 496, 515], ["siRNAs", "TREATMENT", 549, 555], ["RABV genes", "TEST", 587, 597], ["RABV", "TEST", 618, 622], ["N and L transcripts", "TREATMENT", 623, 642], ["different adenovirus", "PROBLEM", 646, 666], ["RABV", "TEST", 679, 683], ["infected BHK", "PROBLEM", 684, 696], ["GAPDH housekeeping gene", "TREATMENT", 765, 788], ["stained cells", "OBSERVATION", 4, 17], ["left", "ANATOMY_MODIFIER", 123, 127], ["column", "ANATOMY", 128, 134], ["right", "ANATOMY_MODIFIER", 197, 202], ["column", "ANATOMY", 203, 209], ["siRNAs", "OBSERVATION", 231, 237], ["siRNAs", "OBSERVATION", 450, 456]]], ["The results from six independent experiments demonstrated that the RABV-N and L transcripts were significantly decreased to 1442-fold and 380-fold in BHK-21 cells treated with Ad-N compared to control.", [["BHK-21 cells", "ANATOMY", 150, 162], ["Ad-N", "CHEMICAL", 176, 180], ["RABV-N", "GENE_OR_GENE_PRODUCT", 67, 73], ["L", "GENE_OR_GENE_PRODUCT", 78, 79], ["BHK-21 cells", "CELL", 150, 162], ["Ad-N", "GENE_OR_GENE_PRODUCT", 176, 180], ["RABV-N and L transcripts", "RNA", 67, 91], ["BHK-21 cells", "CELL_LINE", 150, 162], ["RABV", "SPECIES", 67, 71], ["the RABV", "TEST", 63, 71], ["N and L transcripts", "TEST", 72, 91], ["BHK", "TEST", 150, 153], ["Ad-N", "TREATMENT", 176, 180]]], ["The effect was less pronounced (1.4-fold reduction) for both the transcripts in BHK-21 cells-treated with Ad-L (Fig. 4) .", [["BHK-21 cells", "ANATOMY", 80, 92], ["BHK-21", "CHEMICAL", 80, 86], ["BHK-21 cells", "CELL", 80, 92], ["Ad-L", "GENE_OR_GENE_PRODUCT", 106, 110], ["BHK-21 cells", "CELL_LINE", 80, 92], ["1.4-fold reduction", "TREATMENT", 32, 50], ["BHK", "TEST", 80, 83], ["Ad-L (Fig.", "TREATMENT", 106, 116], ["less pronounced", "OBSERVATION_MODIFIER", 15, 30]]], ["This indicated that both adenoviruses (Ad-L and Ad-N) were effective in delivering siRNAs in BHK-21 cells and causing reduction in levels of target mRNA transcripts, however, the effect was significant only with Ad-N expressing siRNA against RABV-N.In vivo evaluation of anti-rabies effect of different siRNA delivered through adenoviral vectorTo assess whether siRNAs could inhibit RABV multiplication in vivo, we used an established murine model of RABV infection.", [["BHK-21 cells", "ANATOMY", 93, 105], ["RABV infection", "DISEASE", 451, 465], ["adenoviruses", "ORGANISM", 25, 37], ["Ad-L", "ORGANISM", 39, 43], ["Ad-N", "GENE_OR_GENE_PRODUCT", 48, 52], ["BHK-21 cells", "CELL", 93, 105], ["Ad-N", "GENE_OR_GENE_PRODUCT", 212, 216], ["RABV-N.In", "ORGANISM", 242, 251], ["adenoviral", "ORGANISM", 327, 337], ["RABV", "ORGANISM", 383, 387], ["murine", "ORGANISM", 435, 441], ["RABV", "ORGANISM", 451, 455], ["BHK-21 cells", "CELL_LINE", 93, 105], ["target mRNA transcripts", "RNA", 141, 164], ["murine", "SPECIES", 435, 441], ["BHK-21", "SPECIES", 93, 99], ["RABV", "SPECIES", 242, 246], ["RABV", "SPECIES", 383, 387], ["RABV", "SPECIES", 451, 455], ["both adenoviruses", "PROBLEM", 20, 37], ["Ad", "TEST", 39, 41], ["siRNAs in BHK", "PROBLEM", 83, 96], ["reduction in levels of target mRNA transcripts", "PROBLEM", 118, 164], ["vivo evaluation", "TEST", 252, 267], ["anti-rabies effect", "TREATMENT", 271, 289], ["different siRNA", "TREATMENT", 293, 308], ["adenoviral vector", "TREATMENT", 327, 344], ["siRNAs", "PROBLEM", 362, 368], ["RABV infection", "PROBLEM", 451, 465], ["adenoviruses", "OBSERVATION", 25, 37], ["reduction", "OBSERVATION_MODIFIER", 118, 127], ["RABV infection", "OBSERVATION", 451, 465]]], ["Different adenovirus treated mice were challenged with 20 LD 50 of lethal RABV CVS-11 by intramuscular route in masseter muscle and percent protection was determined.", [["intramuscular", "ANATOMY", 89, 102], ["masseter muscle", "ANATOMY", 112, 127], ["CVS-11", "CHEMICAL", 79, 85], ["adenovirus", "ORGANISM", 10, 20], ["mice", "ORGANISM", 29, 33], ["RABV", "ORGANISM", 74, 78], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["masseter muscle", "TISSUE", 112, 127], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["RABV", "SPECIES", 74, 78], ["Different adenovirus", "TREATMENT", 0, 20], ["lethal RABV CVS", "TEST", 67, 82], ["percent protection", "TREATMENT", 132, 150], ["masseter muscle", "ANATOMY", 112, 127], ["percent protection", "OBSERVATION", 132, 150]]], ["All the control mice and mice treated with adenovirus expressing control siRNA developed rabies-specific symptoms and died within 6-10 days post-challenge with median survival of 6 and 7 days, respectively.", [["rabies-specific symptoms", "DISEASE", 89, 113], ["mice", "ORGANISM", 16, 20], ["mice", "ORGANISM", 25, 29], ["adenovirus", "ORGANISM", 43, 53], ["rabies", "ORGANISM", 89, 95], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 25, 29], ["adenovirus", "SPECIES", 43, 53], ["rabies", "SPECIES", 89, 95], ["adenovirus expressing control siRNA", "TREATMENT", 43, 78], ["rabies-specific symptoms", "PROBLEM", 89, 113], ["median survival", "TREATMENT", 160, 175]]], ["The median survival increased to 11.5 days and protection to 33.3% in a group of mice treated with Ad-L (adenovirus expressing siRNA against RABV-L).", [["Ad-L", "CHEMICAL", 99, 103], ["mice", "ORGANISM", 81, 85], ["Ad-L", "ORGANISM", 99, 103], ["adenovirus", "ORGANISM", 105, 115], ["RABV-L", "ORGANISM", 141, 147], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["RABV", "SPECIES", 141, 145], ["The median survival", "TREATMENT", 0, 19], ["Ad-L (adenovirus expressing siRNA", "TREATMENT", 99, 132], ["11.5 days", "OBSERVATION_MODIFIER", 33, 42]]], ["Treatment of mice with Ad-N (adenovirus expressing siRNA against RABV-N) demonstrated 66.6% protection (Fig. 5) .", [["Ad-N", "CHEMICAL", 23, 27], ["mice", "ORGANISM", 13, 17], ["Ad-N (adenovirus", "ORGANISM", 23, 39], ["RABV", "ORGANISM", 65, 69], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["RABV", "SPECIES", 65, 69], ["Ad-N (adenovirus expressing siRNA", "TREATMENT", 23, 56]]], ["The mice that survived did not develop symptoms and remained healthy till the entire period of experimentation.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["symptoms", "PROBLEM", 39, 47]]], ["The result indicated that treatment of mice with adenovirus expressing Fig. 3 .", [["mice", "ORGANISM", 39, 43], ["adenovirus", "ORGANISM", 49, 59], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["treatment of mice with adenovirus", "TREATMENT", 26, 59]]], ["Inhibition of RABV production in BHK-21 cells treated with different adenoviruses expressing siRNAs.", [["BHK-21 cells", "ANATOMY", 33, 45], ["RABV", "ORGANISM", 14, 18], ["BHK-21 cells", "CELL", 33, 45], ["adenoviruses", "ORGANISM", 69, 81], ["BHK-21 cells", "CELL_LINE", 33, 45], ["RABV", "SPECIES", 14, 18], ["BHK-21", "SPECIES", 33, 39], ["RABV production in BHK", "PROBLEM", 14, 36], ["different adenoviruses", "TREATMENT", 59, 81], ["RABV production", "OBSERVATION", 14, 29], ["21 cells", "OBSERVATION_MODIFIER", 37, 45], ["siRNAs", "OBSERVATION", 93, 99]]], ["BHK-21 cells were first treated with different adenoviruses expressing siRNAs and then infected with 0.01 MOI of RABV-PV-11 strain.", [["BHK-21 cells", "ANATOMY", 0, 12], ["BHK-21 cells", "CELL", 0, 12], ["adenoviruses", "ORGANISM", 47, 59], ["RABV-PV-11 strain", "ORGANISM", 113, 130], ["BHK-21 cells", "CELL_LINE", 0, 12], ["RABV-PV-11", "SPECIES", 113, 123], ["BHK", "TEST", 0, 3], ["different adenoviruses expressing siRNAs", "TREATMENT", 37, 77], ["RABV", "TEST", 113, 117], ["PV", "TEST", 118, 120], ["21 cells", "OBSERVATION_MODIFIER", 4, 12]]], ["The infected cell culture supernatant was harvested at 48 h post-infection and RABV titers were measured by the rabies fluorescent foci unit (ffu) assay.", [["cell", "ANATOMY", 13, 17], ["supernatant", "ANATOMY", 26, 37], ["cell", "CELL", 13, 17], ["RABV", "ORGANISM", 79, 83], ["RABV", "SPECIES", 79, 83], ["The infected cell culture supernatant", "TEST", 0, 37], ["infection", "PROBLEM", 65, 74], ["RABV titers", "TEST", 79, 90], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["cell", "OBSERVATION", 13, 17], ["culture", "OBSERVATION_MODIFIER", 18, 25], ["supernatant", "OBSERVATION_MODIFIER", 26, 37], ["infection", "OBSERVATION", 65, 74]]], ["One-way ANOVA statistical analysis on log10-transformed data, followed by comparison with control using Dunnett's method.Fig.", [["Dunnett's method", "TREATMENT", 104, 120]]], ["4.siRNA against RABV-L conferred modest protection against lethal rabies challenge.", [["rabies", "DISEASE", 66, 72], ["RABV-L", "ORGANISM", 16, 22], ["RABV", "SPECIES", 16, 20], ["rabies", "SPECIES", 66, 72], ["lethal rabies challenge", "TREATMENT", 59, 82]]], ["The protection increased significantly in mice treated with adenovirus expressing siRNA against RABV-N gene indicating effectiveness of si-N over si-L against rabies in vivo.DiscussionRABV, once introduced through the broken skin or mucous membrane, replicates in the myocytes for hours or weeks and then migrates to nerves (Fekadu and Shaddock, 1984; Murphy, 1985) .", [["skin", "ANATOMY", 225, 229], ["mucous membrane", "ANATOMY", 233, 248], ["myocytes", "ANATOMY", 268, 276], ["nerves", "ANATOMY", 317, 323], ["si-L", "CHEMICAL", 146, 150], ["rabies", "DISEASE", 159, 165], ["mice", "ORGANISM", 42, 46], ["adenovirus", "ORGANISM", 60, 70], ["RABV-N", "GENE_OR_GENE_PRODUCT", 96, 102], ["si-N", "SIMPLE_CHEMICAL", 136, 140], ["si-L", "SIMPLE_CHEMICAL", 146, 150], ["rabies", "ORGANISM", 159, 165], ["skin", "ORGAN", 225, 229], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 233, 248], ["myocytes", "CELL", 268, 276], ["nerves", "MULTI-TISSUE_STRUCTURE", 317, 323], ["RABV-N gene", "DNA", 96, 107], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["adenovirus", "SPECIES", 60, 70], ["RABV", "SPECIES", 96, 100], ["rabies", "SPECIES", 159, 165], ["The protection", "TREATMENT", 0, 14], ["adenovirus expressing siRNA", "TREATMENT", 60, 87], ["si-N", "TREATMENT", 136, 140], ["DiscussionRABV", "TREATMENT", 174, 188], ["mucous membrane", "PROBLEM", 233, 248], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["significantly", "OBSERVATION_MODIFIER", 25, 38], ["skin", "ANATOMY", 225, 229], ["mucous membrane", "ANATOMY", 233, 248], ["myocytes", "ANATOMY", 268, 276], ["nerves", "ANATOMY", 317, 323]]], ["After development of infection in spinal cord or brain stem neurons, RABV disseminates rapidly throughout the central nervous system (CNS) by fast axonal transport along neuroanatomical connections.", [["spinal cord", "ANATOMY", 34, 45], ["brain stem neurons", "ANATOMY", 49, 67], ["central nervous system", "ANATOMY", 110, 132], ["CNS", "ANATOMY", 134, 137], ["axonal", "ANATOMY", 147, 153], ["infection", "DISEASE", 21, 30], ["spinal cord", "ORGAN", 34, 45], ["brain stem neurons", "CELL", 49, 67], ["RABV", "ORGANISM", 69, 73], ["central nervous system", "ANATOMICAL_SYSTEM", 110, 132], ["CNS", "ANATOMICAL_SYSTEM", 134, 137], ["axonal", "MULTI-TISSUE_STRUCTURE", 147, 153], ["brain stem neurons", "CELL_TYPE", 49, 67], ["RABV", "SPECIES", 69, 73], ["infection in spinal cord or brain stem neurons", "PROBLEM", 21, 67], ["infection", "OBSERVATION", 21, 30], ["spinal cord", "ANATOMY", 34, 45], ["brain stem neurons", "ANATOMY", 49, 67], ["RABV disseminates", "OBSERVATION", 69, 86], ["central", "ANATOMY_MODIFIER", 110, 117], ["nervous system", "ANATOMY", 118, 132], ["neuroanatomical connections", "OBSERVATION", 170, 197]]], ["Mice (n = 12, per group) were treated intracerebrally with different adenoviruses (Ad-N or Ad-L or Ad-Neg) or control (saline) and challenged by the intramuscular route in masseter muscle with 20 LD50 of lethal RABV-CVS-11 strain.", [["intramuscular", "ANATOMY", 149, 162], ["masseter muscle", "ANATOMY", 172, 187], ["Mice", "ORGANISM", 0, 4], ["adenoviruses", "ORGANISM", 69, 81], ["Ad", "ORGANISM", 83, 85], ["Ad", "ORGANISM", 91, 93], ["-L", "GENE_OR_GENE_PRODUCT", 93, 95], ["Ad", "ORGANISM", 99, 101], ["saline", "SIMPLE_CHEMICAL", 119, 125], ["masseter muscle", "TISSUE", 172, 187], ["RABV", "ORGANISM", 211, 215], ["Mice", "SPECIES", 0, 4], ["RABV-CVS-11", "SPECIES", 211, 222], ["different adenoviruses", "PROBLEM", 59, 81], ["Ad", "TEST", 83, 85], ["control (saline)", "TREATMENT", 110, 126], ["lethal RABV", "TEST", 204, 215], ["CVS", "TEST", 216, 219], ["strain", "PROBLEM", 223, 229], ["masseter muscle", "ANATOMY", 172, 187]]], ["The percent survival post-challenge was monitored.", [["The percent survival", "TREATMENT", 0, 20], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["survival", "OBSERVATION_MODIFIER", 12, 20]]], ["Ad-N-treated mice group differs from control or Ad-Neg-treated for survival (p < 0.05; Log-rank).DiscussionUnder natural conditions, RABV infection of the CNS causes only relatively mild neuropathological changes without prominent evidence of neuronal death (Iwasaki and Tobita, 2002) .", [["CNS", "ANATOMY", 155, 158], ["neuronal", "ANATOMY", 243, 251], ["Ad-N-", "CHEMICAL", 0, 5], ["RABV infection", "DISEASE", 133, 147], ["neuronal death", "DISEASE", 243, 257], ["Ad-N-", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 13, 17], ["Ad", "ORGANISM", 48, 50], ["RABV", "ORGANISM", 133, 137], ["CNS", "ANATOMICAL_SYSTEM", 155, 158], ["neuronal", "CELL", 243, 251], ["mice", "SPECIES", 13, 17], ["RABV", "SPECIES", 133, 137], ["RABV infection of the CNS", "PROBLEM", 133, 158], ["relatively mild neuropathological changes", "PROBLEM", 171, 212], ["neuronal death", "PROBLEM", 243, 257], ["CNS", "ANATOMY", 155, 158], ["mild", "OBSERVATION_MODIFIER", 182, 186], ["neuropathological", "OBSERVATION", 187, 204], ["neuronal death", "OBSERVATION", 243, 257]]], ["Altogether, these observations have led to the concept that the neurological disease in rabies results from neuronal dysfunction rather than neuronal cell death.", [["neurological", "ANATOMY", 64, 76], ["neuronal", "ANATOMY", 108, 116], ["neuronal cell", "ANATOMY", 141, 154], ["neurological disease", "DISEASE", 64, 84], ["rabies", "DISEASE", 88, 94], ["neuronal dysfunction", "DISEASE", 108, 128], ["death", "DISEASE", 155, 160], ["rabies", "ORGANISM", 88, 94], ["neuronal", "CELL", 108, 116], ["neuronal cell", "CELL", 141, 154], ["rabies", "SPECIES", 88, 94], ["the neurological disease", "PROBLEM", 60, 84], ["neuronal dysfunction", "PROBLEM", 108, 128], ["neuronal cell death", "PROBLEM", 141, 160], ["neuronal dysfunction", "OBSERVATION", 108, 128], ["neuronal cell death", "OBSERVATION", 141, 160]]], ["With this fact, if a strategy is developed to inhibit the RABV multiplication in CNS to block the pathogenic process of rabies and therefore disease progression and development may be prevented in infected individuals.DiscussionRABV has approximately 12 kb long single-stranded RNA genome consisting of a 50 nucleotides long leader followed by nucleoprotein (N), phosphoprotein (P), matrix (M), glycoprotein (G) and large polymerase (L) genes that encode proteins, namely N, P, M and G and L. There are few reports on in vitro evaluation of RNAi on rabies targeting viral structural genes like, N, and G (Israsena et al., 2009) where targeting N gene was found to be effective.", [["CNS", "ANATOMY", 81, 84], ["rabies", "DISEASE", 120, 126], ["DiscussionRABV", "CHEMICAL", 218, 232], ["RABV", "ORGANISM", 58, 62], ["CNS", "ANATOMICAL_SYSTEM", 81, 84], ["rabies", "ORGANISM", 120, 126], ["nucleoprotein (N)", "GENE_OR_GENE_PRODUCT", 344, 361], ["matrix", "CELLULAR_COMPONENT", 383, 389], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 395, 411], ["large polymerase (L)", "GENE_OR_GENE_PRODUCT", 416, 436], ["rabies", "ORGANISM", 549, 555], ["12 kb long single-stranded RNA genome", "DNA", 251, 288], ["50 nucleotides long leader", "DNA", 305, 331], ["nucleoprotein (N), phosphoprotein (P)", "PROTEIN", 344, 381], ["matrix (M), glycoprotein (G) and large polymerase (L) genes", "DNA", 383, 442], ["N", "PROTEIN", 472, 473], ["P", "PROTEIN", 475, 476], ["viral structural genes", "DNA", 566, 588], ["N gene", "DNA", 644, 650], ["RABV", "SPECIES", 58, 62], ["rabies", "SPECIES", 120, 126], ["rabies", "SPECIES", 549, 555], ["disease progression", "PROBLEM", 141, 160], ["infected individuals", "PROBLEM", 197, 217], ["stranded RNA genome", "PROBLEM", 269, 288], ["a 50 nucleotides long leader", "PROBLEM", 303, 331], ["phosphoprotein (P), matrix (M)", "TREATMENT", 363, 393], ["glycoprotein (G)", "TREATMENT", 395, 411], ["large polymerase (L) genes", "PROBLEM", 416, 442], ["vitro evaluation", "TEST", 521, 537], ["may be prevented", "UNCERTAINTY", 177, 193], ["infected", "OBSERVATION", 197, 205]]], ["RABV-G remained a unsuccessful target for RNAi because RABV-G is considered to be non-essential for virus replication in vitro in cultured cells and required only for trans-synaptic viral spread between neurons in vivo (Etessami et al., 2000; Yan et al., 2002) .", [["cells", "ANATOMY", 139, 144], ["neurons", "ANATOMY", 203, 210], ["RABV-G", "GENE_OR_GENE_PRODUCT", 0, 6], ["RABV-G", "GENE_OR_GENE_PRODUCT", 55, 61], ["cells", "CELL", 139, 144], ["neurons", "CELL", 203, 210], ["cultured cells", "CELL_LINE", 130, 144], ["RABV", "SPECIES", 0, 4], ["RABV", "SPECIES", 55, 59], ["RNAi", "PROBLEM", 42, 46], ["RABV", "TEST", 55, 59], ["virus replication", "PROBLEM", 100, 117], ["vitro in cultured cells", "TREATMENT", 121, 144]]], ["A modified RABV-G has been used to deliver siRNA across the blood-brain barrier (Kumar et al., 2007) .", [["blood", "ANATOMY", 60, 65], ["brain", "ANATOMY", 66, 71], ["RABV-G", "CHEMICAL", 11, 17], ["RABV-G", "GENE_OR_GENE_PRODUCT", 11, 17], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 66, 79], ["RABV-G", "PROTEIN", 11, 17], ["RABV", "SPECIES", 11, 15], ["A modified RABV-G", "TREATMENT", 0, 17], ["siRNA", "TREATMENT", 43, 48], ["brain", "ANATOMY", 66, 71]]], ["Other targets for RNAi on rabies were nonstructural genes, like, P (Israsena et al., 2009) and L (Brandao et al., 2007) with limited antiviral potential.DiscussionTo design siRNAs that remain effective requires regions of the viral genome that are conserved among different strains of virus.", [["rabies", "ORGANISM", 26, 32], ["nonstructural genes", "DNA", 38, 57], ["viral genome", "DNA", 226, 238], ["rabies", "SPECIES", 26, 32], ["RNAi", "PROBLEM", 18, 22], ["design siRNAs", "PROBLEM", 166, 179], ["the viral genome", "PROBLEM", 222, 238], ["different strains of virus", "PROBLEM", 264, 290], ["antiviral potential", "OBSERVATION", 133, 152], ["viral genome", "OBSERVATION", 226, 238]]], ["Consequently, we selected RABV-N and L as our target genes for designing siRNAs as these are conserved and essential for virus multiplication.", [["RABV", "ORGANISM", 26, 30], ["RABV-N and L as our target genes", "DNA", 26, 58], ["RABV", "SPECIES", 26, 30], ["RABV", "TEST", 26, 30], ["designing siRNAs", "PROBLEM", 63, 79], ["virus multiplication", "PROBLEM", 121, 141]]], ["Moreover, while selecting siRNAs, the conserved region on RABV genome with no potential region for secondary structure formation was considered using siRNA designing algorithm.", [["RABV", "ORGANISM", 58, 62], ["RABV genome", "DNA", 58, 69], ["RABV", "SPECIES", 58, 62], ["secondary structure formation", "PROBLEM", 99, 128], ["siRNA designing algorithm", "TREATMENT", 150, 175], ["RABV genome", "OBSERVATION", 58, 69], ["no potential", "UNCERTAINTY", 75, 87], ["secondary structure", "OBSERVATION", 99, 118]]], ["Since screening of effective siRNAs with infectious viruses is tedious, time-consuming and requires intense safety conditions, a simple method for the screening of potent siRNAs was used in the present study.", [["infectious viruses", "DISEASE", 41, 59], ["effective siRNAs", "TREATMENT", 19, 35], ["infectious viruses", "PROBLEM", 41, 59], ["a simple method", "TREATMENT", 127, 142], ["the screening", "TEST", 147, 160], ["potent siRNAs", "TREATMENT", 164, 177], ["the present study", "TEST", 190, 207]]], ["We demonstrated that transient co-transfection of a reporter gene construct and a silencing construct was an appropriate method to screen potent siRNAs by inducing cleavage of the mRNA fused to red fluorescent protein (RFP) reporter by gene-specific siRNA.", [["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 194, 217], ["RFP", "GENE_OR_GENE_PRODUCT", 219, 222], ["reporter gene construct", "DNA", 52, 75], ["silencing construct", "DNA", 82, 101], ["mRNA", "RNA", 180, 184], ["red fluorescent protein (RFP) reporter", "DNA", 194, 232], ["a reporter gene construct", "TREATMENT", 50, 75], ["a silencing construct", "PROBLEM", 80, 101], ["potent siRNAs", "TREATMENT", 138, 151], ["the mRNA fused", "PROBLEM", 176, 190], ["red fluorescent protein", "TEST", 194, 217], ["transient", "OBSERVATION_MODIFIER", 21, 30], ["co-transfection", "OBSERVATION", 31, 46], ["specific siRNA", "OBSERVATION", 241, 255]]], ["This provided a simple model for assessing the siRNA efficiency for gene silencing by analysis (reduced expression) of the fusion protein expression with fluorescent microscope.", [["a simple model", "TREATMENT", 14, 28], ["the siRNA efficiency", "TREATMENT", 43, 63], ["gene silencing", "PROBLEM", 68, 82], ["the fusion protein expression", "TREATMENT", 119, 148], ["fluorescent microscope", "TEST", 154, 176]]], ["The si-N and si-L consistently inhibited the expression of RFP fusion version of RABV-N or L proteins in three independent experiments and indicated potent siRNAs for further studies.", [["si-N", "GENE_OR_GENE_PRODUCT", 4, 8], ["si-L", "GENE_OR_GENE_PRODUCT", 13, 17], ["RFP", "GENE_OR_GENE_PRODUCT", 59, 62], ["RABV-N or L proteins", "GENE_OR_GENE_PRODUCT", 81, 101], ["si-N and si-L", "PROTEIN", 4, 17], ["RFP fusion version", "PROTEIN", 59, 77], ["RABV-N or L proteins", "PROTEIN", 81, 101], ["RABV", "SPECIES", 81, 85], ["RFP fusion version", "TEST", 59, 77], ["RABV", "TEST", 81, 85], ["L proteins", "PROBLEM", 91, 101], ["further studies", "TEST", 167, 182], ["RFP fusion", "OBSERVATION", 59, 69], ["potent siRNAs", "OBSERVATION", 149, 162]]], ["Screening of effective siRNAs using transient co-transfection of plasmids has been reported previously for targets other than RABV genes (Sanchez et al., 2005; Meng et al., 2007; Ong et al., 2008) .DiscussionDelivery of siRNA remained a significant obstacle to the development of siRNA-based therapeutics.", [["plasmids", "ANATOMY", 65, 73], ["RABV", "ORGANISM", 126, 130], ["plasmids", "DNA", 65, 73], ["RABV genes", "DNA", 126, 136], ["RABV", "SPECIES", 126, 130], ["effective siRNAs", "TREATMENT", 13, 29], ["transient co-transfection of plasmids", "TREATMENT", 36, 73], ["siRNA", "PROBLEM", 220, 225], ["siRNA", "TREATMENT", 280, 285], ["siRNA", "OBSERVATION", 220, 225], ["significant", "OBSERVATION_MODIFIER", 237, 248]]], ["The different approaches that are being used to efficiently deliver siRNAs to neuronal tissue included the use of non-viral (Posadas et al., 2010 , for review) and viral vectors (Sliva and Schnierle, 2010, for review) .", [["neuronal tissue", "ANATOMY", 78, 93], ["neuronal tissue", "TISSUE", 78, 93], ["The different approaches", "TREATMENT", 0, 24]]], ["For in vivo delivery of siRNA against rabies, a technology is required that could deliver the RNAi therapeutic to neuronal cells.", [["neuronal cells", "ANATOMY", 114, 128], ["rabies", "DISEASE", 38, 44], ["rabies", "ORGANISM", 38, 44], ["neuronal cells", "CELL", 114, 128], ["neuronal cells", "CELL_TYPE", 114, 128], ["rabies", "SPECIES", 38, 44], ["siRNA", "TREATMENT", 24, 29], ["rabies", "PROBLEM", 38, 44]]], ["Adenovirus and lentivirus based viral vectors carry out precisely this task and have become a major delivery system for siRNA into nerve tissues (Sliva and Schnierle, 2010) .", [["nerve tissues", "ANATOMY", 131, 144], ["Adenovirus", "ORGANISM", 0, 10], ["lentivirus", "ORGANISM", 15, 25], ["nerve tissues", "TISSUE", 131, 144], ["Adenovirus", "SPECIES", 0, 10], ["lentivirus", "SPECIES", 15, 25], ["Adenovirus", "PROBLEM", 0, 10], ["lentivirus based viral vectors", "TREATMENT", 15, 45], ["a major delivery system", "TREATMENT", 92, 115], ["siRNA into nerve tissues", "PROBLEM", 120, 144], ["lentivirus", "OBSERVATION", 15, 25], ["nerve tissues", "ANATOMY", 131, 144]]], ["The first study employing an adenoviral vector for in vivo RNAi was published in 2002 for an application in the central nervous system (Xia et al., 2002) .", [["central nervous system", "ANATOMY", 112, 134], ["adenoviral", "ORGANISM", 29, 39], ["central nervous system", "ANATOMICAL_SYSTEM", 112, 134], ["The first study", "TEST", 0, 15], ["an adenoviral vector", "TREATMENT", 26, 46], ["central", "ANATOMY_MODIFIER", 112, 119], ["nervous system", "ANATOMY", 120, 134]]], ["In this study also, we selected adenovirus vector system to deliver siRNA into brain cells.DiscussionThe efficiency of different siRNAs delivered by recombinant adenoviruses was analyzed in BHK-21 cells after challenging with RABV-PV-11.", [["brain cells", "ANATOMY", 79, 90], ["BHK-21 cells", "ANATOMY", 190, 202], ["adenovirus", "ORGANISM", 32, 42], ["brain cells", "CELL", 79, 90], ["adenoviruses", "ORGANISM", 161, 173], ["BHK-21 cells", "CELL", 190, 202], ["RABV-PV-11", "ORGANISM", 226, 236], ["brain cells", "CELL_TYPE", 79, 90], ["BHK-21 cells", "CELL_LINE", 190, 202], ["BHK-21", "SPECIES", 190, 196], ["RABV-PV-11", "SPECIES", 226, 236], ["this study", "TEST", 3, 13], ["adenovirus vector system", "TREATMENT", 32, 56], ["siRNA into brain cells", "PROBLEM", 68, 90], ["different siRNAs", "TREATMENT", 119, 135], ["recombinant adenoviruses", "TREATMENT", 149, 173], ["RABV", "TEST", 226, 230], ["PV", "TEST", 231, 233], ["brain cells", "ANATOMY", 79, 90]]], ["Since RABV-PV-11 strain is adapted to BHK-21 cells, it served as a model to analyze the efficiency of siRNAs in vitro.", [["BHK-21 cells", "ANATOMY", 38, 50], ["RABV-PV-11 strain", "ORGANISM", 6, 23], ["BHK-21 cells", "CELL", 38, 50], ["BHK-21 cells", "CELL_LINE", 38, 50], ["RABV-PV-11", "SPECIES", 6, 16], ["BHK-21", "SPECIES", 38, 44], ["RABV", "TEST", 6, 10], ["PV", "TEST", 11, 13], ["strain", "PROBLEM", 17, 23], ["BHK", "TEST", 38, 41], ["siRNAs in vitro", "PROBLEM", 102, 117], ["PV", "ANATOMY", 11, 13], ["siRNAs", "OBSERVATION", 102, 108]]], ["RNAi functions by identifying and degrading mRNA that shares sequence complementarity with the siRNA.", [["mRNA", "RNA", 44, 48], ["the siRNA", "PROBLEM", 91, 100], ["siRNA", "ANATOMY", 95, 100]]], ["Therefore, real-time PCR analysis was used to analyze the effect of si-N or si-L on RABV-N or L mRNA expression, respectively.", [["si-N", "GENE_OR_GENE_PRODUCT", 68, 72], ["si-L", "GENE_OR_GENE_PRODUCT", 76, 80], ["RABV-N or L", "GENE_OR_GENE_PRODUCT", 84, 95], ["RABV", "SPECIES", 84, 88], ["real-time PCR analysis", "TEST", 11, 33], ["RABV", "TREATMENT", 84, 88]]], ["The level of RABV-N mRNA in the Ad-Ntreated, RABV-infected cells was significantly reduced (1442-fold) compared to the Ad-L-treated cells (1.43-fold).", [["cells", "ANATOMY", 59, 64], ["cells", "ANATOMY", 132, 137], ["RABV-N", "GENE_OR_GENE_PRODUCT", 13, 19], ["Ad-Ntreated", "ORGANISM", 32, 43], ["RABV", "ORGANISM", 45, 49], ["cells", "CELL", 59, 64], ["Ad-L", "GENE_OR_GENE_PRODUCT", 119, 123], ["cells", "CELL", 132, 137], ["RABV-N mRNA", "RNA", 13, 24], ["Ad-Ntreated, RABV-infected cells", "CELL_LINE", 32, 64], ["Ad-L-treated cells", "CELL_LINE", 119, 137], ["RABV", "SPECIES", 13, 17], ["RABV", "SPECIES", 45, 49], ["RABV", "TEST", 13, 17], ["mRNA", "TEST", 20, 24], ["the Ad", "TEST", 28, 34], ["RABV", "TEST", 45, 49], ["infected cells", "PROBLEM", 50, 64], ["the Ad", "TEST", 115, 121], ["infected cells", "OBSERVATION", 50, 64], ["reduced", "OBSERVATION_MODIFIER", 83, 90]]], ["GAPDH was used as a cellular mRNA control and showed no effect of the siRNA treatment.", [["cellular", "ANATOMY", 20, 28], ["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 20, 28], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["a cellular mRNA control", "TREATMENT", 18, 41], ["the siRNA treatment", "TREATMENT", 66, 85], ["no", "UNCERTAINTY", 53, 55], ["siRNA treatment", "OBSERVATION", 70, 85]]], ["Further, the level of RABV-L mRNA in Ad-N-treated cells was also reduced (380-fold), indicating an interrelated effect.", [["cells", "ANATOMY", 50, 55], ["Ad-N", "CHEMICAL", 37, 41], ["RABV-L", "GENE_OR_GENE_PRODUCT", 22, 28], ["Ad-N", "SIMPLE_CHEMICAL", 37, 41], ["cells", "CELL", 50, 55], ["RABV-L mRNA", "RNA", 22, 33], ["Ad-N-treated cells", "CELL_LINE", 37, 55], ["RABV", "SPECIES", 22, 26], ["RABV", "TEST", 22, 26], ["L mRNA", "TEST", 27, 33], ["Ad", "TEST", 37, 39], ["interrelated effect", "OBSERVATION", 99, 118]]], ["This may be due to the fact that RABV-N performs its effect on RABV multiplication in two ways; RABV-N is a major structural protein and also plays a regulatory role in the switch from gene expression (mRNA production) to genome replication.", [["RABV", "ORGANISM", 33, 37], ["RABV", "ORGANISM", 63, 67], ["RABV-N", "GENE_OR_GENE_PRODUCT", 96, 102], ["genome", "CELLULAR_COMPONENT", 222, 228], ["RABV-N", "PROTEIN", 33, 39], ["RABV-N", "PROTEIN", 96, 102], ["major structural protein", "PROTEIN", 108, 132], ["RABV", "SPECIES", 33, 37], ["RABV", "SPECIES", 63, 67], ["RABV", "SPECIES", 96, 100], ["RABV multiplication", "TREATMENT", 63, 82], ["may be due to", "UNCERTAINTY", 5, 18]]], ["The intracellular ratio of leader RNA to N protein has been reported to regulate the switch from viral gene transcription to genome replication (Wunner, 1991) .", [["intracellular", "ANATOMY", 4, 17], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["leader RNA", "RNA", 27, 37], ["N protein", "PROTEIN", 41, 50], ["leader RNA", "PROBLEM", 27, 37], ["viral gene transcription", "TREATMENT", 97, 121]]], ["To confirm the antiviral potential of RABV-N-specific siRNAs, we monitored the presence of viral progeny in the supernatants of siRNA-treated-RABV infected cells.", [["progeny", "ANATOMY", 97, 104], ["supernatants", "ANATOMY", 112, 124], ["cells", "ANATOMY", 156, 161], ["RABV", "ORGANISM", 38, 42], ["RABV", "ORGANISM", 142, 146], ["cells", "CELL", 156, 161], ["siRNA-treated-RABV infected cells", "CELL_LINE", 128, 161], ["RABV", "SPECIES", 38, 42], ["RABV", "SPECIES", 142, 146], ["RABV", "PROBLEM", 38, 42], ["N-specific siRNAs", "PROBLEM", 43, 60], ["viral progeny", "PROBLEM", 91, 104], ["siRNA", "PROBLEM", 128, 133], ["RABV infected cells", "PROBLEM", 142, 161], ["viral progeny", "OBSERVATION", 91, 104], ["siRNA", "ANATOMY", 128, 133], ["infected cells", "OBSERVATION", 147, 161]]], ["The level of fold-decrease in RABV-N expression was correlated with decrease in infective virus titer in Ad-N treated cells.", [["cells", "ANATOMY", 118, 123], ["Ad-N", "CHEMICAL", 105, 109], ["RABV-N", "GENE_OR_GENE_PRODUCT", 30, 36], ["Ad", "ORGANISM", 105, 107], ["cells", "CELL", 118, 123], ["Ad-N treated cells", "CELL_LINE", 105, 123], ["RABV", "SPECIES", 30, 34], ["decrease in infective virus titer", "PROBLEM", 68, 101], ["Ad-N treated cells", "TREATMENT", 105, 123], ["fold", "OBSERVATION_MODIFIER", 13, 17], ["decrease", "OBSERVATION_MODIFIER", 18, 26], ["infective virus", "OBSERVATION", 80, 95]]], ["The decrease in infective RABV titer in Ad-N-treated cells was 88.4% compared to 41.5% in Ad-L-treated cells.DiscussionThe efficiency of siRNAs was also analyzed to inhibit RABV multiplication in vivo in mice.", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 103, 108], ["Ad-N", "CHEMICAL", 40, 44], ["Ad-L", "CHEMICAL", 90, 94], ["RABV", "ORGANISM", 26, 30], ["Ad-N", "SIMPLE_CHEMICAL", 40, 44], ["cells", "CELL", 53, 58], ["Ad-L", "SIMPLE_CHEMICAL", 90, 94], ["cells", "CELL", 103, 108], ["RABV", "ORGANISM", 173, 177], ["mice", "ORGANISM", 204, 208], ["Ad-N-treated cells", "CELL_LINE", 40, 58], ["Ad-L-treated cells", "CELL_LINE", 90, 108], ["mice", "SPECIES", 204, 208], ["RABV", "SPECIES", 26, 30], ["RABV", "SPECIES", 173, 177], ["mice", "SPECIES", 204, 208], ["The decrease", "PROBLEM", 0, 12], ["infective RABV titer", "TEST", 16, 36], ["Ad", "TEST", 40, 42], ["Ad", "TEST", 90, 92], ["siRNAs", "TREATMENT", 137, 143], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["infective", "OBSERVATION_MODIFIER", 16, 25], ["RABV titer", "OBSERVATION", 26, 36]]], ["The protective efficacy of different siRNAs against lethal RABV challenge was evaluated by injecting recombinant adenoviruses carrying appropriate siRNAs intracerebrally in mice and challenging with mouse adapted RABV-CVS-11 strain.", [["RABV", "ORGANISM", 59, 63], ["adenoviruses", "ORGANISM", 113, 125], ["mice", "ORGANISM", 173, 177], ["mouse", "ORGANISM", 199, 204], ["RABV-CVS-11 strain", "ORGANISM", 213, 231], ["mice", "SPECIES", 173, 177], ["mouse", "SPECIES", 199, 204], ["RABV", "SPECIES", 59, 63], ["mice", "SPECIES", 173, 177], ["mouse", "SPECIES", 199, 204], ["RABV-CVS-11", "SPECIES", 213, 224], ["different siRNAs", "TREATMENT", 27, 43], ["lethal RABV challenge", "TREATMENT", 52, 73], ["RABV", "TEST", 213, 217], ["CVS", "TEST", 218, 221], ["strain", "PROBLEM", 225, 231]]], ["Mice treated with Ad-N, which showed maximum inhibitory effect on RABV multiplication in vitro in BHK-21 cells also demonstrated significantly high protection (66.6%).", [["BHK-21 cells", "ANATOMY", 98, 110], ["Ad-N", "CHEMICAL", 18, 22], ["Mice", "ORGANISM", 0, 4], ["Ad-N", "SIMPLE_CHEMICAL", 18, 22], ["RABV", "ORGANISM", 66, 70], ["BHK-21 cells", "CELL", 98, 110], ["BHK-21 cells", "CELL_LINE", 98, 110], ["Mice", "SPECIES", 0, 4], ["RABV", "SPECIES", 66, 70], ["BHK-21", "SPECIES", 98, 104], ["Ad-N", "TREATMENT", 18, 22], ["maximum inhibitory effect", "PROBLEM", 37, 62], ["RABV multiplication", "TREATMENT", 66, 85], ["vitro in BHK", "TEST", 89, 101], ["RABV multiplication", "OBSERVATION", 66, 85], ["significantly", "OBSERVATION_MODIFIER", 129, 142], ["high", "OBSERVATION_MODIFIER", 143, 147]]], ["In contrast, mice treated with Ad-L, which was less effective in vitro, were moderately protected (33.3%).", [["Ad-L", "CHEMICAL", 31, 35], ["mice", "ORGANISM", 13, 17], ["Ad-L", "GENE_OR_GENE_PRODUCT", 31, 35], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Ad-L", "TREATMENT", 31, 35], ["less", "OBSERVATION_MODIFIER", 47, 51], ["effective", "OBSERVATION_MODIFIER", 52, 61]]], ["The control siRNA-expressing adenovirus could not demonstrate protection, indicating lethal nature of the challenge virus.", [["adenovirus", "ORGANISM", 29, 39], ["adenovirus", "SPECIES", 29, 39], ["The control siRNA", "TREATMENT", 0, 17], ["adenovirus", "PROBLEM", 29, 39], ["the challenge virus", "PROBLEM", 102, 121]]], ["Recent studies have also indicated that short RABV-N cDNA and artificial microRNAs could interfere with RABV replication in cells (Wunner et al., 2004; Israsena et al., 2009 ) and synthetic siRNA against RABV-N could reduce RABV multiplication in BHK-21 cells (Brandao et al., 2007) .", [["cells", "ANATOMY", 124, 129], ["BHK-21 cells", "ANATOMY", 247, 259], ["RABV-N", "CHEMICAL", 204, 210], ["RABV-N cDNA", "GENE_OR_GENE_PRODUCT", 46, 57], ["RABV", "ORGANISM", 104, 108], ["cells", "CELL", 124, 129], ["RABV-N", "ORGANISM", 204, 210], ["RABV", "ORGANISM", 224, 228], ["BHK-21 cells", "CELL", 247, 259], ["RABV-N cDNA", "DNA", 46, 57], ["BHK-21 cells", "CELL_LINE", 247, 259], ["RABV", "SPECIES", 104, 108], ["RABV", "SPECIES", 204, 208], ["RABV", "SPECIES", 224, 228], ["BHK-21", "SPECIES", 247, 253], ["Recent studies", "TEST", 0, 14], ["short RABV", "TEST", 40, 50], ["artificial microRNAs", "PROBLEM", 62, 82], ["RABV replication in cells", "PROBLEM", 104, 129], ["synthetic siRNA", "TREATMENT", 180, 195], ["RABV", "PROBLEM", 204, 208], ["RABV multiplication in BHK", "PROBLEM", 224, 250]]], ["Intracranial injection of siRNA in mice has shown immense potential in suppressing encephalitis caused by Chandipura virus belonging to family Rhabdoviridae (Kumar and Arankalle, 2010) and two flaviviruses, JEV (Japanese encephalitis virus) and WNV (West Nile virus) (Kumar et al., 2006) .DiscussionOn the basis of the results in this report, we concluded that, (i) siRNA against RABV-N could knockdown expression of RABV mRNAs and subsequently inhibiting RABV production efficiently, and (ii) inhibitory effect of siRNA against RABV-N interferes with viral gene expression, which significantly increased protection against lethal RABV challenge.", [["Intracranial", "ANATOMY", 0, 12], ["encephalitis", "DISEASE", 83, 95], ["JEV", "DISEASE", 207, 210], ["Japanese encephalitis virus", "DISEASE", 212, 239], ["RABV-N", "CHEMICAL", 380, 386], ["RABV-N", "CHEMICAL", 529, 535], ["mice", "ORGANISM", 35, 39], ["Chandipura virus", "ORGANISM", 106, 122], ["JEV (", "ORGANISM", 207, 212], ["Japanese encephalitis virus", "ORGANISM", 212, 239], ["WNV", "ORGANISM", 245, 248], ["West Nile virus", "ORGANISM", 250, 265], ["RABV-N", "GENE_OR_GENE_PRODUCT", 380, 386], ["RABV", "ORGANISM", 417, 421], ["RABV", "ORGANISM", 456, 460], ["RABV-N", "ORGANISM", 529, 535], ["RABV", "ORGANISM", 631, 635], ["RABV mRNAs", "RNA", 417, 427], ["mice", "SPECIES", 35, 39], ["Chandipura virus", "SPECIES", 106, 122], ["Japanese encephalitis virus", "SPECIES", 212, 239], ["West Nile virus", "SPECIES", 250, 265], ["mice", "SPECIES", 35, 39], ["Chandipura virus", "SPECIES", 106, 122], ["JEV", "SPECIES", 207, 210], ["Japanese encephalitis virus", "SPECIES", 212, 239], ["WNV", "SPECIES", 245, 248], ["West Nile virus", "SPECIES", 250, 265], ["RABV", "SPECIES", 380, 384], ["RABV", "SPECIES", 417, 421], ["RABV", "SPECIES", 456, 460], ["RABV", "SPECIES", 529, 533], ["RABV", "SPECIES", 631, 635], ["Intracranial injection of siRNA in mice", "TREATMENT", 0, 39], ["suppressing encephalitis", "PROBLEM", 71, 95], ["Chandipura virus", "PROBLEM", 106, 122], ["two flaviviruses", "PROBLEM", 189, 205], ["JEV (Japanese encephalitis virus", "PROBLEM", 207, 239], ["WNV", "PROBLEM", 245, 248], ["RABV", "PROBLEM", 380, 384], ["RABV mRNAs", "PROBLEM", 417, 427], ["siRNA", "TREATMENT", 515, 520], ["viral gene expression", "TREATMENT", 552, 573], ["lethal RABV challenge", "TREATMENT", 624, 645], ["siRNA", "ANATOMY", 26, 31], ["encephalitis", "OBSERVATION", 83, 95], ["RABV mRNAs", "OBSERVATION", 417, 427]]], ["These findings have significant implications for the use of siRNA as therapeutic agent against RABV infection.", [["RABV infection", "DISEASE", 95, 109], ["RABV", "ORGANISM", 95, 99], ["RABV", "SPECIES", 95, 99], ["siRNA", "TREATMENT", 60, 65], ["therapeutic agent", "TREATMENT", 69, 86], ["RABV infection", "PROBLEM", 95, 109], ["infection", "OBSERVATION", 100, 109]]], ["However, to attain absolute protection other siRNA delivery methods (e.g., lentiviral), route (intravenous crossing blood-brain barrier), dose (single or multiple siRNAs) and time of therapeutic administration of siRNAs have to be carefully optimized in mice and in non-human primates before recommending for therapeutic use.", [["intravenous", "ANATOMY", 95, 106], ["blood", "ANATOMY", 116, 121], ["brain", "ANATOMY", 122, 127], ["lentiviral", "ORGANISM", 75, 85], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 106], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 122, 135], ["mice", "ORGANISM", 254, 258], ["primates", "ORGANISM", 276, 284], ["mice", "SPECIES", 254, 258], ["mice", "SPECIES", 254, 258], ["absolute protection other siRNA delivery methods", "TREATMENT", 19, 67], ["lentiviral)", "TREATMENT", 75, 86], ["route (intravenous crossing blood-brain barrier)", "TREATMENT", 88, 136], ["dose (single or multiple siRNAs)", "TREATMENT", 138, 170], ["therapeutic administration of siRNAs", "TREATMENT", 183, 219]]]], "PMC7405654": [["IntroductionThe new pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, disrupting health systems and critical care, even within the most developed heath systems and economies (1).", [["acute respiratory syndrome coronavirus", "DISEASE", 50, 88], ["SARS-CoV-2", "ORGANISM", 92, 102], ["severe acute respiratory syndrome coronavirus", "SPECIES", 43, 88], ["SARS-CoV-2", "SPECIES", 92, 102], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 39, 88], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory syndrome", "OBSERVATION", 56, 76]]], ["As of April 22nd, 2020, 2.5 million confirmed cases of COVID-19 have been reported globally (2).", [["COVID", "TEST", 55, 60]]], ["Sustained community transmission is expected in low- and middle- income countries (LMICs) where COVID-19 containment strategies continue to be a challenge (3).", [["COVID-19 containment strategies", "TREATMENT", 96, 127], ["middle", "ANATOMY_MODIFIER", 57, 63]]], ["Extreme mitigation strategies have been put in place in many countries to control COVID-19, to reduce disease transmission and to avoid overburdening healthcare systems including mass lockdowns, curfews, and social distancing measures (4).", [["Extreme mitigation strategies", "TREATMENT", 0, 29], ["COVID", "TEST", 82, 87], ["disease transmission", "PROBLEM", 102, 122], ["mass lockdowns", "PROBLEM", 179, 193]]], ["SARS-CoV-2 and interventions to reduce transmission are negatively impacting already impoverished communities in LMICs and will test heath systems that have little capacity for the management of high dependency patients, or sufficient PPE to protect health workers (5).", [["SARS", "DISEASE", 0, 4], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["interventions", "TREATMENT", 15, 28], ["little capacity", "PROBLEM", 157, 172]]], ["Interventions will have long-lasting detrimental impacts on LMIC economies, and, in the absence of reliable and efficient tools for early detection of infected and exposed individuals, are likely to extend beyond 2020/21 including in Africa (6).IntroductionAfrica is vulnerable to being overwhelmed by COVID-19.", [["COVID-19", "CHEMICAL", 302, 310], ["Interventions", "TREATMENT", 0, 13], ["LMIC economies", "TREATMENT", 60, 74], ["infected and exposed individuals", "PROBLEM", 151, 183], ["COVID", "TEST", 302, 307], ["infected", "OBSERVATION", 151, 159]]], ["On Apr 17, 2020, the WHO estimated 10 million cases of COVID-19 spreading rapidly across Africa and up to 3 million deaths within 6 months (8).", [["deaths", "DISEASE", 116, 122], ["COVID", "TEST", 55, 60]]], ["Cases are expected to rise quickly due to a chronic lack of testing, lack of personal protective equipment (PPE), and poor patient care facilities of basic equipment to contain the pandemic, such as PPE (9, 10).", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["a chronic lack of testing", "PROBLEM", 42, 67], ["basic equipment", "TREATMENT", 150, 165], ["the pandemic", "PROBLEM", 177, 189]]], ["The ability to contain COVID-19 will depend on the success of social distancing and the ability to diagnose, isolate, and treat cases (11).IntroductionCase finding and reporting for COVID-19 in Africa is making less than ideal progress.", [["COVID-19", "CHEMICAL", 23, 31], ["COVID", "TREATMENT", 23, 28], ["COVID", "TEST", 182, 187]]], ["Data from the African Centers for Disease Control (CDC) shows that while risk of importation of COVID-19 to Africa was lower than that to Europe (1 vs. 11%), response and reaction capacity are also lower; the latter being intrinsically linked to individual country wealth and resources for detection, prevention, and control (12).", [["COVID-19", "CHEMICAL", 96, 104], ["COVID", "TEST", 96, 101], ["response and reaction capacity", "PROBLEM", 158, 188], ["detection", "TEST", 290, 299]]], ["As of 18 April 2020, Africa had reported 1,000 deaths with COVID-19 and more than 19,800 cases in 52 out of 54 countries on the African continent (13).", [["deaths", "DISEASE", 47, 53], ["COVID", "TEST", 59, 64]]], ["While many African nations have employed lessons learned from Ebola (15).", [["Ebola", "DISEASE", 62, 67], ["Ebola", "ORGANISM", 62, 67]]], ["Quantifying the pandemic growth across the African sub-continent and assessing the impact of interventions put in place will be compromised by the lack of diagnostic capacity (16).IntroductionAcross East Africa, in April 2020, countries lack a coordinated response against COVID-19.", [["COVID-19", "DNA", 273, 281], ["the pandemic growth", "PROBLEM", 12, 31], ["interventions", "TREATMENT", 93, 106], ["diagnostic capacity", "TEST", 155, 174], ["COVID", "TEST", 273, 278], ["pandemic", "OBSERVATION_MODIFIER", 16, 24], ["growth", "OBSERVATION_MODIFIER", 25, 31]]], ["The president of Tanzania encouraged people to \u201cpray for 3 days\u201d against COVID-19 and has not imposed any movement restrictions\u2014places of worship remain open (17).", [["COVID-19", "CHEMICAL", 73, 81], ["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43]]], ["In Kenya, only a partial lockdown is in place in major cities and many are not prepared for a total lockdown of the country (18, 19).", [["a partial lockdown", "TREATMENT", 15, 33], ["partial", "OBSERVATION_MODIFIER", 17, 24], ["lockdown", "OBSERVATION", 25, 33]]], ["In Uganda and Rwanda more extreme actions have been taken with total national lockdowns that have involved closure of all non-essential businesses, public transport, and the closure of schools and universities.", [["total national lockdowns", "TREATMENT", 63, 87], ["public transport", "TREATMENT", 148, 164]]], ["Only local food stores, supermarkets, medical, and veterinary supplies are exempt and for these services a mandatory curfew has been imposed.", [["food stores", "OBSERVATION", 11, 22]]], ["No motor vehicles/motorists are permitted to use public roads unless they are listed among essential service providers authorized by the Office of the President (20\u201322).", [["motor vehicles", "OBSERVATION", 3, 17]]], ["Countries not abiding with the social distancing guidelines as recommended by the WHO are putting neighboring countries at risk and compromising health security within the East African Community (EAC).", [["EAC", "CANCER", 196, 199]]], ["The EAC continues to show a disorganized response against COVID-19 and this high level of disorganization has created confusion in the general public as to what is \u201ctrue\u201d and \u201cfalse\u201d COVID-19 information.", [["EAC", "ANATOMY", 4, 7], ["confusion", "DISEASE", 118, 127], ["EAC", "CANCER", 4, 7], ["a disorganized response", "PROBLEM", 26, 49], ["COVID", "TEST", 58, 63], ["disorganization", "PROBLEM", 90, 105], ["created confusion", "PROBLEM", 110, 127], ["confusion", "OBSERVATION", 118, 127]]], ["Rumors and misinformation have spread widely within the community and the media; for example, a religious leader in Uganda claimed that there was no COVID-19 in Uganda and stated that it was just \u201csimple flu\u201d and an individual at Kampala City Council Football Club falsely claimed that Uganda had lost a patient to COVID-19; these culprits are currently in jail awaiting trial for spreading false information (23, 24).", [["patient", "ORGANISM", 304, 311], ["patient", "SPECIES", 304, 311], ["Rumors", "PROBLEM", 0, 6], ["COVID", "TEST", 149, 154], ["spread", "OBSERVATION_MODIFIER", 31, 37], ["widely", "OBSERVATION_MODIFIER", 38, 44], ["flu", "OBSERVATION", 204, 207]]], ["Risks and assumptions are causing disharmony in communities, fearful of risk of infection and of the economic consequences of government interventions.IntroductionTo date, COVID-19 cases and deaths have been greatest in Europe, the Americas, the Western Pacific, the Eastern Mediterranean, South East Asia, and Africa, but the situation is fluid and will change as COVID-19 impacts new regions (25).", [["infection", "DISEASE", 80, 89], ["deaths", "DISEASE", 191, 197], ["infection", "PROBLEM", 80, 89], ["government interventions", "TREATMENT", 126, 150], ["COVID", "TEST", 172, 177], ["fluid", "PROBLEM", 340, 345], ["COVID", "TEST", 365, 370], ["infection", "OBSERVATION", 80, 89], ["greatest", "OBSERVATION_MODIFIER", 208, 216], ["fluid", "OBSERVATION", 340, 345]]], ["While most COVID-19 patients have been of European, Asian, and African descent, data from the USA indicates that while African-Americans are at equal risk of infection with SARS-CoV-2, they are at higher risk of severe COVID-19 complications and death.", [["infection", "DISEASE", 158, 167], ["SARS", "DISEASE", 173, 177], ["COVID", "DISEASE", 219, 224], ["death", "DISEASE", 246, 251], ["patients", "ORGANISM", 20, 28], ["African-Americans", "ORGANISM", 119, 136], ["SARS-CoV-2", "ORGANISM", 173, 183], ["patients", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 173, 181], ["infection", "PROBLEM", 158, 167], ["SARS", "PROBLEM", 173, 177], ["severe COVID-19 complications", "PROBLEM", 212, 241], ["death", "PROBLEM", 246, 251], ["infection", "OBSERVATION", 158, 167], ["severe", "OBSERVATION_MODIFIER", 212, 218]]], ["In Illinois, USA, African Americans accounted for 29% of confirmed cases and 41% of deaths, yet comprise 15% of the state's population (26).", [["deaths", "DISEASE", 84, 90]]], ["This is unlikely to have a basis in racial susceptibility but is more likely due to a vulnerability to infection and lack of access to quality medical care\u2014it's not about race but about racism and poverty (28).", [["infection", "DISEASE", 103, 112], ["racial susceptibility", "PROBLEM", 36, 57], ["a vulnerability to infection", "PROBLEM", 84, 112], ["unlikely to", "UNCERTAINTY", 8, 19], ["racial", "OBSERVATION_MODIFIER", 36, 42], ["susceptibility", "OBSERVATION", 43, 57], ["more likely due to", "UNCERTAINTY", 65, 83], ["infection", "OBSERVATION", 103, 112]]], ["These observations are of concern for developing countries in Africa and Latin America (29).IntroductionThe prognosis for COVID-19 infection in Asia and Europe appears to be influenced by sex (being male), pre-existing health conditions (diabetes, cancers, and cardiovascular disease), and age (average age 81 years) (30); other risk factors may include air pollution and smoking (31).", [["cancers", "ANATOMY", 248, 255], ["cardiovascular", "ANATOMY", 261, 275], ["COVID-19", "CHEMICAL", 122, 130], ["infection", "DISEASE", 131, 140], ["diabetes", "DISEASE", 238, 246], ["cancers", "DISEASE", 248, 255], ["cardiovascular disease", "DISEASE", 261, 283], ["smoking", "CHEMICAL", 372, 379], ["COVID-19", "ORGANISM", 122, 130], ["cancers", "CANCER", 248, 255], ["cardiovascular", "ANATOMICAL_SYSTEM", 261, 275], ["COVID-19", "SPECIES", 122, 130], ["COVID", "TEST", 122, 127], ["infection", "PROBLEM", 131, 140], ["diabetes", "PROBLEM", 238, 246], ["cancers", "PROBLEM", 248, 255], ["cardiovascular disease)", "PROBLEM", 261, 284], ["other risk factors", "PROBLEM", 323, 341], ["air pollution", "PROBLEM", 354, 367], ["infection", "OBSERVATION", 131, 140], ["cancers", "OBSERVATION", 248, 255], ["cardiovascular", "ANATOMY", 261, 275], ["air pollution", "OBSERVATION", 354, 367]]], ["Reports released by the Chinese Center for Disease Control and Prevention show that men are more at risk than women (32).", [["men", "ORGANISM", 84, 87], ["women", "ORGANISM", 110, 115], ["men", "SPECIES", 84, 87], ["women", "SPECIES", 110, 115], ["Disease Control", "TREATMENT", 43, 58]]], ["Sex differences in males and females in China are supported by the relatively higher antibodies titer generated in females against COVID-19 (33).", [["the relatively higher antibodies titer", "PROBLEM", 63, 101], ["COVID", "TEST", 131, 136]]], ["Reports from Italy showed no significant differences between males and females infected with COVID-19 (34).", [["COVID-19", "CHEMICAL", 93, 101], ["COVID-19", "CHEMICAL", 93, 101], ["COVID", "TEST", 93, 98], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["Older males continue to be disproportionally affected by COVID-19 (35).IntroductionIn young people (<18 years), reported COVID-19 infections, hospitalization, and death are low (36).", [["infections", "DISEASE", 130, 140], ["death", "DISEASE", 163, 168], ["COVID-19", "CHEMICAL", 57, 65], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["COVID", "TEST", 57, 62]]], ["COVID-19 generally presents with milder symptoms in children than in adults (3, 7), but the evidence-base is unclear.", [["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["COVID", "TEST", 0, 5], ["milder symptoms", "PROBLEM", 33, 48], ["base", "ANATOMY_MODIFIER", 101, 105]]], ["This does not mean children are immune, and children are considered important asymptomatic carriers able to facilitate SARS-CoV-2 transmission within households (37).IntroductionWhile most COVID-19 infections are mild (with <20% of cases being severe to critical) (38), communities of heavy smokers or those with lung function impairments are believed to be particularly susceptible to complications (39).", [["lung", "ANATOMY", 313, 317], ["SARS", "DISEASE", 119, 123], ["infections", "DISEASE", 198, 208], ["lung function impairments", "DISEASE", 313, 338], ["children", "ORGANISM", 19, 27], ["children", "ORGANISM", 44, 52], ["CoV-2", "ORGANISM", 124, 129], ["lung", "ORGAN", 313, 317], ["children", "SPECIES", 19, 27], ["children", "SPECIES", 44, 52], ["lung function impairments", "PROBLEM", 313, 338], ["mild", "OBSERVATION_MODIFIER", 213, 217], ["lung", "ANATOMY", 313, 317]]], ["The WHO has stated that women in Africa are most likely to die from COVID-19 due to sex inequity, chronic poverty among women, weak economic capacity, sexual, and gender-based violence (40).", [["chronic poverty", "DISEASE", 98, 113], ["violence", "DISEASE", 176, 184], ["women", "ORGANISM", 24, 29], ["women", "ORGANISM", 120, 125], ["women", "SPECIES", 24, 29], ["women", "SPECIES", 120, 125], ["COVID", "TEST", 68, 73], ["chronic poverty among women", "PROBLEM", 98, 125], ["weak economic capacity", "PROBLEM", 127, 149], ["most likely", "UNCERTAINTY", 44, 55], ["chronic", "OBSERVATION_MODIFIER", 98, 105]]], ["The elderly are more vulnerable to coronavirus (41) and underlying non-communicable diseases that are pervasive in Africa will predispose individuals to complications from SARS-CoV-2 infection.IntroductionThis study aimed to identify perceptions of COVID-19 risk among Ugandans in order to identify novel strategies to guide the national COVID-19 Task Force (nCTF) to improve, control, and prevent COVID-19 infections.Statistical Analysis ::: MethodsData was exported from Q survey in MS Excel and univariate statistics were conducted using WinPEPI\u00ae and significance was reported at a 95% confidence interval using questions which were asked to both males and females in Uganda.COVID-19 Perceptions Amongst Male and Female Ugandans ::: ResultsOf 161 Ugandan respondents, 64% (n = 103, 95% CI: 56.3\u201371.1) were male and 36% were female (n = 58, 95% CI: 28.9\u201343.7).", [["coronavirus", "DISEASE", 35, 46], ["non-communicable diseases", "DISEASE", 67, 92], ["SARS-CoV-2 infection", "DISEASE", 172, 192], ["infections", "DISEASE", 407, 417], ["SARS-CoV-2", "ORGANISM", 172, 182], ["SARS-CoV", "SPECIES", 172, 180], ["coronavirus", "PROBLEM", 35, 46], ["underlying non-communicable diseases", "PROBLEM", 56, 92], ["complications", "PROBLEM", 153, 166], ["SARS", "PROBLEM", 172, 176], ["CoV", "PROBLEM", 177, 180], ["2 infection", "PROBLEM", 181, 192], ["This study", "TEST", 205, 215], ["COVID", "TEST", 249, 254], ["the national COVID", "TREATMENT", 325, 343], ["Task Force (nCTF)", "TREATMENT", 347, 364], ["COVID-19 infections", "PROBLEM", 398, 417], ["CI", "TEST", 789, 791], ["CI", "TEST", 847, 849], ["non-communicable diseases", "OBSERVATION", 67, 92], ["infection", "OBSERVATION", 183, 192], ["infections", "OBSERVATION", 407, 417]]], ["A total of 52.7% of male respondents (54/102) considered males to be more vulnerable to infection with COVID-19 while 70.4% of female respondents (38/54) did not consider males to be more vulnerable; a significant difference between the groups (RR = 1.79, 95% CI: 1.14\u20132.8).", [["infection", "DISEASE", 88, 97], ["infection", "PROBLEM", 88, 97], ["COVID", "TEST", 103, 108], ["RR", "TEST", 245, 247], ["CI", "TEST", 260, 262], ["total", "OBSERVATION_MODIFIER", 2, 7], ["infection", "OBSERVATION", 88, 97], ["significant", "OBSERVATION_MODIFIER", 202, 213]]], ["Most female respondents considered infection risk to be equally distributed between genders and there was no significant difference in this perception between male and female respondents.COVID-19 Perceptions Amongst Male and Female Ugandans ::: ResultsMore male (52.5%, 52/99, 95% CI: 42.7\u201362.2) respondents believed they were more likely to die from COVID-19 than females (29.6%, 16/54, 95% CI: 18.6\u201342.8); however 70.2% (40/57) of females disagreed with them on who is more likely to die.", [["infection", "DISEASE", 35, 44], ["infection risk", "PROBLEM", 35, 49], ["CI", "TEST", 281, 283], ["COVID", "TEST", 351, 356], ["CI", "TEST", 392, 394], ["infection", "OBSERVATION", 35, 44], ["no", "UNCERTAINTY", 106, 108], ["significant", "OBSERVATION_MODIFIER", 109, 120]]], ["Females were half as convinced that men were more likely to die than the male respondents (RR = 1.76, 95% CI: 1.1\u20132.7).", [["men", "ORGANISM", 36, 39], ["men", "SPECIES", 36, 39], ["RR", "TEST", 91, 93], ["CI", "TEST", 106, 108]]], ["There was no significant difference between the groups of male and female respondents on whether both sexes were equally at risk of death (RR = 0.8, 95% CI: 0.7\u20131.0).", [["death", "DISEASE", 132, 137], ["death", "PROBLEM", 132, 137], ["RR", "TEST", 139, 141], ["CI", "TEST", 153, 155], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["The majority of males (41.4%, 41/99) believed that males present with more severe signs; however, females (71.4%, 40/56) were over two times more likely to disagree with this statement.", [["males", "ORGANISM", 16, 21], ["more severe signs", "PROBLEM", 70, 87], ["females", "TEST", 98, 105], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Female respondents (79%, 45/57) disagreed with the statement that symptoms presented more in males (OR = 1.8, 95% CI: 0.8\u20134.2).", [["symptoms", "PROBLEM", 66, 74], ["CI", "TEST", 114, 116]]], ["Most female respondents agreed that both sexes showed equal signs for COVID-19 (46/56) however no significant differences were found in males and females (RR = 0.9, 95% CI: 0.8\u20131.1).", [["COVID", "TEST", 70, 75], ["significant differences", "PROBLEM", 98, 121], ["RR", "TEST", 155, 157], ["CI", "TEST", 169, 171]]], ["The majority of female respondents (n = 40/56, 71.4%, 95% CI: 58.6\u201382.1) did not think males present with more severe signs of COVID-19 than women, although no significant differences were found (RR = 1.5, 95% CI: 0.9\u20132.3).", [["women", "ORGANISM", 141, 146], ["women", "SPECIES", 141, 146], ["CI", "TEST", 58, 60], ["COVID", "TEST", 127, 132], ["significant differences", "PROBLEM", 160, 183], ["RR", "TEST", 196, 198], ["CI", "TEST", 210, 212], ["no", "UNCERTAINTY", 157, 159]]], ["Most study participants indicated that both sexes shared the same symptoms (Table 2).Perceptions on COVID-19 Toward Children and Young Adults Amongst Ugandans ::: ResultsOverall, most respondents, 53.5%, 95% CI: 45.7\u201361.2 (84/157) considered children to be less vulnerable than adults; no significant differences were found between males and females (RR = 1.1, 95% CI: 0.8\u20131.5).", [["children", "ORGANISM", 242, 250], ["participants", "SPECIES", 11, 23], ["Children", "SPECIES", 116, 124], ["Adults", "SPECIES", 135, 141], ["children", "SPECIES", 242, 250], ["Most study", "TEST", 0, 10], ["the same symptoms", "PROBLEM", 57, 74], ["CI", "TEST", 208, 210], ["significant differences", "PROBLEM", 289, 312], ["RR", "TEST", 351, 353], ["CI", "TEST", 365, 367]]], ["Similar observations were found on participant responses for children being as equally vulnerable as adults.", [["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69]]], ["Most respondents considered mortalities to be less in children (male = 63.7%, 65/102, females = 55.4%, 31/56); however, no significant differences were found among those who disagreed with this perception (RR = 1.15, 95% CI: 0.9, 1.5).", [["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["females", "TEST", 86, 93], ["RR", "TEST", 206, 208], ["CI", "TEST", 221, 223]]], ["In addition, most respondents considered children to present with fewer signs of COVID-19 (82/158), and that the signs of infection are not the same in children (77/156), being less severe than in adults (80/155); there were no significant differences between males and females in these responses (Table 3).Perceptions on COVID-19 Risks Among the Elderly ::: ResultsA significantly large proportion of female respondents (76.4%, 42/55) (compared to male respondents 59.4%, 60/101) did not believe mortality rates to be equal in the young and elderly (RR = 1.7, 95% CI: 1.0\u20132.9).", [["infection", "DISEASE", 122, 131], ["children", "ORGANISM", 41, 49], ["children", "ORGANISM", 152, 160], ["children", "SPECIES", 41, 49], ["children", "SPECIES", 152, 160], ["COVID", "TEST", 81, 86], ["infection", "PROBLEM", 122, 131], ["COVID", "TEST", 322, 327], ["mortality rates", "TEST", 497, 512], ["RR", "TEST", 551, 553], ["CI", "TEST", 565, 567], ["infection", "OBSERVATION", 122, 131], ["less severe", "OBSERVATION_MODIFIER", 177, 188], ["no", "UNCERTAINTY", 225, 227], ["significant", "OBSERVATION_MODIFIER", 228, 239]]], ["Amongst those who believed that young adults show fewer signs than the elderly, a majority (92.7%, 51/55) of female respondents believed this to be true compared to 84.2% (85/101) of males.", [["adults", "ORGANISM", 38, 44]]], ["Furthermore, a majority of female respondents (71.4%, 40/56)\u2014compared to only 53.1% (52/98) of male respondents agreed that elderly COVID-19 patients would show more severe signs than the young (OR = 2.2, 95% CI: 1.4, 4.8) as shown in Table 4.", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["elderly COVID", "TEST", 124, 137], ["more severe signs", "PROBLEM", 161, 178], ["CI", "TEST", 209, 211]]], ["Among those who believed that young adults are more likely to die of COVID-19 than the elderly (19/156), 16% were males while 5.4% were females and there was no significant difference between them.Perceptions of Risk and Race Among Ugandans ::: ResultsA majority of participants agreed that all races were at risk of COVID-19, however some participants thought that other races were more at risk than others.", [["adults", "ORGANISM", 36, 42], ["participants", "ORGANISM", 266, 278], ["participants", "SPECIES", 266, 278], ["participants", "SPECIES", 340, 352], ["COVID", "TEST", 69, 74], ["COVID", "TEST", 317, 322], ["no", "UNCERTAINTY", 158, 160], ["significant", "OBSERVATION_MODIFIER", 161, 172], ["difference", "OBSERVATION", 173, 183]]], ["Amongst those who thought that COVID was a disease of \u201cthe whites,\u201d a majority of these were males (32.4%, 33/102, 95% CI: 23.82\u201341.88) compared to 26.3% females (n = 15/57, 95% CI: 16.1\u201338.9).", [["a disease of \u201cthe whites", "PROBLEM", 41, 65], ["CI", "TEST", 119, 121], ["CI", "TEST", 178, 180]]], ["Furthermore, no significant differences were found between males (5.9%, 6/102) and females (5.3%, 3/57) toward agreement that the disease also affects Blacks.", [["males", "TEST", 59, 64], ["the disease", "PROBLEM", 126, 137], ["no", "UNCERTAINTY", 13, 15], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["disease", "OBSERVATION", 130, 137]]], ["Furthermore, a majority of respondents stated that all races show severe signs of COVID-19 and of these, a majority were females (57.9, 33/57%,) compared to 49.5% (50/101) who were males (Table 5).Study Limitations ::: DiscussionThe study was conducted through an Online application, meaning that Ugandans without smart phones connected to the internet were not able to participate.", [["COVID", "TEST", 82, 87], ["The study", "TEST", 229, 238], ["severe", "OBSERVATION_MODIFIER", 66, 72]]], ["Recruitment was achieved through sharing of the online link via social media and email platforms and data in this study was generally from the same age group i.e., 18\u201331 years.", [["Recruitment", "TREATMENT", 0, 11], ["this study", "TEST", 109, 119]]], ["The sample size was small and further large-scale studies are needed to extend this exploratory study.", [["The sample size", "TEST", 0, 15], ["further large-scale studies", "TEST", 30, 57], ["this exploratory study", "TEST", 79, 101], ["size", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 20, 25], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["Furthermore, results should be approached with caution until more large-scale studies are conducted which would include asymptomatic variables not investigated in the current study.Data Availability StatementThe datasets presented in this study can be found in online repositories.", [["large-scale studies", "TEST", 66, 85], ["asymptomatic variables", "PROBLEM", 120, 142], ["the current study", "TEST", 163, 180], ["this study", "TEST", 234, 244]]], ["Consent to participate was acquired through online acceptance to participate in the study.Author ContributionsKK and SW conceptualized the study.", [["the study", "TEST", 80, 89], ["the study", "TEST", 135, 144]]], ["KK, SW, and FS designed the study.", [["the study", "TEST", 24, 33]]], ["KK, FS, KM, GM, RS, IE, EA, RM, GN, HO, GZ, and JE conducted data acquisition.", [["GM", "CHEMICAL", 12, 14], ["FS", "TEST", 4, 6]]], ["KK, EM, KB, MM, and SW conducted statistical analysis.", [["MM", "TEST", 12, 14], ["statistical analysis", "TEST", 33, 53]]], ["KK, FW-S, EM, KB, MM, and SW conducted interpretation.", [["KK", "TEST", 0, 2], ["FW", "TEST", 4, 6], ["MM", "TEST", 18, 20]]], ["KK, EM, KB, FS, MM, KM, GM, RS, FW-S, IE, EA, RM, GN, HO, GZ, JE, and SW revised the manuscript for intellectual content and approved the final version for publication.", [["GM", "CHEMICAL", 24, 26], ["KB", "TEST", 8, 10], ["FS", "TEST", 12, 14], ["MM", "TEST", 16, 18], ["KM", "TEST", 20, 22], ["GM", "TEST", 24, 26], ["RS", "TEST", 28, 30], ["FW", "TEST", 32, 34], ["IE", "TEST", 38, 40], ["EA", "TEST", 42, 44], ["intellectual content", "PROBLEM", 100, 120], ["GN", "OBSERVATION", 50, 52]]]], "PMC7422656": [["IntroductionHuman papillomavirus (HPV) is the most common sexually transmitted infection and a necessary cause of cervical cancer.1 2 Epidemiological studies of genital HPV infection are mostly focused on women or men individually, assessing the acquisition of HPV infection and its determinants.", [["cervical cancer", "ANATOMY", 114, 129], ["IntroductionHuman papillomavirus (HPV)", "DISEASE", 0, 38], ["sexually transmitted infection", "DISEASE", 58, 88], ["cervical cancer", "DISEASE", 114, 129], ["genital HPV infection", "DISEASE", 161, 182], ["HPV infection", "DISEASE", 261, 274], ["IntroductionHuman papillomavirus", "ORGANISM", 0, 32], ["HPV", "ORGANISM", 34, 37], ["cervical cancer", "CANCER", 114, 129], ["genital HPV", "ORGANISM", 161, 172], ["women", "ORGANISM", 205, 210], ["men", "ORGANISM", 214, 217], ["HPV", "ORGANISM", 261, 264], ["women", "SPECIES", 205, 210], ["men", "SPECIES", 214, 217], ["HPV", "SPECIES", 34, 37], ["HPV", "SPECIES", 169, 172], ["HPV", "SPECIES", 261, 264], ["IntroductionHuman papillomavirus (HPV", "PROBLEM", 0, 37], ["transmitted infection", "PROBLEM", 67, 88], ["cervical cancer", "PROBLEM", 114, 129], ["Epidemiological studies", "TEST", 134, 157], ["genital HPV infection", "PROBLEM", 161, 182], ["HPV infection", "PROBLEM", 261, 274], ["infection", "OBSERVATION", 79, 88], ["cervical", "ANATOMY", 114, 122], ["cancer", "OBSERVATION", 123, 129], ["genital", "ANATOMY", 161, 168], ["HPV infection", "OBSERVATION", 169, 182], ["infection", "OBSERVATION", 265, 274]]], ["However, by excluding the sexual partners, these studies cannot explore the dynamics of HPV transmission within a heterosexual couple.", [["HPV", "ORGANISM", 88, 91], ["HPV", "SPECIES", 88, 91], ["these studies", "TEST", 43, 56]]], ["Hence, HPV transmission is best investigated in couple-based studies by examining concordance and discordance of HPV genotypes in partners over time.", [["HPV", "ORGANISM", 7, 10], ["HPV", "ORGANISM", 113, 116], ["HPV", "SPECIES", 7, 10], ["HPV", "SPECIES", 113, 116]]], ["In such studies, one must include those in recently formed relationships as transmission events would be more likely to occur during the onset of a couple\u2019s sexual activity.3 A couple-based observational study recently provided evidence that HPV vaccination received by women confers some protection against HPV infection to their unvaccinated male sexual partners.4 To the best of our knowledge, no randomised controlled trials (RCTs) have studied the impact of vaccination on transmission dynamics within a couple-based study.IntroductionThree prophylactic HPV vaccines (cervarix, a bivalent vaccine (types 16 and 18) by GlaxoSmithKline; Gardasil, a quadrivalent vaccine (types 6, 11, 16 and 18) and Gardasil 9, a nonavalent vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58), both by Merck) have been proven in individual-based RCT to be highly effective in preventing infection with the targeted HPV types and associated cervical precancerous lesions.5\u20137 Indisputably, HPV vaccination has shifted the paradigm of prevention measures and is expected to have a major impact in reducing the burden of cervical cancer and other HPV-associated malignancies, such as vulvar, vaginal, penile, anal and oropharyngeal cancers, as well as benign conditions, such as anogenital warts and respiratory papillomatosis.8\u201310 However, much remains to be understood regarding the effects of HPV vaccination in preventing transmission of target HPV types to sexual partners of vaccinated individuals and its impact on herd immunity.IntroductionThe objective of the Transmission Reduction and Prevention with HPV vaccination (TRAP-HPV) study is to determine the efficacy of an HPV vaccine in reducing transmission of genital and oral HPV infection in sexual partners of vaccinated individuals.", [["cervical precancerous lesions", "ANATOMY", 927, 956], ["cervical cancer", "ANATOMY", 1104, 1119], ["malignancies", "ANATOMY", 1145, 1157], ["vulvar", "ANATOMY", 1167, 1173], ["vaginal", "ANATOMY", 1175, 1182], ["penile", "ANATOMY", 1184, 1190], ["anal", "ANATOMY", 1192, 1196], ["oropharyngeal cancers", "ANATOMY", 1201, 1222], ["anogenital warts", "ANATOMY", 1262, 1278], ["respiratory papillomatosis", "ANATOMY", 1283, 1309], ["genital", "ANATOMY", 1703, 1710], ["oral", "ANATOMY", 1715, 1719], ["HPV infection", "DISEASE", 308, 321], ["cervarix", "CHEMICAL", 573, 581], ["GlaxoSmithKline", "CHEMICAL", 623, 638], ["Gardasil", "CHEMICAL", 640, 648], ["Gardasil 9", "CHEMICAL", 702, 712], ["infection", "DISEASE", 874, 883], ["cervical precancerous lesions", "DISEASE", 927, 956], ["cervical cancer", "DISEASE", 1104, 1119], ["malignancies", "DISEASE", 1145, 1157], ["vulvar, vaginal, penile, anal and oropharyngeal cancers", "DISEASE", 1167, 1222], ["anogenital warts", "DISEASE", 1262, 1278], ["respiratory papillomatosis", "DISEASE", 1283, 1309], ["HPV infection", "DISEASE", 1720, 1733], ["HPV", "ORGANISM", 242, 245], ["women", "ORGANISM", 270, 275], ["HPV", "ORGANISM", 308, 311], ["HPV", "ORGANISM", 559, 562], ["Gardasil", "SIMPLE_CHEMICAL", 640, 648], ["Gardasil 9", "ORGANISM", 702, 712], ["HPV", "ORGANISM", 902, 905], ["cervical precancerous lesions", "CANCER", 927, 956], ["HPV", "ORGANISM", 975, 978], ["cervical cancer", "CANCER", 1104, 1119], ["HPV", "ORGANISM", 1130, 1133], ["malignancies", "CANCER", 1145, 1157], ["vulvar", "CANCER", 1167, 1173], ["vaginal", "ORGANISM_SUBDIVISION", 1175, 1182], ["penile", "ORGANISM_SUBDIVISION", 1184, 1190], ["anal", "CANCER", 1192, 1196], ["oropharyngeal cancers", "CANCER", 1201, 1222], ["HPV", "ORGANISM", 1379, 1382], ["HPV", "ORGANISM", 1432, 1435], ["herd", "ORGANISM_SUBDIVISION", 1505, 1509], ["HPV", "ORGANISM", 1595, 1598], ["HPV", "ORGANISM", 1663, 1666], ["genital", "ORGANISM_SUBDIVISION", 1703, 1710], ["oral", "ORGANISM_SUBDIVISION", 1715, 1719], ["HPV", "ORGANISM", 1720, 1723], ["women", "SPECIES", 270, 275], ["HPV", "SPECIES", 242, 245], ["HPV", "SPECIES", 308, 311], ["HPV", "SPECIES", 559, 562], ["HPV", "SPECIES", 902, 905], ["HPV", "SPECIES", 975, 978], ["HPV", "SPECIES", 1379, 1382], ["HPV", "SPECIES", 1663, 1666], ["HPV", "SPECIES", 1720, 1723], ["observational study", "TEST", 190, 209], ["HPV vaccination", "TREATMENT", 242, 257], ["HPV infection", "PROBLEM", 308, 321], ["randomised controlled trials (RCTs", "TREATMENT", 400, 434], ["transmission dynamics", "TEST", 478, 499], ["a couple-based study", "TEST", 507, 527], ["Three prophylactic HPV vaccines", "TREATMENT", 540, 571], ["cervarix", "TREATMENT", 573, 581], ["a bivalent vaccine", "TREATMENT", 583, 601], ["GlaxoSmithKline", "TREATMENT", 623, 638], ["Gardasil", "TREATMENT", 640, 648], ["a quadrivalent vaccine", "TREATMENT", 650, 672], ["Gardasil", "TREATMENT", 702, 710], ["a nonavalent vaccine", "TREATMENT", 714, 734], ["infection", "PROBLEM", 874, 883], ["the targeted HPV types", "PROBLEM", 889, 911], ["associated cervical precancerous lesions", "PROBLEM", 916, 956], ["HPV vaccination", "TREATMENT", 975, 990], ["prevention measures", "TREATMENT", 1019, 1038], ["cervical cancer", "PROBLEM", 1104, 1119], ["other HPV", "PROBLEM", 1124, 1133], ["associated malignancies", "PROBLEM", 1134, 1157], ["vulvar, vaginal, penile, anal and oropharyngeal cancers", "PROBLEM", 1167, 1222], ["benign conditions", "PROBLEM", 1235, 1252], ["anogenital warts", "PROBLEM", 1262, 1278], ["respiratory papillomatosis", "PROBLEM", 1283, 1309], ["HPV vaccination", "TREATMENT", 1379, 1394], ["vaccinated individuals", "PROBLEM", 1464, 1486], ["the Transmission Reduction", "TREATMENT", 1548, 1574], ["HPV vaccination", "TREATMENT", 1595, 1610], ["TRAP-HPV) study", "TEST", 1612, 1627], ["an HPV vaccine", "TREATMENT", 1660, 1674], ["genital and oral HPV infection", "PROBLEM", 1703, 1733], ["infection", "OBSERVATION", 874, 883], ["HPV", "OBSERVATION", 902, 905], ["cervical", "ANATOMY", 927, 935], ["precancerous", "OBSERVATION_MODIFIER", 936, 948], ["lesions", "OBSERVATION", 949, 956], ["cervical", "ANATOMY", 1104, 1112], ["cancer", "OBSERVATION", 1113, 1119], ["malignancies", "OBSERVATION", 1145, 1157], ["vulvar", "ANATOMY", 1167, 1173], ["vaginal", "ANATOMY", 1175, 1182], ["penile", "ANATOMY", 1184, 1190], ["anal", "ANATOMY", 1192, 1196], ["oropharyngeal", "ANATOMY", 1201, 1214], ["cancers", "OBSERVATION", 1215, 1222], ["respiratory", "ANATOMY", 1283, 1294], ["papillomatosis", "OBSERVATION", 1295, 1309], ["genital", "ANATOMY", 1703, 1710], ["infection", "OBSERVATION", 1724, 1733]]], ["TRAP-HPV will also assess whether a previously infected individual, once vaccinated, is less infective to her or his sexual partner.Study design ::: Methods and analysisThe TRAP-HPV study is a randomised, placebo-controlled, double-blinded trial being conducted in Montreal, Canada.", [["TRAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRAP", "GENE_OR_GENE_PRODUCT", 173, 177], ["TRAP", "PROTEIN", 0, 4], ["TRAP", "PROTEIN", 173, 177], ["a previously infected individual", "PROBLEM", 34, 66], ["analysis", "TEST", 161, 169], ["The TRAP-HPV study", "TEST", 169, 187], ["double-blinded trial", "TREATMENT", 225, 245]]], ["This protocol follows the Standard Protocol Items: Recommendations for Intervention Trials checklist of recommended items to address in a clinical trial protocol.11 The study received ethical approval by institutional review boards at McGill University (A04-M37-12A), Concordia University (30001405), and Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (2014\u20132019, CE 13.016).", [["This protocol", "TREATMENT", 0, 13], ["a clinical trial protocol", "TREATMENT", 136, 161], ["The study", "TEST", 165, 174]]], ["The protocol was last revised on 12 June 2018 (10th revised version).", [["The protocol", "TREATMENT", 0, 12]]], ["Before taking part in this exploratory clinical trial, all participants provide informed written consent to the research nurse (online supplementary appendix 1\u20133 for women, men and the addendum for active study participants during the COVID-19 pandemic, respectively).Study setting and participant recruitment ::: Methods and analysisParticipant\u2019s enrolment started in January 2014, and is ongoing.", [["women", "ORGANISM", 166, 171], ["men", "ORGANISM", 173, 176], ["participants", "SPECIES", 59, 71], ["women", "SPECIES", 166, 171], ["men", "SPECIES", 173, 176], ["participants", "SPECIES", 211, 223], ["active study", "TEST", 198, 210], ["the COVID", "TEST", 231, 240], ["Methods", "TREATMENT", 314, 321], ["analysisParticipant\u2019s enrolment", "TREATMENT", 326, 357]]], ["Our study coordinator enrols participants.", [["participants", "SPECIES", 29, 41]]], ["Initially, participants attended one of two venues for their clinic visit, which provide medical care year-round to students: the McGill University Health Services Clinic or Concordia University Health Services Clinic.", [["participants", "SPECIES", 11, 23]]], ["At present, starting in September 2018, all participants are seen at the Division of Cancer Epidemiology\u2019s research clinic at the Gerald Bronfman Department of Oncology, McGill University.Study setting and participant recruitment ::: Methods and analysisRecruitment is bolstered through campus-wide appeals, including posters, emails to student lists, promotional videos, online-classified advertising services and word-of-mouth advertising.", [["Cancer", "DISEASE", 85, 91], ["participants", "ORGANISM", 44, 56], ["mouth", "ORGANISM_SUBDIVISION", 423, 428], ["participants", "SPECIES", 44, 56], ["Methods", "TREATMENT", 234, 241], ["Cancer", "OBSERVATION", 85, 91]]], ["Additional efforts include mail-outs to students living in residence, classroom presentations in professional schools and information booths at student activities where promotional products are distributed (ie, brochures, promo-button pins and keychains).", [["promotional products", "TREATMENT", 169, 189]]], ["In July 2017, we implemented a new strategy to boost enrolment.", [["boost enrolment", "TREATMENT", 47, 62]]], ["Traditionally, study coordinator(s) would ask potential participants a set of questions to determine their eligibility during the enrolment or screening phase (online supplementary appendix 4).", [["participants", "SPECIES", 56, 68], ["screening phase", "TEST", 143, 158]]], ["We opted to complement this approach with an online pre-eligibility survey that consists of nine eligibility questions that are answered by potential participants on their own (online supplementary appendix 5).", [["participants", "SPECIES", 150, 162]]], ["Eligibility is then assessed using a predefined automatically generated algorithm.", [["a predefined automatically generated algorithm", "TEST", 35, 81]]], ["Potential participants are contacted and informed of their eligibility.", [["participants", "SPECIES", 10, 22]]], ["This questionnaire is posted on social media, the McGill Cancer Epidemiology website (https://www.mcgill.ca/traphpv/), and online-classified advertising services.", [["Cancer", "DISEASE", 57, 63]]], ["To promote participant retention, we send reminder emails to participants before their scheduled study visits and reschedule appointments with participants when they cannot attend their visit.Eligibility criteria ::: Methods and analysisTo be eligible, volunteer couples must (1) not have received the intervention vaccine (Gardasil prior to 8 July 2015 and Gardasil 9 afterwards); (2) plan on remaining in Montreal for at least 1 year; (3) be in a new relationship (onset of sexual activity) that started no more than 6 months prior to study entry; (4) plan on having continued sexual contact with partner; (5) be between 18 and 45 years old; (6) have no history of cervical, penile, oral or anal cancers and (7) be willing to comply with study procedures.", [["cervical", "ANATOMY", 667, 675], ["penile", "ANATOMY", 677, 683], ["oral", "ANATOMY", 685, 689], ["anal cancers", "ANATOMY", 693, 705], ["oral or anal cancers", "DISEASE", 685, 705], ["cervical", "ORGANISM_SUBDIVISION", 667, 675], ["penile", "ORGANISM_SUBDIVISION", 677, 683], ["oral", "ORGANISM_SUBDIVISION", 685, 689], ["anal cancers", "CANCER", 693, 705], ["participants", "SPECIES", 61, 73], ["participants", "SPECIES", 143, 155], ["the intervention vaccine", "TREATMENT", 298, 322], ["cervical, penile, oral or anal cancers", "PROBLEM", 667, 705], ["study procedures", "TEST", 740, 756], ["cervical", "ANATOMY", 667, 675], ["penile", "ANATOMY", 677, 683], ["oral", "ANATOMY", 685, 689], ["anal", "ANATOMY", 693, 697], ["cancers", "OBSERVATION", 698, 705]]], ["Concerning criteria 3 and 4, we screen couples based on the Dyadic Adjustment Scale (DAS), a validated instrument to measure the stability of couples\u2019 relationships.12\u201314 Although the questionnaire is intended for married and common-law couples, participants answer 4 questions (in English or French) applicable to non-cohabitating couples from the Dyadic Satisfaction subscale of the DAS (table 1).", [["participants", "SPECIES", 246, 258]]], ["Couples in which one of the partners scores less than 80% of the maximum score are not enrolled.Interventions ::: Methods and analysisOnce recruited, couples were randomised to one of four treatment or placebo vaccine combinations (table 2) via a 2-by-2 design where both partners either receive the intervention vaccine or the placebo vaccine, or receive discordant vaccination regimens from the research nurse.", [["four treatment", "TREATMENT", 184, 198], ["placebo vaccine combinations", "TREATMENT", 202, 230], ["the intervention vaccine", "TREATMENT", 296, 320], ["the placebo vaccine", "TREATMENT", 324, 343], ["discordant vaccination regimens", "TREATMENT", 356, 387]]], ["Prior to 8 July 2015, Gardasil was used as the intervention vaccine, which allowed for the observation of four infection outcomes (HPVs 6, 11, 16, 18).", [["Gardasil", "CHEMICAL", 22, 30], ["infection", "DISEASE", 111, 120], ["HPVs", "DISEASE", 131, 135], ["Gardasil", "TREATMENT", 22, 30], ["the intervention vaccine", "TREATMENT", 43, 67], ["four infection outcomes", "PROBLEM", 106, 129], ["HPVs", "TEST", 131, 135], ["infection", "OBSERVATION", 111, 120]]], ["Henceforth, intervention has been defined as vaccination with Gardasil 9 (Merck).7 This vaccine allows for the observation of nine HPV outcomes (HPVs 6, 11, 16, 18, 31, 33, 45, 52, 58).", [["Gardasil 9", "CHEMICAL", 62, 72], ["HPV", "ORGANISM", 131, 134], ["HPV", "SPECIES", 131, 134], ["intervention", "TREATMENT", 12, 24], ["Gardasil", "TREATMENT", 62, 70], ["This vaccine", "TREATMENT", 83, 95], ["the observation", "TEST", 107, 122], ["HPVs", "TEST", 145, 149]]], ["The placebo vaccine is the hepatitis A vaccine Avaxim (Sanofi Pasteur).", [["hepatitis", "DISEASE", 27, 36], ["Avaxim", "CHEMICAL", 47, 53], ["Avaxim", "SIMPLE_CHEMICAL", 47, 53], ["The placebo vaccine", "TREATMENT", 0, 19], ["the hepatitis A vaccine Avaxim", "TREATMENT", 23, 53]]], ["Initially, Havrix (GlaxoSmithKline) was administered as the placebo vaccine until 11 June 2018 (refer to discussion and table 3 for more details regarding intervention and placebo vaccine amendments).", [["Havrix", "CHEMICAL", 11, 17], ["GlaxoSmithKline", "CHEMICAL", 19, 34], ["Havrix", "SIMPLE_CHEMICAL", 11, 17], ["Havrix (GlaxoSmithKline)", "TREATMENT", 11, 35], ["the placebo vaccine", "TREATMENT", 56, 75], ["intervention", "TREATMENT", 155, 167], ["placebo vaccine amendments", "TREATMENT", 172, 198]]], ["Hepatitis A vaccine was chosen as the placebo vaccine because hepatitis A immunisation provides a similar health prevention incentive to study participants as HPV vaccination while preserving the scientific cogency of a \u2018placebo\u2019 comparator.", [["Hepatitis A", "DISEASE", 0, 11], ["hepatitis A", "CHEMICAL", 62, 73], ["Hepatitis A", "ORGANISM", 0, 11], ["HPV", "ORGANISM", 159, 162], ["participants", "SPECIES", 143, 155], ["Hepatitis A", "SPECIES", 0, 11], ["hepatitis A", "SPECIES", 62, 73], ["HPV", "SPECIES", 159, 162], ["Hepatitis A vaccine", "TREATMENT", 0, 19], ["the placebo vaccine", "TREATMENT", 34, 53], ["hepatitis A immunisation", "TREATMENT", 62, 86], ["HPV vaccination", "TREATMENT", 159, 174], ["a \u2018placebo\u2019 comparator", "TREATMENT", 218, 240]]], ["Gardasil 9 requires administration of three doses, while Avaxim only requires 2 doses.", [["Gardasil 9", "CHEMICAL", 0, 10], ["Avaxim", "CHEMICAL", 57, 63], ["Gardasil 9", "CHEMICAL", 0, 10], ["Avaxim", "CHEMICAL", 57, 63], ["Avaxim", "SIMPLE_CHEMICAL", 57, 63], ["Gardasil", "TREATMENT", 0, 8], ["Avaxim", "TREATMENT", 57, 63]]], ["Hence, a placebo injection (saline solution) is administered between the hepatitis A vaccination regimen.", [["hepatitis A", "DISEASE", 73, 84], ["saline", "SIMPLE_CHEMICAL", 28, 34], ["hepatitis A", "SPECIES", 73, 84], ["a placebo injection (saline solution)", "TREATMENT", 7, 44], ["the hepatitis A vaccination regimen", "TREATMENT", 69, 104]]], ["Accordingly, both treatment and control vaccines have similar regimens, that is, at study entry, 2 months and 6 months.Interventions ::: Methods and analysisTo ensure that all study participants gain similar health benefits and incentives, and in keeping with ethical values, a crossover of interventions is implemented at the end of the study; the HPV vaccine is offered to all control participants and hepatitis A vaccine to all HPV-immunised participants.", [["hepatitis A", "DISEASE", 404, 415], ["HPV", "ORGANISM", 349, 352], ["hepatitis A", "ORGANISM", 404, 415], ["HPV", "ORGANISM", 431, 434], ["participants", "ORGANISM", 445, 457], ["participants", "SPECIES", 182, 194], ["participants", "SPECIES", 387, 399], ["participants", "SPECIES", 445, 457], ["HPV", "SPECIES", 349, 352], ["hepatitis A", "SPECIES", 404, 415], ["both treatment", "TREATMENT", 13, 27], ["control vaccines", "TREATMENT", 32, 48], ["similar regimens", "TREATMENT", 54, 70], ["Methods and analysis", "TEST", 137, 157], ["all study", "TEST", 172, 181], ["ethical values", "TEST", 260, 274], ["a crossover of interventions", "TREATMENT", 276, 304], ["the study", "TEST", 334, 343], ["the HPV vaccine", "TREATMENT", 345, 360], ["hepatitis A vaccine", "TREATMENT", 404, 423]]], ["The benefit of HPV vaccination would not be significantly delayed for control participants since the study is relatively short (12 months).Incentives for participation ::: Methods and analysisHPV and hepatitis A vaccines are provided free of charge and participants receive a monetary incentive at every visit.", [["hepatitis A", "DISEASE", 200, 211], ["HPV", "ORGANISM", 15, 18], ["participants", "SPECIES", 78, 90], ["participants", "SPECIES", 253, 265], ["HPV", "SPECIES", 15, 18], ["hepatitis A", "SPECIES", 200, 211], ["HPV vaccination", "TREATMENT", 15, 30], ["the study", "TEST", 97, 106], ["Methods", "TREATMENT", 172, 179], ["analysisHPV", "TREATMENT", 184, 195], ["hepatitis A vaccines", "TREATMENT", 200, 220]]], ["Remuneration per participant is distributed as follows: CAN$120 at enrolment visit; CAN$60 for visits 2, 3 and 4; CAN$80 at visit 5; and CAN$120 at the last visit.", [["CAN", "DISEASE", 84, 87], ["CAN", "DISEASE", 114, 117], ["participant", "SPECIES", 17, 28]]], ["In total, individuals are each given CAN$500 (CAN$1000 per couple) as a cash incentive for their participation, if all study visits were to be completed.Randomisation and blinding ::: Methods and analysisRandom allocation of study participants is determined via computer-assisted simple randomisation.", [["CAN", "DISEASE", 37, 40], ["participants", "SPECIES", 231, 243]]], ["Participants, investigators and outcome assessors are blinded to vaccination assignment.", [["Participants", "SPECIES", 0, 12]]], ["Participant blinding is assured because both vaccines (HPV and hepatitis A) and their syringes look identical (previously drawn from blinded vials in a separate room by the nurse) so that participants are unaware of their content.", [["HPV and hepatitis A", "DISEASE", 55, 74], ["HPV", "ORGANISM", 55, 58], ["participants", "SPECIES", 188, 200], ["HPV", "SPECIES", 55, 58], ["both vaccines", "TREATMENT", 40, 53], ["their syringes", "TREATMENT", 80, 94]]], ["Furthermore, injection pain is expected to be similar for both vaccines.", [["pain", "DISEASE", 23, 27], ["injection pain", "PROBLEM", 13, 27], ["both vaccines", "TREATMENT", 58, 71]]], ["At the end of the study, participants are informed of their allocation.Self-administered web-based questionnaire ::: Data collection procedures ::: Methods and analysisParticipants complete a self-administered baseline questionnaire at enrolment and a follow-up questionnaire at each of their five subsequent visits (online supplementary appendix 6 and 7 for women, respectively; online supplementary appendix 8 and 9 for men, respectively).", [["women", "ORGANISM", 359, 364], ["men", "ORGANISM", 422, 425], ["participants", "SPECIES", 25, 37], ["women", "SPECIES", 359, 364], ["men", "SPECIES", 422, 425], ["the study", "TEST", 14, 23]]], ["At enrolment, participants are introduced to the web-based system and then individually complete their enrolment questionnaire in private.", [["participants", "SPECIES", 14, 26]]], ["We use a secure, confidential study-designated internet site to provide participants with protected access to the web-based questionnaires by assigned login names and passwords.Collection of blood specimens ::: Data collection procedures ::: Methods and analysisThe study nurse collects the blood specimen at baseline according to the Protocol for Collection of Blood Specimens (online supplementary appendix 10).", [["blood specimens", "ANATOMY", 191, 206], ["blood specimen", "ANATOMY", 291, 305], ["Blood Specimens", "ANATOMY", 362, 377], ["blood specimens", "ORGANISM_SUBSTANCE", 191, 206], ["blood specimen", "MULTI-TISSUE_STRUCTURE", 291, 305], ["Blood Specimens", "MULTI-TISSUE_STRUCTURE", 362, 377], ["internet site", "DNA", 47, 60], ["participants", "SPECIES", 72, 84], ["confidential study", "TEST", 17, 35], ["Collection of blood specimens", "TEST", 177, 206], ["Methods and analysis", "TEST", 242, 262], ["The study", "TEST", 262, 271], ["the blood specimen", "TEST", 287, 305], ["Collection of Blood Specimens", "TEST", 348, 377]]], ["Merck Research Laboratory at Merck\u2019s headquarters in Pennsylvania, USA, will conduct competitive Luminex immunoassay with the serum samples to detect and quantify any neutralising antibody response to HPV infection.15 16Collection of oral specimens ::: Data collection procedures ::: Methods and analysisThe nurse collects a sample of exfoliated cells from representative sites in the oral cavity using a toothbrush and mouthwash according to the Protocol for Collection of Specimens of Exfoliated Cells from the Mouth (online supplementary appendix 11).17 Samples are centrifuged and the pellet is processed as described below for DNA extraction.Collection of vaginal specimens ::: Data collection procedures ::: Methods and analysisWomen are asked to abstain from intercourse a minimum of 48 hours before specimen collection to minimise the risk of contamination with residual male epithelial cells, urethral secretions and/or semen.18 The instructions for self-collection of vaginal specimens follow those of the validated protocol of Gravitt et al (online supplementary appendix 12).19 The swab is placed directly into the plastic vial with the PreservCyt transport medium (ThinPrep PreserveCyt Solution, Hologic, Marlborough, Mass.), which adequately preserves exfoliated specimens for DNA, RNA and protein analyses.", [["serum samples", "ANATOMY", 126, 139], ["oral specimens", "ANATOMY", 234, 248], ["cells", "ANATOMY", 346, 351], ["sites", "ANATOMY", 372, 377], ["oral cavity", "ANATOMY", 385, 396], ["Cells", "ANATOMY", 498, 503], ["vaginal specimens", "ANATOMY", 661, 678], ["specimen", "ANATOMY", 807, 815], ["epithelial cells", "ANATOMY", 884, 900], ["urethral secretions", "ANATOMY", 902, 921], ["semen", "ANATOMY", 929, 934], ["vaginal specimens", "ANATOMY", 978, 995], ["swab", "ANATOMY", 1094, 1098], ["specimens", "ANATOMY", 1277, 1286], ["HPV infection", "DISEASE", 201, 214], ["serum samples", "ORGANISM_SUBSTANCE", 126, 139], ["HPV", "ORGANISM", 201, 204], ["oral specimens", "CANCER", 234, 248], ["exfoliated cells", "CELL", 335, 351], ["oral cavity", "ORGANISM_SUBDIVISION", 385, 396], ["Cells", "CELL", 498, 503], ["Mouth", "ORGANISM_SUBDIVISION", 513, 518], ["DNA", "CELLULAR_COMPONENT", 632, 635], ["vaginal specimens", "CANCER", 661, 678], ["epithelial cells", "CELL", 884, 900], ["urethral secretions", "ORGANISM_SUBSTANCE", 902, 921], ["semen", "ORGANISM_SUBSTANCE", 929, 934], ["vaginal specimens", "MULTI-TISSUE_STRUCTURE", 978, 995], ["PreservCyt", "SIMPLE_CHEMICAL", 1149, 1159], ["exfoliated specimens", "TISSUE", 1266, 1286], ["DNA", "CELLULAR_COMPONENT", 1291, 1294], ["exfoliated cells", "CELL_TYPE", 335, 351], ["residual male epithelial cells", "CELL_TYPE", 870, 900], ["HPV", "SPECIES", 201, 204], ["competitive Luminex immunoassay", "TEST", 85, 116], ["the serum samples", "TEST", 122, 139], ["any neutralising antibody response", "PROBLEM", 163, 197], ["HPV infection", "PROBLEM", 201, 214], ["Methods and analysis", "TEST", 284, 304], ["exfoliated cells", "PROBLEM", 335, 351], ["a toothbrush and mouthwash", "TREATMENT", 403, 429], ["Collection of Specimens", "TEST", 460, 483], ["Exfoliated Cells", "PROBLEM", 487, 503], ["DNA extraction", "TREATMENT", 632, 646], ["specimen collection", "TEST", 807, 826], ["contamination", "PROBLEM", 851, 864], ["residual male epithelial cells", "PROBLEM", 870, 900], ["urethral secretions and/or semen", "PROBLEM", 902, 934], ["vaginal specimens", "TEST", 978, 995], ["the validated protocol", "TREATMENT", 1012, 1034], ["Gravitt et al (online supplementary appendix", "TREATMENT", 1038, 1082], ["The swab", "TREATMENT", 1090, 1098], ["the PreservCyt transport medium (ThinPrep PreserveCyt Solution", "TREATMENT", 1145, 1207], ["DNA", "PROBLEM", 1291, 1294], ["RNA and protein analyses", "TEST", 1296, 1320], ["infection", "OBSERVATION", 205, 214], ["exfoliated cells", "OBSERVATION", 335, 351], ["oral cavity", "ANATOMY", 385, 396], ["Exfoliated Cells", "OBSERVATION", 487, 503], ["Mouth", "ANATOMY", 513, 518], ["vaginal", "ANATOMY", 661, 668], ["contamination", "OBSERVATION", 851, 864], ["epithelial cells", "OBSERVATION", 884, 900], ["urethral", "ANATOMY", 902, 910], ["secretions", "OBSERVATION", 911, 921], ["vaginal", "ANATOMY", 978, 985], ["swab", "OBSERVATION", 1094, 1098], ["Mass", "OBSERVATION", 1231, 1235]]], ["Self-collected vaginal samples have been shown to be valid for research and clinical purposes, and acceptable to women.19 20Collection of penile skin swabs ::: Data collection procedures ::: Methods and analysisMen are asked to abstain from sexual intercourse for 48 hours preceding collection to reduce the possibility of detecting HPV carriage from residual female secretions.21 The research nurse conducts an external examination of the genital area to note circumcision status and presence of any relevant clinical findings.", [["vaginal samples", "ANATOMY", 15, 30], ["penile skin swabs", "ANATOMY", 138, 155], ["secretions", "ANATOMY", 367, 377], ["genital area", "ANATOMY", 440, 452], ["vaginal samples", "CANCER", 15, 30], ["women", "ORGANISM", 113, 118], ["penile skin swabs", "TISSUE", 138, 155], ["HPV", "ORGANISM", 333, 336], ["genital area", "ORGANISM_SUBDIVISION", 440, 452], ["women", "SPECIES", 113, 118], ["HPV", "SPECIES", 333, 336], ["clinical purposes", "TEST", 76, 93], ["HPV carriage", "PROBLEM", 333, 345], ["residual female secretions", "PROBLEM", 351, 377], ["an external examination", "TEST", 409, 432], ["any relevant clinical findings", "PROBLEM", 497, 527], ["penile", "ANATOMY", 138, 144], ["skin", "ANATOMY", 145, 149], ["swabs", "OBSERVATION", 150, 155], ["secretions", "OBSERVATION", 367, 377], ["genital", "ANATOMY", 440, 447]]], ["The nurse collects the penile sample according to the Protocol for Collection of Specimens of Male Penile Skin Swabs (online supplementary appendix 13).", [["penile sample", "ANATOMY", 23, 36], ["Skin", "ANATOMY", 106, 110], ["penile", "ORGANISM_SUBDIVISION", 23, 29], ["the penile sample", "TREATMENT", 19, 36], ["Collection of Specimens", "TEST", 67, 90], ["penile", "ANATOMY", 23, 29], ["Penile Skin", "ANATOMY", 99, 110]]], ["The research nurse collects the specimen using emery paper (600A-grit Wetordry Tri-M-ite; 3M) exfoliation, followed by swabbing with a Dacron applicator moistened with sterile normal saline.22 The nurse uses a new wet swab and sweep 360\u00b0 around the coronal sulcus and then another 360\u00b0 around the glans penis.", [["specimen", "ANATOMY", 32, 40], ["wet swab", "ANATOMY", 214, 222], ["coronal sulcus", "ANATOMY", 249, 263], ["glans penis", "ANATOMY", 297, 308], ["exfoliation", "DISEASE", 94, 105], ["coronal sulcus", "CANCER", 249, 263], ["glans penis", "ORGAN", 297, 308], ["Tri-M-ite", "TREATMENT", 79, 88], ["exfoliation", "TREATMENT", 94, 105], ["a Dacron applicator", "TREATMENT", 133, 152], ["sterile normal saline", "TREATMENT", 168, 189], ["a new wet swab", "TREATMENT", 208, 222], ["coronal sulcus", "ANATOMY", 249, 263], ["glans penis", "ANATOMY", 297, 308]]], ["The nurse proceeds to use a new wet swab to sample the entire skin surface of each quadrant of the penile shaft (left and right ventral, and left and right dorsal).", [["skin surface", "ANATOMY", 62, 74], ["penile shaft", "ANATOMY", 99, 111], ["left", "ANATOMY", 113, 117], ["right ventral", "ANATOMY", 122, 135], ["left", "ANATOMY", 141, 145], ["right dorsal", "ANATOMY", 150, 162], ["skin surface", "MULTI-TISSUE_STRUCTURE", 62, 74], ["penile shaft", "MULTI-TISSUE_STRUCTURE", 99, 111], ["ventral", "ORGANISM_SUBDIVISION", 128, 135], ["a new wet swab", "TREATMENT", 26, 40], ["skin", "ANATOMY", 62, 66], ["surface", "ANATOMY_MODIFIER", 67, 74], ["each", "ANATOMY_MODIFIER", 78, 82], ["quadrant", "ANATOMY_MODIFIER", 83, 91], ["penile shaft", "ANATOMY", 99, 111], ["left", "ANATOMY_MODIFIER", 113, 117], ["right", "ANATOMY_MODIFIER", 122, 127], ["ventral", "ANATOMY_MODIFIER", 128, 135], ["left", "ANATOMY_MODIFIER", 141, 145], ["right", "ANATOMY_MODIFIER", 150, 155], ["dorsal", "ANATOMY_MODIFIER", 156, 162]]], ["Afterwards, each swab is placed into an individual PreservCyt-containing vial and labelled according to the anatomic site.", [["swab", "ANATOMY", 17, 21], ["PreservCyt", "SIMPLE_CHEMICAL", 51, 61], ["PreservCyt", "DNA", 51, 61], ["each swab", "TREATMENT", 12, 21], ["an individual PreservCyt-containing vial", "TREATMENT", 37, 77], ["anatomic site", "OBSERVATION", 108, 121]]], ["Previous research on penile skin swabbing to detect HPV DNA has proven this method to be reliable.23HPV testing ::: Methods and analysisDNA is extracted from samples using the Master Pure extraction kit (Epicentre, Madison, Wisconsin, USA).24 HPV genotyping is done using the Linear Array HPV Genotyping Test (Roche Molecular Systems, Indianapolis, Indiana, USA).25 Using the PGMY09/11 consensus primer system which targets the L1 gene of the HPV genome, this assay can detect 36 types (HPVs 6, 11, 16, 18, 26, 31, 33\u201335, 39, 40, 42, 44, 45, 51\u201354, 56, 58, 59, 61, 62, 66\u201373, 81\u201384 and 89).", [["penile skin", "ANATOMY", 21, 32], ["samples", "ANATOMY", 158, 165], ["penile skin", "MULTI-TISSUE_STRUCTURE", 21, 32], ["HPV", "ORGANISM", 52, 55], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["HPV", "ORGANISM", 100, 103], ["HPV", "ORGANISM", 243, 246], ["PGMY09/11", "GENE_OR_GENE_PRODUCT", 376, 385], ["HPV", "ORGANISM", 443, 446], ["PGMY09/11 consensus primer system", "DNA", 376, 409], ["L1 gene", "DNA", 428, 435], ["HPV genome", "DNA", 443, 453], ["HPV", "SPECIES", 52, 55], ["HPV", "SPECIES", 100, 103], ["HPV", "SPECIES", 243, 246], ["HPV", "SPECIES", 443, 446], ["penile skin swabbing", "TREATMENT", 21, 41], ["HPV DNA", "PROBLEM", 52, 59], ["HPV genotyping", "TEST", 243, 257], ["the Linear Array HPV Genotyping Test", "TEST", 272, 308], ["this assay", "TEST", 455, 465], ["HPVs", "TEST", 487, 491], ["penile", "ANATOMY", 21, 27], ["skin", "ANATOMY", 28, 32], ["swabbing", "OBSERVATION", 33, 41], ["HPV genome", "OBSERVATION", 443, 453]]], ["Coamplification of \u03b2-Globin is performed to assess specimen quality.Study outcomes ::: Methods and analysisFor each anatomic site, the primary outcome will be transmission reduction of HPV infections of target HPV vaccine types (HPVs 6, 11, 16, 18, 31, 33, 45, 52, and 58) over time in Avaxim-administered sexual partners of HPV vaccinated individuals, corresponding to the combinations MTFP and MPFT (table 2).", [["specimen", "ANATOMY", 51, 59], ["HPV infections", "DISEASE", 185, 199], ["\u03b2-Globin", "GENE_OR_GENE_PRODUCT", 19, 27], ["HPV", "ORGANISM", 185, 188], ["HPV", "ORGANISM", 210, 213], ["HPV", "ORGANISM", 325, 328], ["\u03b2-Globin", "PROTEIN", 19, 27], ["MPFT", "PROTEIN", 396, 400], ["HPV", "SPECIES", 185, 188], ["HPV", "SPECIES", 325, 328], ["Coamplification of \u03b2-Globin", "TEST", 0, 27], ["Methods and analysis", "TEST", 87, 107], ["each anatomic site", "PROBLEM", 111, 129], ["transmission reduction", "TREATMENT", 159, 181], ["HPV infections", "PROBLEM", 185, 199], ["HPVs", "TEST", 229, 233], ["Avaxim", "TREATMENT", 286, 292], ["HPV vaccinated individuals", "PROBLEM", 325, 351]]], ["The control group consists of couples randomised to both participants receiving Avaxim, denoted as the MPFP group.", [["Avaxim", "CHEMICAL", 80, 86], ["Avaxim", "CHEMICAL", 80, 86], ["Avaxim", "SIMPLE_CHEMICAL", 80, 86], ["MPFP", "CANCER", 103, 107], ["participants", "SPECIES", 57, 69], ["Avaxim", "TREATMENT", 80, 86]]], ["The fully protected group is represented by the combination MTFT.", [["MTFT", "PROTEIN", 60, 64], ["protected", "OBSERVATION", 10, 19]]], ["We will also measure prevalence and incidence of HPV types covered by the intervention vaccine in all collected samples, for each visit and among all participants.Study outcomes ::: Methods and analysisReduction in HPV type concordance (for the nine target types) will be evaluated over time between vaccination groups.", [["samples", "ANATOMY", 112, 119], ["HPV", "ORGANISM", 49, 52], ["HPV", "ORGANISM", 215, 218], ["participants", "SPECIES", 150, 162], ["HPV", "SPECIES", 49, 52], ["HPV types", "TREATMENT", 49, 58], ["the intervention vaccine", "TREATMENT", 70, 94], ["Methods", "TREATMENT", 182, 189], ["analysisReduction", "TREATMENT", 194, 211], ["vaccination groups", "TREATMENT", 300, 318]]], ["These comparisons will be done with due attention to the enrolment HPV type-specific infection status of participants.", [["infection", "DISEASE", 85, 94], ["HPV", "ORGANISM", 67, 70], ["participants", "ORGANISM", 105, 117], ["participants", "SPECIES", 105, 117], ["the enrolment HPV type-specific infection", "PROBLEM", 53, 94], ["infection", "OBSERVATION", 85, 94]]], ["For instance, we expect that an Avaxim-treated woman who is positive for HPV6 in the oral specimen, but negative for this type in the vaginal specimen, may derive benefit if her partner had received the intervention vaccine, even if he is HPV6 positive in the penile sample.", [["oral specimen", "ANATOMY", 85, 98], ["vaginal specimen", "ANATOMY", 134, 150], ["penile sample", "ANATOMY", 260, 273], ["Avaxim", "CHEMICAL", 32, 38], ["Avaxim", "CHEMICAL", 32, 38], ["Avaxim", "SIMPLE_CHEMICAL", 32, 38], ["woman", "ORGANISM", 47, 52], ["HPV6", "GENE_OR_GENE_PRODUCT", 73, 77], ["oral specimen", "ORGAN", 85, 98], ["vaginal specimen", "MULTI-TISSUE_STRUCTURE", 134, 150], ["HPV6", "GENE_OR_GENE_PRODUCT", 239, 243], ["penile", "ORGANISM_SUBDIVISION", 260, 266], ["woman", "SPECIES", 47, 52], ["HPV6", "SPECIES", 73, 77], ["HPV6", "SPECIES", 239, 243], ["HPV6", "PROBLEM", 73, 77], ["the oral specimen", "TEST", 81, 98], ["this type in the vaginal specimen", "PROBLEM", 117, 150], ["the intervention vaccine", "TREATMENT", 199, 223], ["HPV6 positive in the penile sample", "PROBLEM", 239, 273], ["vaginal", "ANATOMY", 134, 141], ["penile", "ANATOMY", 260, 266]]], ["We assume that protection via vaccination is pan-mucosal, via transudation of neutralising antibodies and may mediate transmission.Data management ::: Methods and analysisData management and project coordination is done at the McGill\u2019s Division of Cancer Epidemiology coordination centre.", [["pan-mucosal", "ANATOMY", 45, 56], ["Cancer", "DISEASE", 248, 254], ["neutralising antibodies", "PROTEIN", 78, 101], ["protection via vaccination", "TREATMENT", 15, 41], ["neutralising antibodies", "TREATMENT", 78, 101], ["Methods", "TREATMENT", 151, 158], ["analysisData management", "TREATMENT", 163, 186], ["project coordination", "TEST", 191, 211], ["Cancer", "OBSERVATION", 248, 254]]], ["The research staff have access to the secure study-designated website containing participant and study visit information.", [["the secure study", "TEST", 34, 50]]], ["All participant data are checked monthly for quality assurance.Sample size ::: Methods and analysisThere are no published empirical estimates of the expected level of transmission reduction.", [["All participant data", "TEST", 0, 20], ["Methods and analysis", "TEST", 79, 99], ["transmission reduction", "TREATMENT", 167, 189], ["size", "OBSERVATION_MODIFIER", 70, 74], ["no", "UNCERTAINTY", 109, 111], ["reduction", "OBSERVATION_MODIFIER", 180, 189]]], ["Our informal consultation with experts in the field indicated that 40% reduction in transmission would be a conservative estimate; it would represent the expected magnitude of a protective effect in the discordant vaccination groups where the partner receiving a placebo is the one to be protected.", [["40% reduction", "TREATMENT", 67, 80], ["a placebo", "TREATMENT", 261, 270]]], ["Using the Bernstein and Lagakos approach,26 we determined that a total of 500 couples (125 couples per group/cell in table 2) are required for 90% power, with type 1 error of 0.05, and one-sided hypothesis for a 40% reduction in transmission rate, assuming a cumulative 16% lost to follow-up at month 12 (attrition rate of 2.7% per-visit).", [["cell", "ANATOMY", 109, 113], ["cell", "CELL", 109, 113], ["a 40% reduction", "TREATMENT", 210, 225], ["transmission rate", "TEST", 229, 246], ["attrition rate", "TEST", 305, 319], ["sided", "ANATOMY_MODIFIER", 189, 194]]], ["Empirically based estimates of parameters for sample size calculation were obtained from our unit\u2019s molecular epidemiological investigations of the HITCH cohort study.27\u201329 We also assumed gender equivalent rates of transmission as per findings in the HITCH study.29Statistical methods ::: Methods and analysisWe hypothesise that HPV vaccination would be effective in reducing the risk of HPV transmission to sexual partners.", [["27\u201329", "CHEMICAL", 167, 172], ["HPV", "ORGANISM", 330, 333], ["HPV", "ORGANISM", 389, 392], ["HPV", "SPECIES", 330, 333], ["HPV", "SPECIES", 389, 392], ["sample size calculation", "TEST", 46, 69], ["the HITCH cohort study", "TEST", 144, 166], ["the HITCH study", "TEST", 248, 263], ["Methods and analysisWe hypothesise", "TREATMENT", 290, 324], ["HPV vaccination", "TREATMENT", 330, 345], ["equivalent", "OBSERVATION_MODIFIER", 196, 206], ["rates", "OBSERVATION_MODIFIER", 207, 212]]], ["The study design offers the opportunity to measure transmission events in multiple mucosal sites for multiple HPV types, over multiple clinic visits, and for both directionalities (ie, male to female and female to male).", [["mucosal sites", "ANATOMY", 83, 96], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 83, 96], ["The study", "TEST", 0, 9], ["transmission events", "PROBLEM", 51, 70], ["multiple mucosal sites", "PROBLEM", 74, 96], ["multiple", "OBSERVATION_MODIFIER", 101, 109], ["HPV", "OBSERVATION", 110, 113]]], ["We will take advantage of advanced regression methods as a framework for measuring the effects expected via HPV vaccination.Statistical methods ::: Methods and analysisIn the simplest core formulation (eg, analysing a single HPV type and a single mucosal site), we will use the Kaplan-Meier technique to plot the cumulative probability of HPV infection in sexual partners of vaccinated versus unvaccinated individuals against follow-up time.", [["mucosal site", "ANATOMY", 247, 259], ["HPV infection", "DISEASE", 339, 352], ["HPV", "ORGANISM", 108, 111], ["HPV", "ORGANISM", 225, 228], ["mucosal", "ORGAN", 247, 254], ["HPV", "ORGANISM", 339, 342], ["HPV", "SPECIES", 108, 111], ["HPV", "SPECIES", 339, 342], ["advanced regression methods", "TREATMENT", 26, 53], ["HPV vaccination", "TREATMENT", 108, 123], ["Methods", "TREATMENT", 148, 155], ["the simplest core formulation", "TREATMENT", 171, 200], ["a single HPV type", "TREATMENT", 216, 233], ["a single mucosal site", "TREATMENT", 238, 259], ["HPV infection", "PROBLEM", 339, 352], ["infection", "OBSERVATION", 343, 352]]], ["Using the layout in table 2, this implies comparing HPV infection histories of women in the MTFP and MPFP groups and men in the MPFT and MPFP groups.", [["HPV infection", "DISEASE", 52, 65], ["HPV", "ORGANISM", 52, 55], ["women", "ORGANISM", 79, 84], ["men", "ORGANISM", 117, 120], ["women", "SPECIES", 79, 84], ["men", "SPECIES", 117, 120], ["HPV", "SPECIES", 52, 55], ["HPV infection", "PROBLEM", 52, 65], ["infection", "OBSERVATION", 56, 65]]], ["Expectedly, protection is also likely to occur via cumulative effects observable via HPV detection in multiple mucosal sites; we will address this by conducting time to event analysis.Statistical methods ::: Methods and analysisWe will use the log-rank test for statistical comparisons in HPV transmission between vaccine and control groups.", [["mucosal sites", "ANATOMY", 111, 124], ["HPV", "ORGANISM", 85, 88], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 111, 124], ["HPV", "ORGANISM", 289, 292], ["HPV", "SPECIES", 85, 88], ["HPV", "SPECIES", 289, 292], ["HPV detection", "TEST", 85, 98], ["multiple mucosal sites", "PROBLEM", 102, 124], ["event analysis", "TEST", 169, 183], ["the log-rank test", "TEST", 240, 257], ["HPV transmission between vaccine", "TREATMENT", 289, 321]]], ["Cox proportional hazard regression models will be used to estimate the effect of vaccination on HPV transmission to sexual partners based on HRs and their respective 95% CIs.", [["HPV", "ORGANISM", 96, 99], ["HPV", "SPECIES", 96, 99], ["Cox proportional hazard regression models", "PROBLEM", 0, 41], ["vaccination", "TREATMENT", 81, 92], ["HPV transmission", "TREATMENT", 96, 112]]], ["Time to HPV infection in days will be defined as the time from study enrolment to infection date.", [["HPV infection", "DISEASE", 8, 21], ["infection", "DISEASE", 82, 91], ["HPV", "ORGANISM", 8, 11], ["HPV", "SPECIES", 8, 11], ["HPV infection", "PROBLEM", 8, 21], ["infection", "OBSERVATION", 12, 21]]], ["In addition to the intention-to-treat analysis approach, we will perform regression models to examine the role of several candidate determinants in mediating transmission and protective effects.Statistical methods ::: Methods and analysisFurthermore, cumulative risk models will be fitted with type-specific transmission as an outcome.", [["analysis approach", "TEST", 38, 55], ["regression models", "TEST", 73, 90], ["Methods", "TREATMENT", 218, 225]]], ["Generalised estimating equations (GEE) models will be used to incorporate data across multiple HPV types,30 to account for repeated HPV prevalence data across types and study visits involving the same participant.", [["HPV", "ORGANISM", 95, 98], ["participant", "SPECIES", 201, 212], ["HPV", "SPECIES", 132, 135], ["Generalised estimating equations (GEE) models", "PROBLEM", 0, 45], ["repeated HPV prevalence data", "PROBLEM", 123, 151]]], ["In a single GEE logistic regression model, we will consider type-specific infection events for each vaccine HPV type as separate transmission endpoints and then estimate the exposure effect on selected HPVs as a group, as we have published.27 28 Mixed-effects models will also be fitted incorporating repeated HPV transmission data across HPV types and visits involving the same participant.31 Couples who break-up and end their relationship before their last visit will be censored of the study.", [["infection", "DISEASE", 74, 83], ["HPVs", "DISEASE", 202, 206], ["HPV", "ORGANISM", 108, 111], ["HPVs", "ORGANISM", 202, 206], ["HPV", "ORGANISM", 339, 342], ["participant", "SPECIES", 379, 390], ["HPV", "SPECIES", 310, 313], ["HPV", "SPECIES", 339, 342], ["type-specific infection events", "PROBLEM", 60, 90], ["the study", "TEST", 486, 495], ["infection", "OBSERVATION", 74, 83]]], ["Since vaccination protection is expected to begin as early as the first dose, we can expect to analyse reductions in transmission with a subset of visits for a few couples before the full set of visits is completed, which will allow for an interim analysis to be conducted before study termination.Data monitoring and adverse events ::: Methods and analysisAn independent data safety monitoring board will review the interim analysis results.", [["vaccination protection", "TREATMENT", 6, 28], ["an interim analysis", "TEST", 237, 256], ["Data monitoring", "TEST", 298, 313], ["the interim analysis", "TEST", 413, 433]]], ["The analysis is planned for when we have recruited half of the target sample size (250 couples) or when 100 couples complete all six visits.", [["The analysis", "TEST", 0, 12]]], ["The type 1 error for concluding efficacy will be controlled by the Lan-Demets spending function32 with O\u2019Brien and Fleming type boundaries.33Patient and public involvement ::: Methods and analysisPrior to commencement of the TRAP-HPV study, we conducted a qualitative assessment to explore the acceptability of proposed study procedures and invite recommendations on ways to improve them.", [["TRAP", "GENE_OR_GENE_PRODUCT", 225, 229], ["TRAP", "PROTEIN", 225, 229], ["the TRAP-HPV study", "TEST", 221, 239], ["a qualitative assessment", "TEST", 254, 278], ["proposed study procedures", "TEST", 311, 336]]], ["We held a focus group with 13 heterosexual couples within the eligible age range of the TRAP-HPV study to resemble potential participants.", [["TRAP", "GENE_OR_GENE_PRODUCT", 88, 92], ["TRAP", "PROTEIN", 88, 92], ["participants", "SPECIES", 125, 137], ["the TRAP", "TEST", 84, 92], ["HPV study", "TEST", 93, 102]]], ["Focus group participants attended a presentation of the proposed trial procedures then engaged in discussions regarding potential concerns and improvements.", [["participants", "SPECIES", 12, 24], ["the proposed trial procedures", "TREATMENT", 52, 81]]], ["Topics discussed related to inclusion criteria, censoring due to break-up, lost of follow-up, ethical considerations regarding the placebo and attractiveness of the study to similar couples.", [["the placebo", "TREATMENT", 127, 138], ["the study", "TEST", 161, 170]]], ["Results from the focus group inform our trial procedures.Dissemination policy ::: Methods and analysisInformation gained from this study will be published in peer-reviewed journals and presented at national and international conferences.", [["our trial procedures", "TREATMENT", 36, 56], ["this study", "TEST", 126, 136]]], ["In the context of knowledge translation, the generated empirical evidence could be used in mathematical models of vaccination to inform policymakers in Canada and elsewhere.", [["vaccination", "TREATMENT", 114, 125]]], ["The implications for mathematical models is discussed further in the discussion.Preliminary recruitment findings ::: Methods and analysisAs of April 2020, we have enrolled 167 couples since recruitment commenced in January 2014.", [["mathematical models", "TREATMENT", 21, 40]]], ["Our records show that 81 couples have been recruited via posters, 47 via online-classified ads (Kijiji, McGill Classified ads and Facebook), 18 couples via word of mouth, and one via a study promotion during a university orientation event, while 12 couples did not specify the recruitment method.", [["mouth", "ORGANISM_SUBDIVISION", 164, 169], ["mouth", "ANATOMY", 164, 169]]], ["So far, 71 couples have completed all six visits, 62 couples withdrew before their last visit and 31 couples with ongoing participation.DiscussionLogistical issues have been the main challenge for the slow accrual rates.", [["the slow accrual rates", "PROBLEM", 197, 219]]], ["We have since made some changes to the eligibility criteria to improve enrolment while simultaneously conserving the integrity of the study design.", [["the study", "TEST", 130, 139]]], ["The greatest hindrance was the initial short-latency requirement of a new relationship.", [["greatest", "OBSERVATION_MODIFIER", 4, 12], ["hindrance", "OBSERVATION_MODIFIER", 13, 22]]], ["Other efforts to improve recruitment rates involved increasing the upper age limit for participants from 26 to 40 years of age after two couples were recruited and increasing it once more for an upper age limit of 45 years old after enrolling 31 couples.", [["upper", "ORGANISM_SUBDIVISION", 67, 72], ["upper", "ORGANISM_SUBDIVISION", 195, 200], ["participants", "SPECIES", 87, 99], ["recruitment rates", "TEST", 25, 42]]], ["In addition, compensation was increased twice.", [["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["After recruiting 15 couples, it was increased from CAN$350 to CAN$500 per couple and further increased to CAN$1000 after 68 couples were recruited.", [["CAN", "DISEASE", 51, 54], ["CAN", "DISEASE", 62, 65]]], ["Because our recruiters refer to conversations with candidate participants in which they disclose feelings of embarrassment, pain or discomfort in undergoing anal sampling, as deterrents to their participation in TRAP-HPV, the decision was made to discontinue the collection of anal samples after 48 couples were recruited.DiscussionThree other protocol amendments have been implemented, unrelated to increasing enrolment rates.", [["anal", "ANATOMY", 157, 161], ["anal samples", "ANATOMY", 277, 289], ["embarrassment", "DISEASE", 109, 122], ["pain", "DISEASE", 124, 128], ["anal", "ORGANISM_SUBDIVISION", 157, 161], ["TRAP", "GENE_OR_GENE_PRODUCT", 212, 216], ["anal samples", "CANCER", 277, 289], ["TRAP", "PROTEIN", 212, 216], ["participants", "SPECIES", 61, 73], ["embarrassment", "PROBLEM", 109, 122], ["pain", "PROBLEM", 124, 128], ["discomfort", "PROBLEM", 132, 142], ["anal sampling", "TREATMENT", 157, 170], ["anal samples", "TEST", 277, 289], ["increasing enrolment rates", "PROBLEM", 400, 426], ["anal", "ANATOMY", 157, 161], ["anal", "ANATOMY", 277, 281]]], ["After recruiting 23 couples, Gardasil was replaced with Gardasil 9 as the intervention vaccine to increase the study's efficiency in measuring the outcome and to confer increased health benefits to participants.", [["Gardasil", "CHEMICAL", 29, 37], ["Gardasil 9", "CHEMICAL", 56, 66], ["Gardasil", "SIMPLE_CHEMICAL", 29, 37], ["participants", "SPECIES", 198, 210], ["Gardasil", "TREATMENT", 29, 37], ["Gardasil", "TREATMENT", 56, 64], ["the intervention vaccine", "TREATMENT", 70, 94], ["the study", "TEST", 107, 116]]], ["The other protocol amendment was the placebo vaccine substitution, from Havrix (GlaxoSmithKline) to Avaxim (Sanofi Pasteur) after 114 couples were recruited due to increased price of the former.", [["Havrix", "CHEMICAL", 72, 78], ["Avaxim", "CHEMICAL", 100, 106], ["The other protocol amendment", "TREATMENT", 0, 28], ["the placebo vaccine substitution", "TREATMENT", 33, 65], ["Havrix (GlaxoSmithKline)", "TREATMENT", 72, 96], ["Avaxim", "TREATMENT", 100, 106]]], ["Study enrolment and clinic visits were put on hold on 13 March 2020, following the university lockdown due to the COVID-19 pandemic.", [["the COVID", "TEST", 110, 119], ["pandemic", "PROBLEM", 123, 131]]], ["On 26 May 2020, we received approval from the university to resume clinic visits for participants with impending vaccination visits.", [["participants", "SPECIES", 85, 97]]], ["We have put a number of safety measures in place to optimise the safety of participants and our research nurse, such as the use of personal protective equipment, distancing while in the research clinic, scheduling appointments at sufficiently spaced time intervals, and sanitising keyboards and other common areas after each use.", [["participants", "SPECIES", 75, 87], ["safety measures", "TREATMENT", 24, 39], ["personal protective equipment", "TREATMENT", 131, 160]]], ["For a more detailed list of amendments, refer to table 3.DiscussionTo our knowledge, this is the first RCT to investigate HPV transmission reduction via vaccination within couples.", [["HPV", "ORGANISM", 122, 125], ["HPV", "SPECIES", 122, 125], ["HPV transmission reduction", "TREATMENT", 122, 148]]], ["Additionally, the balanced randomised population of men and women may help shed light into whether biological sex-specific differences exist concerning the efficacy of HPV vaccination.", [["men", "ORGANISM", 52, 55], ["women", "ORGANISM", 60, 65], ["HPV", "ORGANISM", 168, 171], ["men", "SPECIES", 52, 55], ["women", "SPECIES", 60, 65], ["HPV", "SPECIES", 168, 171], ["HPV vaccination", "TREATMENT", 168, 183]]], ["Few previous studies34\u201338 have explored HPV transmission between sexually active partners, among which only two couple-based studies have recruited ~500 couples,39 40 similar to our target sample size.", [["HPV", "ORGANISM", 40, 43], ["HPV", "SPECIES", 40, 43], ["Few previous studies", "TEST", 0, 20], ["size", "OBSERVATION_MODIFIER", 196, 200]]], ["One distinct feature of our study is the implementation of HPV vaccination to a couple-based transmission study.", [["HPV", "ORGANISM", 59, 62], ["HPV", "SPECIES", 59, 62], ["our study", "TEST", 24, 33], ["HPV vaccination", "TREATMENT", 59, 74], ["a couple-based transmission study", "TEST", 78, 111], ["distinct", "OBSERVATION_MODIFIER", 4, 12]]], ["In general, vaccination programmes aim to be cost-effective by reaching sufficiently high coverage to reduce transmission to levels that are low enough to permit additional protection to susceptible, unvaccinated individuals; a concept broadly designated as herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 258, 262], ["vaccination programmes", "TREATMENT", 12, 34]]], ["Given the long timescales involved, mathematical models have played an important role in predicting herd immunity thresholds and informing policy decisions regarding HPV vaccination strategies.", [["herd", "ORGANISM_SUBDIVISION", 100, 104], ["HPV", "ORGANISM", 166, 169], ["HPV", "SPECIES", 166, 169], ["HPV vaccination strategies", "TREATMENT", 166, 192]]], ["Indeed, health economic models on the impact of HPV vaccination have shown the cost-effectiveness of HPV vaccination in 12-year-old North American girls compared with screening.41\u201344 The added benefits of vaccinating boys have been also evaluated, with mixed results.45 46 We concluded that potential incremental gains of vaccinating boys may be limited by the predicted herd immunity impact of vaccinating girls under moderate to high vaccine coverage.47 However, differences in model structure and assumptions have made it difficult to compare findings across studies and apply them to policy evaluations.", [["HPV", "ORGANISM", 48, 51], ["HPV", "ORGANISM", 101, 104], ["boys", "ORGANISM", 217, 221], ["girls", "SPECIES", 147, 152], ["boys", "SPECIES", 217, 221], ["boys", "SPECIES", 334, 338], ["girls", "SPECIES", 407, 412], ["HPV", "SPECIES", 48, 51], ["HPV", "SPECIES", 101, 104], ["HPV vaccination", "TREATMENT", 48, 63], ["HPV vaccination", "TREATMENT", 101, 116], ["screening", "TEST", 167, 176], ["vaccinating boys", "TREATMENT", 205, 221], ["vaccinating girls", "TREATMENT", 395, 412], ["high vaccine coverage", "TREATMENT", 431, 452], ["findings across studies", "TEST", 546, 569], ["policy evaluations", "TEST", 588, 606]]], ["A key source of heterogeneity in health economic studies of the impact of HPV vaccination relates to HPV transmission dynamics.48 Since no vaccination study has examined the dynamics of HPV transmission, the TRAP-HPV study would provide relevant empirically derived estimates for health economic models.", [["HPV", "ORGANISM", 74, 77], ["HPV", "ORGANISM", 101, 104], ["HPV", "ORGANISM", 186, 189], ["TRAP", "GENE_OR_GENE_PRODUCT", 208, 212], ["TRAP", "PROTEIN", 208, 212], ["HPV", "SPECIES", 74, 77], ["HPV", "SPECIES", 101, 104], ["HPV", "SPECIES", 186, 189], ["health economic studies", "TEST", 33, 56], ["HPV vaccination", "PROBLEM", 74, 89], ["HPV transmission dynamics", "PROBLEM", 101, 126], ["vaccination study", "TEST", 139, 156], ["HPV transmission", "TEST", 186, 202], ["the TRAP-HPV study", "TEST", 204, 222], ["heterogeneity", "OBSERVATION_MODIFIER", 16, 29], ["HPV", "OBSERVATION", 74, 77]]], ["These estimates would confirm whether a universal vaccination strategy is appropriate in settings that have adopted such a strategy and if it should be implemented in places where the HPV vaccination strategy is focused solely on individuals assigned female at birth.", [["HPV", "ORGANISM", 184, 187], ["a universal vaccination strategy", "TREATMENT", 38, 70], ["the HPV vaccination strategy", "TREATMENT", 180, 208]]]], "8666c802be0f784cd46d8a002832de0d7a2e62e5": [["IntroductionThe unfolded protein response (UPR) in the endoplasmic reticulum (ER) represents an ancient but critical cellular mechanism in response to various deleterious stresses within the ER lumen.", [["endoplasmic reticulum", "ANATOMY", 55, 76], ["ER", "ANATOMY", 78, 80], ["cellular", "ANATOMY", 117, 125], ["ER lumen", "ANATOMY", 191, 199], ["UPR", "GENE_OR_GENE_PRODUCT", 43, 46], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 55, 76], ["ER", "GENE_OR_GENE_PRODUCT", 78, 80], ["cellular", "CELL", 117, 125], ["ER lumen", "CELLULAR_COMPONENT", 191, 199], ["UPR", "PROTEIN", 43, 46], ["The unfolded protein response", "PROBLEM", 12, 41], ["critical cellular mechanism", "PROBLEM", 108, 135], ["various deleterious stresses", "PROBLEM", 151, 179], ["unfolded", "OBSERVATION_MODIFIER", 16, 24], ["protein response", "OBSERVATION", 25, 41], ["endoplasmic reticulum", "ANATOMY", 55, 76], ["cellular mechanism", "OBSERVATION", 117, 135], ["various", "OBSERVATION_MODIFIER", 151, 158], ["deleterious stresses", "OBSERVATION", 159, 179], ["lumen", "ANATOMY_MODIFIER", 194, 199]]], ["It maintains ER homeostasis by increasing protein-folding capacity, reducing global protein synthesis, and clearing misfolded proteins [1] [2] [3] .", [["ER", "GENE_OR_GENE_PRODUCT", 13, 15], ["ER", "PROTEIN", 13, 15], ["misfolded proteins", "PROTEIN", 116, 134], ["increasing protein-folding capacity", "PROBLEM", 31, 66], ["global protein synthesis", "PROBLEM", 77, 101], ["clearing misfolded proteins", "TEST", 107, 134], ["protein synthesis", "OBSERVATION", 84, 101]]], ["Protein loads and quality within the ER lumen are monitored by three transmembrane proteins: PKR-like ER kinase (PERK), activating transcriptional factor 6 (ATF6) and inositol requiring enzyme 1 (IRE1) [4, 5] .", [["ER lumen", "ANATOMY", 37, 45], ["inositol", "CHEMICAL", 167, 175], ["inositol", "CHEMICAL", 167, 175], ["ER", "GENE_OR_GENE_PRODUCT", 37, 39], ["PKR-like ER kinase", "GENE_OR_GENE_PRODUCT", 93, 111], ["PERK", "GENE_OR_GENE_PRODUCT", 113, 117], ["activating transcriptional factor 6", "GENE_OR_GENE_PRODUCT", 120, 155], ["ATF6", "GENE_OR_GENE_PRODUCT", 157, 161], ["inositol requiring enzyme 1", "GENE_OR_GENE_PRODUCT", 167, 194], ["IRE1", "GENE_OR_GENE_PRODUCT", 196, 200], ["transmembrane proteins", "PROTEIN", 69, 91], ["PKR", "PROTEIN", 93, 96], ["ER kinase", "PROTEIN", 102, 111], ["PERK", "PROTEIN", 113, 117], ["activating transcriptional factor 6", "PROTEIN", 120, 155], ["ATF6", "PROTEIN", 157, 161], ["inositol requiring enzyme 1", "PROTEIN", 167, 194], ["IRE1", "PROTEIN", 196, 200], ["Protein loads", "TEST", 0, 13], ["PKR", "TEST", 93, 96], ["activating transcriptional factor", "TEST", 120, 153], ["inositol requiring enzyme", "TEST", 167, 192], ["lumen", "ANATOMY_MODIFIER", 40, 45]]], ["These sensors are normally kept in an inactive state by GRP78 (also known as BiP or HSPA5), which is an ER-resident chaperone and the master regulator of UPR [6, 7] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 56, 61], ["BiP", "GENE_OR_GENE_PRODUCT", 77, 80], ["HSPA5", "GENE_OR_GENE_PRODUCT", 84, 89], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["UPR", "GENE_OR_GENE_PRODUCT", 154, 157], ["GRP78", "PROTEIN", 56, 61], ["BiP", "PROTEIN", 77, 80], ["HSPA5", "PROTEIN", 84, 89], ["ER", "PROTEIN", 104, 106], ["chaperone", "PROTEIN", 116, 125], ["UPR", "PROTEIN", 154, 157]]], ["Under ER stress conditions, GRP78 detaches from the sensors to allow their activation as it proceeds to binds to exposed hydrophobic regions of nascent polypeptides [6, 8] .IntroductionThe three sensors regulated by GRP78 control distinct pathways.", [["ER", "GENE_OR_GENE_PRODUCT", 6, 8], ["GRP78", "GENE_OR_GENE_PRODUCT", 28, 33], ["GRP78", "GENE_OR_GENE_PRODUCT", 216, 221], ["ER", "PROTEIN", 6, 8], ["GRP78", "PROTEIN", 28, 33], ["hydrophobic regions", "PROTEIN", 121, 140], ["GRP78", "PROTEIN", 216, 221], ["GRP78 detaches", "PROBLEM", 28, 42], ["stress conditions", "OBSERVATION", 9, 26]]], ["Activated PERK phosphorylates eIF2\u03b1.", [["PERK", "GENE_OR_GENE_PRODUCT", 10, 14], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["PERK", "PROTEIN", 10, 14], ["eIF2\u03b1", "PROTEIN", 30, 35]]], ["Although this leads to global translational attenuation, it does allow the preferential translation of a subset of stress-related mRNAs, including the activating transcription factor 4 (ATF4) [9] [10] [11] , which is a pro-survival protein that regulates the expression of stressrelated genes involved in anti-oxidation, amino acid biosynthesis and transport, apoptosis, etc [12] [13] [14] [15] .", [["amino acid", "CHEMICAL", 321, 331], ["[12] [13] [14] [15]", "CHEMICAL", 375, 394], ["amino acid", "CHEMICAL", 321, 331], ["ATF4) [9] [10] [11]", "GENE_OR_GENE_PRODUCT", 186, 205], ["amino acid", "AMINO_ACID", 321, 331], ["etc [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 371, 394], ["mRNAs", "RNA", 130, 135], ["ATF4", "PROTEIN", 186, 190], ["pro-survival protein", "PROTEIN", 219, 239], ["stressrelated genes", "DNA", 273, 292], ["global translational attenuation", "PROBLEM", 23, 55], ["stress-related mRNAs", "PROBLEM", 115, 135], ["the activating transcription factor", "TREATMENT", 147, 182], ["a pro-survival protein", "PROBLEM", 217, 239], ["anti-oxidation", "TREATMENT", 305, 319], ["amino acid biosynthesis", "TREATMENT", 321, 344], ["global", "OBSERVATION_MODIFIER", 23, 29], ["translational attenuation", "OBSERVATION", 30, 55]]], ["Sensor ATF6 can detect folding perturbations such as disruptions in disulfide bonding and protein under-glycosylation, and its activation leads to its translocation and cleavage within Golgi by host proteases to release a transcriptionally-active fragment that induces expression of genes involved in protein folding, such as GRP78, PDI and GRP94, etc [1, [16] [17] [18] [19] .", [["Golgi", "ANATOMY", 185, 190], ["1, [16] [17] [18] [19", "CHEMICAL", 353, 374], ["disulfide", "CHEMICAL", 68, 77], ["ATF6", "GENE_OR_GENE_PRODUCT", 7, 11], ["Golgi", "CELLULAR_COMPONENT", 185, 190], ["GRP78", "GENE_OR_GENE_PRODUCT", 326, 331], ["PDI", "GENE_OR_GENE_PRODUCT", 333, 336], ["GRP94", "GENE_OR_GENE_PRODUCT", 341, 346], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 356, 375], ["ATF6", "PROTEIN", 7, 11], ["host proteases", "PROTEIN", 194, 208], ["GRP78", "PROTEIN", 326, 331], ["PDI", "PROTEIN", 333, 336], ["GRP94", "PROTEIN", 341, 346], ["Sensor ATF6", "PROBLEM", 0, 11], ["folding perturbations", "PROBLEM", 23, 44], ["disruptions in disulfide bonding", "PROBLEM", 53, 85], ["protein under-glycosylation", "TREATMENT", 90, 117], ["a transcriptionally-active fragment", "PROBLEM", 220, 255], ["protein folding", "PROBLEM", 301, 316], ["GRP78", "TEST", 326, 331], ["PDI", "TEST", 333, 336], ["GRP94", "TEST", 341, 346]]], ["Lastly, the IRE1-XBP1 branch is evolutionarily conserved from yeast to humans and responds to all types of ER stress [20, 21] .", [["IRE1", "GENE_OR_GENE_PRODUCT", 12, 16], ["XBP1", "GENE_OR_GENE_PRODUCT", 17, 21], ["humans", "ORGANISM", 71, 77], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["IRE1", "PROTEIN", 12, 16], ["XBP1", "PROTEIN", 17, 21], ["ER", "PROTEIN", 107, 109], ["yeast", "SPECIES", 62, 67], ["humans", "SPECIES", 71, 77], ["yeast", "SPECIES", 62, 67], ["humans", "SPECIES", 71, 77], ["branch", "ANATOMY_MODIFIER", 22, 28]]], ["Activated IRE1 has the endoribonuclease activity and splices many mRNA targets destined for translation at the ER, which causes IRE1-dependent mRNA decay [22, 23] .", [["ER", "ANATOMY", 111, 113], ["IRE1", "GENE_OR_GENE_PRODUCT", 10, 14], ["ER", "GENE_OR_GENE_PRODUCT", 111, 113], ["IRE1", "GENE_OR_GENE_PRODUCT", 128, 132], ["IRE1", "PROTEIN", 10, 14], ["endoribonuclease", "PROTEIN", 23, 39], ["mRNA targets", "RNA", 66, 78], ["ER", "PROTEIN", 111, 113], ["IRE1", "PROTEIN", 128, 132], ["the endoribonuclease activity", "TREATMENT", 19, 48], ["IRE1-dependent mRNA decay", "PROBLEM", 128, 153], ["endoribonuclease activity", "OBSERVATION_MODIFIER", 23, 48]]], ["Although most of the target mRNAs are degraded, the unconventional splicing of XBP1 mRNA produces a functional transcript that encodes the transcription factor XBP1s, which controls the expression of many target genes involved in lipid synthesis, ERassociated degradation (ERAD), and chaperones [24] [25] [26] .IntroductionThe cellular UPR has been increasingly recognized as an intrinsic line among innate defenses that can result in either degradation of microbial components, translational inhibition, or apoptosis [27] [28] [29] .", [["cellular", "ANATOMY", 327, 335], ["XBP1", "GENE_OR_GENE_PRODUCT", 79, 83], ["XBP1s", "GENE_OR_GENE_PRODUCT", 160, 165], ["lipid", "SIMPLE_CHEMICAL", 230, 235], ["ERAD", "GENE_OR_GENE_PRODUCT", 273, 277], ["cellular", "CELL", 327, 335], ["target mRNAs", "RNA", 21, 33], ["XBP1 mRNA", "RNA", 79, 88], ["transcription factor", "PROTEIN", 139, 159], ["XBP1s", "PROTEIN", 160, 165], ["target genes", "DNA", 205, 217], ["ERAD", "PROTEIN", 273, 277], ["UPR", "PROTEIN", 336, 339], ["XBP1 mRNA", "PROBLEM", 79, 88], ["the transcription factor XBP1s", "PROBLEM", 135, 165], ["lipid synthesis", "TREATMENT", 230, 245], ["ERassociated degradation", "PROBLEM", 247, 271], ["microbial components", "PROBLEM", 457, 477], ["translational inhibition", "PROBLEM", 479, 503], ["apoptosis", "PROBLEM", 508, 517], ["XBP1 mRNA", "OBSERVATION", 79, 88], ["functional transcript", "OBSERVATION", 100, 121], ["target genes", "OBSERVATION", 205, 217], ["lipid synthesis", "OBSERVATION", 230, 245], ["intrinsic line", "OBSERVATION", 379, 393]]], ["Moreover, the UPR can regulate autophagy, inflammation, and type I interferon responses [30] [31] [32] .", [["inflammation", "DISEASE", 42, 54], ["UPR", "GENE_OR_GENE_PRODUCT", 14, 17], ["type I interferon", "GENE_OR_GENE_PRODUCT", 60, 77], ["UPR", "PROTEIN", 14, 17], ["inflammation", "PROBLEM", 42, 54], ["type I interferon responses", "PROBLEM", 60, 87], ["inflammation", "OBSERVATION", 42, 54]]], ["Consequently, investigations of how pathogens interface with this cellular response is required for a thorough understanding of how they replicate and cause disease [33] .", [["cellular", "ANATOMY", 66, 74], ["cellular", "CELL", 66, 74], ["disease", "PROBLEM", 157, 164]]], ["The experiments described in this report address the interplay of UPR signaling with porcine reproductive and respiratory syndrome virus (PRRSV), a positive-strand RNA virus within the Arteriviridae family in the order Nidovirales [34, 35] .IntroductionPRRSV mainly causes reproductive failure of sows and respiratory diseases of young pigs, and it has remained a major threat to global pork production since the first outbreak in late 1980s [36] .", [["respiratory", "ANATOMY", 306, 317], ["porcine reproductive and respiratory syndrome", "DISEASE", 85, 130], ["IntroductionPRRSV", "CHEMICAL", 241, 258], ["respiratory diseases", "DISEASE", 306, 326], ["UPR", "GENE_OR_GENE_PRODUCT", 66, 69], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 85, 136], ["PRRSV", "ORGANISM", 138, 143], ["sows", "ORGANISM_SUBDIVISION", 297, 301], ["pigs", "ORGANISM", 336, 340], ["pork", "ORGANISM_SUBDIVISION", 387, 391], ["UPR", "PROTEIN", 66, 69], ["PRRSV", "SPECIES", 138, 143], ["pigs", "SPECIES", 336, 340], ["PRRSV", "SPECIES", 138, 143], ["pigs", "SPECIES", 336, 340], ["pork", "SPECIES", 387, 391], ["UPR signaling", "PROBLEM", 66, 79], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 85, 136], ["a positive-strand RNA virus", "PROBLEM", 146, 173], ["IntroductionPRRSV", "TREATMENT", 241, 258], ["reproductive failure of sows", "PROBLEM", 273, 301], ["respiratory diseases of young pigs", "PROBLEM", 306, 340], ["respiratory syndrome", "OBSERVATION", 110, 130], ["respiratory diseases", "OBSERVATION", 306, 326]]], ["Currently, there are no effective vaccines or anti-viral drugs available for this virus [37] .", [["effective vaccines", "TREATMENT", 24, 42], ["anti-viral drugs", "TREATMENT", 46, 62], ["this virus", "PROBLEM", 77, 87], ["no", "UNCERTAINTY", 21, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33]]], ["Persistent infections, dysregulation of host immunity, and rapid genetic mutation/recombination all contribute to the difficulty of disease control and the emergence of many highly virulent strains, including the deadly Chinese highly pathogenic PRRSV in 2006 [37] [38] [39] [40] .", [["infections", "DISEASE", 11, 21], ["PRRSV", "ORGANISM", 246, 251], ["Persistent infections", "PROBLEM", 0, 21], ["dysregulation of host immunity", "PROBLEM", 23, 53], ["rapid genetic mutation", "PROBLEM", 59, 81], ["disease control", "TREATMENT", 132, 147], ["many highly virulent strains", "PROBLEM", 169, 197], ["infections", "OBSERVATION", 11, 21], ["host immunity", "OBSERVATION_MODIFIER", 40, 53]]], ["Clearly, a better understanding of the interactions between this pathogen and its host is needed for developing effective prophylactic and therapeutic measures.IntroductionPRRSV has recently been shown to induce the activation of the PERK and IRE1 branches of the UPR in porcine alveolar macrophage cell line ZMAC [41] , but the significance of these events for virus replication is unknown.", [["alveolar macrophage cell line ZMAC", "ANATOMY", 279, 313], ["IntroductionPRRSV", "CHEMICAL", 160, 177], ["PERK", "GENE_OR_GENE_PRODUCT", 234, 238], ["IRE1", "GENE_OR_GENE_PRODUCT", 243, 247], ["UPR", "GENE_OR_GENE_PRODUCT", 264, 267], ["porcine", "ORGANISM", 271, 278], ["alveolar macrophage cell line ZMAC [41]", "CELL", 279, 318], ["IntroductionPRRSV", "PROTEIN", 160, 177], ["PERK", "PROTEIN", 234, 238], ["IRE1 branches", "PROTEIN", 243, 256], ["UPR", "PROTEIN", 264, 267], ["porcine alveolar macrophage cell line", "CELL_LINE", 271, 308], ["ZMAC [41", "CELL_LINE", 309, 317], ["porcine", "SPECIES", 271, 278], ["this pathogen", "PROBLEM", 60, 73], ["therapeutic measures", "TREATMENT", 139, 159], ["these events", "PROBLEM", 345, 357], ["virus replication", "PROBLEM", 362, 379], ["branches", "ANATOMY_MODIFIER", 248, 256], ["porcine", "ANATOMY_MODIFIER", 271, 278], ["alveolar", "ANATOMY", 279, 287], ["macrophage cell line", "OBSERVATION", 288, 308]]], ["Here, we show that the virus encodes a protein, GP2a, which targets GRP78 for degradation.", [["GP2a", "GENE_OR_GENE_PRODUCT", 48, 52], ["GRP78", "GENE_OR_GENE_PRODUCT", 68, 73], ["GP2a", "PROTEIN", 48, 52], ["GRP78", "PROTEIN", 68, 73], ["the virus", "PROBLEM", 19, 28], ["degradation", "PROBLEM", 78, 89]]], ["Moreover, we show that the UPR does not inhibit but instead stimulates efficient replication of PRRSV.", [["UPR", "GENE_OR_GENE_PRODUCT", 27, 30], ["PRRSV", "ORGANISM", 96, 101], ["UPR", "PROTEIN", 27, 30], ["PRRSV", "SPECIES", 96, 101], ["PRRSV", "PROBLEM", 96, 101]]], ["In particular, the virus appears to hijack ATF4 to viral replication and transcription complexes (RTCs) to facilitate viral RNA synthesis.", [["ATF4", "GENE_OR_GENE_PRODUCT", 43, 47], ["RTCs", "GENE_OR_GENE_PRODUCT", 98, 102], ["ATF4", "PROTEIN", 43, 47], ["transcription complexes", "PROTEIN", 73, 96], ["RTCs", "PROTEIN", 98, 102], ["viral RNA", "RNA", 118, 127], ["the virus", "PROBLEM", 15, 24], ["viral replication", "TREATMENT", 51, 68], ["transcription complexes", "TREATMENT", 73, 96], ["viral RNA synthesis", "PROBLEM", 118, 137], ["virus", "OBSERVATION", 19, 24], ["viral replication", "OBSERVATION", 51, 68], ["viral RNA synthesis", "OBSERVATION", 118, 137]]], ["Thus, our results reveal that PRRSV exploits UPR signaling for its own advantage.PRRSV targets the UPR master regulator GRP78 for degradation despite an increase at its mRNA levelTo investigate the mechanism of UPR induction by PRRSV, we initially focused on GRP78 because it is the master regulator that binds to and negatively controls sensors PERK, ATF6, and IRE1 [7, 42] .", [["PRRSV", "ORGANISM", 30, 35], ["UPR", "GENE_OR_GENE_PRODUCT", 45, 48], ["PRRSV", "ORGANISM", 81, 86], ["GRP78", "GENE_OR_GENE_PRODUCT", 120, 125], ["UPR", "GENE_OR_GENE_PRODUCT", 211, 214], ["PRRSV", "ORGANISM", 228, 233], ["GRP78", "GENE_OR_GENE_PRODUCT", 259, 264], ["PERK", "GENE_OR_GENE_PRODUCT", 346, 350], ["ATF6", "GENE_OR_GENE_PRODUCT", 352, 356], ["IRE1", "GENE_OR_GENE_PRODUCT", 362, 366], ["UPR", "PROTEIN", 45, 48], ["UPR master regulator", "PROTEIN", 99, 119], ["GRP78", "PROTEIN", 120, 125], ["UPR", "PROTEIN", 211, 214], ["GRP78", "PROTEIN", 259, 264], ["PERK", "PROTEIN", 346, 350], ["ATF6", "PROTEIN", 352, 356], ["IRE1", "PROTEIN", 362, 366], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 81, 86], ["PRRSV", "SPECIES", 228, 233], ["PRRSV", "PROBLEM", 30, 35], ["degradation", "PROBLEM", 130, 141], ["an increase at its mRNA level", "PROBLEM", 150, 179], ["UPR induction", "TREATMENT", 211, 224], ["ATF6", "TEST", 352, 356]]], ["When levels of misfolded proteins rise, GRP78 is released, resulting in activation of the UPR [7] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 40, 45], ["misfolded proteins", "PROTEIN", 15, 33], ["GRP78", "PROTEIN", 40, 45], ["misfolded proteins rise", "PROBLEM", 15, 38]]], ["For many DNA and RNA viruses, their infections cause increased levels of GRP78, which is also a chaperone, so that the protein folding capacity of the cell can be enhanced [43] [44] [45] .", [["cell", "ANATOMY", 151, 155], ["infections", "DISEASE", 36, 46], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["GRP78", "GENE_OR_GENE_PRODUCT", 73, 78], ["cell", "CELL", 151, 155], ["GRP78", "PROTEIN", 73, 78], ["chaperone", "PROTEIN", 96, 105], ["many DNA", "PROBLEM", 4, 12], ["RNA viruses", "PROBLEM", 17, 28], ["their infections", "PROBLEM", 30, 46], ["increased levels of GRP78", "PROBLEM", 53, 78], ["the protein folding capacity", "TEST", 115, 143], ["RNA viruses", "OBSERVATION", 17, 28]]], ["In the case of PRRSV, we observed an elevation of GRP78 at the mRNA level in both PRRSV-infected MARC-145 cells (used for in vitro propagation of the virus; Fig 1A) and primary PAMs (porcine alveolar macrophages, the major in vivo cell target; Fig 1C) .", [["MARC-145 cells", "ANATOMY", 97, 111], ["alveolar macrophages", "ANATOMY", 191, 211], ["cell", "ANATOMY", 231, 235], ["PRRSV", "ORGANISM", 15, 20], ["GRP78", "GENE_OR_GENE_PRODUCT", 50, 55], ["PRRSV", "ORGANISM", 82, 87], ["MARC-145 cells", "CELL", 97, 111], ["PAMs", "CELL", 177, 181], ["porcine", "ORGANISM", 183, 190], ["alveolar macrophages", "CELL", 191, 211], ["cell", "CELL", 231, 235], ["GRP78", "PROTEIN", 50, 55], ["MARC-145 cells", "CELL_LINE", 97, 111], ["primary PAMs", "CELL_TYPE", 169, 181], ["porcine alveolar macrophages", "CELL_TYPE", 183, 211], ["PRRSV", "SPECIES", 15, 20], ["PRRSV", "SPECIES", 82, 87], ["MARC-145", "SPECIES", 97, 105], ["PRRSV", "PROBLEM", 15, 20], ["an elevation of GRP78", "PROBLEM", 34, 55], ["the mRNA level", "TEST", 59, 73], ["the virus", "PROBLEM", 146, 155], ["primary PAMs (porcine alveolar macrophages", "TREATMENT", 169, 211], ["elevation", "OBSERVATION", 37, 46], ["both", "ANATOMY_MODIFIER", 77, 81], ["PRRSV", "ANATOMY", 82, 87], ["infected MARC", "OBSERVATION", 88, 101], ["alveolar macrophages", "OBSERVATION", 191, 211]]], ["But in spite of these increases, we found that GRP78 protein levels actually declined as the infection proceeded (Fig 1B and 1D ).", [["infection", "DISEASE", 93, 102], ["GRP78", "GENE_OR_GENE_PRODUCT", 47, 52], ["GRP78", "PROTEIN", 47, 52], ["GRP78 protein levels", "TEST", 47, 67], ["the infection", "PROBLEM", 89, 102], ["infection", "OBSERVATION", 93, 102]]], ["In contrast, treatment with the potent ER-stress inducer thapsigargin (TG) resulted in a dramatic increase of GRP78 (Fig 1B) , indicating that uninfected cells have the capacity to produce large amounts of this protein.The glycoprotein GP2a contributes to the GRP78 decay via proteasomal pathwayThe mechanism of PRRSV-induced GRP78 decay was probed by treating mock or infected MARC-145 cells with either MG-132 (a proteasome inhibitor), Bafilomycin A1 (a lysosomal inhibitor), Z-VAD-FMK (an apoptosis inhibitor), or DMSO before collecting samples for analysis.", [["cells", "ANATOMY", 154, 159], ["proteasomal", "ANATOMY", 276, 287], ["MARC-145 cells", "ANATOMY", 378, 392], ["samples", "ANATOMY", 540, 547], ["thapsigargin", "CHEMICAL", 57, 69], ["TG", "CHEMICAL", 71, 73], ["MG-132", "CHEMICAL", 405, 411], ["Bafilomycin A1", "CHEMICAL", 438, 452], ["Z-VAD-FMK", "CHEMICAL", 478, 487], ["DMSO", "CHEMICAL", 517, 521], ["thapsigargin", "CHEMICAL", 57, 69], ["MG-132", "CHEMICAL", 405, 411], ["Bafilomycin A1", "CHEMICAL", 438, 452], ["Z-VAD-FMK", "CHEMICAL", 478, 487], ["DMSO", "CHEMICAL", 517, 521], ["ER", "GENE_OR_GENE_PRODUCT", 39, 41], ["thapsigargin", "SIMPLE_CHEMICAL", 57, 69], ["TG", "SIMPLE_CHEMICAL", 71, 73], ["GRP78", "GENE_OR_GENE_PRODUCT", 110, 115], ["Fig 1B", "GENE_OR_GENE_PRODUCT", 117, 123], ["cells", "CELL", 154, 159], ["GP2a", "GENE_OR_GENE_PRODUCT", 236, 240], ["GRP78", "GENE_OR_GENE_PRODUCT", 260, 265], ["PRRSV", "ORGANISM", 312, 317], ["GRP78", "GENE_OR_GENE_PRODUCT", 326, 331], ["MARC-145 cells", "CELL", 378, 392], ["MG-132", "SIMPLE_CHEMICAL", 405, 411], ["Bafilomycin A1", "SIMPLE_CHEMICAL", 438, 452], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 478, 487], ["DMSO", "SIMPLE_CHEMICAL", 517, 521], ["ER", "PROTEIN", 39, 41], ["GRP78", "PROTEIN", 110, 115], ["Fig 1B", "PROTEIN", 117, 123], ["uninfected cells", "CELL_TYPE", 143, 159], ["glycoprotein GP2a", "PROTEIN", 223, 240], ["GRP78", "PROTEIN", 260, 265], ["GRP78", "PROTEIN", 326, 331], ["MARC-145 cells", "CELL_LINE", 378, 392], ["PRRSV", "SPECIES", 312, 317], ["MARC-145", "SPECIES", 378, 386], ["treatment", "TREATMENT", 13, 22], ["stress inducer thapsigargin", "TREATMENT", 42, 69], ["a dramatic increase of GRP78", "PROBLEM", 87, 115], ["uninfected cells", "PROBLEM", 143, 159], ["the capacity", "PROBLEM", 165, 177], ["this protein", "PROBLEM", 206, 218], ["The glycoprotein GP2a", "TREATMENT", 219, 240], ["proteasomal pathway", "TREATMENT", 276, 295], ["PRRSV", "PROBLEM", 312, 317], ["MG", "TEST", 405, 407], ["a proteasome inhibitor", "TREATMENT", 413, 435], ["Bafilomycin A1", "TREATMENT", 438, 452], ["a lysosomal inhibitor", "TREATMENT", 454, 475], ["Z-VAD", "TREATMENT", 478, 483], ["FMK", "TREATMENT", 484, 487], ["an apoptosis inhibitor", "TREATMENT", 489, 511], ["DMSO", "TREATMENT", 517, 521], ["collecting samples", "TEST", 529, 547], ["analysis", "TEST", 552, 560], ["dramatic", "OBSERVATION_MODIFIER", 89, 97], ["increase", "OBSERVATION_MODIFIER", 98, 106], ["uninfected cells", "OBSERVATION", 143, 159], ["large", "OBSERVATION_MODIFIER", 189, 194], ["amounts", "OBSERVATION_MODIFIER", 195, 202], ["PRRSV", "OBSERVATION", 312, 317]]], ["Additions of DMSO, Bafilomycin A1, or Z-VAD-FMK did not have a significant effect, but treatment with MG-132 restored GRP78 to a level similar to that of uninfected cells ( Fig 1E) .", [["cells", "ANATOMY", 165, 170], ["DMSO", "CHEMICAL", 13, 17], ["Bafilomycin A1", "CHEMICAL", 19, 33], ["Z-VAD-FMK", "CHEMICAL", 38, 47], ["MG-132", "CHEMICAL", 102, 108], ["DMSO", "CHEMICAL", 13, 17], ["Bafilomycin A1", "CHEMICAL", 19, 33], ["Z-VAD-FMK", "CHEMICAL", 38, 47], ["MG-132", "CHEMICAL", 102, 108], ["DMSO", "SIMPLE_CHEMICAL", 13, 17], ["Bafilomycin A1", "SIMPLE_CHEMICAL", 19, 33], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 38, 47], ["MG-132", "SIMPLE_CHEMICAL", 102, 108], ["GRP78", "GENE_OR_GENE_PRODUCT", 118, 123], ["cells", "CELL", 165, 170], ["GRP78", "PROTEIN", 118, 123], ["uninfected cells", "CELL_TYPE", 154, 170], ["DMSO", "TREATMENT", 13, 17], ["Bafilomycin A1", "TREATMENT", 19, 33], ["Z-VAD", "TREATMENT", 38, 43], ["MG", "TEST", 102, 104], ["uninfected cells", "OBSERVATION", 154, 170]]], ["Thus, the proteasomal degradation pathway contributes to the reduced levels of GRP78 seen in PRRSV-infected cells.The glycoprotein GP2a contributes to the GRP78 decay via proteasomal pathwayTo identify the viral protein(s) needed for GRP78 decay, we used transfection assays in MARC-145 cells and HEK-293FT cells.", [["proteasomal", "ANATOMY", 10, 21], ["cells", "ANATOMY", 108, 113], ["MARC-145 cells", "ANATOMY", 278, 292], ["HEK-293FT cells", "ANATOMY", 297, 312], ["PRRSV-infected", "DISEASE", 93, 107], ["GRP78", "GENE_OR_GENE_PRODUCT", 79, 84], ["PRRSV", "ORGANISM", 93, 98], ["cells", "CELL", 108, 113], ["GP2a", "GENE_OR_GENE_PRODUCT", 131, 135], ["GRP78", "GENE_OR_GENE_PRODUCT", 155, 160], ["GRP78", "GENE_OR_GENE_PRODUCT", 234, 239], ["MARC-145 cells", "CELL", 278, 292], ["HEK-293FT cells", "CELL", 297, 312], ["GRP78", "PROTEIN", 79, 84], ["PRRSV-infected cells", "CELL_TYPE", 93, 113], ["glycoprotein GP2a", "PROTEIN", 118, 135], ["GRP78", "PROTEIN", 155, 160], ["viral protein", "PROTEIN", 206, 219], ["GRP78", "PROTEIN", 234, 239], ["MARC-145 cells", "CELL_LINE", 278, 292], ["HEK-293FT cells", "CELL_LINE", 297, 312], ["PRRSV", "SPECIES", 93, 98], ["MARC-145", "SPECIES", 278, 286], ["the proteasomal degradation pathway", "PROBLEM", 6, 41], ["the reduced levels of GRP78", "PROBLEM", 57, 84], ["infected cells", "PROBLEM", 99, 113], ["the viral protein", "TEST", 202, 219], ["GRP78 decay", "PROBLEM", 234, 245], ["transfection assays", "TEST", 255, 274], ["HEK", "TEST", 297, 300], ["infected cells", "OBSERVATION", 99, 113]]], ["Expression of nonstructural proteins (S1 Fig) and the major envelope membrane proteins (S2 Fig) did not decrease GRP78 expression but seemed to activate the UPR, as indicated by the apparently increased levels of this protein.", [["membrane", "ANATOMY", 69, 77], ["nonstructural proteins (S1 Fig", "GENE_OR_GENE_PRODUCT", 14, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 113, 118], ["UPR", "GENE_OR_GENE_PRODUCT", 157, 160], ["nonstructural proteins", "PROTEIN", 14, 36], ["S1 Fig", "PROTEIN", 38, 44], ["major envelope membrane proteins", "PROTEIN", 54, 86], ["S2", "PROTEIN", 88, 90], ["GRP78", "PROTEIN", 113, 118], ["UPR", "PROTEIN", 157, 160], ["nonstructural proteins (S1 Fig", "PROBLEM", 14, 44], ["the apparently increased levels of this protein", "PROBLEM", 178, 225], ["nonstructural proteins", "OBSERVATION", 14, 36]]], ["In contrast, the minor envelope protein GP2a did not increase GRP78 expression (S2A Fig) but instead caused a decrease of this protein in about 50% of the cells (S2B Fig).", [["cells", "ANATOMY", 155, 160], ["GP2a", "GENE_OR_GENE_PRODUCT", 40, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 62, 67], ["cells", "CELL", 155, 160], ["minor envelope protein", "PROTEIN", 17, 39], ["GP2a", "PROTEIN", 40, 44], ["GRP78", "PROTEIN", 62, 67], ["the minor envelope protein GP2a", "TEST", 13, 44], ["a decrease of this protein", "PROBLEM", 108, 134], ["decrease", "OBSERVATION_MODIFIER", 110, 118]]], ["This activity was confirmed by Western blot analyses in a dose-response experiment, which showed that increasing levels of GP2a caused decreasing levels of GRP78 (Fig 1F) , and this effect could be reversed by treatment of the cells with MG-132 ( Fig 1G) .", [["cells", "ANATOMY", 227, 232], ["GP2a", "CHEMICAL", 123, 127], ["MG-132", "CHEMICAL", 238, 244], ["GP2a", "CHEMICAL", 123, 127], ["MG-132", "CHEMICAL", 238, 244], ["GP2a", "GENE_OR_GENE_PRODUCT", 123, 127], ["GRP78", "GENE_OR_GENE_PRODUCT", 156, 161], ["Fig 1F", "GENE_OR_GENE_PRODUCT", 163, 169], ["cells", "CELL", 227, 232], ["MG-132", "SIMPLE_CHEMICAL", 238, 244], ["GP2a", "PROTEIN", 123, 127], ["GRP78", "PROTEIN", 156, 161], ["increasing levels of GP2a", "PROBLEM", 102, 127], ["decreasing levels of GRP78", "PROBLEM", 135, 161], ["the cells", "PROBLEM", 223, 232], ["MG", "TEST", 238, 240]]], ["Because subgenomic mRNA2 contains the open reading frames for both GP2a and the E protein, we made constructs that eliminate the start codon for E (construct GP2a\u0394E-HA) or express only the E protein (E-HA).", [["mRNA2", "GENE_OR_GENE_PRODUCT", 19, 24], ["GP2a", "GENE_OR_GENE_PRODUCT", 67, 71], ["GP2a\u0394E-HA", "GENE_OR_GENE_PRODUCT", 158, 167], ["E-HA", "GENE_OR_GENE_PRODUCT", 200, 204], ["subgenomic mRNA2", "DNA", 8, 24], ["open reading frames", "DNA", 38, 57], ["GP2a", "DNA", 67, 71], ["E protein", "PROTEIN", 80, 89], ["start codon", "DNA", 129, 140], ["E", "DNA", 145, 146], ["GP2a\u0394E", "DNA", 158, 164], ["HA", "DNA", 165, 167], ["E protein", "PROTEIN", 189, 198], ["E", "PROTEIN", 200, 201], ["HA", "PROTEIN", 202, 204], ["subgenomic mRNA2", "PROBLEM", 8, 24], ["the E protein", "TEST", 76, 89], ["HA", "PROBLEM", 165, 167], ["the E protein", "TEST", 185, 198]]], ["The results show that GP2a but not E protein decreased levels of GRP78 (Fig 1H) .The downstream effectors ATF4 and XBP1s of UPR signaling are activated at an early stage of PRRSV infectionTo verify that MARC-145 cells will exhibit the expected responses upon induction of the UPR, we transfected them with an siRNA that knockdowns expression of GRP78.", [["MARC-145 cells", "ANATOMY", 203, 217], ["PRRSV infection", "DISEASE", 173, 188], ["1H", "CHEMICAL", 76, 78], ["GP2a", "GENE_OR_GENE_PRODUCT", 22, 26], ["E protein", "GENE_OR_GENE_PRODUCT", 35, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 65, 70], ["Fig 1H", "GENE_OR_GENE_PRODUCT", 72, 78], ["ATF4", "GENE_OR_GENE_PRODUCT", 106, 110], ["XBP1s", "GENE_OR_GENE_PRODUCT", 115, 120], ["UPR", "GENE_OR_GENE_PRODUCT", 124, 127], ["PRRSV", "ORGANISM", 173, 178], ["MARC-145 cells", "CELL", 203, 217], ["UPR", "GENE_OR_GENE_PRODUCT", 276, 279], ["GRP78", "GENE_OR_GENE_PRODUCT", 345, 350], ["GP2a", "PROTEIN", 22, 26], ["E protein", "PROTEIN", 35, 44], ["GRP78", "PROTEIN", 65, 70], ["ATF4", "PROTEIN", 106, 110], ["XBP1s", "PROTEIN", 115, 120], ["UPR", "PROTEIN", 124, 127], ["MARC-145 cells", "CELL_LINE", 203, 217], ["UPR", "PROTEIN", 276, 279], ["GRP78", "PROTEIN", 345, 350], ["PRRSV", "SPECIES", 173, 178], ["GP2a", "TEST", 22, 26], ["GRP78", "TEST", 65, 70], ["The downstream effectors ATF4", "PROBLEM", 81, 110], ["UPR signaling", "PROBLEM", 124, 137], ["PRRSV infection", "PROBLEM", 173, 188], ["an siRNA", "TREATMENT", 306, 314], ["PRRSV infection", "OBSERVATION", 173, 188]]], ["In contrast to the mock-transfected control, RNAi silencing of GRP78 (Fig 2A) resulted in an increased amount of XBP1s (Fig 2B) , elevated phosphorylation of eIF2\u03b1 (Fig 2C) , and increased expression of (Fig 2C and 2D ).", [["GRP78", "GENE_OR_GENE_PRODUCT", 63, 68], ["Fig 2A", "GENE_OR_GENE_PRODUCT", 70, 76], ["XBP1s", "GENE_OR_GENE_PRODUCT", 113, 118], ["Fig 2B", "GENE_OR_GENE_PRODUCT", 120, 126], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 158, 163], ["Fig 2C", "GENE_OR_GENE_PRODUCT", 165, 171], ["GRP78", "PROTEIN", 63, 68], ["Fig 2A", "PROTEIN", 70, 76], ["XBP1s", "PROTEIN", 113, 118], ["eIF2\u03b1", "PROTEIN", 158, 163], ["Fig 2C", "PROTEIN", 165, 171], ["an increased amount of XBP1s", "PROBLEM", 90, 118], ["elevated phosphorylation of eIF2\u03b1", "PROBLEM", 130, 163], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["amount", "OBSERVATION_MODIFIER", 103, 109], ["increased", "OBSERVATION_MODIFIER", 179, 188]]], ["As expected, the scrambled-sequence control (siNC) did not induce these effects.The downstream effectors ATF4 and XBP1s of UPR signaling are activated at an early stage of PRRSV infectionWhile it seemed likely that the reduced levels of GRP78 in PRRSV infections (Fig 1B and 1D ) would result in elevated expression of downstream components of the UPR, it was possible that these would be targeted for degradation, too.", [["PRRSV infections", "DISEASE", 246, 262], ["ATF4", "GENE_OR_GENE_PRODUCT", 105, 109], ["XBP1s", "GENE_OR_GENE_PRODUCT", 114, 119], ["UPR", "GENE_OR_GENE_PRODUCT", 123, 126], ["PRRSV", "ORGANISM", 172, 177], ["GRP78", "GENE_OR_GENE_PRODUCT", 237, 242], ["PRRSV", "ORGANISM", 246, 251], ["UPR", "GENE_OR_GENE_PRODUCT", 348, 351], ["ATF4", "PROTEIN", 105, 109], ["XBP1s", "PROTEIN", 114, 119], ["UPR", "PROTEIN", 123, 126], ["GRP78", "PROTEIN", 237, 242], ["UPR", "PROTEIN", 348, 351], ["PRRSV", "SPECIES", 172, 177], ["PRRSV", "SPECIES", 246, 251], ["The downstream effectors ATF4", "PROBLEM", 80, 109], ["UPR signaling", "PROBLEM", 123, 136], ["PRRSV infectionWhile", "PROBLEM", 172, 192], ["the reduced levels of GRP78", "PROBLEM", 215, 242], ["PRRSV infections", "PROBLEM", 246, 262], ["elevated expression of downstream components", "PROBLEM", 296, 340], ["PRRSV infectionWhile", "OBSERVATION", 172, 192], ["seemed likely", "UNCERTAINTY", 196, 209], ["reduced", "OBSERVATION_MODIFIER", 219, 226], ["PRRSV infections", "OBSERVATION", 246, 262], ["elevated", "OBSERVATION", 296, 304]]], ["To investigate this, the expression levels of the various UPR components were examined.", [["UPR", "GENE_OR_GENE_PRODUCT", 58, 61], ["UPR components", "PROTEIN", 58, 72]]], ["In MARC-145 cells, we found that both the PERK-eIF2\u03b1-ATF4 and IRE1-XBP1s branches of the UPR were activated (Fig 3A, 3C and 3E ).", [["MARC-145 cells", "ANATOMY", 3, 17], ["MARC-145 cells", "CELL", 3, 17], ["PERK", "GENE_OR_GENE_PRODUCT", 42, 46], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["ATF4", "GENE_OR_GENE_PRODUCT", 53, 57], ["IRE1", "GENE_OR_GENE_PRODUCT", 62, 66], ["XBP1s", "GENE_OR_GENE_PRODUCT", 67, 72], ["UPR", "GENE_OR_GENE_PRODUCT", 89, 92], ["MARC-145 cells", "CELL_LINE", 3, 17], ["PERK", "PROTEIN", 42, 46], ["eIF2\u03b1", "PROTEIN", 47, 52], ["ATF4", "PROTEIN", 53, 57], ["IRE1", "PROTEIN", 62, 66], ["XBP1s", "PROTEIN", 67, 72], ["UPR", "PROTEIN", 89, 92], ["the PERK", "TEST", 38, 46], ["IRE1", "TEST", 62, 66], ["145 cells", "OBSERVATION_MODIFIER", 8, 17], ["branches", "ANATOMY_MODIFIER", 73, 81], ["UPR", "ANATOMY_MODIFIER", 89, 92]]], ["In particular, there was a gradual increase in the phosphorylation of PERK and eIF2\u03b1, a concurrent increased in expression of ATF4, and an elevation of the spliced form (XBP1s) of XBP1 at both the protein and mRNA levels.", [["PERK", "GENE_OR_GENE_PRODUCT", 70, 74], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["ATF4", "GENE_OR_GENE_PRODUCT", 126, 130], ["XBP1s", "GENE_OR_GENE_PRODUCT", 170, 175], ["XBP1", "GENE_OR_GENE_PRODUCT", 180, 184], ["PERK", "PROTEIN", 70, 74], ["eIF2\u03b1", "PROTEIN", 79, 84], ["ATF4", "PROTEIN", 126, 130], ["XBP1s", "PROTEIN", 170, 175], ["XBP1", "PROTEIN", 180, 184], ["a gradual increase", "PROBLEM", 25, 43], ["ATF4", "TEST", 126, 130], ["an elevation of the spliced form", "PROBLEM", 136, 168], ["XBP1", "TEST", 180, 184], ["mRNA levels", "TEST", 209, 220], ["gradual", "OBSERVATION_MODIFIER", 27, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["elevation", "OBSERVATION_MODIFIER", 139, 148], ["mRNA levels", "OBSERVATION", 209, 220]]], ["In contrast, ATF6 was not activated, and the cleaved fragment of ATF6 was not detectable during infection.", [["infection", "DISEASE", 96, 105], ["ATF6", "GENE_OR_GENE_PRODUCT", 13, 17], ["ATF6", "GENE_OR_GENE_PRODUCT", 65, 69], ["ATF6", "PROTEIN", 13, 17], ["ATF6", "PROTEIN", 65, 69], ["ATF6", "TREATMENT", 13, 17], ["the cleaved fragment of ATF6", "PROBLEM", 41, 69], ["infection", "PROBLEM", 96, 105], ["fragment", "OBSERVATION_MODIFIER", 53, 61], ["not detectable", "UNCERTAINTY", 74, 88], ["infection", "OBSERVATION", 96, 105]]], ["Similar results were observed in infected, primary PAMs (Fig 3B, 3D and 3F); however, the antibodies to ATF6 did not work on PAMs extracts, and PDI was used as a surrogate since its expression is subject to regulation by ATF6 [46] .The downstream effectors ATF4 and XBP1s of UPR signaling are activated at an early stage of PRRSV infectionThe degradation of GRP78 and strong induction of downstream components raised the possibility that PRRSV might utilize some of the UPR machinery for its own benefit.", [["extracts", "ANATOMY", 130, 138], ["PRRSV infection", "DISEASE", 324, 339], ["ATF6", "GENE_OR_GENE_PRODUCT", 104, 108], ["PAMs extracts", "ORGANISM_SUBSTANCE", 125, 138], ["PDI", "GENE_OR_GENE_PRODUCT", 144, 147], ["ATF6", "GENE_OR_GENE_PRODUCT", 221, 225], ["ATF4", "GENE_OR_GENE_PRODUCT", 257, 261], ["XBP1s", "GENE_OR_GENE_PRODUCT", 266, 271], ["UPR", "GENE_OR_GENE_PRODUCT", 275, 278], ["PRRSV", "ORGANISM", 324, 329], ["GRP78", "GENE_OR_GENE_PRODUCT", 358, 363], ["PRRSV", "ORGANISM", 438, 443], ["UPR", "GENE_OR_GENE_PRODUCT", 470, 473], ["antibodies", "PROTEIN", 90, 100], ["ATF6", "PROTEIN", 104, 108], ["PDI", "PROTEIN", 144, 147], ["ATF6", "PROTEIN", 221, 225], ["ATF4", "PROTEIN", 257, 261], ["XBP1s", "PROTEIN", 266, 271], ["UPR", "PROTEIN", 275, 278], ["GRP78", "PROTEIN", 358, 363], ["PRRSV", "SPECIES", 324, 329], ["PRRSV", "SPECIES", 438, 443], ["PAMs extracts", "TREATMENT", 125, 138], ["PDI", "TREATMENT", 144, 147], ["The downstream effectors ATF4", "PROBLEM", 232, 261], ["UPR signaling", "PROBLEM", 275, 288], ["PRRSV infection", "PROBLEM", 324, 339], ["The degradation of GRP78", "PROBLEM", 339, 363], ["downstream components", "PROBLEM", 388, 409], ["PRRSV", "PROBLEM", 438, 443], ["infected", "OBSERVATION_MODIFIER", 33, 41], ["PRRSV infection", "OBSERVATION", 324, 339], ["strong", "OBSERVATION_MODIFIER", 368, 374]]], ["To begin exploring this, we measured the temporal relationship between UPR induction and infectious virion production.", [["UPR", "GENE_OR_GENE_PRODUCT", 71, 74], ["UPR", "PROTEIN", 71, 74], ["UPR induction", "TREATMENT", 71, 84], ["infectious virion production", "PROBLEM", 89, 117], ["infectious", "OBSERVATION_MODIFIER", 89, 99]]], ["Upregulation of ATF4 and XBP1s was detectable around 12 hpi in MARC-145 cells ( Fig 3E) and 6 hpi in PAMs ( Fig 3F) .", [["MARC-145 cells", "ANATOMY", 63, 77], ["ATF4", "GENE_OR_GENE_PRODUCT", 16, 20], ["XBP1s", "GENE_OR_GENE_PRODUCT", 25, 30], ["MARC-145 cells", "CELL", 63, 77], ["Fig 3E", "CELL", 80, 86], ["PAMs", "CELL", 101, 105], ["ATF4", "PROTEIN", 16, 20], ["XBP1s", "PROTEIN", 25, 30], ["MARC-145 cells", "CELL_LINE", 63, 77], ["PAMs", "CELL_TYPE", 101, 105], ["MARC-145", "SPECIES", 63, 71], ["Upregulation of ATF4", "PROBLEM", 0, 20], ["XBP1s", "TEST", 25, 30]]], ["This coincided with detectable viral protein expression (here assayed for N; Fig 3A and 3B ), but it occurred earlier than peak virus replication, which was at 36 hpi in MARC-145 cells ( Fig 3G) and 24 hpi in PAMs (Fig 3H) .", [["MARC-145 cells", "ANATOMY", 170, 184], ["N; Fig 3A", "GENE_OR_GENE_PRODUCT", 74, 83], ["3B", "GENE_OR_GENE_PRODUCT", 88, 90], ["MARC-145 cells", "CELL", 170, 184], ["Fig 3G", "CELL", 187, 193], ["PAMs", "CELL", 209, 213], ["viral protein", "PROTEIN", 31, 44], ["MARC-145 cells", "CELL_LINE", 170, 184], ["PAMs", "CELL_TYPE", 209, 213], ["detectable viral protein expression", "PROBLEM", 20, 55], ["peak virus replication", "PROBLEM", 123, 145], ["viral protein expression", "OBSERVATION", 31, 55]]], ["The observed correlation of the timing of UPR induction and virus production in both cell types is consistent with the possibility of UPR machinery being needed for PRRSV replication.Both ATF4 and XBP1s are critical for PRRSV replicationThe importance of both ATF4 and XBP1s for PRRSV replication was subsequently investigated with an RNAi knockdown approach.", [["cell", "ANATOMY", 85, 89], ["UPR", "GENE_OR_GENE_PRODUCT", 42, 45], ["cell", "CELL", 85, 89], ["UPR", "GENE_OR_GENE_PRODUCT", 134, 137], ["PRRSV", "ORGANISM", 165, 170], ["ATF4", "GENE_OR_GENE_PRODUCT", 188, 192], ["XBP1s", "GENE_OR_GENE_PRODUCT", 197, 202], ["PRRSV", "ORGANISM", 220, 225], ["ATF4", "GENE_OR_GENE_PRODUCT", 260, 264], ["XBP1s", "GENE_OR_GENE_PRODUCT", 269, 274], ["PRRSV", "ORGANISM", 279, 284], ["UPR", "PROTEIN", 42, 45], ["ATF4", "PROTEIN", 188, 192], ["XBP1s", "PROTEIN", 197, 202], ["ATF4", "PROTEIN", 260, 264], ["XBP1s", "PROTEIN", 269, 274], ["PRRSV", "SPECIES", 165, 170], ["PRRSV", "SPECIES", 220, 225], ["PRRSV", "SPECIES", 279, 284], ["UPR induction", "TREATMENT", 42, 55], ["virus production", "PROBLEM", 60, 76], ["UPR machinery", "TREATMENT", 134, 147], ["PRRSV replication", "TREATMENT", 165, 182], ["PRRSV replication", "TREATMENT", 220, 237], ["both ATF4", "TREATMENT", 255, 264], ["XBP1s", "TREATMENT", 269, 274], ["PRRSV replication", "TREATMENT", 279, 296], ["an RNAi knockdown approach", "TREATMENT", 332, 358], ["both cell types", "OBSERVATION", 80, 95], ["consistent with", "UNCERTAINTY", 99, 114], ["PRRSV replication", "OBSERVATION", 220, 237], ["RNAi knockdown", "OBSERVATION", 335, 349]]], ["All siRNAs could efficiently silence the expression of the respective protein at 36 h post transfection ( Fig 4A) without affecting cell viability ( Fig 4B) .", [["cell", "ANATOMY", 132, 136], ["cell", "CELL", 132, 136], ["All siRNAs", "TREATMENT", 0, 10], ["the respective protein", "TEST", 55, 77], ["transfection ( Fig 4A", "TEST", 91, 112], ["affecting cell viability", "PROBLEM", 122, 146], ["siRNAs", "OBSERVATION", 4, 10], ["cell viability", "OBSERVATION", 132, 146]]], ["Infection of these cells with PRRSV revealed a reduction in virus titers when either ATF4 or XBP1s expression was reduced, but depletion of ATF6 did not have this effect ( Fig 4C) .", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["PRRSV", "ORGANISM", 30, 35], ["ATF4", "GENE_OR_GENE_PRODUCT", 85, 89], ["XBP1s", "GENE_OR_GENE_PRODUCT", 93, 98], ["ATF6", "GENE_OR_GENE_PRODUCT", 140, 144], ["ATF4", "PROTEIN", 85, 89], ["XBP1s", "PROTEIN", 93, 98], ["ATF6", "PROTEIN", 140, 144], ["PRRSV", "SPECIES", 30, 35], ["Infection of these cells", "PROBLEM", 0, 24], ["PRRSV", "PROBLEM", 30, 35], ["a reduction in virus titers", "PROBLEM", 45, 72], ["depletion of ATF6", "PROBLEM", 127, 144], ["reduction", "OBSERVATION_MODIFIER", 47, 56], ["virus titers", "OBSERVATION", 60, 72]]], ["Also, overexpression of ATF4 or XBP1s in MARC-145 cells by means of lentivirus transduction significantly increased the virus yields ( Fig 4D) .", [["MARC-145 cells", "ANATOMY", 41, 55], ["ATF4", "GENE_OR_GENE_PRODUCT", 24, 28], ["XBP1s", "GENE_OR_GENE_PRODUCT", 32, 37], ["MARC-145 cells", "CELL", 41, 55], ["lentivirus", "ORGANISM", 68, 78], ["ATF4", "PROTEIN", 24, 28], ["XBP1s", "PROTEIN", 32, 37], ["MARC-145 cells", "CELL_LINE", 41, 55], ["MARC-145", "SPECIES", 41, 49], ["lentivirus", "SPECIES", 68, 78], ["ATF4", "PROBLEM", 24, 28], ["XBP1s", "TEST", 32, 37], ["lentivirus transduction", "TREATMENT", 68, 91], ["145 cells", "OBSERVATION_MODIFIER", 46, 55]]], ["Thus, both ATF4 and XBP1s, two downstream effectors of the UPR, are critical for PRRSV replication.ATF4 is hijacked to PRRSV replication complexes during infectionTo explore the roles of ATF4 and XBP1s in PRRSV replication, we began by using a cytoplasmic-nuclear fractionation assay to measure their cellular distribution.", [["cytoplasmic", "ANATOMY", 244, 255], ["nuclear", "ANATOMY", 256, 263], ["cellular", "ANATOMY", 301, 309], ["infection", "DISEASE", 154, 163], ["ATF4", "GENE_OR_GENE_PRODUCT", 11, 15], ["XBP1s", "GENE_OR_GENE_PRODUCT", 20, 25], ["UPR", "GENE_OR_GENE_PRODUCT", 59, 62], ["PRRSV", "ORGANISM", 81, 86], ["ATF4", "GENE_OR_GENE_PRODUCT", 99, 103], ["PRRSV", "ORGANISM", 119, 124], ["ATF4", "GENE_OR_GENE_PRODUCT", 187, 191], ["XBP1s", "GENE_OR_GENE_PRODUCT", 196, 201], ["PRRSV", "ORGANISM", 205, 210], ["cytoplasmic", "ORGANISM_SUBSTANCE", 244, 255], ["nuclear", "CELLULAR_COMPONENT", 256, 263], ["cellular", "CELL", 301, 309], ["ATF4", "PROTEIN", 11, 15], ["XBP1s", "PROTEIN", 20, 25], ["UPR", "PROTEIN", 59, 62], ["ATF4", "PROTEIN", 99, 103], ["PRRSV replication complexes", "PROTEIN", 119, 146], ["ATF4", "PROTEIN", 187, 191], ["XBP1s", "PROTEIN", 196, 201], ["PRRSV", "SPECIES", 205, 210], ["PRRSV", "SPECIES", 81, 86], ["PRRSV", "SPECIES", 119, 124], ["PRRSV", "SPECIES", 205, 210], ["XBP1s", "TREATMENT", 20, 25], ["PRRSV replication", "TREATMENT", 81, 98], ["infection", "PROBLEM", 154, 163], ["ATF4", "TREATMENT", 187, 191], ["XBP1s", "TREATMENT", 196, 201], ["PRRSV replication", "TREATMENT", 205, 222], ["a cytoplasmic-nuclear fractionation assay", "TEST", 242, 283], ["PRRSV replication", "OBSERVATION", 81, 98], ["PRRSV replication", "OBSERVATION", 119, 136], ["infection", "OBSERVATION", 154, 163], ["cellular distribution", "OBSERVATION", 301, 322]]], ["MARC-145 cells were either infected with PRRSV or mock infected, and duplicates of these cultures were then treated with either thapsigargin (TG) or DMSO at 24 hpi for 0.5 h.", [["MARC-145 cells", "ANATOMY", 0, 14], ["cultures", "ANATOMY", 89, 97], ["MARC-145", "CHEMICAL", 0, 8], ["thapsigargin", "CHEMICAL", 128, 140], ["TG", "CHEMICAL", 142, 144], ["DMSO", "CHEMICAL", 149, 153], ["thapsigargin", "CHEMICAL", 128, 140], ["DMSO", "CHEMICAL", 149, 153], ["MARC-145 cells", "CELL", 0, 14], ["PRRSV", "ORGANISM", 41, 46], ["thapsigargin", "SIMPLE_CHEMICAL", 128, 140], ["TG", "SIMPLE_CHEMICAL", 142, 144], ["DMSO", "SIMPLE_CHEMICAL", 149, 153], ["MARC-145 cells", "CELL_LINE", 0, 14], ["PRRSV", "SPECIES", 41, 46], ["PRRSV", "PROBLEM", 41, 46], ["these cultures", "TEST", 83, 97], ["thapsigargin (TG", "TREATMENT", 128, 144], ["DMSO", "TREATMENT", 149, 153], ["145 cells", "OBSERVATION_MODIFIER", 5, 14]]], ["The cytoplasmic and nuclear fractions were isolated and probed for the presence of ATF4 and XBP1s (Fig 5A) .", [["cytoplasmic", "ANATOMY", 4, 15], ["nuclear fractions", "ANATOMY", 20, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["nuclear", "CELLULAR_COMPONENT", 20, 27], ["ATF4", "GENE_OR_GENE_PRODUCT", 83, 87], ["XBP1s", "GENE_OR_GENE_PRODUCT", 92, 97], ["ATF4", "PROTEIN", 83, 87], ["XBP1s", "PROTEIN", 92, 97], ["Fig 5A", "PROTEIN", 99, 105], ["cytoplasmic", "OBSERVATION_MODIFIER", 4, 15], ["nuclear fractions", "OBSERVATION", 20, 37]]], ["The quality of the fractionation was checked by assaying for cytoplasmic GAPDH and nuclear histone subunit H3.", [["cytoplasmic", "ANATOMY", 61, 72], ["nuclear", "ANATOMY", 83, 90], ["cytoplasmic", "ORGANISM_SUBSTANCE", 61, 72], ["GAPDH", "GENE_OR_GENE_PRODUCT", 73, 78], ["nuclear", "CELLULAR_COMPONENT", 83, 90], ["histone subunit H3", "GENE_OR_GENE_PRODUCT", 91, 109], ["cytoplasmic GAPDH", "PROTEIN", 61, 78], ["nuclear histone subunit H3", "PROTEIN", 83, 109], ["the fractionation", "TEST", 15, 32], ["cytoplasmic GAPDH", "PROBLEM", 61, 78], ["nuclear histone subunit H3", "PROBLEM", 83, 109], ["nuclear histone", "OBSERVATION", 83, 98]]], ["As expected, TG-treatment and PRRSV infection upregulated the expression of both ATF4 and XBP1s (Fig 5A, compare lanes 1 and 4 with lane 3 ).", [["TG", "CHEMICAL", 13, 15], ["PRRSV infection", "DISEASE", 30, 45], ["TG", "SIMPLE_CHEMICAL", 13, 15], ["PRRSV", "ORGANISM", 30, 35], ["ATF4", "GENE_OR_GENE_PRODUCT", 81, 85], ["XBP1s", "GENE_OR_GENE_PRODUCT", 90, 95], ["TG", "PROTEIN", 13, 15], ["ATF4", "PROTEIN", 81, 85], ["XBP1s", "PROTEIN", 90, 95], ["Fig 5A", "PROTEIN", 97, 103], ["PRRSV", "SPECIES", 30, 35], ["TG-treatment", "TREATMENT", 13, 25], ["PRRSV infection", "PROBLEM", 30, 45], ["XBP1s", "TEST", 90, 95]]], ["In the case of XBP1s, the protein was enriched in the nuclear fraction whether the cells were treated with TG (compare lanes 5 and 9) or infected (compare lanes 8 and 12).", [["nuclear fraction", "ANATOMY", 54, 70], ["cells", "ANATOMY", 83, 88], ["TG", "DISEASE", 107, 109], ["XBP1s", "GENE_OR_GENE_PRODUCT", 15, 20], ["nuclear", "CELLULAR_COMPONENT", 54, 61], ["cells", "CELL", 83, 88], ["TG", "SIMPLE_CHEMICAL", 107, 109], ["XBP1s", "PROTEIN", 15, 20], ["TG", "PROTEIN", 107, 109], ["XBP1s", "PROBLEM", 15, 20], ["the protein", "TEST", 22, 33], ["TG", "TEST", 107, 109]]], ["To our surprise, ATF4 behaved differently.", [["ATF4", "GENE_OR_GENE_PRODUCT", 17, 21], ["ATF4", "PROTEIN", 17, 21]]], ["In TG-treated cells, this protein was almost exclusively found in the nuclear fraction (compare lanes 5 and 9), but in infected cells, it was found almost exclusively in the cytoplasmic fraction (compare lanes 8 and 12).", [["cells", "ANATOMY", 14, 19], ["nuclear fraction", "ANATOMY", 70, 86], ["cells", "ANATOMY", 128, 133], ["cytoplasmic", "ANATOMY", 174, 185], ["TG", "DISEASE", 3, 5], ["TG", "SIMPLE_CHEMICAL", 3, 5], ["cells", "CELL", 14, 19], ["nuclear", "CELLULAR_COMPONENT", 70, 77], ["cells", "CELL", 128, 133], ["cytoplasmic", "ORGANISM_SUBSTANCE", 174, 185], ["TG-treated cells", "CELL_LINE", 3, 19], ["infected cells", "CELL_TYPE", 119, 133], ["this protein", "TEST", 21, 33], ["infected cells", "PROBLEM", 119, 133], ["infected cells", "OBSERVATION", 119, 133], ["cytoplasmic fraction", "OBSERVATION", 174, 194]]], ["In addition, PRRSV infection blocked the TG-induced ATF4 (Fig 5A, compare lanes 6 and 10) .", [["PRRSV infection", "DISEASE", 13, 28], ["TG", "DISEASE", 41, 43], ["PRRSV", "ORGANISM", 13, 18], ["TG", "SIMPLE_CHEMICAL", 41, 43], ["ATF4", "GENE_OR_GENE_PRODUCT", 52, 56], ["TG", "PROTEIN", 41, 43], ["ATF4", "PROTEIN", 52, 56], ["Fig 5A", "PROTEIN", 58, 64], ["PRRSV", "SPECIES", 13, 18], ["PRRSV infection", "PROBLEM", 13, 28], ["the TG", "TEST", 37, 43], ["compare lanes", "TEST", 66, 79], ["PRRSV", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28]]], ["Thus, PRRSV appears to have a mechanism for retaining ATF4 in the cytoplasm.ATF4 is hijacked to PRRSV replication complexes during infectionTo verify these observations in situ, an immunofluorescence assay (IFA) was used to detect the subcellular location of ATF4.", [["cytoplasm", "ANATOMY", 66, 75], ["subcellular", "ANATOMY", 235, 246], ["PRRSV", "ORGANISM", 6, 11], ["ATF4", "GENE_OR_GENE_PRODUCT", 54, 58], ["cytoplasm", "ORGANISM_SUBSTANCE", 66, 75], ["ATF4", "GENE_OR_GENE_PRODUCT", 76, 80], ["PRRSV", "ORGANISM", 96, 101], ["ATF4", "GENE_OR_GENE_PRODUCT", 259, 263], ["ATF4", "PROTEIN", 54, 58], ["ATF4", "PROTEIN", 76, 80], ["PRRSV replication complexes", "PROTEIN", 96, 123], ["ATF4", "PROTEIN", 259, 263], ["PRRSV", "SPECIES", 6, 11], ["PRRSV", "SPECIES", 96, 101], ["PRRSV", "PROBLEM", 6, 11], ["retaining ATF4 in the cytoplasm", "PROBLEM", 44, 75], ["these observations", "TEST", 150, 168], ["an immunofluorescence assay", "TEST", 178, 205], ["cytoplasm", "OBSERVATION_MODIFIER", 66, 75]]], ["(Unfortunately, the antibodies against XBP1s did not work in this assay).", [["antibodies", "PROTEIN", 20, 30], ["XBP1s", "PROTEIN", 39, 44], ["the antibodies", "TEST", 16, 30]]], ["We found that ATF4 was not within nuclei but instead was present at perinuclear regions in PRRSV-infected cells (Fig 5B, right panels) , and the TG-induced ATF4 nuclear translocation was blocked by PRRSV infection (S3A Fig).", [["nuclei", "ANATOMY", 34, 40], ["perinuclear regions", "ANATOMY", 68, 87], ["cells", "ANATOMY", 106, 111], ["nuclear", "ANATOMY", 161, 168], ["TG", "DISEASE", 145, 147], ["PRRSV infection", "DISEASE", 198, 213], ["ATF4", "GENE_OR_GENE_PRODUCT", 14, 18], ["nuclei", "CELLULAR_COMPONENT", 34, 40], ["perinuclear regions", "CELLULAR_COMPONENT", 68, 87], ["PRRSV", "ORGANISM", 91, 96], ["cells", "CELL", 106, 111], ["TG", "GENE_OR_GENE_PRODUCT", 145, 147], ["ATF4", "GENE_OR_GENE_PRODUCT", 156, 160], ["PRRSV", "ORGANISM", 198, 203], ["ATF4", "PROTEIN", 14, 18], ["PRRSV-infected cells", "CELL_TYPE", 91, 111], ["TG", "PROTEIN", 145, 147], ["ATF4", "PROTEIN", 156, 160], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 198, 203], ["ATF4", "PROBLEM", 14, 18], ["infected cells", "PROBLEM", 97, 111], ["Fig 5B", "TEST", 113, 119], ["right panels", "TEST", 121, 133], ["the TG", "TEST", 141, 147], ["ATF4 nuclear translocation", "PROBLEM", 156, 182], ["PRRSV infection", "PROBLEM", 198, 213], ["infected cells", "OBSERVATION", 97, 111], ["right", "ANATOMY_MODIFIER", 121, 126], ["PRRSV infection", "OBSERVATION", 198, 213]]], ["Moreover, ATF4 was found to colocalize very well with PRRSV nsp2 and nsp9 ( Fig 5B, right panels) , which are key components of viral replication and transcription complexes (RTCs) [47] , suggesting that ATF4 is hijacked to viral RTCs during infection.", [["RTCs", "ANATOMY", 230, 234], ["infection", "DISEASE", 242, 251], ["ATF4", "GENE_OR_GENE_PRODUCT", 10, 14], ["PRRSV", "ORGANISM", 54, 59], ["nsp2", "GENE_OR_GENE_PRODUCT", 60, 64], ["nsp9 ( Fig 5B", "GENE_OR_GENE_PRODUCT", 69, 82], ["ATF4", "GENE_OR_GENE_PRODUCT", 204, 208], ["RTCs", "GENE_OR_GENE_PRODUCT", 230, 234], ["ATF4", "PROTEIN", 10, 14], ["PRRSV nsp2", "PROTEIN", 54, 64], ["nsp9", "PROTEIN", 69, 73], ["Fig 5B", "PROTEIN", 76, 82], ["transcription complexes", "PROTEIN", 150, 173], ["RTCs", "PROTEIN", 175, 179], ["ATF4", "PROTEIN", 204, 208], ["PRRSV", "SPECIES", 54, 59], ["PRRSV nsp2", "TEST", 54, 64], ["nsp9", "TEST", 69, 73], ["Fig 5B", "TEST", 76, 82], ["right panels", "TEST", 84, 96], ["viral replication", "PROBLEM", 128, 145], ["ATF4", "PROBLEM", 204, 208], ["viral RTCs during infection", "PROBLEM", 224, 251], ["viral replication", "OBSERVATION", 128, 145], ["viral RTCs", "OBSERVATION", 224, 234], ["infection", "OBSERVATION", 242, 251]]], ["Similar results were obtained in PRRSV-infected primary PAMs (S4 Fig) .", [["PRRSV", "ORGANISM", 33, 38], ["PAMs", "CELL", 56, 60], ["PRRSV", "SPECIES", 33, 38]]], ["Consistent with cytoplasmic retention, the canonical ATF4-target genes GADD34 and ASNS [48] were not upregulated during infection as compared with the mock or TG-treated cells (S3B and S3C Fig) .", [["cytoplasmic", "ANATOMY", 16, 27], ["cells", "ANATOMY", 170, 175], ["infection", "DISEASE", 120, 129], ["cytoplasmic", "ORGANISM_SUBSTANCE", 16, 27], ["ATF4", "GENE_OR_GENE_PRODUCT", 53, 57], ["GADD34", "GENE_OR_GENE_PRODUCT", 71, 77], ["ASNS [48]", "GENE_OR_GENE_PRODUCT", 82, 91], ["TG", "SIMPLE_CHEMICAL", 159, 161], ["cells", "CELL", 170, 175], ["S3B", "CELL", 177, 180], ["ATF4", "PROTEIN", 53, 57], ["target genes", "DNA", 58, 70], ["GADD34", "DNA", 71, 77], ["ASNS", "DNA", 82, 86], ["TG", "PROTEIN", 159, 161], ["treated cells", "CELL_TYPE", 162, 175], ["S3B", "PROTEIN", 177, 180], ["cytoplasmic retention", "PROBLEM", 16, 37], ["the canonical ATF4", "TEST", 39, 57], ["ASNS", "TEST", 82, 86], ["infection", "PROBLEM", 120, 129], ["the mock", "TEST", 147, 155], ["TG", "TEST", 159, 161], ["cytoplasmic retention", "OBSERVATION", 16, 37], ["infection", "OBSERVATION", 120, 129]]], ["Also, we found that this phenomenon is independent of PRRSV strain used (S5 FigPRRSV nsp2/3 is sufficient to retain ATF4 in the cytoplasmTo gain insight to how ATF4 is diverted to viral RTCs, individual nonstructural proteins (nsps) were screened for their ability to cause cytoplasmic retention of ATF4 in MARC-145 cells that were treated with TG for 0.5 h at 24 h post-transfection (S7A Fig) .", [["cytoplasm", "ANATOMY", 128, 137], ["cytoplasmic", "ANATOMY", 274, 285], ["MARC-145 cells", "ANATOMY", 307, 321], ["TG", "DISEASE", 345, 347], ["PRRSV strain", "ORGANISM", 54, 66], ["nsp2/3", "GENE_OR_GENE_PRODUCT", 85, 91], ["ATF4", "GENE_OR_GENE_PRODUCT", 116, 120], ["cytoplasm", "ORGANISM_SUBSTANCE", 128, 137], ["ATF4", "GENE_OR_GENE_PRODUCT", 160, 164], ["RTCs", "GENE_OR_GENE_PRODUCT", 186, 190], ["nsps", "GENE_OR_GENE_PRODUCT", 227, 231], ["cytoplasmic", "ORGANISM_SUBSTANCE", 274, 285], ["ATF4", "GENE_OR_GENE_PRODUCT", 299, 303], ["MARC-145 cells", "CELL", 307, 321], ["TG", "SIMPLE_CHEMICAL", 345, 347], ["nsp2/3", "PROTEIN", 85, 91], ["ATF4", "PROTEIN", 116, 120], ["ATF4", "PROTEIN", 160, 164], ["viral RTCs", "PROTEIN", 180, 190], ["nonstructural proteins", "PROTEIN", 203, 225], ["nsps", "PROTEIN", 227, 231], ["ATF4", "PROTEIN", 299, 303], ["MARC-145 cells", "CELL_LINE", 307, 321], ["PRRSV", "SPECIES", 54, 59], ["MARC-145", "SPECIES", 307, 315], ["this phenomenon", "PROBLEM", 20, 35], ["PRRSV strain", "PROBLEM", 54, 66], ["viral RTCs", "PROBLEM", 180, 190], ["individual nonstructural proteins", "TEST", 192, 225], ["cytoplasmic retention of ATF4", "PROBLEM", 274, 303], ["TG", "TREATMENT", 345, 347], ["PRRSV strain", "OBSERVATION", 54, 66], ["cytoplasm", "OBSERVATION", 128, 137], ["145 cells", "OBSERVATION_MODIFIER", 312, 321]]], ["We found that PRRSV nsp2 was able to partially retain ATF4 in the cytoplasm ( Fig 5C and S7B Fig) , but coexpression with nsp3, which is known to form heterodimer with nsp2, dramatically increased the retention efficiency, even though nsp3 by itself-like nsp5-did not have any activity ( Fig 5C) .", [["cytoplasm", "ANATOMY", 66, 75], ["PRRSV", "ORGANISM", 14, 19], ["nsp2", "GENE_OR_GENE_PRODUCT", 20, 24], ["ATF4", "GENE_OR_GENE_PRODUCT", 54, 58], ["cytoplasm", "ORGANISM_SUBSTANCE", 66, 75], ["S7B Fig", "GENE_OR_GENE_PRODUCT", 89, 96], ["nsp3", "GENE_OR_GENE_PRODUCT", 122, 126], ["nsp2", "GENE_OR_GENE_PRODUCT", 168, 172], ["nsp3", "GENE_OR_GENE_PRODUCT", 235, 239], ["nsp5", "GENE_OR_GENE_PRODUCT", 255, 259], ["PRRSV nsp2", "PROTEIN", 14, 24], ["ATF4", "PROTEIN", 54, 58], ["nsp3", "PROTEIN", 122, 126], ["nsp2", "PROTEIN", 168, 172], ["nsp3", "PROTEIN", 235, 239], ["nsp5", "PROTEIN", 255, 259], ["PRRSV", "SPECIES", 14, 19], ["PRRSV nsp2", "PROBLEM", 14, 24], ["nsp3", "TREATMENT", 122, 126], ["nsp2", "PROBLEM", 168, 172], ["the retention efficiency", "PROBLEM", 197, 221], ["nsp3", "PROBLEM", 235, 239], ["PRRSV nsp2", "OBSERVATION", 14, 24], ["dramatically", "OBSERVATION_MODIFIER", 174, 186], ["increased", "OBSERVATION_MODIFIER", 187, 196], ["retention efficiency", "OBSERVATION", 201, 221]]], ["The interaction between nsp2 and endogenous ATF4 was also confirmed with a co-IP assay using infected cell lysates ( Fig 5D) .", [["cell lysates", "ANATOMY", 102, 114], ["nsp2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ATF4", "GENE_OR_GENE_PRODUCT", 44, 48], ["cell lysates", "CELL", 102, 114], ["nsp2", "PROTEIN", 24, 28], ["ATF4", "PROTEIN", 44, 48], ["The interaction between nsp2 and endogenous ATF4", "PROBLEM", 0, 48], ["a co-IP assay", "TREATMENT", 73, 86], ["infected cell lysates", "TREATMENT", 93, 114], ["infected cell lysates", "OBSERVATION", 93, 114]]], ["These results indicate that nsp2/3 contributes to the recruitment of ATF4, which is also consistent with the proposed role of nsp2/3 as membrane scaffolding proteins for viral RTCs assembly [49, 50] .Recruitment of ATF4 to viral RTCs is an early event in PRRSV infectionTo learn when ATF4 is redirected to viral RTCs, we used immunofluorescence staining at different times after infection.", [["membrane", "ANATOMY", 136, 144], ["RTCs", "ANATOMY", 176, 180], ["RTCs", "ANATOMY", 312, 316], ["nsp2/3", "CHEMICAL", 28, 34], ["PRRSV infection", "DISEASE", 255, 270], ["infection", "DISEASE", 379, 388], ["nsp2/3", "GENE_OR_GENE_PRODUCT", 28, 34], ["ATF4", "GENE_OR_GENE_PRODUCT", 69, 73], ["nsp2/3", "GENE_OR_GENE_PRODUCT", 126, 132], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["ATF4", "GENE_OR_GENE_PRODUCT", 215, 219], ["RTCs", "GENE_OR_GENE_PRODUCT", 229, 233], ["PRRSV", "ORGANISM", 255, 260], ["ATF4", "GENE_OR_GENE_PRODUCT", 284, 288], ["RTCs", "CELL", 312, 316], ["nsp2/3", "PROTEIN", 28, 34], ["ATF4", "PROTEIN", 69, 73], ["nsp2/3", "PROTEIN", 126, 132], ["membrane scaffolding proteins", "PROTEIN", 136, 165], ["ATF4", "PROTEIN", 215, 219], ["ATF4", "PROTEIN", 284, 288], ["PRRSV", "SPECIES", 255, 260], ["nsp2/3", "PROBLEM", 28, 34], ["the recruitment of ATF4", "PROBLEM", 50, 73], ["viral RTCs", "TEST", 170, 180], ["ATF4", "TREATMENT", 215, 219], ["viral RTCs", "PROBLEM", 223, 233], ["PRRSV infection", "PROBLEM", 255, 270], ["ATF4", "TREATMENT", 284, 288], ["viral RTCs", "PROBLEM", 306, 316], ["immunofluorescence staining", "TEST", 326, 353], ["infection", "PROBLEM", 379, 388], ["recruitment", "OBSERVATION_MODIFIER", 54, 65], ["consistent with", "UNCERTAINTY", 89, 104], ["PRRSV infection", "OBSERVATION", 255, 270], ["infection", "OBSERVATION", 379, 388]]], ["The results showed that ATF4 became detectable around 8 hpi in MARC-145 cells, concurrent with the expression of the nsp2 replicase protein, and both colocalized well at the perinuclear region ( Fig 6A) .", [["MARC-145 cells", "ANATOMY", 63, 77], ["perinuclear region", "ANATOMY", 174, 192], ["ATF4", "GENE_OR_GENE_PRODUCT", 24, 28], ["MARC-145 cells", "CELL", 63, 77], ["nsp2", "GENE_OR_GENE_PRODUCT", 117, 121], ["perinuclear region", "CELLULAR_COMPONENT", 174, 192], ["ATF4", "PROTEIN", 24, 28], ["MARC-145 cells", "CELL_LINE", 63, 77], ["nsp2 replicase protein", "PROTEIN", 117, 139], ["perinuclear region", "PROTEIN", 174, 192], ["MARC-145", "SPECIES", 63, 71], ["ATF4", "TEST", 24, 28], ["the nsp2 replicase protein", "PROBLEM", 113, 139], ["nsp2", "OBSERVATION", 117, 121], ["replicase protein", "OBSERVATION", 122, 139], ["perinuclear", "ANATOMY_MODIFIER", 174, 185]]], ["The detection of ATF4 was earlier than observed with Western blots (Fig 3) , and this is likely because a low MOI was used (0.1).", [["ATF4", "GENE_OR_GENE_PRODUCT", 17, 21], ["ATF4", "PROTEIN", 17, 21], ["ATF4", "PROBLEM", 17, 21], ["a low MOI", "PROBLEM", 104, 113]]], ["Because most cells are not infected, the IFA would be expected to have greater sensitivity because it enables the detection of protein expression at the single cell level.", [["cells", "ANATOMY", 13, 18], ["cell", "ANATOMY", 160, 164], ["cells", "CELL", 13, 18], ["cell", "CELL", 160, 164], ["infected", "PROBLEM", 27, 35], ["the IFA", "TEST", 37, 44], ["protein expression", "PROBLEM", 127, 145], ["not", "UNCERTAINTY", 23, 26], ["infected", "OBSERVATION", 27, 35], ["protein expression", "OBSERVATION", 127, 145]]], ["In any case, it is clear that recruitment of ATF4 to viral RTCs is an early event in PRRSV infection. infection, the cells were collected and subject to western blot analysis with antibodies against the indicated proteins.", [["cells", "ANATOMY", 117, 122], ["PRRSV infection", "DISEASE", 85, 100], ["infection", "DISEASE", 102, 111], ["ATF4", "GENE_OR_GENE_PRODUCT", 45, 49], ["RTCs", "GENE_OR_GENE_PRODUCT", 59, 63], ["PRRSV", "ORGANISM", 85, 90], ["cells", "CELL", 117, 122], ["ATF4", "PROTEIN", 45, 49], ["antibodies", "PROTEIN", 180, 190], ["PRRSV", "SPECIES", 85, 90], ["ATF4", "PROBLEM", 45, 49], ["viral RTCs", "PROBLEM", 53, 63], ["PRRSV infection", "PROBLEM", 85, 100], ["infection", "PROBLEM", 102, 111], ["the cells", "PROBLEM", 113, 122], ["blot analysis", "TEST", 161, 174], ["antibodies", "TREATMENT", 180, 190], ["PRRSV infection", "OBSERVATION", 85, 100]]], ["Nucleocapsid protein N and \u03b2-actin served as the indicator for infection and the loading control, respectively.", [["infection", "DISEASE", 63, 72], ["Nucleocapsid protein N", "GENE_OR_GENE_PRODUCT", 0, 22], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 27, 34], ["Nucleocapsid protein N", "PROTEIN", 0, 22], ["\u03b2-actin", "PROTEIN", 27, 34], ["Nucleocapsid protein N", "TEST", 0, 22], ["\u03b2-actin", "TREATMENT", 27, 34], ["infection", "PROBLEM", 63, 72], ["the loading control", "TREATMENT", 77, 96], ["infection", "OBSERVATION", 63, 72]]], ["(C and D) Detection of XBP1 mRNA splicing.", [["XBP1", "GENE_OR_GENE_PRODUCT", 23, 27], ["XBP1 mRNA", "RNA", 23, 32], ["XBP1 mRNA splicing", "PROBLEM", 23, 41], ["XBP1 mRNA splicing", "OBSERVATION", 23, 41]]], ["PRRSV-infected cells were harvested at the indicated times post infection.", [["cells", "ANATOMY", 15, 20], ["infection", "DISEASE", 64, 73], ["PRRSV", "ORGANISM", 0, 5], ["cells", "CELL", 15, 20], ["PRRSV-infected cells", "CELL_TYPE", 0, 20], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["infected cells", "PROBLEM", 6, 20], ["infection", "PROBLEM", 64, 73], ["infected cells", "OBSERVATION", 6, 20], ["infection", "OBSERVATION", 64, 73]]], ["The XBP1 mRNA sequence was amplified by RT-PCR followed by digestion with Pst I and the products were analyzed by electrophoresis on a 1.5% agarose gel.", [["XBP1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Pst I", "GENE_OR_GENE_PRODUCT", 74, 79], ["agarose", "SIMPLE_CHEMICAL", 140, 147], ["XBP1 mRNA sequence", "RNA", 4, 22], ["Pst I", "DNA", 74, 79], ["Pst I", "SPECIES", 74, 79], ["The XBP1 mRNA sequence", "TEST", 0, 22], ["RT-PCR", "TEST", 40, 46], ["Pst I and the products", "TREATMENT", 74, 96], ["a 1.5% agarose gel", "TREATMENT", 133, 151]]], ["(E and F) Quantification of the proteins or mRNAs during PRRSV infections.", [["PRRSV infections", "DISEASE", 57, 73], ["PRRSV", "ORGANISM", 57, 62], ["mRNAs", "RNA", 44, 49], ["PRRSV", "SPECIES", 57, 62], ["the proteins", "PROBLEM", 28, 40], ["mRNAs during PRRSV infections", "PROBLEM", 44, 73], ["PRRSV infections", "OBSERVATION", 57, 73]]], ["The abundance of pPERK, peIF2a, ATF4, XBP1s, ATF6, and PDI were expressed as fold changes compared to mock-infected control after being normalized against \u03b2-actin.ATF4 interacts with PRRSV RNA and promotes viral RNA accumulationHaving found that ATF4 is critical for high virus titers and co-localizes with viral RTCs in PRRSV infections, we hypothesized that this component of the UPR facilitates viral RNA synthesis.", [["fold", "ANATOMY", 77, 81], ["PRRSV infections", "DISEASE", 321, 337], ["pPERK", "GENE_OR_GENE_PRODUCT", 17, 22], ["peIF2a", "GENE_OR_GENE_PRODUCT", 24, 30], ["ATF4", "GENE_OR_GENE_PRODUCT", 32, 36], ["XBP1s", "GENE_OR_GENE_PRODUCT", 38, 43], ["ATF6", "GENE_OR_GENE_PRODUCT", 45, 49], ["PDI", "GENE_OR_GENE_PRODUCT", 55, 58], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 155, 162], ["ATF4", "GENE_OR_GENE_PRODUCT", 163, 167], ["PRRSV", "ORGANISM", 183, 188], ["ATF4", "GENE_OR_GENE_PRODUCT", 246, 250], ["RTCs", "GENE_OR_GENE_PRODUCT", 313, 317], ["PRRSV", "ORGANISM", 321, 326], ["UPR", "GENE_OR_GENE_PRODUCT", 382, 385], ["pPERK", "PROTEIN", 17, 22], ["peIF2a", "PROTEIN", 24, 30], ["ATF4", "PROTEIN", 32, 36], ["XBP1s", "PROTEIN", 38, 43], ["ATF6", "PROTEIN", 45, 49], ["PDI", "PROTEIN", 55, 58], ["\u03b2-actin", "PROTEIN", 155, 162], ["ATF4", "PROTEIN", 163, 167], ["PRRSV RNA", "RNA", 183, 192], ["ATF4", "PROTEIN", 246, 250], ["UPR", "PROTEIN", 382, 385], ["viral RNA", "RNA", 398, 407], ["PRRSV", "SPECIES", 321, 326], ["PRRSV", "SPECIES", 183, 188], ["PRRSV", "SPECIES", 321, 326], ["pPERK", "TEST", 17, 22], ["peIF2a", "TEST", 24, 30], ["ATF4", "TEST", 32, 36], ["XBP1s", "TREATMENT", 38, 43], ["ATF6", "TREATMENT", 45, 49], ["PDI", "TREATMENT", 55, 58], ["fold changes", "PROBLEM", 77, 89], ["\u03b2-actin", "TREATMENT", 155, 162], ["PRRSV RNA", "TREATMENT", 183, 192], ["viral RNA accumulation", "PROBLEM", 206, 228], ["high virus titers", "PROBLEM", 267, 284], ["viral RTCs in PRRSV infections", "PROBLEM", 307, 337], ["viral RNA synthesis", "PROBLEM", 398, 417], ["viral RNA accumulation", "OBSERVATION", 206, 228], ["viral RTCs", "OBSERVATION", 307, 317], ["PRRSV infections", "OBSERVATION", 321, 337], ["viral RNA synthesis", "OBSERVATION", 398, 417]]], ["Consistent with this, RNAi knockdown of ATF4 greatly reduced the level of total viral RNAs, as measured by RT-qPCR analysis (Fig 7A) , and this correlated well with the impaired virus production (Fig 4C) .", [["ATF4", "GENE_OR_GENE_PRODUCT", 40, 44], ["ATF4", "PROTEIN", 40, 44], ["viral RNAs", "RNA", 80, 90], ["ATF4", "PROBLEM", 40, 44], ["total viral RNAs", "PROBLEM", 74, 90], ["RT-qPCR analysis", "TEST", 107, 123], ["the impaired virus production", "PROBLEM", 165, 194], ["viral RNAs", "OBSERVATION", 80, 90]]], ["To investigate which step of viral RNA synthesis was affected, we measured the relative abundance of negative-and positive-stranded RNAs in MARC-145 cells that had been transfected with either siRNA-ATF4 or the scrambled siNC 36 h prior to infection.", [["MARC-145 cells", "ANATOMY", 140, 154], ["infection", "DISEASE", 240, 249], ["MARC-145 cells", "CELL", 140, 154], ["ATF4", "GENE_OR_GENE_PRODUCT", 199, 203], ["viral RNA", "RNA", 29, 38], ["negative-and positive-stranded RNAs", "RNA", 101, 136], ["MARC-145 cells", "CELL_LINE", 140, 154], ["ATF4", "PROTEIN", 199, 203], ["MARC-145", "SPECIES", 140, 148], ["viral RNA synthesis", "PROBLEM", 29, 48], ["stranded RNAs in MARC", "PROBLEM", 123, 144], ["siRNA-ATF4", "TREATMENT", 193, 203], ["infection", "PROBLEM", 240, 249], ["negative", "OBSERVATION", 101, 109], ["stranded RNAs", "OBSERVATION", 123, 136], ["145 cells", "OBSERVATION_MODIFIER", 145, 154], ["infection", "OBSERVATION", 240, 249]]], ["RNA levels were analyzed during a single viral replication cycle (i.e., within 12 hours) by RT-qPCR amplifying ORF7 RNA and calculating the amount present relative to the RNA from GAPDH, a house-keeping gene.", [["ORF7", "GENE_OR_GENE_PRODUCT", 111, 115], ["GAPDH", "GENE_OR_GENE_PRODUCT", 180, 185], ["ORF7 RNA", "RNA", 111, 119], ["RNA", "RNA", 171, 174], ["GAPDH", "PROTEIN", 180, 185], ["house-keeping gene", "DNA", 189, 207], ["RNA levels", "TEST", 0, 10], ["a single viral replication cycle", "TREATMENT", 32, 64], ["RT", "TEST", 92, 94], ["qPCR", "TEST", 95, 99]]], ["The relative abundance of each viral RNA was then calculated as the ratio of the siRNA-ATF4-treated group compared to the siNC-treated control.", [["siNC", "CHEMICAL", 122, 126], ["siNC", "CHEMICAL", 122, 126], ["ATF4", "GENE_OR_GENE_PRODUCT", 87, 91], ["siNC", "SIMPLE_CHEMICAL", 122, 126], ["viral RNA", "RNA", 31, 40], ["ATF4", "PROTEIN", 87, 91], ["siNC", "PROTEIN", 122, 126], ["each viral RNA", "PROBLEM", 26, 40], ["the siRNA", "TREATMENT", 77, 86], ["the siNC-treated control", "TREATMENT", 118, 142], ["abundance", "OBSERVATION_MODIFIER", 13, 22], ["viral RNA", "OBSERVATION", 31, 40], ["siRNA", "ANATOMY", 81, 86]]], ["As expected, no negative-stranded viral RNAs could be detected in either the control or siATF4-treated cells at 0 hpi (Fig 7B) .", [["cells", "ANATOMY", 103, 108], ["siATF4", "CHEMICAL", 88, 94], ["siATF4", "GENE_OR_GENE_PRODUCT", 88, 94], ["cells", "CELL", 103, 108], ["negative-stranded viral RNAs", "RNA", 16, 44], ["siATF4-treated cells", "CELL_LINE", 88, 108], ["stranded viral RNAs", "PROBLEM", 25, 44], ["no", "UNCERTAINTY", 13, 15], ["viral RNAs", "OBSERVATION", 34, 44]]], ["At 4-12 hpi, this RNA became detectable, but its accumulation was greatly reduced when ATF4 was depleted.", [["ATF4", "GENE_OR_GENE_PRODUCT", 87, 91], ["ATF4", "PROTEIN", 87, 91], ["its accumulation", "PROBLEM", 45, 61], ["ATF4", "PROBLEM", 87, 91], ["reduced", "OBSERVATION_MODIFIER", 74, 81]]], ["Positive-stranded RNA could be detected at 0 hpi due to the input of virions used to start the infection, but a gradual, obvious decrease was observed over time ( Fig 7C) .", [["virions", "ANATOMY", 69, 76], ["infection", "DISEASE", 95, 104], ["Positive-stranded RNA", "RNA", 0, 21], ["stranded RNA", "PROBLEM", 9, 21], ["virions", "TREATMENT", 69, 76], ["the infection", "PROBLEM", 91, 104], ["obvious decrease", "PROBLEM", 121, 137], ["stranded RNA", "OBSERVATION_MODIFIER", 9, 21], ["infection", "OBSERVATION", 95, 104], ["obvious", "OBSERVATION_MODIFIER", 121, 128], ["decrease", "OBSERVATION", 129, 137]]], ["We also measured the abundance of all subgenomic mRNAs with primers that specifically amplify the leader-body junctions.", [["leader-body junctions", "ANATOMY", 98, 119], ["body junctions", "CELLULAR_COMPONENT", 105, 119], ["subgenomic mRNAs", "RNA", 38, 54], ["leader-body junctions", "DNA", 98, 119], ["all subgenomic mRNAs with primers", "PROBLEM", 34, 67], ["subgenomic mRNAs", "OBSERVATION", 38, 54], ["body junctions", "ANATOMY", 105, 119]]], ["The results show that reduced ATF4 expression had an effect on all RNA species regardless of the strands (S8A and S8B Fig) , suggesting that this protein is a host factor required for viral RNA synthesis.ATF4 interacts with PRRSV RNA and promotes viral RNA accumulationIn support of our hypothesis, antibodies to ATF4, but not the isotype control (IgG), could immunoprecipitate viral RNA from infected MARC-145 cells, as detected by RT-qPCR of the PRRSV 5'UTR region ( Fig 7D) .", [["MARC-145 cells", "ANATOMY", 402, 416], ["ATF4", "GENE_OR_GENE_PRODUCT", 30, 34], ["S8B Fig", "GENE_OR_GENE_PRODUCT", 114, 121], ["ATF4", "GENE_OR_GENE_PRODUCT", 204, 208], ["PRRSV", "ORGANISM", 224, 229], ["ATF4", "GENE_OR_GENE_PRODUCT", 313, 317], ["IgG", "GENE_OR_GENE_PRODUCT", 348, 351], ["MARC-145 cells", "CELL", 402, 416], ["ATF4", "PROTEIN", 30, 34], ["RNA species", "RNA", 67, 78], ["S8A", "DNA", 106, 109], ["viral RNA", "RNA", 184, 193], ["ATF4", "PROTEIN", 204, 208], ["PRRSV RNA", "RNA", 224, 233], ["antibodies", "PROTEIN", 299, 309], ["ATF4", "PROTEIN", 313, 317], ["IgG", "PROTEIN", 348, 351], ["viral RNA", "RNA", 378, 387], ["MARC-145 cells", "CELL_LINE", 402, 416], ["PRRSV 5'UTR region", "DNA", 448, 466], ["PRRSV", "SPECIES", 224, 229], ["MARC-145", "SPECIES", 402, 410], ["PRRSV", "SPECIES", 448, 453], ["reduced ATF4 expression", "PROBLEM", 22, 45], ["all RNA species", "PROBLEM", 63, 78], ["the strands (S8A and S8B Fig", "PROBLEM", 93, 121], ["this protein", "PROBLEM", 141, 153], ["a host factor", "PROBLEM", 157, 170], ["viral RNA synthesis", "PROBLEM", 184, 203], ["PRRSV RNA", "TREATMENT", 224, 233], ["viral RNA accumulationIn support", "TREATMENT", 247, 279], ["our hypothesis", "PROBLEM", 283, 297], ["antibodies to ATF4", "TREATMENT", 299, 317], ["the isotype control", "TREATMENT", 327, 346], ["immunoprecipitate viral RNA", "PROBLEM", 360, 387], ["RT", "TEST", 433, 435], ["reduced", "OBSERVATION_MODIFIER", 22, 29], ["ATF4 expression", "OBSERVATION", 30, 45], ["viral RNA", "OBSERVATION", 247, 256], ["viral RNA", "OBSERVATION", 378, 387], ["145 cells", "OBSERVATION_MODIFIER", 407, 416]]], ["Also, a purified GST-ATF4 chimera, but not GST alone, could pull down viral RNA from purified infected-cell RNA (Fig 7F) , which suggests that an ATF4-RNA interaction can occur in the absence of other viral factors.", [["cell", "ANATOMY", 103, 107], ["GST", "GENE_OR_GENE_PRODUCT", 17, 20], ["ATF4", "GENE_OR_GENE_PRODUCT", 21, 25], ["GST", "GENE_OR_GENE_PRODUCT", 43, 46], ["ATF4", "GENE_OR_GENE_PRODUCT", 146, 150], ["GST", "PROTEIN", 17, 20], ["ATF4 chimera", "PROTEIN", 21, 33], ["GST", "PROTEIN", 43, 46], ["viral RNA", "RNA", 70, 79], ["purified infected-cell RNA", "RNA", 85, 111], ["ATF4", "PROTEIN", 146, 150], ["viral factors", "PROTEIN", 201, 214], ["a purified GST", "TEST", 6, 20], ["ATF4 chimera", "PROBLEM", 21, 33], ["viral RNA", "PROBLEM", 70, 79], ["purified infected-cell RNA", "PROBLEM", 85, 111], ["an ATF4-RNA interaction", "PROBLEM", 143, 166], ["other viral factors", "PROBLEM", 195, 214], ["viral RNA", "OBSERVATION", 70, 79], ["infected", "OBSERVATION_MODIFIER", 94, 102], ["cell RNA", "OBSERVATION", 103, 111]]], ["As negative controls, neither the ATF4 antibodies nor the GST-ATF4 chimera pulled down GAPDH RNA (Fig 7E and 7G ).", [["ATF4", "GENE_OR_GENE_PRODUCT", 34, 38], ["GST", "GENE_OR_GENE_PRODUCT", 58, 61], ["ATF4", "GENE_OR_GENE_PRODUCT", 62, 66], ["GAPDH", "GENE_OR_GENE_PRODUCT", 87, 92], ["ATF4 antibodies", "PROTEIN", 34, 49], ["GST", "PROTEIN", 58, 61], ["ATF4 chimera", "PROTEIN", 62, 74], ["GAPDH RNA", "RNA", 87, 96], ["the ATF4 antibodies", "TEST", 30, 49], ["the GST", "TEST", 54, 61], ["ATF4 chimera", "TEST", 62, 74]]], ["Lastly, confocal microscopy of infected cells showed that ATF4 exhibited remarkable co-localization with negative-stranded viral RNA (detected by RNAscope in situ hybridization), as well as the viral polymerase nsp9 in infected cells (Fig 7H) .", [["cells", "ANATOMY", 40, 45], ["cells", "ANATOMY", 228, 233], ["cells", "CELL", 40, 45], ["ATF4", "GENE_OR_GENE_PRODUCT", 58, 62], ["nsp9", "GENE_OR_GENE_PRODUCT", 211, 215], ["cells", "CELL", 228, 233], ["Fig 7H", "CELL", 235, 241], ["infected cells", "CELL_TYPE", 31, 45], ["ATF4", "PROTEIN", 58, 62], ["negative-stranded viral RNA", "RNA", 105, 132], ["viral polymerase nsp9", "PROTEIN", 194, 215], ["infected cells", "CELL_TYPE", 219, 233], ["confocal microscopy", "TEST", 8, 27], ["infected cells", "PROBLEM", 31, 45], ["ATF4", "PROBLEM", 58, 62], ["remarkable co-localization", "PROBLEM", 73, 99], ["stranded viral RNA", "PROBLEM", 114, 132], ["the viral polymerase nsp9 in infected cells", "PROBLEM", 190, 233], ["infected cells", "OBSERVATION", 31, 45], ["stranded", "OBSERVATION_MODIFIER", 114, 122], ["viral RNA", "OBSERVATION", 123, 132], ["viral polymerase", "OBSERVATION", 194, 210], ["infected cells", "OBSERVATION", 219, 233]]], ["Together, the above results provide strong evidence for a critical role of ATF4 in PRRSV RNA synthesis via an interaction with viral RNA.DiscussionThe endoplasmic reticulum has complex roles in autophagy, apoptosis, and innate immunity, and thus, is an important organelle in viral pathogenesis [34] .", [["endoplasmic reticulum", "ANATOMY", 151, 172], ["organelle", "ANATOMY", 263, 272], ["ATF4", "GENE_OR_GENE_PRODUCT", 75, 79], ["PRRSV", "ORGANISM", 83, 88], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 151, 172], ["organelle", "CELLULAR_COMPONENT", 263, 272], ["ATF4", "PROTEIN", 75, 79], ["viral RNA", "RNA", 127, 136], ["PRRSV", "SPECIES", 83, 88], ["ATF4 in PRRSV RNA synthesis", "TREATMENT", 75, 102], ["viral RNA", "PROBLEM", 127, 136], ["autophagy", "PROBLEM", 194, 203], ["apoptosis", "PROBLEM", 205, 214], ["viral RNA", "OBSERVATION", 127, 136], ["endoplasmic reticulum", "OBSERVATION", 151, 172]]], ["This is also the location where the UPR originates, and previous studies have revealed an association of this response with PRRSV-induced apoptosis and dysregulation of TNF-\u03b1 production in cell culture [41, 51] .", [["cell culture", "ANATOMY", 189, 201], ["PRRSV", "ORGANISM", 124, 129], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 169, 174], ["cell", "CELL", 189, 193], ["UPR", "PROTEIN", 36, 39], ["TNF", "PROTEIN", 169, 172], ["PRRSV", "SPECIES", 124, 129], ["previous studies", "TEST", 56, 72], ["this response", "PROBLEM", 105, 118], ["PRRSV", "PROBLEM", 124, 129], ["induced apoptosis", "PROBLEM", 130, 147], ["dysregulation of TNF", "PROBLEM", 152, 172], ["cell culture", "TEST", 189, 201]]], ["In this study, two unexpected findings were made that together reveal a novel way in which PRRSV reprograms the cellular UPR to its own advantage.", [["cellular", "ANATOMY", 112, 120], ["PRRSV", "ORGANISM", 91, 96], ["cellular", "CELL", 112, 120], ["UPR", "PROTEIN", 121, 124], ["PRRSV", "SPECIES", 91, 96], ["this study", "TEST", 3, 13]]], ["In particular, the virus targets GRP78 for degradation to induce or potentiate the UPR, and it then hijacks ATF4 to viral strain JXwn06 at an MOI of 0.1.", [["GRP78", "GENE_OR_GENE_PRODUCT", 33, 38], ["UPR", "GENE_OR_GENE_PRODUCT", 83, 86], ["ATF4", "GENE_OR_GENE_PRODUCT", 108, 112], ["JXwn06", "GENE_OR_GENE_PRODUCT", 129, 135], ["GRP78", "PROTEIN", 33, 38], ["UPR", "PROTEIN", 83, 86], ["ATF4", "PROTEIN", 108, 112], ["the UPR", "TEST", 79, 86], ["viral strain JXwn06", "PROBLEM", 116, 135], ["an MOI", "TEST", 139, 145]]], ["At the indicated times, the total titer of infectious virus present in each culture was measured by the endpoint dilution assay.", [["infectious virus", "PROBLEM", 43, 59], ["each culture", "TEST", 71, 83], ["the endpoint dilution assay", "TEST", 100, 127], ["infectious", "OBSERVATION", 43, 53]]], ["(D) MARC-145 cells were transduced with lentivirus expressing ATF4-myc, XBP1s-myc, or the empty vector.", [["MARC-145 cells", "ANATOMY", 4, 18], ["D) MARC-145 cells", "CELL", 1, 18], ["lentivirus", "ORGANISM", 40, 50], ["ATF4-myc", "GENE_OR_GENE_PRODUCT", 62, 70], ["XBP1s-myc", "GENE_OR_GENE_PRODUCT", 72, 81], ["MARC-145 cells", "CELL_LINE", 4, 18], ["ATF4", "PROTEIN", 62, 66], ["myc", "PROTEIN", 67, 70], ["XBP1s", "PROTEIN", 72, 77], ["myc", "PROTEIN", 78, 81], ["empty vector", "DNA", 90, 102], ["lentivirus", "SPECIES", 40, 50], ["ATF4", "TEST", 62, 66], ["XBP1s", "TEST", 72, 77], ["empty vector", "OBSERVATION", 90, 102]]], ["At 36 h post transduction, the cells were infected with PRRSV at an MOI of 0.1.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["PRRSV", "ORGANISM", 56, 61], ["PRRSV", "SPECIES", 56, 61], ["the cells", "PROBLEM", 27, 36], ["PRRSV", "PROBLEM", 56, 61], ["an MOI", "TEST", 65, 71], ["infected", "OBSERVATION", 42, 50]]], ["At 24 hpi, the total viral titer in each culture was measured by the end-point dilution assay (right panel), and the expression of the transduced proteins was analyzed by Western blot (left).", [["transduced proteins", "PROTEIN", 135, 154], ["the total viral titer", "TEST", 11, 32], ["each culture", "TEST", 36, 48], ["right panel", "TEST", 95, 106], ["the transduced proteins", "TREATMENT", 131, 154], ["left", "ANATOMY_MODIFIER", 185, 189]]], ["Data information: Statistical analysis was performed by two-tailed Student's t-test, and asterisks ( \ufffd ) indicate the statistical significance: NS, no significance; \ufffd , P < 0.05; \ufffd\ufffd , P < 0.01; \ufffd\ufffd\ufffd , P < 0.001.", [["Statistical analysis", "TEST", 18, 38], ["P", "TEST", 169, 170], ["\ufffd\ufffd", "TEST", 179, 181], ["P", "TEST", 184, 185], ["\ufffd\ufffd\ufffd", "TEST", 194, 197], ["P", "TEST", 200, 201]]], ["Data were presented as means \u00b1 standard deviations (SD) of three independent experiments.Discussionhttps://doi.org/10.1371/journal.ppat.1008169.g004DiscussionRepurposing cellular UPR by PRRSVDegradation of GRP78, the UPR regulator and chaperoneThe first unexpected finding from this study was the downregulation of GRP78 in a manner that is proteasome dependent and requires a viral membrane protein GP2a.", [["cellular", "ANATOMY", 170, 178], ["membrane", "ANATOMY", 383, 391], ["cellular", "CELL", 170, 178], ["GRP78", "GENE_OR_GENE_PRODUCT", 206, 211], ["GRP78", "GENE_OR_GENE_PRODUCT", 315, 320], ["GP2a", "GENE_OR_GENE_PRODUCT", 400, 404], ["UPR", "PROTEIN", 179, 182], ["GRP78", "PROTEIN", 206, 211], ["UPR regulator", "PROTEIN", 217, 230], ["chaperone", "PROTEIN", 235, 244], ["GRP78", "PROTEIN", 315, 320], ["proteasome", "PROTEIN", 341, 351], ["viral membrane protein", "PROTEIN", 377, 399], ["GP2a", "PROTEIN", 400, 404], ["the UPR regulator", "TREATMENT", 213, 230], ["chaperone", "TREATMENT", 235, 244], ["this study", "TEST", 278, 288], ["proteasome dependent", "PROBLEM", 341, 361], ["a viral membrane protein GP2a", "TEST", 375, 404], ["proteasome dependent", "OBSERVATION", 341, 361]]], ["It is likely that the ERAD pathway is utilized to retrotranslocate GPR78 into the cytosol, where proteasomes reside [52] , but the details of how GP2a might cause this remain to be elucidated.", [["cytosol", "ANATOMY", 82, 89], ["ERAD", "GENE_OR_GENE_PRODUCT", 22, 26], ["GPR78", "GENE_OR_GENE_PRODUCT", 67, 72], ["cytosol", "CELLULAR_COMPONENT", 82, 89], ["GP2a", "GENE_OR_GENE_PRODUCT", 146, 150], ["ERAD", "PROTEIN", 22, 26], ["GPR78", "PROTEIN", 67, 72], ["proteasomes", "PROTEIN", 97, 108], ["GP2a", "PROTEIN", 146, 150], ["the ERAD pathway", "PROBLEM", 18, 34], ["is likely", "UNCERTAINTY", 3, 12]]], ["In any case, downregulation of GRP78 was surprising because many viruses, especially enveloped viruses and ER-tropic viruses (e.g., the flaviviruses and coronaviruses), quickly produce large amounts of membrane proteins and thereby place a large burden on the folding machinery in the ER [53] [54] [55] .", [["membrane", "ANATOMY", 202, 210], ["GRP78", "GENE_OR_GENE_PRODUCT", 31, 36], ["ER", "GENE_OR_GENE_PRODUCT", 107, 109], ["membrane", "CELLULAR_COMPONENT", 202, 210], ["ER", "GENE_OR_GENE_PRODUCT", 285, 287], ["GRP78", "PROTEIN", 31, 36], ["ER", "PROTEIN", 107, 109], ["membrane proteins", "PROTEIN", 202, 219], ["downregulation of GRP78", "PROBLEM", 13, 36], ["many viruses", "PROBLEM", 60, 72], ["enveloped viruses", "PROBLEM", 85, 102], ["tropic viruses", "PROBLEM", 110, 124], ["the flaviviruses", "PROBLEM", 132, 148], ["coronaviruses", "PROBLEM", 153, 166], ["large amounts of membrane proteins", "PROBLEM", 185, 219], ["a large burden", "PROBLEM", 238, 252], ["viruses", "OBSERVATION", 65, 72], ["viruses", "OBSERVATION", 95, 102], ["tropic viruses", "OBSERVATION", 110, 124], ["large", "OBSERVATION_MODIFIER", 185, 190], ["amounts", "OBSERVATION_MODIFIER", 191, 198], ["membrane proteins", "OBSERVATION", 202, 219], ["large", "OBSERVATION_MODIFIER", 240, 245], ["burden", "OBSERVATION", 246, 252]]], ["In response to this stress, most viruses tend to upregulate chaperon GRP78 and other factors to meet the increased demand for folding and post-translational modifications [56] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 69, 74], ["chaperon GRP78", "PROTEIN", 60, 74], ["this stress", "PROBLEM", 15, 26], ["most viruses", "PROBLEM", 28, 40], ["other factors", "PROBLEM", 79, 92], ["the increased demand", "PROBLEM", 101, 121]]], ["This is not the case for PRRSV.", [["PRRSV", "ORGANISM", 25, 30], ["PRRSV", "SPECIES", 25, 30], ["PRRSV", "PROBLEM", 25, 30]]], ["Because GRP78 is the master regulator, its reduced accumulation likely prevents any modulation of the UPR, keeping the ER stress pathways induced for The abundance of viral RNA was assessed by RT-PCR of ORF7, normalized against the house-keeping gene GAPDH, and then compared the benefit of the virus.", [["GRP78", "GENE_OR_GENE_PRODUCT", 8, 13], ["UPR", "GENE_OR_GENE_PRODUCT", 102, 105], ["ER", "GENE_OR_GENE_PRODUCT", 119, 121], ["ORF7", "GENE_OR_GENE_PRODUCT", 203, 207], ["GAPDH", "GENE_OR_GENE_PRODUCT", 251, 256], ["GRP78", "PROTEIN", 8, 13], ["UPR", "PROTEIN", 102, 105], ["ER", "PROTEIN", 119, 121], ["viral RNA", "RNA", 167, 176], ["ORF7", "DNA", 203, 207], ["house-keeping gene", "DNA", 232, 250], ["GAPDH", "DNA", 251, 256], ["its reduced accumulation", "PROBLEM", 39, 63], ["viral RNA", "PROBLEM", 167, 176], ["RT-PCR", "TEST", 193, 199], ["ORF7", "TEST", 203, 207], ["gene GAPDH", "PROBLEM", 246, 256], ["the virus", "PROBLEM", 291, 300], ["viral RNA", "OBSERVATION", 167, 176]]], ["In addition to providing downstream factors such as ATF4 that this virus utilizes for replication, the reduced levels of GRP78 will likely result in increased levels of misfolded cellular proteins, potentially aiding in immune evasion [42, 57, 58] .", [["cellular", "ANATOMY", 179, 187], ["ATF4", "GENE_OR_GENE_PRODUCT", 52, 56], ["GRP78", "GENE_OR_GENE_PRODUCT", 121, 126], ["cellular", "CELL", 179, 187], ["ATF4", "PROTEIN", 52, 56], ["GRP78", "PROTEIN", 121, 126], ["misfolded cellular proteins", "PROTEIN", 169, 196], ["downstream factors", "TREATMENT", 25, 43], ["ATF4", "TREATMENT", 52, 56], ["this virus", "TREATMENT", 62, 72], ["replication", "TREATMENT", 86, 97], ["the reduced levels of GRP78", "PROBLEM", 99, 126], ["increased levels of misfolded cellular proteins", "PROBLEM", 149, 196], ["misfolded cellular proteins", "OBSERVATION", 169, 196]]], ["What remains unclear is how PRRSV promotes the folding of its own proteins in this situation.Repurposing ATF4 for the replication of PRRSVThe second unexpected, and perhaps most exciting, finding from this study is the dependence of PRRSV on two downstream UPR effectors, ATF4 and XBP1s, which were induced in the reduction of GPR78.", [["PRRSV", "ORGANISM", 28, 33], ["ATF4", "GENE_OR_GENE_PRODUCT", 105, 109], ["PRRSV", "ORGANISM", 233, 238], ["UPR", "GENE_OR_GENE_PRODUCT", 257, 260], ["ATF4", "GENE_OR_GENE_PRODUCT", 272, 276], ["XBP1s", "GENE_OR_GENE_PRODUCT", 281, 286], ["GPR78", "GENE_OR_GENE_PRODUCT", 327, 332], ["ATF4", "PROTEIN", 105, 109], ["UPR effectors", "PROTEIN", 257, 270], ["ATF4", "PROTEIN", 272, 276], ["XBP1s", "PROTEIN", 281, 286], ["GPR78", "PROTEIN", 327, 332], ["PRRSV", "SPECIES", 28, 33], ["PRRSV", "SPECIES", 233, 238], ["Repurposing ATF4", "TREATMENT", 93, 109], ["this study", "TEST", 201, 211], ["PRRSV", "PROBLEM", 233, 238], ["ATF4", "TEST", 272, 276], ["XBP1s", "TEST", 281, 286]]], ["With regard to the PERK-eIF2\u03b1-ATF4 signaling branch of the UPR, previous studies of how viruses utilize ATF4 have only revealed effects that depend upon its activity as a DNA transcription factor.", [["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["ATF4", "GENE_OR_GENE_PRODUCT", 30, 34], ["UPR", "GENE_OR_GENE_PRODUCT", 59, 62], ["ATF4", "GENE_OR_GENE_PRODUCT", 104, 108], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["PERK", "PROTEIN", 19, 23], ["eIF2\u03b1", "PROTEIN", 24, 29], ["ATF4", "PROTEIN", 30, 34], ["UPR", "PROTEIN", 59, 62], ["ATF4", "PROTEIN", 104, 108], ["DNA transcription factor", "PROTEIN", 171, 195], ["the PERK", "TEST", 15, 23], ["previous studies", "TEST", 64, 80], ["ATF4", "TEST", 104, 108], ["a DNA transcription factor", "PROBLEM", 169, 195], ["branch", "ANATOMY_MODIFIER", 45, 51]]], ["For example, in the cases of West Nile virus (WNV) and Infectious Bronchitis virus (IBV) [59, 60] , ATF4 upregulates transcription factor CHOP to induce apoptosis and virus release.", [["West Nile virus (WNV)", "DISEASE", 29, 50], ["Infectious Bronchitis virus", "DISEASE", 55, 82], ["West Nile virus", "ORGANISM", 29, 44], ["WNV", "ORGANISM", 46, 49], ["Infectious Bronchitis virus", "ORGANISM", 55, 82], ["IBV", "ORGANISM", 84, 87], ["ATF4", "GENE_OR_GENE_PRODUCT", 100, 104], ["CHOP", "GENE_OR_GENE_PRODUCT", 138, 142], ["ATF4", "PROTEIN", 100, 104], ["transcription factor", "PROTEIN", 117, 137], ["CHOP", "PROTEIN", 138, 142], ["West Nile virus", "SPECIES", 29, 44], ["Infectious Bronchitis virus", "SPECIES", 55, 82], ["West Nile virus", "SPECIES", 29, 44], ["WNV", "SPECIES", 46, 49], ["Infectious Bronchitis virus", "SPECIES", 55, 82], ["IBV", "SPECIES", 84, 87], ["West Nile virus (WNV", "PROBLEM", 29, 49], ["Infectious Bronchitis virus", "PROBLEM", 55, 82], ["ATF4 upregulates transcription factor CHOP", "TREATMENT", 100, 142], ["apoptosis", "PROBLEM", 153, 162], ["virus release", "PROBLEM", 167, 180], ["Infectious", "OBSERVATION_MODIFIER", 55, 65]]], ["In these cases, activation takes place during the late stages of infection, after high titers of viruses have been made.", [["infection", "DISEASE", 65, 74], ["infection", "PROBLEM", 65, 74], ["high titers of viruses", "PROBLEM", 82, 104], ["late stages", "OBSERVATION_MODIFIER", 50, 61], ["infection", "OBSERVATION", 65, 74]]], ["Other viruses (e.g., HSV-1 and dengue virus) use ATF4 to upregulate GADD34 to antagonize eIF2\u03b1 phosphorylation [61, 62] .", [["HSV-1", "ORGANISM", 21, 26], ["dengue virus", "ORGANISM", 31, 43], ["ATF4", "GENE_OR_GENE_PRODUCT", 49, 53], ["GADD34", "GENE_OR_GENE_PRODUCT", 68, 74], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["ATF4", "PROTEIN", 49, 53], ["GADD34", "PROTEIN", 68, 74], ["eIF2\u03b1", "PROTEIN", 89, 94], ["HSV-1", "SPECIES", 21, 26], ["dengue virus", "SPECIES", 31, 43], ["HSV-1", "SPECIES", 21, 26], ["dengue virus", "SPECIES", 31, 43], ["Other viruses", "PROBLEM", 0, 13], ["HSV", "TEST", 21, 24], ["dengue virus", "PROBLEM", 31, 43], ["phosphorylation", "TEST", 95, 110], ["viruses", "OBSERVATION", 6, 13]]], ["In the case of retroviruses (e.g., HIV), ATF4 has been found to be diverted and bound to viral promoters to mediate transcriptional activation, and thus virus replication [63] .Repurposing ATF4 for the replication of PRRSVIn our studies, ATF4 was found to be sequestered in the cytoplasm during PRRSV infections, and consistent with this observation, the canonical ATF4 target genes such as GADD34 and ASNS [51] were not upregulated and eIF2\u03b1 remained phosphorylated.", [["cytoplasm", "ANATOMY", 278, 287], ["PRRSV infections", "DISEASE", 295, 311], ["retroviruses", "ORGANISM", 15, 27], ["HIV", "ORGANISM", 35, 38], ["ATF4", "GENE_OR_GENE_PRODUCT", 41, 45], ["ATF4", "GENE_OR_GENE_PRODUCT", 189, 193], ["ATF4", "GENE_OR_GENE_PRODUCT", 238, 242], ["cytoplasm", "ORGANISM_SUBSTANCE", 278, 287], ["PRRSV", "ORGANISM", 295, 300], ["ATF4", "GENE_OR_GENE_PRODUCT", 365, 369], ["GADD34", "GENE_OR_GENE_PRODUCT", 391, 397], ["ASNS [51]", "GENE_OR_GENE_PRODUCT", 402, 411], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 437, 442], ["ATF4", "PROTEIN", 41, 45], ["viral promoters", "DNA", 89, 104], ["ATF4", "PROTEIN", 189, 193], ["PRRSVIn", "DNA", 217, 224], ["ATF4", "PROTEIN", 238, 242], ["ATF4 target genes", "DNA", 365, 382], ["GADD34", "PROTEIN", 391, 397], ["ASNS", "DNA", 402, 406], ["eIF2\u03b1", "PROTEIN", 437, 442], ["HIV", "SPECIES", 35, 38], ["PRRSV", "SPECIES", 295, 300], ["retroviruses", "PROBLEM", 15, 27], ["HIV", "PROBLEM", 35, 38], ["ATF4", "PROBLEM", 41, 45], ["viral promoters", "TREATMENT", 89, 104], ["Repurposing ATF4", "TREATMENT", 177, 193], ["PRRSVIn our studies", "TEST", 217, 236], ["ATF4", "PROBLEM", 238, 242], ["PRRSV infections", "PROBLEM", 295, 311], ["this observation", "TEST", 333, 349], ["GADD34", "TEST", 391, 397], ["ASNS", "TEST", 402, 406], ["eIF2", "TEST", 437, 441], ["phosphorylated", "PROBLEM", 452, 466], ["retroviruses", "OBSERVATION", 15, 27], ["PRRSV infections", "OBSERVATION", 295, 311], ["consistent with", "UNCERTAINTY", 317, 332]]], ["This property of PRRSV appears to be similar to that of mouse hepatitis virus (MHV) [64] , where high levels of phosphorylated eIF2\u03b1 and activation of ATF4 were found without subsequent expression of GADD34; however, in that work, the authors did not examine possible roles for, or the intracellular location of, ATF4.Repurposing ATF4 for the replication of PRRSVMechanistically, we found that ATF4 is recruited by nsp2/3 to viral RTCs to promote viral replication.", [["intracellular", "ANATOMY", 286, 299], ["mouse hepatitis virus", "DISEASE", 56, 77], ["PRRSV", "ORGANISM", 17, 22], ["mouse hepatitis virus (MHV) [64", "ORGANISM", 56, 87], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["ATF4", "GENE_OR_GENE_PRODUCT", 151, 155], ["GADD34", "GENE_OR_GENE_PRODUCT", 200, 206], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 286, 299], ["ATF4", "GENE_OR_GENE_PRODUCT", 313, 317], ["ATF4", "GENE_OR_GENE_PRODUCT", 330, 334], ["ATF4", "GENE_OR_GENE_PRODUCT", 394, 398], ["nsp2/3", "GENE_OR_GENE_PRODUCT", 415, 421], ["RTCs", "GENE_OR_GENE_PRODUCT", 431, 435], ["phosphorylated eIF2\u03b1", "PROTEIN", 112, 132], ["ATF4", "PROTEIN", 151, 155], ["GADD34", "PROTEIN", 200, 206], ["ATF4", "PROTEIN", 313, 317], ["ATF4", "PROTEIN", 330, 334], ["ATF4", "PROTEIN", 394, 398], ["nsp2/3", "PROTEIN", 415, 421], ["mouse", "SPECIES", 56, 61], ["hepatitis virus", "SPECIES", 62, 77], ["PRRSV", "SPECIES", 17, 22], ["mouse hepatitis virus", "SPECIES", 56, 77], ["MHV", "SPECIES", 79, 82], ["PRRSV", "PROBLEM", 17, 22], ["mouse hepatitis virus", "PROBLEM", 56, 77], ["phosphorylated eIF2", "TREATMENT", 112, 131], ["activation of ATF4", "TREATMENT", 137, 155], ["GADD34", "PROBLEM", 200, 206], ["Repurposing ATF4", "TREATMENT", 318, 334], ["ATF4", "PROBLEM", 394, 398], ["viral RTCs", "TREATMENT", 425, 435], ["viral replication", "TREATMENT", 447, 464], ["PRRSV", "OBSERVATION", 17, 22], ["viral replication", "OBSERVATION", 447, 464]]], ["When this protein was depleted with siRNAs, the accumulation of viral RNA was severely attenuated for both the positive and negative strands.", [["viral RNA", "RNA", 64, 73], ["positive and negative strands", "DNA", 111, 140], ["siRNAs", "TREATMENT", 36, 42], ["the accumulation of viral RNA", "PROBLEM", 44, 73], ["severely attenuated", "PROBLEM", 78, 97], ["viral RNA", "OBSERVATION", 64, 73], ["negative strands", "OBSERVATION", 124, 140]]], ["Indeed, the effect seems to be equal on the accumulation of all viral RNA species at the transcriptional level, suggesting that ATF4 serves as a general facilitator for viral RNA biogenesis.", [["ATF4", "GENE_OR_GENE_PRODUCT", 128, 132], ["viral RNA species", "RNA", 64, 81], ["ATF4", "PROTEIN", 128, 132], ["all viral RNA species", "PROBLEM", 60, 81], ["viral RNA biogenesis", "TREATMENT", 169, 189], ["viral RNA species", "OBSERVATION", 64, 81]]], ["This is unlike host RNA helicase DDX1, which is relocated to the cytoplasm in coronavirus infections [65] and is needed for the synthesis of much longer viral RNA species [66] .", [["cytoplasm", "ANATOMY", 65, 74], ["coronavirus infections", "DISEASE", 78, 100], ["DDX1", "GENE_OR_GENE_PRODUCT", 33, 37], ["cytoplasm", "ORGANISM_SUBSTANCE", 65, 74], ["coronavirus", "ORGANISM", 78, 89], ["RNA helicase", "PROTEIN", 20, 32], ["DDX1", "PROTEIN", 33, 37], ["viral RNA species", "RNA", 153, 170], ["coronavirus infections", "PROBLEM", 78, 100], ["much longer viral RNA species", "PROBLEM", 141, 170], ["host RNA", "OBSERVATION", 15, 23], ["cytoplasm", "OBSERVATION_MODIFIER", 65, 74], ["coronavirus", "OBSERVATION_MODIFIER", 78, 89], ["infections", "OBSERVATION", 90, 100]]], ["Further evidence supporting the association of ATF4 with the replication machinery of PRRSV includes its interaction with viral RNA in pulldown assays and co-localization with negative-strand RNAs during infection.", [["infection", "DISEASE", 204, 213], ["ATF4", "GENE_OR_GENE_PRODUCT", 47, 51], ["PRRSV", "ORGANISM", 86, 91], ["ATF4", "PROTEIN", 47, 51], ["viral RNA", "RNA", 122, 131], ["negative-strand RNAs", "RNA", 176, 196], ["PRRSV", "SPECIES", 86, 91], ["ATF4", "PROBLEM", 47, 51], ["PRRSV", "PROBLEM", 86, 91], ["viral RNA", "PROBLEM", 122, 131], ["pulldown assays", "TEST", 135, 150], ["co-localization", "TEST", 155, 170], ["strand RNAs during infection", "PROBLEM", 185, 213], ["strand RNAs", "OBSERVATION_MODIFIER", 185, 196], ["infection", "OBSERVATION", 204, 213]]], ["Whatever its exact role, depletion of this component of the UPR led to a dramatic attenuation of PRRSV titers, whereas overexpression increased the viral yield.", [["UPR", "GENE_OR_GENE_PRODUCT", 60, 63], ["PRRSV", "ORGANISM", 97, 102], ["UPR", "PROTEIN", 60, 63], ["PRRSV", "SPECIES", 97, 102], ["a dramatic attenuation of PRRSV titers", "PROBLEM", 71, 109], ["the viral yield", "PROBLEM", 144, 159], ["dramatic", "OBSERVATION_MODIFIER", 73, 81], ["attenuation", "OBSERVATION_MODIFIER", 82, 93], ["PRRSV titers", "OBSERVATION", 97, 109], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["viral yield", "OBSERVATION", 148, 159]]], ["Future studies are needed to dissect how exactly ATF4 promotes RNA biogenesis and to identify the ATF4-interacting domain or motif within PRRSV so that a mutant virus can be tested for vaccine development.Repurposing ATF4 for the replication of PRRSVto siNC control at 0 to 12 hpi.", [["ATF4", "GENE_OR_GENE_PRODUCT", 49, 53], ["ATF4", "GENE_OR_GENE_PRODUCT", 98, 102], ["PRRSV", "ORGANISM", 138, 143], ["mutant virus", "ORGANISM", 154, 166], ["ATF4", "GENE_OR_GENE_PRODUCT", 217, 221], ["ATF4", "PROTEIN", 49, 53], ["ATF4", "PROTEIN", 98, 102], ["ATF4", "PROTEIN", 217, 221], ["PRRSV", "SPECIES", 138, 143], ["Future studies", "TEST", 0, 14], ["the ATF4", "PROBLEM", 94, 102], ["motif within PRRSV", "PROBLEM", 125, 143], ["a mutant virus", "PROBLEM", 152, 166], ["vaccine development", "TREATMENT", 185, 204], ["Repurposing ATF4", "TREATMENT", 205, 221], ["PRRSVto siNC control", "TREATMENT", 245, 265]]], ["(B and C) The same as (A) except the abundance of positive-and negative stranded RNAs were analyzed by RT-qPCR at 0, 4, 8 and 12 hpi.", [["positive-and negative stranded RNAs", "RNA", 50, 85], ["the abundance", "TEST", 33, 46], ["negative stranded RNAs", "PROBLEM", 63, 85], ["RT", "TEST", 103, 105], ["qPCR", "TEST", 106, 110], ["stranded RNAs", "OBSERVATION", 72, 85]]], ["(D) Control, rabbit IgG or antibodies specific for ATF4 were used for immunoprecipitations from lysates of infected MARC-145 cells (MOI = 0.1, 36 hpi).", [["lysates", "ANATOMY", 96, 103], ["MARC-145 cells", "ANATOMY", 116, 130], ["rabbit", "ORGANISM", 13, 19], ["IgG", "GENE_OR_GENE_PRODUCT", 20, 23], ["ATF4", "GENE_OR_GENE_PRODUCT", 51, 55], ["lysates", "ORGANISM_SUBSTANCE", 96, 103], ["MARC-145 cells", "CELL", 116, 130], ["rabbit IgG", "PROTEIN", 13, 23], ["antibodies", "PROTEIN", 27, 37], ["ATF4", "PROTEIN", 51, 55], ["MARC-145 cells", "CELL_LINE", 116, 130], ["rabbit", "SPECIES", 13, 19], ["rabbit", "SPECIES", 13, 19], ["MARC-145", "SPECIES", 116, 124], ["rabbit IgG", "TREATMENT", 13, 23], ["antibodies", "TREATMENT", 27, 37], ["ATF4", "PROBLEM", 51, 55], ["immunoprecipitations", "PROBLEM", 70, 90], ["infected MARC", "TEST", 107, 120], ["MOI", "TEST", 132, 135]]], ["The presence of viral RNA was assayed by RT-qPCR targeting 5'-UTR sequence or (E) GAPDH as a negative control, and the fold enrichment was calculated against the normal rabbit IgG group.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 82, 87], ["rabbit", "ORGANISM", 169, 175], ["IgG", "GENE_OR_GENE_PRODUCT", 176, 179], ["viral RNA", "RNA", 16, 25], ["5'-UTR sequence", "DNA", 59, 74], ["rabbit", "SPECIES", 169, 175], ["rabbit", "SPECIES", 169, 175], ["viral RNA", "PROBLEM", 16, 25], ["RT-qPCR", "TEST", 41, 48], ["5'-UTR sequence", "TEST", 59, 74], ["GAPDH", "PROBLEM", 82, 87], ["the fold enrichment", "TEST", 115, 134], ["viral RNA", "OBSERVATION", 16, 25], ["rabbit IgG", "OBSERVATION", 169, 179]]], ["(F) GST-ATF4 or GST were purified from E. coli (left panel) and added to RNA extracted from PRRSV-infected MARC-145 cells in an in vitro binding assay.", [["left panel", "ANATOMY", 48, 58], ["MARC-145 cells", "ANATOMY", 107, 121], ["(F) GST", "GENE_OR_GENE_PRODUCT", 0, 7], ["ATF4", "GENE_OR_GENE_PRODUCT", 8, 12], ["GST", "GENE_OR_GENE_PRODUCT", 16, 19], ["E. coli", "ORGANISM", 39, 46], ["PRRSV", "ORGANISM", 92, 97], ["MARC-145 cells", "CELL", 107, 121], ["(F) GST", "PROTEIN", 0, 7], ["ATF4", "PROTEIN", 8, 12], ["GST", "PROTEIN", 16, 19], ["PRRSV-infected MARC-145 cells", "CELL_LINE", 92, 121], ["E. coli", "SPECIES", 39, 46], ["E. coli", "SPECIES", 39, 46], ["PRRSV", "SPECIES", 92, 97], ["MARC-145", "SPECIES", 107, 115], ["ATF4", "PROBLEM", 8, 12], ["GST", "PROBLEM", 16, 19], ["E. coli", "PROBLEM", 39, 46], ["left panel", "TEST", 48, 58], ["PRRSV", "PROBLEM", 92, 97], ["an in vitro binding assay", "TEST", 125, 150], ["145 cells", "OBSERVATION_MODIFIER", 112, 121]]], ["RT-qPCR with primers specific for a 5'UTR sequence was used to detect viral RNA (middle panel) and the fold of enrichment of viral RNA was expressed against the GST control.", [["GST", "GENE_OR_GENE_PRODUCT", 161, 164], ["5'UTR sequence", "DNA", 36, 50], ["viral RNA", "RNA", 70, 79], ["viral RNA", "RNA", 125, 134], ["GST", "PROTEIN", 161, 164], ["primers", "TREATMENT", 13, 20], ["a 5'UTR sequence", "TEST", 34, 50], ["viral RNA", "PROBLEM", 70, 79], ["middle panel", "TEST", 81, 93], ["viral RNA", "PROBLEM", 125, 134], ["the GST control", "TREATMENT", 157, 172], ["viral RNA", "OBSERVATION", 70, 79], ["viral RNA", "OBSERVATION", 125, 134]]], ["(G) In parallel, the pull down of cellular GAPDH mRNA was used as a negative control.", [["cellular", "ANATOMY", 34, 42], ["cellular", "CELL", 34, 42], ["GAPDH", "GENE_OR_GENE_PRODUCT", 43, 48], ["cellular GAPDH mRNA", "RNA", 34, 53], ["cellular GAPDH mRNA", "TREATMENT", 34, 53], ["cellular", "OBSERVATION", 34, 42], ["GAPDH mRNA", "OBSERVATION", 43, 53]]], ["(H) To look for ATF4 within viral replication compartments in infected MARC-145 cells (MOI = 0.1, 24 hpi), the negative-strand RNA was detected by the RNAscope in situ hybridization method, and ATF4 and nsp9 were detected by immunostaining.", [["MARC-145 cells", "ANATOMY", 71, 85], ["ATF4", "GENE_OR_GENE_PRODUCT", 16, 20], ["MARC-145 cells", "CELL", 71, 85], ["ATF4", "GENE_OR_GENE_PRODUCT", 194, 198], ["nsp9", "GENE_OR_GENE_PRODUCT", 203, 207], ["ATF4", "PROTEIN", 16, 20], ["MARC-145 cells", "CELL_LINE", 71, 85], ["negative-strand RNA", "RNA", 111, 130], ["ATF4", "PROTEIN", 194, 198], ["nsp9", "PROTEIN", 203, 207], ["MARC-145", "SPECIES", 71, 79], ["ATF4", "PROBLEM", 16, 20], ["MOI", "TEST", 87, 90], ["strand RNA", "PROBLEM", 120, 130], ["ATF4", "TEST", 194, 198], ["nsp9", "PROBLEM", 203, 207], ["viral replication", "OBSERVATION", 28, 45], ["negative", "OBSERVATION", 111, 119], ["strand RNA", "OBSERVATION", 120, 130]]], ["Data information: Statistical analysis was performed by two-tailed Student's t-test, and error bars indicate standard deviations (SD) of means.", [["Statistical analysis", "TEST", 18, 38], ["standard deviations (SD) of means", "PROBLEM", 109, 142], ["standard deviations", "OBSERVATION", 109, 128]]], ["Asterisks ( \ufffd ) indicate the statistical significance: \ufffd\ufffd\ufffd , P < 0.001; \ufffd\ufffd\ufffd\ufffd , P<0.0001; NS, no significance (n = 3 experiments in each condition).", [["Asterisks", "TEST", 0, 9], ["\ufffd\ufffd\ufffd\ufffd", "TEST", 72, 76], ["P", "TEST", 79, 80], ["NS", "TEST", 89, 91]]], ["Confocal images were acquired with Nikon A1 confocal microscope.", [["Confocal images", "TEST", 0, 15]]], ["Oil objective: 63 X; zoom in 1 X.Repurposing ATF4 for the replication of PRRSVhttps://doi.org/10.1371/journal.ppat.1008169.g007Repurposing ATF4 for the replication of PRRSVInterestingly, ATF4 has also been implicated in cancer progression [67] .", [["cancer", "ANATOMY", 220, 226], ["cancer", "DISEASE", 220, 226], ["ATF4", "GENE_OR_GENE_PRODUCT", 45, 49], ["ATF4", "GENE_OR_GENE_PRODUCT", 139, 143], ["ATF4", "GENE_OR_GENE_PRODUCT", 187, 191], ["cancer", "CANCER", 220, 226], ["ATF4", "PROTEIN", 45, 49], ["ATF4", "PROTEIN", 139, 143], ["ATF4", "PROTEIN", 187, 191], ["PRRSVhttps://doi.org/10.1371/journal.ppat.1008169.g007Repurposing ATF4", "TREATMENT", 73, 143], ["cancer", "OBSERVATION", 220, 226]]], ["In tumors, ATF4 expression is detected in hypoxic-and nutrient-deprived regions where it promotes metabolic homeostasis and cancer cell survival by transcriptionally regulating amino acid uptake and biosynthesis, autophagy, redox balance and angiogenesis [15, [67] [68] [69] .", [["tumors", "ANATOMY", 3, 9], ["cancer cell", "ANATOMY", 124, 135], ["tumors", "DISEASE", 3, 9], ["cancer", "DISEASE", 124, 130], ["amino acid", "CHEMICAL", 177, 187], ["amino acid", "CHEMICAL", 177, 187], ["tumors", "CANCER", 3, 9], ["ATF4", "GENE_OR_GENE_PRODUCT", 11, 15], ["cancer cell", "CELL", 124, 135], ["amino acid", "AMINO_ACID", 177, 187], ["ATF4", "PROTEIN", 11, 15], ["tumors", "PROBLEM", 3, 9], ["ATF4 expression", "TEST", 11, 26], ["cancer cell survival", "PROBLEM", 124, 144], ["amino acid uptake", "TEST", 177, 194], ["biosynthesis", "TEST", 199, 211], ["redox balance", "TEST", 224, 237], ["angiogenesis", "TEST", 242, 254], ["tumors", "OBSERVATION", 3, 9], ["hypoxic", "OBSERVATION_MODIFIER", 42, 49], ["metabolic homeostasis", "OBSERVATION", 98, 119]]], ["As ATF4 is normally expressed at low levels and is not essential for normal cells, this molecule serves as a potential target for drug development in both human and veterinary medicine.", [["cells", "ANATOMY", 76, 81], ["ATF4", "GENE_OR_GENE_PRODUCT", 3, 7], ["cells", "CELL", 76, 81], ["human", "ORGANISM", 155, 160], ["ATF4", "PROTEIN", 3, 7], ["normal cells", "CELL_TYPE", 69, 81], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160]]], ["Currently, there are no approved drugs for this target, and a search for one is warranted.Repurposing ATF4 for the replication of PRRSVWe also found that PRRSV is dependent on XBP1s.", [["ATF4", "GENE_OR_GENE_PRODUCT", 102, 106], ["PRRSVWe", "GENE_OR_GENE_PRODUCT", 130, 137], ["PRRSV", "ORGANISM", 154, 159], ["XBP1s", "GENE_OR_GENE_PRODUCT", 176, 181], ["ATF4", "PROTEIN", 102, 106], ["PRRSVWe", "DNA", 130, 137], ["XBP1s", "PROTEIN", 176, 181], ["PRRSV", "SPECIES", 154, 159], ["drugs", "TREATMENT", 33, 38], ["Repurposing ATF4", "TREATMENT", 90, 106], ["the replication of PRRSVWe", "TREATMENT", 111, 137], ["PRRSV", "PROBLEM", 154, 159], ["no", "UNCERTAINTY", 21, 23], ["PRRSV", "OBSERVATION", 154, 159], ["dependent", "OBSERVATION_MODIFIER", 163, 172]]], ["The IRE1 branch of the UPR is linked to many functions, such as apoptosis through the IRE1-mediated RIDD and JNK pathways, inflammation through IRE1-ASK pathway, autophagy, ERAD, and lipid synthesis through activation of XBP1s [23, 24, 26, 70, 71] .", [["inflammation", "DISEASE", 123, 135], ["IRE1", "GENE_OR_GENE_PRODUCT", 4, 8], ["UPR", "GENE_OR_GENE_PRODUCT", 23, 26], ["IRE1", "GENE_OR_GENE_PRODUCT", 86, 90], ["RIDD", "GENE_OR_GENE_PRODUCT", 100, 104], ["JNK", "GENE_OR_GENE_PRODUCT", 109, 112], ["IRE1", "GENE_OR_GENE_PRODUCT", 144, 148], ["ASK", "GENE_OR_GENE_PRODUCT", 149, 152], ["ERAD", "GENE_OR_GENE_PRODUCT", 173, 177], ["lipid", "SIMPLE_CHEMICAL", 183, 188], ["XBP1s", "GENE_OR_GENE_PRODUCT", 221, 226], ["IRE1", "PROTEIN", 4, 8], ["UPR", "PROTEIN", 23, 26], ["IRE1", "PROTEIN", 86, 90], ["RIDD", "PROTEIN", 100, 104], ["JNK", "PROTEIN", 109, 112], ["IRE1", "PROTEIN", 144, 148], ["ASK", "PROTEIN", 149, 152], ["ERAD", "PROTEIN", 173, 177], ["XBP1s", "PROTEIN", 221, 226], ["apoptosis", "PROBLEM", 64, 73], ["the IRE1", "TEST", 82, 90], ["inflammation", "PROBLEM", 123, 135], ["IRE1", "TEST", 144, 148], ["autophagy", "PROBLEM", 162, 171], ["ERAD", "TEST", 173, 177], ["XBP1s", "TEST", 221, 226], ["IRE1", "OBSERVATION_MODIFIER", 4, 8], ["branch", "OBSERVATION_MODIFIER", 9, 15], ["inflammation", "OBSERVATION", 123, 135]]], ["Our study showed that IRE1 is activated in infected cells, consistent with two previous reports [41, 51] .", [["cells", "ANATOMY", 52, 57], ["IRE1", "GENE_OR_GENE_PRODUCT", 22, 26], ["cells", "CELL", 52, 57], ["IRE1", "PROTEIN", 22, 26], ["infected cells", "CELL_TYPE", 43, 57], ["Our study", "TEST", 0, 9], ["IRE1", "PROBLEM", 22, 26], ["infected cells", "OBSERVATION", 43, 57], ["consistent with", "UNCERTAINTY", 59, 74]]], ["While it is clear that the downstream effector XBP1s is important for virus replication the mechanism was not further explored here.", [["XBP1s", "GENE_OR_GENE_PRODUCT", 47, 52], ["XBP1s", "PROTEIN", 47, 52], ["the downstream effector XBP1s", "PROBLEM", 23, 52], ["virus replication", "TREATMENT", 70, 87], ["clear", "OBSERVATION", 12, 17]]], ["There are several ways that XBP1s might be important.", [["XBP1s", "GENE_OR_GENE_PRODUCT", 28, 33], ["XBP1s", "PROTEIN", 28, 33]]], ["One is for fulfilling the increased demand for lipid synthesis, as the replication of some viruses, including PRRSV, often involves extensive The activated effector XBP1s enters nucleus, but ATF4 is diverted to viral replication complexes by nonstructural proteins nsp2/3 to promote viral RNA synthesis.", [["nucleus", "ANATOMY", 178, 185], ["lipid", "SIMPLE_CHEMICAL", 47, 52], ["PRRSV", "ORGANISM", 110, 115], ["XBP1s", "GENE_OR_GENE_PRODUCT", 165, 170], ["nucleus", "CELLULAR_COMPONENT", 178, 185], ["ATF4", "GENE_OR_GENE_PRODUCT", 191, 195], ["nsp2/3", "GENE_OR_GENE_PRODUCT", 265, 271], ["XBP1s", "PROTEIN", 165, 170], ["ATF4", "PROTEIN", 191, 195], ["viral replication complexes", "PROTEIN", 211, 238], ["nonstructural proteins", "PROTEIN", 242, 264], ["nsp2/3", "PROTEIN", 265, 271], ["viral RNA", "RNA", 283, 292], ["PRRSV", "SPECIES", 110, 115], ["the increased demand", "PROBLEM", 22, 42], ["lipid synthesis", "TREATMENT", 47, 62], ["some viruses", "PROBLEM", 86, 98], ["PRRSV", "PROBLEM", 110, 115], ["ATF4", "PROBLEM", 191, 195], ["viral replication complexes", "TREATMENT", 211, 238], ["nonstructural proteins nsp2/3", "TREATMENT", 242, 271], ["viral RNA synthesis", "PROBLEM", 283, 302], ["viruses", "OBSERVATION", 91, 98], ["extensive", "OBSERVATION_MODIFIER", 132, 141], ["nucleus", "ANATOMY", 178, 185], ["viral replication", "OBSERVATION", 211, 228], ["viral RNA synthesis", "OBSERVATION", 283, 302]]], ["To maintain a favorable environment, PRRSV targets GRP78 for partial proteasomal degradation by viral glycoprotein GP2a, which creates a positive feedback loop to sensitize and potentiate the UPR signaling.Repurposing ATF4 for the replication of PRRSVhttps://doi.org/10.1371/journal.ppat.1008169.g008 modulation, rearrangement and capture of intracellular membranes into virions [24, 25, 72] .", [["proteasomal", "ANATOMY", 69, 80], ["intracellular membranes", "ANATOMY", 342, 365], ["virions", "ANATOMY", 371, 378], ["PRRSV", "ORGANISM", 37, 42], ["GRP78", "GENE_OR_GENE_PRODUCT", 51, 56], ["GP2a", "GENE_OR_GENE_PRODUCT", 115, 119], ["UPR", "GENE_OR_GENE_PRODUCT", 192, 195], ["ATF4", "GENE_OR_GENE_PRODUCT", 218, 222], ["intracellular membranes", "CELLULAR_COMPONENT", 342, 365], ["GRP78", "PROTEIN", 51, 56], ["viral glycoprotein GP2a", "PROTEIN", 96, 119], ["UPR", "PROTEIN", 192, 195], ["ATF4", "PROTEIN", 218, 222], ["PRRSV", "SPECIES", 37, 42], ["partial proteasomal degradation", "PROBLEM", 61, 92], ["viral glycoprotein GP2a", "TEST", 96, 119], ["a positive feedback loop", "PROBLEM", 135, 159], ["the UPR signaling", "PROBLEM", 188, 205], ["Repurposing ATF4", "TREATMENT", 206, 222], ["the replication of PRRSVhttps://doi.org/10.1371/journal.ppat.1008169.g008 modulation", "TREATMENT", 227, 311], ["feedback loop", "OBSERVATION", 146, 159], ["intracellular membranes", "OBSERVATION", 342, 365]]], ["Second, XBP1s may be important for regulation of autophagy [71] .", [["XBP1s", "GENE_OR_GENE_PRODUCT", 8, 13], ["XBP1s", "PROTEIN", 8, 13]]], ["Indeed, XBP1s has been shown to be an important regulator of genes involved in autophagy biogenesis, such as LC3, ULK1, ATG4, Beclin1, and Bcl2 [31, 71, 73] .", [["XBP1s", "CHEMICAL", 8, 13], ["XBP1s", "GENE_OR_GENE_PRODUCT", 8, 13], ["LC3", "GENE_OR_GENE_PRODUCT", 109, 112], ["ULK1", "GENE_OR_GENE_PRODUCT", 114, 118], ["ATG4", "GENE_OR_GENE_PRODUCT", 120, 124], ["Beclin1", "GENE_OR_GENE_PRODUCT", 126, 133], ["Bcl2", "GENE_OR_GENE_PRODUCT", 139, 143], ["XBP1s", "PROTEIN", 8, 13], ["LC3", "PROTEIN", 109, 112], ["ULK1", "PROTEIN", 114, 118], ["ATG4", "PROTEIN", 120, 124], ["Beclin1", "PROTEIN", 126, 133], ["Bcl2", "PROTEIN", 139, 143], ["ULK1", "TEST", 114, 118], ["ATG4", "TEST", 120, 124], ["Beclin1", "TEST", 126, 133], ["Bcl2", "TEST", 139, 143]]], ["Third, XBP1s may facilitate the degradation of misfolded proteins via the ERAD pathway and thereby increase the folding capability via protein chaperones [5, 74] .", [["XBP1s", "GENE_OR_GENE_PRODUCT", 7, 12], ["ERAD", "GENE_OR_GENE_PRODUCT", 74, 78], ["XBP1s", "PROTEIN", 7, 12], ["misfolded proteins", "PROTEIN", 47, 65], ["ERAD", "PROTEIN", 74, 78], ["protein chaperones", "PROTEIN", 135, 153], ["XBP1s", "TREATMENT", 7, 12], ["misfolded proteins", "PROBLEM", 47, 65], ["the ERAD pathway", "TREATMENT", 70, 86], ["the folding capability via protein chaperones", "TREATMENT", 108, 153]]], ["PRRSV appears to be different from closely-related coronaviruses in its requirement for XBP1s signaling.", [["PRRSV", "ORGANISM", 0, 5], ["coronaviruses", "ORGANISM", 51, 64], ["XBP1s", "GENE_OR_GENE_PRODUCT", 88, 93], ["XBP1s", "PROTEIN", 88, 93], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["coronaviruses", "PROBLEM", 51, 64], ["XBP1s signaling", "PROBLEM", 88, 103], ["appears to be", "UNCERTAINTY", 6, 19], ["different", "OBSERVATION_MODIFIER", 20, 29], ["coronaviruses", "OBSERVATION", 51, 64]]], ["For example, MHV induces splicing of XBP1 but suppresses the activation of its downstream target genes [64] .", [["MHV", "ORGANISM", 13, 16], ["XBP1", "GENE_OR_GENE_PRODUCT", 37, 41], ["XBP1", "PROTEIN", 37, 41], ["downstream target genes", "DNA", 79, 102], ["MHV", "SPECIES", 13, 16], ["XBP1", "PROBLEM", 37, 41], ["MHV", "OBSERVATION", 13, 16]]], ["Also, transmissible gastroenteritis virus (TGEV) triggers the activation of IRE1-XBP1s signaling, but this pathway is not required for viral replication [75] .", [["transmissible gastroenteritis", "DISEASE", 6, 35], ["transmissible gastroenteritis virus", "ORGANISM", 6, 41], ["TGEV", "ORGANISM", 43, 47], ["IRE1", "GENE_OR_GENE_PRODUCT", 76, 80], ["XBP1s", "GENE_OR_GENE_PRODUCT", 81, 86], ["IRE1", "PROTEIN", 76, 80], ["XBP1s", "PROTEIN", 81, 86], ["transmissible gastroenteritis virus", "SPECIES", 6, 41], ["transmissible gastroenteritis virus", "SPECIES", 6, 41], ["TGEV", "SPECIES", 43, 47], ["transmissible gastroenteritis virus", "PROBLEM", 6, 41], ["IRE1", "TEST", 76, 80], ["XBP1s signaling", "PROBLEM", 81, 96], ["viral replication", "PROBLEM", 135, 152], ["gastroenteritis virus", "OBSERVATION", 20, 41]]], ["In any case, since XBP1s is a stress-inducing gene product and normally expressed at low level, it represents a potential antiviral target for PRRSV.Repurposing ATF4 for the replication of PRRSVIn summary, the findings reported here provide further insight into the mechanisms by which PRRSV interacts with cellular pathways and reveal a novel paradigm for how pathogens can repurpose components UPR for their own use.", [["cellular", "ANATOMY", 307, 315], ["XBP1s", "CHEMICAL", 19, 24], ["XBP1s", "GENE_OR_GENE_PRODUCT", 19, 24], ["PRRSV", "ORGANISM", 143, 148], ["ATF4", "GENE_OR_GENE_PRODUCT", 161, 165], ["PRRSV", "ORGANISM", 286, 291], ["cellular", "CELL", 307, 315], ["UPR", "GENE_OR_GENE_PRODUCT", 396, 399], ["XBP1s", "PROTEIN", 19, 24], ["stress-inducing gene product", "PROTEIN", 30, 58], ["ATF4", "PROTEIN", 161, 165], ["UPR", "PROTEIN", 396, 399], ["PRRSV", "SPECIES", 143, 148], ["PRRSV", "SPECIES", 286, 291], ["a stress", "PROBLEM", 28, 36], ["PRRSV", "PROBLEM", 143, 148], ["Repurposing ATF4", "TREATMENT", 149, 165], ["cellular pathways", "TEST", 307, 324], ["antiviral target", "OBSERVATION", 122, 138]]], ["Our results also identify potentially druggable targets (ATF4 and XBP1s) and provide new information for making attenuated vaccines to control PRRSV.Ethics statementThe sampling of primary porcine pulmonary alveolar macrophages (PAMs) derived from onemonth-old SPF pigs was performed according to the Chinese Regulations of Laboratory Animals-The Guidelines for the Care of Laboratory Animals (Ministry of Science and Technology of People's Republic of China) and Laboratory Animal-Requirements of Environment and Housing Facilities (GB 14925\u00b12010, National Laboratory Animal Standardization Technical Committee).", [["pulmonary alveolar macrophages", "ANATOMY", 197, 227], ["PAMs", "ANATOMY", 229, 233], ["PRRSV", "DISEASE", 143, 148], ["ATF4", "GENE_OR_GENE_PRODUCT", 57, 61], ["XBP1s", "GENE_OR_GENE_PRODUCT", 66, 71], ["PRRSV", "ORGANISM", 143, 148], ["porcine", "ORGANISM", 189, 196], ["pulmonary alveolar macrophages", "CELL", 197, 227], ["PAMs", "CELL", 229, 233], ["SPF", "ORGANISM", 261, 264], ["pigs", "ORGANISM", 265, 269], ["ATF4", "PROTEIN", 57, 61], ["XBP1s", "PROTEIN", 66, 71], ["primary porcine pulmonary alveolar macrophages", "CELL_TYPE", 181, 227], ["PAMs", "CELL_TYPE", 229, 233], ["PRRSV", "SPECIES", 143, 148], ["porcine", "SPECIES", 189, 196], ["pigs", "SPECIES", 265, 269], ["PRRSV", "SPECIES", 143, 148], ["porcine", "SPECIES", 189, 196], ["ATF4 and XBP1s", "TREATMENT", 57, 71], ["attenuated vaccines", "TREATMENT", 112, 131], ["PRRSV", "PROBLEM", 143, 148], ["primary porcine pulmonary alveolar macrophages (PAMs)", "TREATMENT", 181, 234], ["old SPF pigs", "TREATMENT", 257, 269], ["pulmonary", "ANATOMY", 197, 206], ["alveolar macrophages", "OBSERVATION", 207, 227]]], ["The license number associated with this research protocol was CAU 20120611, which was approved by the Laboratory Animal Ethical Committee of China Agricultural University.Viruses and cellsThe Chinese highly pathogenic PRRSV strain JXwn06 (GenBank accession no: EF641008), low pathogenic PRRSV strain HB1/3.9 (EU360130), the NADC30-like PRRSV CHsx1401 (KP861625) [76, 77] , Porcine epidemic diarrhea virus (PEDV) BJ2011C strain [78] , and Encephalomyocarditis virus (EMCV) strain (BJC3) [79] have been documented previously.Antibodies and chemicalsAntibodies used in this study were obtained from a variety of sources.", [["cells", "ANATOMY", 183, 188], ["CAU 20120611", "CHEMICAL", 62, 74], ["JXwn06", "CHEMICAL", 231, 237], ["Porcine epidemic diarrhea", "DISEASE", 373, 398], ["cells", "CELL", 183, 188], ["PRRSV strain JXwn06", "ORGANISM", 218, 237], ["PRRSV strain HB1", "ORGANISM", 287, 303], ["NADC30-like PRRSV CHsx1401", "ORGANISM", 324, 350], ["Porcine epidemic diarrhea virus", "ORGANISM", 373, 404], ["BJ2011C strain", "ORGANISM", 412, 426], ["Encephalomyocarditis virus", "ORGANISM", 438, 464], ["EMCV", "ORGANISM", 466, 470], ["PRRSV", "SPECIES", 218, 223], ["PRRSV", "SPECIES", 287, 292], ["PRRSV", "SPECIES", 336, 341], ["Porcine epidemic diarrhea virus", "SPECIES", 373, 404], ["Encephalomyocarditis virus", "SPECIES", 438, 464], ["PRRSV CHsx1401 (KP861625)", "SPECIES", 336, 361], ["Porcine epidemic diarrhea virus", "SPECIES", 373, 404], ["PEDV", "SPECIES", 406, 410], ["Encephalomyocarditis virus", "SPECIES", 438, 464], ["EMCV", "SPECIES", 466, 470], ["Viruses", "PROBLEM", 171, 178], ["low pathogenic PRRSV strain", "PROBLEM", 272, 299], ["HB1", "TEST", 300, 303], ["the NADC30", "TEST", 320, 330], ["PRRSV CHsx", "TEST", 336, 346], ["Porcine epidemic diarrhea virus (PEDV) BJ2011C strain", "PROBLEM", 373, 426], ["Encephalomyocarditis virus (EMCV) strain", "PROBLEM", 438, 478], ["Antibodies", "TEST", 523, 533], ["chemicalsAntibodies", "TEST", 538, 557], ["this study", "TEST", 566, 576], ["Encephalomyocarditis virus", "OBSERVATION", 438, 464]]], ["Mouse anti-HA monoclonal antibody (MAb) (#H3663), rabbit anti-Myc polyclonal antibody (PAb) (#C3956) and mouse anti-\u03b2-actin MAb (#A5441) were all purchased from Sigma-Aldrich (MO, USA).", [["Mouse", "ORGANISM", 0, 5], ["anti-HA", "GENE_OR_GENE_PRODUCT", 6, 13], ["rabbit", "ORGANISM", 50, 56], ["anti-Myc", "GENE_OR_GENE_PRODUCT", 57, 65], ["mouse", "ORGANISM", 105, 110], ["Sigma-Aldrich", "ORGANISM", 161, 174], ["Mouse anti-HA monoclonal antibody", "PROTEIN", 0, 33], ["MAb", "PROTEIN", 35, 38], ["#H3663", "PROTEIN", 41, 47], ["rabbit anti-Myc polyclonal antibody", "PROTEIN", 50, 85], ["PAb", "PROTEIN", 87, 90], ["#C3956", "PROTEIN", 93, 99], ["mouse anti-\u03b2-actin MAb", "PROTEIN", 105, 127], ["Mouse", "SPECIES", 0, 5], ["rabbit", "SPECIES", 50, 56], ["mouse", "SPECIES", 105, 110], ["Mouse", "SPECIES", 0, 5], ["rabbit", "SPECIES", 50, 56], ["mouse", "SPECIES", 105, 110], ["Mouse anti-HA monoclonal antibody", "TEST", 0, 33], ["MAb", "TEST", 35, 38], ["rabbit anti-Myc polyclonal antibody", "TEST", 50, 85], ["mouse anti-\u03b2-actin MAb", "TREATMENT", 105, 127]]], ["Rabbit anti-GRP78 MAb (#cs-3177), rabbit anti-PDI PAb (#2446), rabbit anti-PERK MAb (#3192), rabbit anti-eIF2\u03b1 PAb (#cs-5324), and rabbit anti-phospho-eIF2\u03b1 (Ser51) MAb (#cs-5199) were obtained from Cell Signaling Technology (Beverly, MA).", [["Cell", "ANATOMY", 199, 203], ["cs-3177", "CHEMICAL", 24, 31], ["cs-5199", "CHEMICAL", 171, 178], ["Rabbit", "ORGANISM", 0, 6], ["anti-GRP78", "GENE_OR_GENE_PRODUCT", 7, 17], ["rabbit", "ORGANISM", 34, 40], ["anti-PDI PAb", "GENE_OR_GENE_PRODUCT", 41, 53], ["rabbit", "ORGANISM", 63, 69], ["PERK", "GENE_OR_GENE_PRODUCT", 75, 79], ["rabbit", "ORGANISM", 93, 99], ["PAb", "GENE_OR_GENE_PRODUCT", 111, 114], ["#cs-5324", "GENE_OR_GENE_PRODUCT", 116, 124], ["rabbit", "ORGANISM", 131, 137], ["anti-phospho-eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 138, 156], ["Ser51) MAb", "GENE_OR_GENE_PRODUCT", 158, 168], ["Cell", "CELL", 199, 203], ["Rabbit anti-GRP78 MAb", "PROTEIN", 0, 21], ["PDI PAb", "PROTEIN", 46, 53], ["PERK MAb", "PROTEIN", 75, 83], ["#3192", "PROTEIN", 85, 90], ["rabbit anti-eIF2\u03b1", "PROTEIN", 93, 110], ["PAb", "PROTEIN", 111, 114], ["rabbit anti-phospho-eIF2\u03b1 (Ser51) MAb", "PROTEIN", 131, 168], ["Rabbit", "SPECIES", 0, 6], ["rabbit", "SPECIES", 34, 40], ["rabbit", "SPECIES", 63, 69], ["rabbit", "SPECIES", 93, 99], ["rabbit", "SPECIES", 131, 137], ["Rabbit", "SPECIES", 0, 6], ["rabbit", "SPECIES", 34, 40], ["rabbit", "SPECIES", 63, 69], ["rabbit", "SPECIES", 93, 99], ["rabbit", "SPECIES", 131, 137], ["Rabbit", "TEST", 0, 6], ["cs", "TEST", 24, 26], ["rabbit anti-PDI PAb", "TEST", 34, 53], ["rabbit anti-PERK MAb", "TEST", 63, 83], ["PAb", "TEST", 111, 114], ["cs", "TEST", 117, 119], ["rabbit anti-phospho-eIF2", "TEST", 131, 155], ["cs", "TEST", 171, 173]]], ["Rabbit anti-ATF4 PAb (#NBP2-15499) and rabbit anti-XBP1 PAb (#NBP2-20917) were obtained from Novus Biologicals (Littleton, USA).", [["NBP2-15499", "CHEMICAL", 23, 33], ["#NBP2-20917", "CHEMICAL", 61, 72], ["Rabbit", "ORGANISM", 0, 6], ["anti-ATF4", "GENE_OR_GENE_PRODUCT", 7, 16], ["rabbit", "ORGANISM", 39, 45], ["anti-XBP1 PAb", "GENE_OR_GENE_PRODUCT", 46, 59], ["#NBP2-20917", "CELL", 61, 72], ["Rabbit anti-ATF4 PAb", "PROTEIN", 0, 20], ["NBP2", "PROTEIN", 23, 27], ["rabbit anti-XBP1 PAb", "PROTEIN", 39, 59], ["#NBP2", "PROTEIN", 61, 66], ["Rabbit", "SPECIES", 0, 6], ["rabbit", "SPECIES", 39, 45], ["Rabbit", "SPECIES", 0, 6], ["rabbit", "SPECIES", 39, 45], ["Rabbit anti-ATF4 PAb", "TREATMENT", 0, 20], ["NBP2", "TEST", 23, 27], ["rabbit anti-XBP1 PAb", "TEST", 39, 59], ["#NBP2", "TEST", 61, 66]]], ["Rabbit anti-ATF6 PAb (#24169-1-AP), anti-GADD34 PAb (#10449-1-AP), anti-GAPDH PAb (#10494-1-AP) and Histone-H3 PAb (#17168-1-AP) were purchased from Proteintech (Chicago, IL).", [["Rabbit", "ORGANISM", 0, 6], ["anti-ATF6", "GENE_OR_GENE_PRODUCT", 7, 16], ["anti-GADD34 PAb", "SIMPLE_CHEMICAL", 36, 51], ["anti-GAPDH PAb", "SIMPLE_CHEMICAL", 67, 81], ["Histone-H3", "GENE_OR_GENE_PRODUCT", 100, 110], ["Rabbit anti-ATF6 PAb", "PROTEIN", 0, 20], ["#24169-1-AP", "PROTEIN", 22, 33], ["anti-GADD34 PAb", "PROTEIN", 36, 51], ["#10449-1-AP", "PROTEIN", 53, 64], ["anti-GAPDH PAb", "PROTEIN", 67, 81], ["#10494-1-AP", "PROTEIN", 83, 94], ["Histone", "PROTEIN", 100, 107], ["H3 PAb", "PROTEIN", 108, 114], ["AP", "PROTEIN", 125, 127], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit anti-ATF6 PAb", "TREATMENT", 0, 20], ["anti-GADD34 PAb", "TREATMENT", 36, 51], ["anti-GAPDH PAb", "TEST", 67, 81], ["-AP", "TEST", 91, 94], ["Histone", "TEST", 100, 107], ["H3 PAb", "TEST", 108, 114]]], ["Normal mouse IgG used as negative control was purchased from Beyotime (#A7028).", [["mouse", "ORGANISM", 7, 12], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["Normal mouse IgG", "PROTEIN", 0, 16], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12], ["mouse IgG", "OBSERVATION", 7, 16]]], ["Mouse anti-N (PRRSV), anti-nsp1\u03b2 (PRRSV), anti-nsp2 (PRRSV), anti-nsp9 (PRRSV), mouse anti-N (PEDV) and anti-VP2 (EMCV) MAb were produced by our lab at China Agricultural University and used as previously described [81, 82] .Plasmid construction and transfectionThe plasmids expressing nsp1\u03b1, nsp1\u03b2, nsp2, nsp3, nsp4, nsp5, nsp7, nsp8, nsp9, nsp10, nsp11, nsp12, GP2a, GP3, GP4, GP5, M and N were constructed by cloning the corresponding coding region from PRRSV strain JXwn06 genome into the vector pCMV-HA (Clontech, #631604).", [["Plasmid", "ANATOMY", 225, 232], ["plasmids", "ANATOMY", 266, 274], ["Mouse", "ORGANISM", 0, 5], ["anti-N (PRRSV", "ORGANISM", 6, 19], ["anti-nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 22, 32], ["PRRSV", "ORGANISM", 34, 39], ["anti-nsp2", "GENE_OR_GENE_PRODUCT", 42, 51], ["PRRSV", "ORGANISM", 53, 58], ["anti-nsp9", "GENE_OR_GENE_PRODUCT", 61, 70], ["PRRSV", "ORGANISM", 72, 77], ["mouse", "ORGANISM", 80, 85], ["anti-N (PEDV)", "GENE_OR_GENE_PRODUCT", 86, 99], ["anti-VP2", "GENE_OR_GENE_PRODUCT", 104, 112], ["EMCV", "ORGANISM", 114, 118], ["MAb", "GENE_OR_GENE_PRODUCT", 120, 123], ["nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 286, 291], ["nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 293, 298], ["nsp2", "GENE_OR_GENE_PRODUCT", 300, 304], ["nsp3", "GENE_OR_GENE_PRODUCT", 306, 310], ["nsp4", "GENE_OR_GENE_PRODUCT", 312, 316], ["nsp5", "GENE_OR_GENE_PRODUCT", 318, 322], ["nsp7", "GENE_OR_GENE_PRODUCT", 324, 328], ["nsp8", "GENE_OR_GENE_PRODUCT", 330, 334], ["nsp9", "GENE_OR_GENE_PRODUCT", 336, 340], ["nsp10", "GENE_OR_GENE_PRODUCT", 342, 347], ["nsp11", "GENE_OR_GENE_PRODUCT", 349, 354], ["nsp12", "GENE_OR_GENE_PRODUCT", 356, 361], ["GP2a", "GENE_OR_GENE_PRODUCT", 363, 367], ["GP3", "GENE_OR_GENE_PRODUCT", 369, 372], ["GP4", "GENE_OR_GENE_PRODUCT", 374, 377], ["GP5", "GENE_OR_GENE_PRODUCT", 379, 382], ["M", "GENE_OR_GENE_PRODUCT", 384, 385], ["PRRSV", "ORGANISM", 457, 462], ["Mouse anti-N (PRRSV), anti-nsp1\u03b2", "PROTEIN", 0, 32], ["PRRSV", "PROTEIN", 34, 39], ["anti-nsp2", "PROTEIN", 42, 51], ["PRRSV", "PROTEIN", 53, 58], ["anti-nsp9", "PROTEIN", 61, 70], ["PRRSV", "PROTEIN", 72, 77], ["mouse anti", "PROTEIN", 80, 90], ["PEDV", "PROTEIN", 94, 98], ["anti-VP2 (EMCV) MAb", "PROTEIN", 104, 123], ["plasmids", "DNA", 266, 274], ["nsp1\u03b1", "PROTEIN", 286, 291], ["nsp1\u03b2", "DNA", 293, 298], ["nsp2", "DNA", 300, 304], ["nsp3", "DNA", 306, 310], ["nsp4", "DNA", 312, 316], ["nsp5", "DNA", 318, 322], ["nsp7", "DNA", 324, 328], ["nsp8", "DNA", 330, 334], ["nsp9", "DNA", 336, 340], ["nsp10", "DNA", 342, 347], ["nsp11", "DNA", 349, 354], ["nsp12", "DNA", 356, 361], ["GP2a", "DNA", 363, 367], ["GP3", "DNA", 369, 372], ["GP4", "DNA", 374, 377], ["GP5", "DNA", 379, 382], ["M", "DNA", 384, 385], ["N", "DNA", 390, 391], ["PRRSV strain JXwn06 genome", "DNA", 457, 483], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 80, 85], ["Mouse", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 14, 19], ["PRRSV", "SPECIES", 34, 39], ["PRRSV", "SPECIES", 53, 58], ["PRRSV", "SPECIES", 72, 77], ["mouse", "SPECIES", 80, 85], ["PEDV", "SPECIES", 94, 98], ["EMCV", "SPECIES", 114, 118], ["PRRSV strain JXwn06", "SPECIES", 457, 476], ["Mouse anti-N (PRRSV)", "TREATMENT", 0, 20], ["anti-nsp1\u03b2 (PRRSV)", "TREATMENT", 22, 40], ["anti-nsp2 (PRRSV)", "TREATMENT", 42, 59], ["anti-nsp9 (PRRSV)", "TREATMENT", 61, 78], ["mouse anti-N (PEDV)", "TREATMENT", 80, 99], ["anti-VP2 (EMCV) MAb", "TREATMENT", 104, 123], ["Plasmid construction", "TREATMENT", 225, 245], ["The plasmids", "TEST", 262, 274], ["nsp1", "TEST", 286, 290], ["nsp1", "TEST", 293, 297], ["nsp2", "TEST", 300, 304], ["nsp3", "TEST", 306, 310], ["nsp4", "TEST", 312, 316], ["nsp5", "TEST", 318, 322], ["nsp7", "TEST", 324, 328], ["nsp8", "TEST", 330, 334], ["nsp9", "TEST", 336, 340], ["nsp10", "TEST", 342, 347], ["nsp11", "TEST", 349, 354], ["nsp12", "TEST", 356, 361], ["GP2a", "TEST", 363, 367], ["GP3", "TEST", 369, 372], ["GP4", "TEST", 374, 377], ["GP5", "TEST", 379, 382], ["HA", "PROBLEM", 505, 507], ["nsp2", "ANATOMY_MODIFIER", 300, 304], ["nsp3", "ANATOMY_MODIFIER", 306, 310], ["nsp4", "ANATOMY_MODIFIER", 312, 316], ["nsp5", "ANATOMY_MODIFIER", 318, 322], ["nsp7", "ANATOMY_MODIFIER", 324, 328], ["nsp8", "ANATOMY_MODIFIER", 330, 334]]], ["GP2a\u0394E-HA was created by introducing the corresponding mutations into the plasmid pGP2a-HA with the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies, #200523).", [["GP2a\u0394E-HA", "GENE_OR_GENE_PRODUCT", 0, 9], ["GP2a\u0394E", "PROTEIN", 0, 6], ["pGP2a", "DNA", 82, 87], ["the QuikChange Site", "TREATMENT", 96, 115]]], ["The ATF4 gene from MARC-145 cells was cloned into the vector pGEX-6P-1 (GE healthcare #28-9546-48) for expression of the fusion protein GST-ATF4 in E. coli BL21 cells (Takara, #9126).", [["MARC-145 cells", "ANATOMY", 19, 33], ["cells", "ANATOMY", 161, 166], ["ATF4", "GENE_OR_GENE_PRODUCT", 4, 8], ["MARC-145 cells", "CELL", 19, 33], ["GST", "GENE_OR_GENE_PRODUCT", 136, 139], ["ATF4", "GENE_OR_GENE_PRODUCT", 140, 144], ["E. coli BL21 cells", "CELL", 148, 166], ["Takara", "CELL", 168, 174], ["ATF4 gene", "DNA", 4, 13], ["MARC-145 cells", "CELL_LINE", 19, 33], ["vector pGEX-6P-1", "DNA", 54, 70], ["fusion protein", "PROTEIN", 121, 135], ["GST", "PROTEIN", 136, 139], ["ATF4", "PROTEIN", 140, 144], ["E. coli BL21 cells", "CELL_LINE", 148, 166], ["E. coli BL21", "SPECIES", 148, 160], ["MARC-145", "SPECIES", 19, 27], ["E. coli", "SPECIES", 148, 155], ["the fusion protein GST", "TEST", 117, 139], ["ATF4 in E. coli BL21 cells", "PROBLEM", 140, 166], ["coli BL21 cells", "OBSERVATION", 151, 166]]], ["Transfection of plasmid was performed with Lipofectamine\u2122 LTX Reagent (Thermo Fisher, #A12621) according to the manufacturer's instructions.Preparation of nuclear and cytoplasmic fractionsMARC-145 cells were infected with PRRSV strain JXwn06 at an MOI of 0.1.", [["plasmid", "ANATOMY", 16, 23], ["nuclear", "ANATOMY", 155, 162], ["cytoplasmic fractionsMARC-145 cells", "ANATOMY", 167, 202], ["nuclear", "CELLULAR_COMPONENT", 155, 162], ["cytoplasmic", "ORGANISM_SUBSTANCE", 167, 178], ["fractionsMARC-145 cells", "CELL", 179, 202], ["PRRSV", "ORGANISM", 222, 227], ["nuclear and cytoplasmic fractionsMARC-145 cells", "CELL_LINE", 155, 202], ["PRRSV", "SPECIES", 222, 227], ["Transfection of plasmid", "TREATMENT", 0, 23], ["Lipofectamine", "TREATMENT", 43, 56], ["nuclear and cytoplasmic fractionsMARC", "TEST", 155, 192], ["an MOI", "TEST", 245, 251]]], ["At 36 hpi, the cells were washed twice with cold phosphate-buffered saline (PBS) (140 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ), harvested with trypsin-EDTA digestion, and then centrifuged at 2, 000 rpm for 5 minutes.", [["cells", "ANATOMY", 15, 20], ["phosphate", "CHEMICAL", 49, 58], ["NaCl", "CHEMICAL", 89, 93], ["KCl", "CHEMICAL", 102, 105], ["Na", "CHEMICAL", 113, 115], ["trypsin-EDTA", "CHEMICAL", 161, 173], ["phosphate", "CHEMICAL", 49, 58], ["NaCl", "CHEMICAL", 89, 93], ["KCl", "CHEMICAL", 102, 105], ["Na 2 HPO 4", "CHEMICAL", 113, 123], ["KH 2 PO 4", "CHEMICAL", 133, 142], ["trypsin-EDTA", "CHEMICAL", 161, 173], ["cells", "CELL", 15, 20], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 49, 74], ["trypsin-", "SIMPLE_CHEMICAL", 161, 169], ["cold phosphate", "TREATMENT", 44, 58], ["buffered saline (PBS", "TREATMENT", 59, 79], ["NaCl", "TEST", 89, 93], ["KCl", "TEST", 102, 105], ["Na", "TEST", 113, 115], ["HPO", "TEST", 118, 121], ["trypsin-EDTA digestion", "TREATMENT", 161, 183]]], ["The cell pellets were resuspended with PBS, and the cytoplasmic and nuclear fractions were prepared by using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher, #78833), following the manufacturer's instruction.", [["cell", "ANATOMY", 4, 8], ["cytoplasmic", "ANATOMY", 52, 63], ["nuclear fractions", "ANATOMY", 68, 85], ["NE", "CHEMICAL", 109, 111], ["cell", "CELL", 4, 8], ["cytoplasmic", "ORGANISM_SUBSTANCE", 52, 63], ["NE", "PROTEIN", 109, 111], ["The cell pellets", "TREATMENT", 0, 16], ["PBS", "TREATMENT", 39, 42], ["cell pellets", "OBSERVATION", 4, 16]]], ["GAPDH and Histone-H3 were used as the respective cytoplasmic and nuclear makers for monitoring fraction quality by Western blot.XBP1 mRNA splicing assayTotal RNAs from cultured cells were extracted with TRIzol reagent (Thermo Fisher, #15596026) according to the manufacturer's instruction.", [["cytoplasmic", "ANATOMY", 49, 60], ["nuclear", "ANATOMY", 65, 72], ["cells", "ANATOMY", 177, 182], ["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["Histone-H3", "GENE_OR_GENE_PRODUCT", 10, 20], ["cytoplasmic", "ORGANISM_SUBSTANCE", 49, 60], ["XBP1", "GENE_OR_GENE_PRODUCT", 128, 132], ["cells", "CELL", 177, 182], ["GAPDH", "PROTEIN", 0, 5], ["Histone", "PROTEIN", 10, 17], ["H3", "PROTEIN", 18, 20], ["XBP1 mRNA", "RNA", 128, 137], ["assayTotal RNAs", "RNA", 147, 162], ["cultured cells", "CELL_LINE", 168, 182], ["GAPDH", "PROBLEM", 0, 5], ["Histone-H3", "TREATMENT", 10, 20], ["monitoring fraction quality", "TEST", 84, 111], ["XBP1 mRNA splicing assayTotal RNAs", "PROBLEM", 128, 162], ["cultured cells", "TEST", 168, 182], ["TRIzol reagent", "TREATMENT", 203, 217], ["assayTotal RNAs", "OBSERVATION", 147, 162]]], ["The concentration of the extracted RNA was measured using a NanoDrop 1000 spectrophotometer (Thermo Fisher).", [["the extracted RNA", "TREATMENT", 21, 38], ["a NanoDrop 1000 spectrophotometer", "TREATMENT", 58, 91], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["Reverse transcription was performed using a FastKing RT Kit (with gDNase) (TIANGEN, #KR116-02) following the user guide.", [["gDNase", "PROTEIN", 66, 72], ["a FastKing RT Kit", "TREATMENT", 42, 59], ["KR116", "TEST", 85, 90]]], ["The XBP1 gene was amplified by PCR with the forward primer (F1) 5'-AAACAGAGTAGCAGCGCAGACTGC-3' and the reverse primer (R1) 5'-GGATCTCTAA GACTAGAGGCTTGGTG-3'.", [["XBP1", "GENE_OR_GENE_PRODUCT", 4, 8], ["XBP1 gene", "DNA", 4, 13], ["reverse primer (R1) 5'-GGATCTCTAA GACTAGAGGCTTGGTG-3", "DNA", 103, 155], ["PCR", "TEST", 31, 34], ["the forward primer", "TEST", 40, 58], ["AAACAGAGTAGCAGCGCAGACTGC", "TEST", 67, 91], ["GACTAGAGGCTTGGTG", "TEST", 137, 153]]], ["To resolve the spliced forms (XBP1s) and unspliced (XBP1u) of XBP1, the PCR products were digested with the restriction enzyme Pst I-HF 1 (NEB, #R31 40L) and separated on the 1.5% agarose gel.Quantitative PCRThe cDNA was synthesized from the total cellular RNA by reverse transcription using the indicated primers.", [["cellular", "ANATOMY", 248, 256], ["XBP1s", "GENE_OR_GENE_PRODUCT", 30, 35], ["XBP1u", "GENE_OR_GENE_PRODUCT", 52, 57], ["XBP1", "GENE_OR_GENE_PRODUCT", 62, 66], ["agarose", "SIMPLE_CHEMICAL", 180, 187], ["cellular", "CELL", 248, 256], ["spliced forms", "RNA", 15, 28], ["XBP1s", "PROTEIN", 30, 35], ["XBP1u", "PROTEIN", 52, 57], ["XBP1", "PROTEIN", 62, 66], ["restriction enzyme", "PROTEIN", 108, 126], ["Pst I", "PROTEIN", 127, 132], ["HF 1", "PROTEIN", 133, 137], ["NEB", "PROTEIN", 139, 142], ["R31 40L", "PROTEIN", 145, 152], ["PCRThe cDNA", "DNA", 205, 216], ["cellular RNA", "RNA", 248, 260], ["XBP1", "TEST", 62, 66], ["the PCR products", "TREATMENT", 68, 84], ["HF", "TEST", 133, 135], ["NEB", "TEST", 139, 142], ["the 1.5% agarose gel", "TREATMENT", 171, 191], ["Quantitative PCRThe cDNA", "TEST", 192, 216], ["the total cellular RNA", "TREATMENT", 238, 260], ["spliced", "OBSERVATION", 15, 22], ["total", "OBSERVATION_MODIFIER", 242, 247], ["cellular RNA", "OBSERVATION", 248, 260]]], ["The relative quantitative PCR (qPCR) was performed with the Applied Biosys-tems\u2122 SYBR\u2122 Select Master Mix (Thermo Fisher, #4472913) according to the manufacturer's recommendations.", [["The relative quantitative PCR", "TEST", 0, 29]]], ["The PCR was assembled in a 20 \u03bcL reaction containing 0.2 \u03bcM gene specific primer, 10 \u03bcL SYBR\u2122 Select Master Mix, and 2 \u03bcL cDNA template.", [["Master Mix", "DNA", 101, 111], ["cDNA template", "DNA", 122, 135], ["The PCR", "TEST", 0, 7], ["a 20 \u03bcL reaction", "TREATMENT", 25, 41], ["Select Master Mix", "TREATMENT", 94, 111], ["2 \u03bcL cDNA template", "TREATMENT", 117, 135]]], ["The PCR parameter was set up as follows: 50\u02daC for 2 min, 95\u02daC for 2 min; 40 cycles of 95\u02daC for 15 s, 60\u02daC for 15 s, and 72\u02daC for 60 s.", [["The PCR parameter", "TEST", 0, 17]]], ["To measure viral total RNA, a pair of internal primers in the ORF7 gene were used to amplify all sgmRNAs and gRNA.", [["ORF7", "GENE_OR_GENE_PRODUCT", 62, 66], ["sgmRNAs", "GENE_OR_GENE_PRODUCT", 97, 104], ["viral total RNA", "RNA", 11, 26], ["ORF7 gene", "DNA", 62, 71], ["sgmRNAs", "DNA", 97, 104], ["gRNA", "RNA", 109, 113], ["viral total RNA", "PROBLEM", 11, 26], ["internal primers", "TREATMENT", 38, 54], ["gRNA", "PROBLEM", 109, 113], ["viral total RNA", "OBSERVATION", 11, 26], ["internal primers", "OBSERVATION", 38, 54], ["gRNA", "OBSERVATION", 109, 113]]], ["To measure gRNA and each viral sgmRNA, a pair primers in the corresponding ORF were used for the qPCR.", [["sgmRNA", "GENE_OR_GENE_PRODUCT", 31, 37], ["gRNA", "RNA", 11, 15], ["viral sgmRNA", "DNA", 25, 37], ["ORF", "DNA", 75, 78], ["gRNA", "TREATMENT", 11, 15], ["each viral sgmRNA", "PROBLEM", 20, 37], ["a pair primers", "TREATMENT", 39, 53], ["the qPCR", "TEST", 93, 101], ["gRNA", "OBSERVATION", 11, 15], ["viral sgmRNA", "OBSERVATION", 25, 37]]], ["The cellular GAPDH was quantified as the internal control to normalize the cDNA amounts.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["GAPDH", "GENE_OR_GENE_PRODUCT", 13, 18], ["cellular GAPDH", "PROTEIN", 4, 18], ["The cellular GAPDH", "PROBLEM", 0, 18], ["cellular GAPDH", "OBSERVATION", 4, 18], ["cDNA amounts", "OBSERVATION", 75, 87]]], ["The 2 -\u0394\u0394CT method was used to calculate the relative abundance of target genes compared to GAPDH.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 92, 97], ["target genes", "DNA", 67, 79], ["GAPDH", "PROTEIN", 92, 97], ["The 2 -\u0394\u0394CT method", "TREATMENT", 0, 18], ["target genes", "OBSERVATION", 67, 79]]], ["The primers used for qPCR are listed in S2 and S3 Tables.Lentivirus transductionThe lentiviral packaging system containing plasmids pWPXL (#12257), pMD2.G (#12259) and psPAX2 (#12260) was purchased from Addgene.", [["plasmids", "ANATOMY", 123, 131], ["Lentivirus", "ORGANISM", 57, 67], ["lentiviral", "ORGANISM", 84, 94], ["Addgene", "GENE_OR_GENE_PRODUCT", 203, 210], ["plasmids pWPXL", "DNA", 123, 137], ["pMD2", "DNA", 148, 152], ["Lentivirus", "SPECIES", 57, 67], ["The primers", "TREATMENT", 0, 11], ["qPCR", "TEST", 21, 25], ["Lentivirus transduction", "TREATMENT", 57, 80], ["The lentiviral packaging system", "TREATMENT", 80, 111], ["lentiviral packaging", "OBSERVATION", 84, 104]]], ["The genes coding for XBP1s and ATF4 were cloned from MARC-145 cells into the plasmid pWPXL and expressed as c-Myc epitope fusion protein (XBP1s-myc and ATF4-myc).", [["MARC-145 cells", "ANATOMY", 53, 67], ["plasmid", "ANATOMY", 77, 84], ["XBP1s", "GENE_OR_GENE_PRODUCT", 21, 26], ["ATF4", "GENE_OR_GENE_PRODUCT", 31, 35], ["MARC-145 cells", "CELL", 53, 67], ["pWPXL", "GENE_OR_GENE_PRODUCT", 85, 90], ["c-Myc", "GENE_OR_GENE_PRODUCT", 108, 113], ["XBP1s-myc", "GENE_OR_GENE_PRODUCT", 138, 147], ["ATF4-myc", "GENE_OR_GENE_PRODUCT", 152, 160], ["XBP1s", "PROTEIN", 21, 26], ["ATF4", "PROTEIN", 31, 35], ["MARC-145 cells", "CELL_LINE", 53, 67], ["plasmid pWPXL", "DNA", 77, 90], ["c-Myc epitope fusion protein", "PROTEIN", 108, 136], ["XBP1s", "PROTEIN", 138, 143], ["myc", "PROTEIN", 144, 147], ["ATF4", "PROTEIN", 152, 156], ["myc", "PROTEIN", 157, 160], ["XBP1s", "TEST", 21, 26], ["ATF4", "TEST", 31, 35], ["the plasmid pWPXL", "TREATMENT", 73, 90], ["Myc epitope fusion protein", "TEST", 110, 136], ["XBP1s", "TEST", 138, 143]]], ["The recombinant viruses were rescued by co-transfecting the three plasmids into HEK-293FT cells.", [["plasmids", "ANATOMY", 66, 74], ["HEK-293FT cells", "ANATOMY", 80, 95], ["HEK-293FT cells", "CELL", 80, 95], ["plasmids", "DNA", 66, 74], ["HEK-293FT cells", "CELL_LINE", 80, 95], ["The recombinant viruses", "PROBLEM", 0, 23], ["viruses", "OBSERVATION", 16, 23]]], ["At 36 h post-transfection, the supernatants containing lentiviruses were harvested, filtered and concentrated.", [["supernatants", "ANATOMY", 31, 43], ["lentiviruses", "ORGANISM", 55, 67], ["transfection", "TREATMENT", 13, 25], ["the supernatants containing lentiviruses", "TREATMENT", 27, 67], ["lentiviruses", "OBSERVATION", 55, 67]]], ["Titers of the lentiviruses were determined using a QuickTiter\u2122 Lentivirus Titer Kit according to the manufacturer's instruction (Cell Biolabs, #VPK-107).", [["Cell", "ANATOMY", 129, 133], ["lentiviruses", "ORGANISM", 14, 26], ["Lentivirus", "ORGANISM", 63, 73], ["Cell", "CELL", 129, 133], ["Lentivirus", "SPECIES", 63, 73], ["a QuickTiter\u2122 Lentivirus Titer Kit", "TREATMENT", 49, 83], ["Cell Biolabs", "TEST", 129, 141], ["VPK", "TEST", 144, 147]]], ["MARC-145 cells in 24-well plates were transduced with 1\u00d710 6 Lentiviral Particle (LP).", [["MARC-145 cells", "ANATOMY", 0, 14], ["MARC-145", "CHEMICAL", 0, 8], ["MARC-145 cells", "CELL", 0, 14], ["Lentiviral", "ORGANISM", 61, 71], ["MARC-145 cells", "CELL_LINE", 0, 14], ["1\u00d710 6 Lentiviral Particle (LP)", "TREATMENT", 54, 85], ["145 cells", "OBSERVATION_MODIFIER", 5, 14]]], ["At 36 h post-transduction, the cells were infected with PRRSV strain JXwn06 at an MOI of 0.1.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["PRRSV", "ORGANISM", 56, 61], ["PRRSV", "SPECIES", 56, 61], ["the cells", "PROBLEM", 27, 36], ["an MOI", "TEST", 79, 85]]], ["The expression level of XBP1s and ATF4 was assessed by Western blotting with rabbit anti-myc polyclonal antibodies to measure the effect of overexpression of ATF4 and XBP1s on viral replication, and the total virus titer was assessed by end point dilution assay.RNA interference assayFor RNA interference, small interfering RNAs (siRNAs) was designed to target two different coding regions for each given gene.", [["XBP1s", "GENE_OR_GENE_PRODUCT", 24, 29], ["ATF4", "GENE_OR_GENE_PRODUCT", 34, 38], ["rabbit", "ORGANISM", 77, 83], ["ATF4", "GENE_OR_GENE_PRODUCT", 158, 162], ["XBP1s", "GENE_OR_GENE_PRODUCT", 167, 172], ["XBP1s", "PROTEIN", 24, 29], ["ATF4", "PROTEIN", 34, 38], ["rabbit anti-myc polyclonal antibodies", "PROTEIN", 77, 114], ["ATF4", "PROTEIN", 158, 162], ["XBP1s", "PROTEIN", 167, 172], ["small interfering RNAs", "RNA", 306, 328], ["siRNAs", "RNA", 330, 336], ["coding regions", "DNA", 375, 389], ["rabbit", "SPECIES", 77, 83], ["rabbit", "SPECIES", 77, 83], ["XBP1s", "TEST", 24, 29], ["ATF4", "TEST", 34, 38], ["rabbit anti-myc polyclonal antibodies", "TREATMENT", 77, 114], ["overexpression of ATF4", "PROBLEM", 140, 162], ["XBP1s", "TREATMENT", 167, 172], ["viral replication", "TREATMENT", 176, 193], ["the total virus titer", "TEST", 199, 220], ["RNA interference assay", "TEST", 262, 284], ["RNA interference", "PROBLEM", 288, 304], ["small interfering RNAs (siRNAs)", "PROBLEM", 306, 337], ["small", "OBSERVATION_MODIFIER", 306, 311], ["interfering RNAs", "OBSERVATION", 312, 328]]], ["The sequences of siRNAs are listed in S1 Table. siRNAs were transfected with Lipofectamine 1 RNAiMAX (Thermo Fisher, #13778150) according to the manufacturer's instruction.", [["siRNAs", "DNA", 17, 23], ["siRNAs", "TREATMENT", 48, 54], ["Lipofectamine", "TREATMENT", 77, 90]]], ["Cell viability was assessed at 36 h post transfection with CellTiter 96 1 AQueous One Solution Reagent (Promega, #G3582), and the knockdown effect was examined by Western blot analyses of the whole cell lysate with antibodies to ATF4, ATF6, GRP78 or XBP1s, and \u03b2-actin was used as a loading control.", [["Cell", "ANATOMY", 0, 4], ["cell lysate", "ANATOMY", 198, 209], ["Cell", "CELL", 0, 4], ["cell lysate", "ORGANISM_SUBSTANCE", 198, 209], ["ATF4", "GENE_OR_GENE_PRODUCT", 229, 233], ["ATF6", "GENE_OR_GENE_PRODUCT", 235, 239], ["GRP78", "GENE_OR_GENE_PRODUCT", 241, 246], ["XBP1s", "GENE_OR_GENE_PRODUCT", 250, 255], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 261, 268], ["antibodies", "PROTEIN", 215, 225], ["ATF4", "PROTEIN", 229, 233], ["ATF6", "PROTEIN", 235, 239], ["GRP78", "PROTEIN", 241, 246], ["XBP1s", "PROTEIN", 250, 255], ["\u03b2-actin", "PROTEIN", 261, 268], ["Cell viability", "TEST", 0, 14], ["CellTiter", "TEST", 59, 68], ["the knockdown effect", "PROBLEM", 126, 146], ["the whole cell lysate", "TREATMENT", 188, 209], ["ATF4", "TEST", 229, 233], ["ATF6", "TEST", 235, 239], ["GRP78", "TEST", 241, 246], ["XBP1s", "TREATMENT", 250, 255], ["\u03b2-actin", "TREATMENT", 261, 268], ["a loading control", "TREATMENT", 281, 298]]], ["For transfection/infection assay, MARC-145 cells were infected with PRRSV strain JXwn06 at 36 h post transfection of siRNAs, and total viruses were collected at the indicated time points for titration, and total RNAs were extracted for analyzing the viral RNA abundance by relative qPCR.Western blot analysisThe amount of total cellular proteins was quantified by using Pierce\u2122 BCA Protein Assay Kit (Thermo Fisher, #23225), and 20-30 \u03bcg of the whole lysate per sample was subject to western blot analysis.", [["MARC-145 cells", "ANATOMY", 34, 48], ["cellular", "ANATOMY", 328, 336], ["lysate", "ANATOMY", 451, 457], ["sample", "ANATOMY", 462, 468], ["infection", "DISEASE", 17, 26], ["MARC-145 cells", "CELL", 34, 48], ["PRRSV", "ORGANISM", 68, 73], ["cellular", "CELL", 328, 336], ["MARC-145 cells", "CELL_LINE", 34, 48], ["total RNAs", "RNA", 206, 216], ["viral RNA", "RNA", 250, 259], ["total cellular proteins", "PROTEIN", 322, 345], ["PRRSV", "SPECIES", 68, 73], ["MARC-145", "SPECIES", 34, 42], ["PRRSV", "SPECIES", 68, 73], ["transfection/infection assay", "PROBLEM", 4, 32], ["PRRSV strain JXwn06", "TREATMENT", 68, 87], ["transfection of siRNAs", "TREATMENT", 101, 123], ["total viruses", "PROBLEM", 129, 142], ["titration", "TREATMENT", 191, 200], ["total RNAs", "TREATMENT", 206, 216], ["analyzing the viral RNA abundance", "PROBLEM", 236, 269], ["blot analysis", "TEST", 295, 308], ["total cellular proteins", "PROBLEM", 322, 345], ["the whole lysate", "TREATMENT", 441, 457], ["blot analysis", "TEST", 492, 505], ["infection", "OBSERVATION", 17, 26], ["siRNAs", "ANATOMY", 117, 123], ["viral RNA", "OBSERVATION", 250, 259], ["amount", "OBSERVATION_MODIFIER", 312, 318], ["total", "OBSERVATION_MODIFIER", 322, 327], ["cellular proteins", "OBSERVATION", 328, 345]]], ["Briefly, the protein samples were separated by SDS-PAGE, transferred onto PVDF membranes, blocked with PBST (PBS with 0.05% Tween-20) containing 5% milk for 1.5 h, and then probed with appropriate primary antibodies at room temperature.", [["samples", "ANATOMY", 21, 28], ["PVDF membranes", "ANATOMY", 74, 88], ["milk", "ANATOMY", 148, 152], ["Tween-20", "CHEMICAL", 124, 132], ["PVDF", "CHEMICAL", 74, 78], ["Tween-20", "CHEMICAL", 124, 132], ["membranes", "CELLULAR_COMPONENT", 79, 88], ["Tween-20", "SIMPLE_CHEMICAL", 124, 132], ["milk", "ORGANISM_SUBSTANCE", 148, 152], ["primary antibodies", "PROTEIN", 197, 215], ["the protein samples", "TEST", 9, 28], ["PVDF membranes", "TREATMENT", 74, 88], ["PBST (PBS", "TREATMENT", 103, 112]]], ["For detection of phosphorylated proteins, bovine serum albumin (BSA) was used instead of milk.", [["serum", "ANATOMY", 49, 54], ["milk", "ANATOMY", 89, 93], ["bovine", "ORGANISM", 42, 48], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["albumin", "GENE_OR_GENE_PRODUCT", 55, 62], ["BSA", "SIMPLE_CHEMICAL", 64, 67], ["milk", "ORGANISM_SUBSTANCE", 89, 93], ["phosphorylated proteins", "PROTEIN", 17, 40], ["bovine", "SPECIES", 42, 48], ["bovine", "SPECIES", 42, 48], ["phosphorylated proteins", "PROBLEM", 17, 40], ["bovine serum albumin (BSA)", "TEST", 42, 68]]], ["The membranes were then washed with PBST and incubated with appropriate HRP-conjugated secondary antibodies with dilution ratio 1:10, 000.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["HRP", "SIMPLE_CHEMICAL", 72, 75], ["HRP", "PROTEIN", 72, 75], ["PBST", "TREATMENT", 36, 40], ["appropriate HRP", "TEST", 60, 75], ["dilution ratio", "TEST", 113, 127]]], ["The membranes were again washed and then developed with the Pierce ECL Western blot substrate (Thermo Fisher, #32209).Co-immunoprecipitation (Co-IP)MARC-145 cells in six-well plates were infected with PRRSV strain JXwn06 at an MOI of 0.1.", [["membranes", "ANATOMY", 4, 13], ["Co-IP)MARC-145 cells", "ANATOMY", 142, 162], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["MARC-145 cells", "CELL", 148, 162], ["PRRSV", "ORGANISM", 201, 206], ["Co-IP)MARC-145 cells", "CELL_LINE", 142, 162], ["PRRSV", "SPECIES", 201, 206], ["Co-immunoprecipitation", "TEST", 118, 140], ["MARC", "TEST", 148, 152], ["PRRSV strain JXwn06", "PROBLEM", 201, 220], ["an MOI", "TEST", 224, 230], ["infected", "OBSERVATION", 187, 195], ["PRRSV strain", "OBSERVATION", 201, 213]]], ["At 24 hpi, the cells were harvested and lysed in NP-40 lysis buffer (0.5% NP-40, 150 mM NaCl, 50 mM Tris-HCl pH 8.0) containing protease inhibitor (Sigma, #P8340).", [["cells", "ANATOMY", 15, 20], ["NP-40", "CHEMICAL", 74, 79], ["NaCl", "CHEMICAL", 88, 92], ["Tris-HCl", "CHEMICAL", 100, 108], ["NaCl", "CHEMICAL", 88, 92], ["Tris-HCl", "CHEMICAL", 100, 108], ["cells", "CELL", 15, 20], ["Tris-HCl", "SIMPLE_CHEMICAL", 100, 108], ["NP-40 lysis buffer", "TREATMENT", 49, 67], ["NP", "TEST", 74, 76], ["NaCl", "TREATMENT", 88, 92], ["Tris", "TEST", 100, 104], ["HCl pH", "TEST", 105, 111], ["protease inhibitor", "TREATMENT", 128, 146]]], ["After clarifying by centrifugation at 12, 000 rpm for 20 min, the supernatants were precleared with protein A/G sepharose beads (Santa Cruz, #sc-2003) and then incubated with 5 \u03bcL mouse anti-nsp2 MAb (mouse isotype antibody as a negative controls) and 25 \u03bcL protein A&G sepharose beads overnight at 4\u02daC with gentle rotation.", [["supernatants", "ANATOMY", 66, 78], ["mouse", "ORGANISM", 180, 185], ["anti-nsp2", "GENE_OR_GENE_PRODUCT", 186, 195], ["mouse", "ORGANISM", 201, 206], ["anti-nsp2 MAb", "PROTEIN", 186, 199], ["mouse isotype antibody", "PROTEIN", 201, 223], ["A&G", "PROTEIN", 266, 269], ["mouse", "SPECIES", 180, 185], ["mouse", "SPECIES", 201, 206], ["mouse", "SPECIES", 180, 185], ["mouse", "SPECIES", 201, 206], ["the supernatants", "TEST", 62, 78], ["protein A/G sepharose beads", "TREATMENT", 100, 127], ["5 \u03bcL mouse anti-nsp2 MAb", "TREATMENT", 175, 199], ["mouse isotype antibody", "TEST", 201, 223], ["25 \u03bcL protein A&G sepharose beads", "TREATMENT", 252, 285], ["gentle rotation", "TREATMENT", 308, 323]]], ["The beads were washed five times with the NP-40 lysis buffer, and the proteins bounded to the beads were separated by SDS-PAGE, followed by western blot analysis.Confocal microscopyMARC-145 cells grown to 60-70% confluence on coverslips in six-well plates were infected with strain JXwn06 at an MOI of 0.1.", [["beads", "ANATOMY", 4, 9], ["microscopyMARC-145 cells", "ANATOMY", 171, 195], ["coverslips", "ANATOMY", 226, 236], ["microscopyMARC-145", "CHEMICAL", 171, 189], ["microscopyMARC-145 cells", "CELL", 171, 195], ["microscopyMARC-145 cells", "CELL_LINE", 171, 195], ["The beads", "TREATMENT", 0, 9], ["the NP-40 lysis buffer", "TREATMENT", 38, 60], ["blot analysis", "TEST", 148, 161], ["Confocal microscopyMARC", "TEST", 162, 185], ["cells", "TEST", 190, 195], ["coverslips in six-well plates", "TEST", 226, 255], ["strain JXwn06", "PROBLEM", 275, 288], ["an MOI", "TEST", 292, 298], ["beads", "OBSERVATION_MODIFIER", 4, 9], ["145 cells", "OBSERVATION_MODIFIER", 186, 195], ["confluence", "OBSERVATION_MODIFIER", 212, 222]]], ["At indicated time points post infection, the cells were fixed with 3.7% paraformaldehyde for 10 min at room temperature, permeabilized with PBS containing 0.2% Triton X-100 and 2% bovine serum albumin (BSA) for 10 min, and then blocked with 2% BSA-PBS (2% bovine serum albumin in PBS) for 30 min.", [["cells", "ANATOMY", 45, 50], ["serum", "ANATOMY", 187, 192], ["serum", "ANATOMY", 263, 268], ["infection", "DISEASE", 30, 39], ["paraformaldehyde", "CHEMICAL", 72, 88], ["Triton X-100", "CHEMICAL", 160, 172], ["BSA", "CHEMICAL", 244, 247], ["paraformaldehyde", "CHEMICAL", 72, 88], ["cells", "CELL", 45, 50], ["paraformaldehyde", "SIMPLE_CHEMICAL", 72, 88], ["Triton X-100", "SIMPLE_CHEMICAL", 160, 172], ["bovine", "ORGANISM", 180, 186], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["albumin", "SIMPLE_CHEMICAL", 193, 200], ["BSA", "SIMPLE_CHEMICAL", 202, 205], ["BSA-PBS", "SIMPLE_CHEMICAL", 244, 251], ["bovine", "ORGANISM", 256, 262], ["serum", "ORGANISM_SUBSTANCE", 263, 268], ["albumin", "SIMPLE_CHEMICAL", 269, 276], ["bovine", "SPECIES", 180, 186], ["bovine", "SPECIES", 256, 262], ["bovine", "SPECIES", 180, 186], ["infection", "PROBLEM", 30, 39], ["the cells", "PROBLEM", 41, 50], ["3.7% paraformaldehyde", "TREATMENT", 67, 88], ["PBS", "TREATMENT", 140, 143], ["2% bovine serum albumin (BSA", "TREATMENT", 177, 205], ["PBS", "TEST", 248, 251], ["2% bovine serum albumin in PBS", "TREATMENT", 253, 283], ["infection", "OBSERVATION", 30, 39]]], ["The cells were then incubated with primary antibodies as indicated in a humid chamber for 1 h at room temperature or overnight at 4\u02daC. After being washed 3 times with PBS for 5 min each, the cells were incubated with appropriate second antibody (Alexa 488, 647 or 568-conjugated) for additional 1 h.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 191, 196], ["Alexa 488", "CHEMICAL", 246, 255], ["cells", "CELL", 4, 9], ["cells", "CELL", 191, 196], ["Alexa 488", "SIMPLE_CHEMICAL", 246, 255], ["568-conjugated", "SIMPLE_CHEMICAL", 264, 278], ["primary antibodies", "PROTEIN", 35, 53], ["Alexa 488", "PROTEIN", 246, 255], ["primary antibodies", "TREATMENT", 35, 53], ["a humid chamber", "TREATMENT", 70, 85], ["PBS", "TREATMENT", 167, 170]]], ["Nuclear DNA was stained with 4',6-diamidino-2-phenylindole (DAPI) (Thermo Fisher, #62248) for 10 min and then washed with PBS three times for 5 min each.", [["Nuclear", "ANATOMY", 0, 7], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 29, 58], ["4',6-diamidino-2-phenylindole", "CHEMICAL", 29, 58], ["DAPI", "CHEMICAL", 60, 64], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["4',6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 29, 58], ["DAPI", "SIMPLE_CHEMICAL", 60, 64], ["Nuclear DNA", "TEST", 0, 11], ["diamidino", "TEST", 34, 43], ["PBS", "TREATMENT", 122, 125]]], ["The cells were imaged using a Nikon A1 confocal microscope.RNAscope in situ hybridizationTo detect negative-stranded viral RNAs, in situ hybridization was employed by using the RNAscope 1 Multiplex Fluorescent Detection Reagents v2 Kit (ACD, #323110).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["negative-stranded viral RNAs", "RNA", 99, 127], ["RNAscope", "TREATMENT", 59, 67], ["stranded viral RNAs", "PROBLEM", 108, 127], ["negative", "OBSERVATION", 99, 107], ["stranded", "OBSERVATION_MODIFIER", 108, 116], ["viral RNAs", "OBSERVATION", 117, 127]]], ["A total of 20 double-Z branched pairs targeting the regions of ORF6, ORF7 and 3'UTR of the PRRSV genome (nt position 14, 286-15, 273) as RNA probe (ACD, #510989) to detect negative-strand PRRSV RNAs.", [["ORF6", "GENE_OR_GENE_PRODUCT", 63, 67], ["ORF7", "GENE_OR_GENE_PRODUCT", 69, 73], ["3'UTR", "CELLULAR_COMPONENT", 78, 83], ["ORF6", "DNA", 63, 67], ["ORF7", "DNA", 69, 73], ["3'UTR", "DNA", 78, 83], ["PRRSV genome", "DNA", 91, 103], ["nt position 14", "DNA", 105, 119], ["RNA probe", "DNA", 137, 146], ["negative-strand PRRSV RNAs", "RNA", 172, 198], ["PRRSV", "SPECIES", 188, 193], ["20 double-Z branched pairs", "TREATMENT", 11, 37], ["ORF7", "TREATMENT", 69, 73], ["3'UTR", "TREATMENT", 78, 83], ["the PRRSV genome", "TREATMENT", 87, 103], ["nt position", "TEST", 105, 116], ["RNA probe", "TEST", 137, 146], ["ACD", "TEST", 148, 151], ["strand PRRSV RNAs", "PROBLEM", 181, 198], ["PRRSV genome", "OBSERVATION", 91, 103], ["strand PRRSV RNAs", "OBSERVATION", 181, 198]]], ["The hybridization procedure was performed according to the manufacturer's instruction.", [["The hybridization procedure", "TREATMENT", 0, 27]]], ["Briefly, MARC-145 cells on Lab-Tek II Chamber Slides (Thermo Fisher, #154534) were infected with PRRSV at an MOI of 0.1.", [["MARC-145 cells", "ANATOMY", 9, 23], ["MARC-145", "CHEMICAL", 9, 17], ["MARC-145 cells", "CELL", 9, 23], ["PRRSV", "ORGANISM", 97, 102], ["MARC-145 cells", "CELL_LINE", 9, 23], ["PRRSV", "SPECIES", 97, 102], ["Lab", "TEST", 27, 30], ["PRRSV", "PROBLEM", 97, 102]]], ["At the indicated time points post infection, the cells were fixed with 10% neutral buffered formalin (NBF), followed by dehydration and rehydration steps with suggested concentrations of ethanol and subsequent treatment by hydrogen peroxide (ACD) and protease III (ACD).", [["cells", "ANATOMY", 49, 54], ["infection", "DISEASE", 34, 43], ["formalin", "CHEMICAL", 92, 100], ["dehydration", "DISEASE", 120, 131], ["ethanol", "CHEMICAL", 187, 194], ["hydrogen peroxide", "CHEMICAL", 223, 240], ["formalin", "CHEMICAL", 92, 100], ["NBF", "CHEMICAL", 102, 105], ["ethanol", "CHEMICAL", 187, 194], ["hydrogen peroxide", "CHEMICAL", 223, 240], ["cells", "CELL", 49, 54], ["formalin", "SIMPLE_CHEMICAL", 92, 100], ["NBF", "SIMPLE_CHEMICAL", 102, 105], ["ethanol", "SIMPLE_CHEMICAL", 187, 194], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 223, 240], ["ACD", "SIMPLE_CHEMICAL", 242, 245], ["protease III", "GENE_OR_GENE_PRODUCT", 251, 263], ["protease III", "PROTEIN", 251, 263], ["ACD", "PROTEIN", 265, 268], ["infection", "PROBLEM", 34, 43], ["the cells", "PROBLEM", 45, 54], ["10% neutral buffered formalin (NBF", "TREATMENT", 71, 105], ["dehydration", "PROBLEM", 120, 131], ["rehydration steps", "TREATMENT", 136, 153], ["ethanol", "TREATMENT", 187, 194], ["subsequent treatment", "TREATMENT", 199, 219], ["hydrogen peroxide (ACD)", "TREATMENT", 223, 246], ["protease III (ACD)", "TREATMENT", 251, 269], ["infection", "OBSERVATION", 34, 43]]], ["The cells were then incubated with RNA probes for 2 h at 40\u02daC in HybEZ\u2122 Oven (ACD), followed by a cascade of signal amplification and a series of washing procedures.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["RNA probes", "TREATMENT", 35, 45], ["signal amplification", "TREATMENT", 109, 129], ["washing procedures", "TREATMENT", 146, 164]]], ["Hybridization signals were detected by TSA 1 Plus Cyanine 3 (PerkinElmer, #NEL744E001KT).", [["TSA", "CHEMICAL", 39, 42], ["Cyanine 3", "CHEMICAL", 50, 59], ["Cyanine 3", "GENE_OR_GENE_PRODUCT", 50, 59], ["Hybridization signals", "TEST", 0, 21], ["Cyanine", "TREATMENT", 50, 57]]], ["For triple staining, the cells were fixed again with 3.7% paraformaldehyde and then processed following the normal immunofluorescence assay procedure as described above.RNA immunoprecipitation (RIP)RNA immunoprecipitation was carried out using the EZ-Magna RIP\u2122 RNA-Binding Protein Immunoprecipitation Kit by following the manufacture's protocol (Merck Millipore).", [["cells", "ANATOMY", 25, 30], ["paraformaldehyde", "CHEMICAL", 58, 74], ["cells", "CELL", 25, 30], ["paraformaldehyde", "SIMPLE_CHEMICAL", 58, 74], ["RIP", "PROTEIN", 194, 197], ["RIP", "PROTEIN", 257, 260], ["triple staining", "PROBLEM", 4, 19], ["3.7% paraformaldehyde", "TREATMENT", 53, 74], ["the normal immunofluorescence assay procedure", "TREATMENT", 104, 149], ["RNA immunoprecipitation", "TEST", 169, 192], ["RNA immunoprecipitation", "TEST", 198, 221], ["the EZ", "TEST", 244, 250], ["RNA", "TEST", 262, 265], ["Binding Protein Immunoprecipitation", "TEST", 266, 301], ["the manufacture's protocol", "TREATMENT", 319, 345], ["Binding Protein Immunoprecipitation", "OBSERVATION", 266, 301]]], ["Briefly, MARC-145 cells in 100 mm petri dish were infected with PRRSV strain JXwn06 at an MOI of 0.1 for 36 h and then washed twice with ice-cold PBS.", [["MARC-145 cells", "ANATOMY", 9, 23], ["MARC-145", "CHEMICAL", 9, 17], ["JXwn06", "CHEMICAL", 77, 83], ["MARC-145 cells", "CELL", 9, 23], ["PRRSV", "ORGANISM", 64, 69], ["MARC-145 cells", "CELL_LINE", 9, 23], ["PRRSV", "SPECIES", 64, 69], ["PRRSV", "SPECIES", 64, 69], ["100 mm petri dish", "PROBLEM", 27, 44], ["PRRSV strain JXwn06", "PROBLEM", 64, 83], ["ice-cold PBS", "TREATMENT", 137, 149], ["145 cells", "OBSERVATION_MODIFIER", 14, 23]]], ["The cells were then scraped off the plates, collected by centrifugation, and lysed by complete RIP Lysis Buffer with protease inhibitor cocktail (Sigma, #P8340) and RNase inhibitor (Thermo Fisher, #AM2694), followed by a step of centrifugation at 14, 000 rpm for 10 min at 4\u02daC to remove the cell debris.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 291, 295], ["cells", "CELL", 4, 9], ["RNase", "GENE_OR_GENE_PRODUCT", 165, 170], ["C", "SIMPLE_CHEMICAL", 275, 276], ["cell", "CELL", 291, 295], ["RIP", "PROTEIN", 95, 98], ["The cells", "TREATMENT", 0, 9], ["complete RIP Lysis Buffer", "TREATMENT", 86, 111], ["protease inhibitor cocktail", "TREATMENT", 117, 144], ["RNase inhibitor", "TREATMENT", 165, 180], ["the cell debris", "PROBLEM", 287, 302], ["cell debris", "OBSERVATION", 291, 302]]], ["To immunoprecipitate ATF4-RNA complexes, magnetic beads were mixed with rabbit anti-ATF4 polyclonal antibodies or normal rabbit IgG (isotype control), and then added to the clarified cell supernatants for incubation overnight at 4\u02daC. After washing with cold RIP wash buffer six times, the beads-protein-RNA complexes were digested with proteinase K at 55\u02daC for 30 min.", [["cell supernatants", "ANATOMY", 183, 200], ["K", "CHEMICAL", 347, 348], ["ATF4", "GENE_OR_GENE_PRODUCT", 21, 25], ["rabbit", "ORGANISM", 72, 78], ["anti-ATF4", "GENE_OR_GENE_PRODUCT", 79, 88], ["rabbit", "ORGANISM", 121, 127], ["IgG", "GENE_OR_GENE_PRODUCT", 128, 131], ["cell", "CELL", 183, 187], ["proteinase K", "GENE_OR_GENE_PRODUCT", 336, 348], ["55\u02daC", "SIMPLE_CHEMICAL", 352, 356], ["ATF4", "PROTEIN", 21, 25], ["RNA complexes", "PROTEIN", 26, 39], ["rabbit anti-ATF4 polyclonal antibodies", "PROTEIN", 72, 110], ["normal rabbit IgG", "PROTEIN", 114, 131], ["RIP", "PROTEIN", 258, 261], ["protein-RNA complexes", "PROTEIN", 295, 316], ["proteinase K", "PROTEIN", 336, 348], ["rabbit", "SPECIES", 72, 78], ["rabbit", "SPECIES", 121, 127], ["rabbit", "SPECIES", 72, 78], ["rabbit", "SPECIES", 121, 127], ["ATF4", "TEST", 21, 25], ["RNA complexes", "PROBLEM", 26, 39], ["magnetic beads", "TREATMENT", 41, 55], ["rabbit anti-ATF4 polyclonal antibodies", "TREATMENT", 72, 110], ["normal rabbit IgG (isotype control", "TREATMENT", 114, 148], ["cold RIP wash buffer", "TREATMENT", 253, 273], ["the beads-protein-RNA complexes", "TREATMENT", 285, 316], ["proteinase K", "TREATMENT", 336, 348], ["rabbit IgG", "OBSERVATION_MODIFIER", 121, 131]]], ["Afterwards, the supernatants were collected on a magnetic separator and transferred to a new tube for RNA exaction with TRIzol reagent (Thermo Fisher, #15596026).", [["supernatants", "ANATOMY", 16, 28], ["tube", "TISSUE", 93, 97], ["a magnetic separator", "TREATMENT", 47, 67], ["a new tube", "TREATMENT", 87, 97], ["TRIzol reagent", "TREATMENT", 120, 134]]], ["The abundance of viral RNAs was analyzed by relative RT-qPCR targeting PRRSV 5'UTR or GAPDH (as a control).GST Pulldown assayE. coli BL21 cells containing the plasmid pGST-ATF4 or pGEX-6P-1 vector were grown in 100 mL 2 x YT (yeast extract and tryptone) media at 37\u02daC. Protein expression was induced for 3 h with Isopropyl \u03b2-D-1-thiogalactopyranoside (IPTG) at a concentration of 0.1 mM when the optical density at 600 nm reached 0.6.", [["cells", "ANATOMY", 138, 143], ["plasmid", "ANATOMY", 159, 166], ["extract", "ANATOMY", 232, 239], ["tryptone", "CHEMICAL", 244, 252], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 313, 350], ["IPTG", "CHEMICAL", 352, 356], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "CHEMICAL", 313, 350], ["IPTG", "CHEMICAL", 352, 356], ["PRRSV", "ORGANISM", 71, 76], ["GAPDH", "GENE_OR_GENE_PRODUCT", 86, 91], ["GST", "GENE_OR_GENE_PRODUCT", 107, 110], ["BL21 cells", "CELL", 133, 143], ["pGST", "GENE_OR_GENE_PRODUCT", 167, 171], ["ATF4", "GENE_OR_GENE_PRODUCT", 172, 176], ["pGEX-6P-1", "GENE_OR_GENE_PRODUCT", 180, 189], ["tryptone", "SIMPLE_CHEMICAL", 244, 252], ["Isopropyl \u03b2-D-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 313, 350], ["IPTG", "SIMPLE_CHEMICAL", 352, 356], ["viral RNAs", "RNA", 17, 27], ["PRRSV 5'UTR", "DNA", 71, 82], ["GAPDH", "DNA", 86, 91], ["GST", "PROTEIN", 107, 110], ["BL21 cells", "CELL_LINE", 133, 143], ["plasmid pGST-ATF4 or pGEX-6P-1 vector", "DNA", 159, 196], ["coli BL21", "SPECIES", 128, 137], ["yeast", "SPECIES", 226, 231], ["PRRSV", "SPECIES", 71, 76], ["coli", "SPECIES", 128, 132], ["yeast", "SPECIES", 226, 231], ["viral RNAs", "PROBLEM", 17, 27], ["PRRSV", "PROBLEM", 71, 76], ["GAPDH", "PROBLEM", 86, 91], ["coli BL21 cells", "TEST", 128, 143], ["the plasmid pGST", "TEST", 155, 171], ["ATF4", "TEST", 172, 176], ["pGEX", "TEST", 180, 184], ["Protein expression", "PROBLEM", 269, 287], ["Isopropyl", "TREATMENT", 313, 322], ["thiogalactopyranoside (IPTG", "TREATMENT", 329, 356], ["viral RNAs", "OBSERVATION", 17, 27], ["BL21 cells", "OBSERVATION", 133, 143]]], ["The cultures were pelleted at 8, 000 rpm for 5 min, resuspended in PBS supplemented with bacterial protease inhibitors, sonicated, and lysed for 30 min on ice with 1% Triton X-100.", [["cultures", "ANATOMY", 4, 12], ["Triton X-100", "CHEMICAL", 167, 179], ["Triton X-100", "SIMPLE_CHEMICAL", 167, 179], ["The cultures", "TEST", 0, 12], ["bacterial protease inhibitors", "TREATMENT", 89, 118], ["1% Triton", "TREATMENT", 164, 173]]], ["The lysates were cleared twice at 12, 000 rpm for 10 min at 4\u02daC, and the supernatants were incubated with glutathione-Sepharose 4B beads at room temperature for 1 h, washed 3 times with PBS, and resuspended in 300 \u03bcL PBS.GST Pulldown assayTo test the interaction with viral RNA in vitro, total RNA was extracted from PRRSVinfected MARC-145 cells using TRIzol reagent, and 300 \u03bcg were used for incubation with GST-ATF4 or GST beads in 300 \u03bcL NP40 Buffer (0.1% NP-40, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4) with protease inhibitor cocktail (Sigma, #P8340) and RNase inhibitors (Thermo Fisher, #AM2694) overnight at 4\u02daC. After washing six times with NP-40 buffer, the protein-RNA complexes were eluted from beads with 300 \u03bcL elution buffer (5 mM Tris-HCl, pH 7.5, 1 mM EDTA, pH 8.0, 0.05% sodium dodecyl sulfate), and the proteins were digested at 50\u02daC for 0.5 h using proteinase K at a concentration of 0.28 mg/mL.", [["lysates", "ANATOMY", 4, 11], ["supernatants", "ANATOMY", 73, 85], ["MARC-145 cells", "ANATOMY", 331, 345], ["glutathione", "CHEMICAL", 106, 117], ["NaCl", "CHEMICAL", 473, 477], ["Tris-HCl", "CHEMICAL", 485, 493], ["NP-40", "CHEMICAL", 645, 650], ["Tris-HCl", "CHEMICAL", 741, 749], ["sodium dodecyl sulfate", "CHEMICAL", 784, 806], ["K", "CHEMICAL", 875, 876], ["glutathione", "CHEMICAL", 106, 117], ["NaCl", "CHEMICAL", 473, 477], ["Tris-HCl", "CHEMICAL", 485, 493], ["Tris-HCl", "CHEMICAL", 741, 749], ["EDTA", "CHEMICAL", 764, 768], ["sodium dodecyl sulfate", "CHEMICAL", 784, 806], ["lysates", "ORGANISM_SUBSTANCE", 4, 11], ["glutathione", "SIMPLE_CHEMICAL", 106, 117], ["GST", "GENE_OR_GENE_PRODUCT", 221, 224], ["MARC-145 cells", "CELL", 331, 345], ["TRIzol", "ORGANISM", 352, 358], ["GST", "GENE_OR_GENE_PRODUCT", 409, 412], ["ATF4", "GENE_OR_GENE_PRODUCT", 413, 417], ["GST", "GENE_OR_GENE_PRODUCT", 421, 424], ["Tris-HCl", "SIMPLE_CHEMICAL", 485, 493], ["RNase", "GENE_OR_GENE_PRODUCT", 556, 561], ["Tris-HCl", "SIMPLE_CHEMICAL", 741, 749], ["EDTA", "SIMPLE_CHEMICAL", 764, 768], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 784, 806], ["proteinase K", "SIMPLE_CHEMICAL", 864, 876], ["GST", "PROTEIN", 221, 224], ["viral RNA", "RNA", 268, 277], ["PRRSVinfected MARC-145 cells", "CELL_LINE", 317, 345], ["GST", "PROTEIN", 409, 412], ["ATF4", "PROTEIN", 413, 417], ["protein-RNA complexes", "PROTEIN", 663, 684], ["proteinase K", "PROTEIN", 864, 876], ["PRRSVinfected MARC-145", "SPECIES", 317, 339], ["The lysates", "TEST", 0, 11], ["glutathione-Sepharose 4B beads", "TREATMENT", 106, 136], ["PBS", "TREATMENT", 186, 189], ["GST Pulldown assay", "TEST", 221, 239], ["viral RNA", "TREATMENT", 268, 277], ["total RNA", "TREATMENT", 288, 297], ["TRIzol reagent", "TREATMENT", 352, 366], ["GST", "TEST", 409, 412], ["GST beads", "TREATMENT", 421, 430], ["NaCl", "TREATMENT", 473, 477], ["Tris", "TEST", 485, 489], ["pH", "TEST", 495, 497], ["protease inhibitor cocktail", "TREATMENT", 508, 535], ["RNase inhibitors", "TREATMENT", 556, 572], ["NP", "TREATMENT", 645, 647], ["the protein-RNA complexes", "TREATMENT", 659, 684], ["Tris", "TEST", 741, 745], ["pH", "TEST", 751, 753], ["EDTA", "TEST", 764, 768], ["pH", "TEST", 770, 772], ["0.05% sodium dodecyl sulfate", "TREATMENT", 778, 806], ["the proteins", "TEST", 813, 825], ["proteinase K", "TREATMENT", 864, 876], ["viral RNA", "OBSERVATION", 268, 277]]], ["Afterwards, the supernatants were collected by centrifugation at 12, 000 rpm for 2 min and transferred to a new tube where the abundance of viral RNA was analyzed by relative RT-qPCR targeting PRRSV 5'UTR or GAPDH as a control.Virus infection and titrationFollowing treatment with siRNAs or lentivirus transduction, MARC-145 cells were infected with PRRSV strain JXwn06.", [["supernatants", "ANATOMY", 16, 28], ["MARC-145 cells", "ANATOMY", 316, 330], ["Virus infection", "DISEASE", 227, 242], ["MARC-145", "CHEMICAL", 316, 324], ["tube", "TISSUE", 112, 116], ["PRRSV", "ORGANISM", 193, 198], ["GAPDH", "GENE_OR_GENE_PRODUCT", 208, 213], ["Virus", "ORGANISM", 227, 232], ["lentivirus", "ORGANISM", 291, 301], ["MARC-145 cells", "CELL", 316, 330], ["PRRSV", "ORGANISM", 350, 355], ["viral RNA", "RNA", 140, 149], ["PRRSV 5'UTR", "DNA", 193, 204], ["GAPDH", "DNA", 208, 213], ["MARC-145 cells", "CELL_LINE", 316, 330], ["PRRSV", "SPECIES", 350, 355], ["PRRSV", "SPECIES", 193, 198], ["lentivirus", "SPECIES", 291, 301], ["PRRSV", "SPECIES", 350, 355], ["a new tube", "TREATMENT", 106, 116], ["viral RNA", "PROBLEM", 140, 149], ["PRRSV", "PROBLEM", 193, 198], ["GAPDH", "PROBLEM", 208, 213], ["Virus infection", "PROBLEM", 227, 242], ["treatment", "TREATMENT", 266, 275], ["siRNAs", "TREATMENT", 281, 287], ["lentivirus transduction", "TREATMENT", 291, 314], ["PRRSV strain JXwn06", "TREATMENT", 350, 369], ["tube", "OBSERVATION", 112, 116], ["viral RNA", "OBSERVATION", 140, 149], ["infection", "OBSERVATION", 233, 242]]], ["After incubation at 37\u02daC for 1 h, unbound viruses were washed off with serum-free DMEM three times, and the cell cultures were supplemented with maintenance medium containing 2% FBS.", [["serum", "ANATOMY", 71, 76], ["cell cultures", "ANATOMY", 108, 121], ["FBS", "ANATOMY", 178, 181], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["cell cultures", "CELL", 108, 121], ["FBS", "ORGANISM_SUBSTANCE", 178, 181], ["cell cultures", "CELL_LINE", 108, 121], ["unbound viruses", "PROBLEM", 34, 49], ["serum-free DMEM", "TREATMENT", 71, 86], ["the cell cultures", "TEST", 104, 121], ["maintenance medium", "TREATMENT", 145, 163], ["2% FBS", "TREATMENT", 175, 181]]], ["At indicated time points post infection, the whole cell culture was collected, and the virus was titrated by the end point dilution assay.Statistical analysisAll the graphs and relevant statistical tests used in the work were created by GraphPad Prism version 6.00 (La Jolla, CA, USA).", [["cell", "ANATOMY", 51, 55], ["infection", "DISEASE", 30, 39], ["cell", "CELL", 51, 55], ["infection", "PROBLEM", 30, 39], ["the whole cell culture", "TEST", 41, 63], ["the virus", "PROBLEM", 83, 92], ["Statistical analysis", "TEST", 138, 158], ["All the graphs", "TEST", 158, 172], ["relevant statistical tests", "TEST", 177, 203], ["Prism version", "TEST", 246, 259], ["infection", "OBSERVATION", 30, 39]]], ["Statistical significance between two groups was analyzed by two-tailed unpaired Student's t-test or one-way ANOVA, and asterisks indicate the statistical significance: NS, no significance; \ufffd , P < 0.05; \ufffd\ufffd , P < 0.01; \ufffd\ufffd\ufffd , P < 0.001.", [["\ufffd\ufffd", "TEST", 203, 205], ["P", "TEST", 208, 209], ["\ufffd\ufffd\ufffd", "TEST", 218, 221], ["P", "TEST", 224, 225]]]]}